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Introduction 
Metastases in the uvea may lead to partial or even complete blindness and so seriously 
deteriorate the quality of life of cancer patients. 
If an underlying primary tumour elsewhere in the body is already known, the 
diagnosis of the intraocular metastases will be a sign of progression and dissemination. 
Uveal metastases may also, however, be the first sign of a hitherto unknown but 
meanwhile disseminated malignancy. In that case the patient, in addition to the direct eye 
problems, is for the first time to face the fact that he suffers from a serious disease. 
A timely and correct diagnosis of uveal metastases is of great importance for an 
optimal and preferably not too taxing treatment that may contribute to preservation or 
major improvement of the quality of life of the patient in question. 
This study was designed to investigate all aspects of the clinical picture of uveal 
metastases. Attention will be paid to the epidemiology of uveal metastases, to the various 
underlying primary tumours and the relationship with metastases elsewhere in the body, 
diagnostics and differential diagnostics by means of the various examination techniques 
available, the management and the treatment of this condition and its prognosis. The 
results of this study will be discussed in three parts: 
1. The first part will deal with the literature on uveal metastases, with emphasis on 
the diagnosis and differential diagnosis. 
2. The second part consists of a retrospective study of all patients with suspicion of 
an intraocular tumour who were seen in the Ophthalmological Clinic of Nijmegen 
University Hospital for diagnosis and treatment in the period from November 1970 
to November 1990. Apart from patients with uveal metastases, data of patients 
with other intraocular tumours and lesions suspected of being tumours will be 
discussed to the extent of their relevance for the differential diagnosis. Special 
attention will also be given to the management to be conducted in patients in whom 
uveal metastases are established. 
3. In the third part, a description will be given of a prospective study, over the period 
from February 1989 to July 1991, in patients with breast cancer. Its purpose is to 
determine the frequency of ocular symptoms and of uveal metastases in this patient 
population and to consider to what extent it is useful for patients with such a 
malignancy to be screened for ophthalmological abnormalities according to a fixed 
protocol. 
The stereo photographs shown can be viewed with the aid of a prysmatic viewer (e.g. 
KMQ or Nesh prism stereo viewer). This viewer should be held in the right hand and 
used like spectacles. A prism bar held in the right hand, with the base of the prisms 
downward may also be used for this purpose. Instead of the two photographs three 
pictures will be seen. Vary the distance between the eyes and the photographs until the 
central picture is seen sharp without double contours. This picture will be three-dimensional. 
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Part 1 
Review of the literature 

1.1 Historical survey 
In 1872 Perls published the findings at autopsy of a male aged 43 years who died of 
lungcancer. The eyes had been examined histologically. 
'Beim Herausnehmen des hinteren Augenabschnittes links erscheint die Retina auf 
der inneren Seite und nach unten abgelöst, die Chonoidea hier fast in der ganzen 
Ausdehnung der hinteren Hälfte des Bulbus stark verdickt (bis zu 2 Mm ) , in der 
Tiefe thedweise sehr derb, fast knorpelhart, nach der Oberfläche zu rundliche, 
sechsergrosse, opak-weisse, wenig und leichtkörnig promimrende Geschwulstmassen 
bildend, von denen fast jede ein etwas venefies Centrum hat Am rechten Auge liegt 
die Retina der Chonoidea an, aber auch hier finden sich im hinteren 
Augenabschnitte in der Chonoidea mehrere flachpromimrende bis linsengrosse 
Infiltrate von ähnlicher Beschaffenheit Die Infiltrate der Chonoidea gehören 
thedweise ihren tieferen Schichten an, eine dünne, gefilssreiche, bräunliche Schicht 
zieht an vielen Stellen Über sie weg, und ist namentlich in den Vemefungen 
zwischen den körnigen Hervorragungen reichlich Nur die einzelnen Körner selbst 
sowie verschiedene vereinzelte ganz kleine Infiltrate von 1/2-1 Mm Durchmesser 
erschienen mit ganz weisser Oberfläche und liegen vollständig oberhalb der 
pigmentmen Gewebsschicht Die grösseren Infiltrate gehen bis an die Sklerotica, 
und sind derselben zum Theil angelöthet, ohne aber irgendwo in sie 
hineinzugreifen Auf dem Durchschnitte erscheinen die Infiltrate opak, gelblich-
weiss, trocken, zum Theil etwas bröcklich, und namentlich in den grösseren zeigen 
sich dicht liegende gelbliche Pfropfe zwischen denen hier und da ein bläulich 
weisses prominirendes und festeres Gewebe zu erkennen ist ' 
Microscopically infiltrates of malignant cells were observed in the choroid as well as in 
the chonocapillans The diagnosis of a choroidal metastasis was made The patient had 
not been known with visual complaints and had not been subjected to ocular examination 
This article is generally considered as the earliest publication regarding a uveal 
metastasis (Duke-Elder and Perkins, 1966; Albert et al., 1967). 
In 1870, Bromser described a patient with a malignant melanoma of the cheek who 
developed visual complaints in one eye. Five years later, orbital exenteration was 
performed because of an intraocular tumour. Leber (1885), who himself examined the 
patient in question and who directed the histological examination, was of the opinion that 
while the metastatic nature of the lesion had not been established with certainty, this 
diagnosis was highly probable Fuchs (1882) and Sattler (1926) did not regard the lesion 
as a metastasis, mainly because of the slow growth of the intraocular tumour and the 
absence of metastases elsewhere in the body (Fuchs, 1882; Sattler, 1926). However, in 
1967 Font et al. in their article on malignant cutaneous melanomas metastatic to the uvea 
did mention Bromser's patient as the first case of uveal metastasis reported. 
Hirschberg (1882) probably described the first patient in whom the diagnosis of a 
choroidal metastasis was made on clinical grounds. The patient was a female aged 52 
known with breast cancer with visual complaints in the right eye since three months. 
Visual acuity on the right was 1/6, on the left vision was virtually normal 
Ophthalmoscopy revealed a few small pale-yellow, round, almost punctate foci near the 
optic disk in both eyes On the right there was in addition a vaguely delimited flat 
15 
elevation of the choroid which lifted the retina about 1.5 mm. The lesions were bilaterally 
progressive; vision deteriorated and the patient died. No autopsy was performed. 
Ewing in 1890 described a patient with deterioration of vision due to a retinal 
detachment and an intraocular tumour in whom breast cancer was detected immediately 
after enucleation. This is the first patient known with a uveal metastasis in whom, apart 
from the choroid, the iris and ciliary body were involved also. 
The first report in the Netherlands of a patient with a uveal metastasis was 
published by Nicolai (1915). 
In 1891, Elschnig in an article presented a survey of the 16 patients with uveal 
metastases known at the time. The survey was followed by numerous similar publications 
by, inter alia, Schultze (1893), Lagrange (1901), Usher (1923), Ask (1934), Lemoine and 
McLeod (1936), Greer (1950), Albert et al., (1967) and Schiffer et al. (1978). Up to 1991 
some 1500 publications were directly or indirectly concerned with uveal metastases. 
The earlier articles described almost exclusively the clinical picture and histological 
findings. Later publications refer to the treatment as well (Ucherman, 1917; Lemoine and 
McLeod, 1936). 
Some important histopathological studies were reported by, inter alia, Hart (1962), 
Jensen (1970) and Hutchison and Smith (1979). Ferry and Font in three articles described 
patients with metastases to the eye and orbit of which histopathological material was 
available. The first part dealt with a clinicopathological study of 227 patients (Ferry and 
Font, 1974), in the second part, the 26 patients with metastases to the anterior segment 
were discussed in greater detail (Ferry and Font, 1975). The third part concerned 28 
patients with orbital metastases (Font and Ferry, 1976). 
Bloch and Gartner (1971) and Nelson et al. (1983) made post-mortem studies of 
patients with cancer at the time of death to determine the frequency of uveal metastases. 
In 1967, Albert et al. with the same objective published a series of articles on tumours 
metastatic to the eye. In the first part, the clinical incidence among 213 adult patients with 
a systemic malignancy was discussed (1967), the second part concerned a study in 
children in whom, however, no intraocular metastases could be demonstrated (1967a). The 
third part described a study of the fate of circulating tumour cells to the eye (1967b). 
Mewis and Young (1982) performed clinical ophtha!mological examinations of 
patients known with breast cancer in order to determine the incidence of choroidal 
metastases in this group of patients. Authors of other important publications on uveal 
metastases of breast cancer are Thatcher and Thomas (1975) and Freedman and Folk 
(1987). Mention should also be made of the article by Hemmes in the Nederlands 
Tijdschrift voor Geneeskunde of 1969 in which he described all 121 patients with uveal 
metastases in the Netherlands over the period 1909-1968. 
Stephens and Shields in 1979 published their extensive clinical study on the 
diagnosis and treatment of uveal metastases. Finally, in 1990, Saßmannshausen et al. 
published an article reporting the largest number of patients (161) with uveal metastases 
from one clinic. 
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1.2 Anatomy and pathophysiology 
Good insight into the pathogenesis and further development of uveal metastases requires 
knowledge of the anatomy of the vascular middle eye coat, the uvea. 
1.2.1 Anatomy 
Early practitioners of the anatomy of the eye were of the opinion that the uveal tract 
resembled the inside of a dark-coloured grape. Consequently, the word 'uvea' derives 
from the Latin for grape (Torczynski, 1982). 
The uvea constitutes a thin continuous layer of blood vessels, melanocytes and 
connective tissues and has three distinct subdivisions: the choroid, the ciliary body and the 
iris. 
The transition from iris to ciliary body is situated at the site of the recessus of the 
anterior chamber. Posteriorly the pars plana of the ciliary body merges with the choroid. 
Internally the boundary is marked by the ora serrata, a pigmented scalloped band situated 
anteriorly to the equator. Externally this juncture is situated at the level of the scleral 
insertion of the extraocular muscles of the eye. The optic nerve constitutes the posterior 
delineation of the choroid (Duke-Elder, 1946; Torczynski, 1982). 
Internally the uvea is lined by derivatives of the neuroectoderm, viz. the retinal, 
ciliary and iridic epithelia, respectively. The boundary between the uvea and the 
epithelium is marked by a basement membrane. Externally the uvea is bordered by the 
sclera for the uveal part behind the scleral spur and by the aqueous humour of the anterior 
chamber at the site of the iris (Figure 1.2.1.1). 
1.2.1.1 The choroid 
The choroid, the posterior portion of the uvea, consists mainly of blood vessels in a loose 
connective tissue matrix with a profusion of nerve fibres and pigmented cells. The prime 
function of the choroid is the nourishing of the major part of the eye and especially of the 
retina (Jakobiec and Ozanics, 1982). The retina is supplied by the choroid to a depth of 
130 μηι. This comprises the layer of pigment epithelium, the rods and cones, the outer 
nuclear and plexiform layers and the entire thickness of the foveal retina. Sometimes, a 
cilioretinal artery is present which may supply a variable portion of the inner retinal layers 
(Hayreh, 1975). 
The choroid is situated between the pigment epithelium and the sclera. Its 
attachment to the sclera is strongest at the scleral spur, round the optic nerve and at the 
entrance and exit points of the emissary vessels passing through the sclera. The choroid is 
thickest under the fovea (approximately 0.3 mm) and thinnest at the site of the ora serrata 
(0.1 to 0.15 mm) (Jakobiec and Ozanics, 1982). The thickness depends on the 
concentration of arteries and veins (Torczynski, 1982). 
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Figure 1.2.1.1 Horizontal section through the eye (after: Bloom and Fawcett, 1975; Ferner and 
Staubesand, 1975; Longman and Woerdeman, 1978). 
From the outside inward the choroid is divided into four layers (Duke-Elder, 1946; 
Torczynski, 1982): 
1. the suprachoroid; 
2. the layer with the choroidal vessels; 
3. the choriocapillaris; 
4. Bruch's membrane. 
On the outside the choroid is separated from the sclera by a loose connective tissue, the 
epi- or suprachoroid. This provides transit for the main branches of the ciliary arteries and 
nerves to the inside of the globe (Jakobiec and Ozanics, 1982). 
The largest and outermost choroidal vessels constitute Haller's layer. Sattler's 
layer, which is situated below it, consists of intermediate-sized vessels. 
The choriocapillary network is situated in close proximity to the retinal 
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photoreceptors (Jakobiec and Ozanics, 1982). 
The distinction between these three layers can only be made at the posterior pole. 
The boundary between the choriocapillaris and the retina is formed by Bruch's 
membrane which derives from both the choriocapillaris and the pigment epithelium. 
Bruch's membrane is an acellular membrane, approximately 2 μπι thick, consisting of a 
network of collagenous and elastic fibres. It constitutes a filter or diffusion barrier to the 
passage of molecules from the choriocapillaris (Torczynski, 1982). 
The outermost vessels round the papilla are choroidal branches of the short 
posterior ciliary arteries and radiate from the papilla. Most of the vessels of the outermost 
portion of the choroid, apart from the area surrounding the optic disk and below the 
macula, are veins. The arterioles have their closest concentration round the optic disk, 
especially nasally and temporally. 
The choroidal arteries run a tortuous course and extend from the optic disk to the 
equator. Part of the branches curve posteriorly to supply the juxtaneural capillaries. 
Another part virtually immediately plunges deeply into the innermost layers of the 
choroid. In the submacular layer, individual branches are difficult to follow because of 
pronounced intertwining of arteries and veins (Torczynski, 1982. 
The large choroidal arteries branch dichotomously, in rapid succession. 
Anastomoses between the larger choroidal arteries are infrequent. Frequent anastomoses 
are seen, on the other hand, in the smaller branches which form various plexuses. 
According to Hayreh (1975), however, choroidal arteries in vivo do not anastomose with 
each other at any level and constitute functional end arteries. He alleges that formation of 
anastomoses has only been demonstrated in post-mortem studies. 
The terminal or precapillary arterioles that enter the choriocapillaris originate from 
the smaller arteries. Small branches of the short posterior ciliary arteries together with 
recurrent branches from the major arterial circle enter the choroid anteriorly (Torczynski, 
1982). 
The choriocapillaris consists of one single layer of large capillaries. The density of 
capillaries is practically the same in all portions of the choroid but the density of 
precapillary arterioles and postcapillary venules is higher in the submacular portion than 
equatorially. The capillaries consist of a continuous layer of fenestrated endolethial cells 
surrounded by a basement membrane. They are similar to the capillaries in the renal 
glomeruli and the small intestine. Among the endothelial cells zonulae occludentes exist. 
Arterioles and venules form an alternating system segmenting the choriocapillaris. 
This lobular distribution in the posterior pole is supplied centrally by one or several 
precapillary terminal arteries and drains peripherally through venules (Torczynski, 1982). 
Each segment is a functional unit, in general with a polygonal shape without anastomoses 
with adjacent segments being demonstrable in vivo. Together they form a mosaic pattern 
bounded by the venous vessels (Hayreh, 1975). 
At the site of the equator and anteriorly the arteries and veins join the 
choriocapillaris. Junctions of arterioles and capillaries as well as capillaries and venules 
have been described. There exists a transition zone between the posterior capillaries with a 
network-like configuration and the straighter peripheral capillaries where the pattern is 
more irregular. Anteriorly the capillaries end at the site of the ora serrata. Posteriorly, 
there is a sharp delineation at the site of entrance of the optic nerve. 
The only capillaries in the choroid are located in the choriocapillaris. All vessels 
that supply and drain the choriocapillaris enter from the choroidal side (Torczynski, 
1982). 
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1.2.1.2 The ciliary body 
The ciliary body extends from the ora serrata, where the peripheral retina ends, to the 
root of the iris. In the meridian plane, the ciliary body is divided into the pars plana or 
orbicularis ciliaris and the pars plicata or corona ciliaris. The pars plana begins at the site 
of the ora serrata and ends distally in a thickened folded part, the pars plicata. The latter 
surrounds the main parts of the ciliary muscle. The connective tissue components anchor 
the ciliary body and the entire uvea behind it to the scleral spur (Figure 1.2.1.2.1). 
Figure 1.2.1.2.1 Anatomy of the ciliary body and the iris (after: Duke-Elder, 1946; Feneis, 1974; 
Bloom and Fawcett, 1975; Gardner et al., 1975; Langman and Woerdeman, 1975; Ferner and 
Staubesand, 1978). 
From the inside (vitreal) to the outside (scleral) the ciliary body consists of (Duke-Elder, 
1946; Jakobiec and Ozanics, 1982): 
1. the internal limiting membrane, continuous with that of the retina; 
2. the neuroectodermal unpigmented ciliary epithelium, a continuation of the 
neurosensory retinal tissue, which is responsible for the production of aqueous 
humour; 
3. the neuroectodermal pigmented ciliary epithelium, a continuation of the retinal 
pigment epithelium; 
4. the connective tissue stroma, which contains the ciliary muscles, nerves and 
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vessels; the stroma with the blood vessels constitutes the core of the ciliary 
processes; 
5. the supraciliaris, a continuation of the lamina suprachoroidea, a loose fibroelastic 
tissue which connects the ciliary portion of the uvea with the sclera. 
1.2.1.3 The iris 
The anterior part of the uvea is formed by the iris. The thickness of the iris varies, with 
an average of 0.6 mm. In the horizontal plane a division may be made into the pupillary 
and the ciliary zone. The iridai stroma is continuous with the ciliary body. 
Proceeding from the anterior chamber towards the lens, the uveal portions include 
(Jakobiec and Ozanics, 1982): 
1. the anterior border layer, a discontinuous endothelium-like layer with fibroblasts, 
pigment and nerve cells; the colour of the iris depends primarily on the thickness 
of this layer and the amount of pigment it contains; 
2. a thin fibrous layer, the anterior layer of the stroma; 
3. the posterior layer or deep mesodermal layer which provides the supporting and 
supplying connective tissue together with nerves and blood vessels; 
4. the sphincter muscle; 
5. the dilator muscle; 
6. the pigmented iris epithelium; 
7. the pigmented posterior epithelium, a continuation of the unpigmented ciliary 
epithelium; 
8. the lamina basalis, a forward extension of the retinal and ciliary basement 
membrane. 
1.2.1.4 Uveal blood supply 
The choroid receives its blood from three sources, all of them orbital branches of the 
ophthalmic artery which in its tum is a branch of the internal carotid artery. These three 
sources are the short posterior ciliary arteries, the long posterior ciliary arteries and the 
anterior ciliary arteries. Although the retinal vessels also arise from the ophthalmic artery, 
these two systems are entirely separate and distinct (Torczynski, 1982). The retina is 
supplied with blood by the central retinal artery, a branch of the ophthalmic artery which 
pierces the optic nerve to reach the retina (Figure 1.2.1.4.1). 
The posterior ciliary arteries as a rule arise from the ophthalmic artery in two 
trunks, the nasal and the temporal (lateral) ciliary arteries, from which arise the long and 
short posterior ciliary arteries (Hayreh, 1975). Variations are frequent and six to eight 
branches, a combination of long and short posterior ciliary arteries, may arise directly 
from the ophthalmic artery. The pattern of scleral canals, through which the posterior 
ciliary arteries enter the sclera, is relatively constant, however. The lateral trunk of the 
ciliary arteries as a rule ultimately supplies a larger portion of the choroid than the medial 
trunk. The dividing line between the two areas of blood supply passes through the papilla 
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(Hayreh, 1975) The arterial and venous systems of the choroid do not parallel each other 
as is usual elsewhere in the body (Torczynski, 1982). 
Figure 12 14 1 Arterial blood supply of the eye (after Duke-Elder, 1946, Feneis, 1974, 
Gardner et al, 1975, Langman and Woerdeman, 1978) 
Fifteen to 20 short posterior ciliary arteries, ansing from the ophthalmic artery or the 
combined ciliary artenes, pierce the sclera near the optic nerve. The vessels are not 
distnbuted symmetrically round the disk but cluster in groups round the horizontal 
meridian, more vessels as a rule being situated temporally than nasally. The artenes are 
located between the optic nerve and the wreath of ciliary nerves, ι e not farther than 2 to 
2 5 mm from the dural sheath of the disk. Most vessels are found laterally and slightly 
infenor to the honzontal line at the site of the temporal border of the optic nerve, 
postenor to the site of entrance of the canal for the long temporal postenor ciliary artery 
and nerve (Torczynski, 1982). They pass the sclera at the level of the macula (Hayreh, 
1975). A few short ciliary artenes enter above and below the optic nerve and a smaller 
cluster occurs nasally (Torczynski, 1982). The pan of the fundus that is supplied by each 
individual artery vanes markedly in size, shape and localization (Hayreh, 1975). 
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The short posterior ciliary arteries branch in the suprachoroid or in the outer layer 
of the choroid, and the choroidal branches radiate towards the equator in the outermost 
layer of the choroid. Some branches curve in a posterior direction to supply the 
choriocapillaris adjacent to the optic nerve. The short posterior ciliary arteries terminate 
principally in the choroid (Torczynski, 1982). Each terminal choroidal arteriole supplies a 
small segment of the choriocapillaris, bringing about a mosaic-like segmentation (Hayreh, 
1975). In addition they supply the episcleral plexus, contribute to the pial plexus of the 
optic nerve and form the circle of Zinn-Haller, which is often incomplete. Occasionally, a 
branch enters the retina as a cilioretinal artery (Torczynski, 1982). 
Two branches of the ophthalmic artery or of the two respective ciliary trunks 
constitute the nasal and temporal long posterior ciliary arteries. In the orbit they run 
parallel to the optic nerve and pierce the sclera together with the long posterior ciliary 
nerve, 3 or 4 mm distant from the optic nerve and outside of the ring of the short ciliary 
nerves. These canals are 3 to 7 mm long and pass the sclera obliquely. The artery enters 
the suprachoroidal space posterior to the equator and slightly anterior to the macula. 
Generally, the long temporal posterior ciliary artery passes the sclera and the suprachoroid 
without ramifications, although these have been described in the scleral canal (Duke-
Elder, 1946; Torczynski, 1982). The temporal long posterior ciliary artery supplies a part 
of the choroid directly behind the equator, virtually immediately from the moment when 
the artery pierces the sclera (Hayreh, 1975). The tributary of the temporal artery turns 
posteriorly and enters the submacular choroid. The main trunk of the artery branches 
anterior to the ora serrata, giving off a few recurrent branches to the anterior choroid, 
either directly to the choriocapillaris or as branches of the major anterior circle of the iris. 
The principal trunks of the long posterior ciliary arteries terminate in the major arterial 
circle of the iris (Figure 1.2.1.4.2). 
The muscular arteries of the four rectus muscles of the eye follow the tendons to 
their scleral insertions where they pierce the sclera as the anterior ciliary arteries. They 
are branches of the lacrimal artery which in its turn is a branch of the ophthalmic artery. 
The superior, medial and inferior rectus muscles each contain two arteries, while the 
lateral rectus muscle contains one. Other small branches of the muscular arteries supply 
the anterior conjunctiva, the episclera and the sclera near Schlemm's canal. The anterior 
ciliary arteries pass the sclera and the suprachoroidal space, enter the ciliary muscle and 
join the major circle of the iris. The latter does not constitute one single vessel but rather, 
an arterial plexus in the root of the iris which encircles the uvea anteriorly. Ten to 12 
recurrent branches from the major arterial circle posteriorly enter the choroid for the 
blood supply of the choriocapillaris anterior. Recurrent branches anastomose with the 
choroidal branches of the short posterior ciliary arteries (Duke-Elder, 1946; Torczynski, 
1982). 
The ciliary blood supply is provided by the two long posterior ciliary arteries and 
by the anterior ciliary arteries. The posterior ciliary arteries run forward in the 
suprachoroidal space and close to the posterior margin of the ciliary body divide into two 
or more parts. These parts run forward to anastomose with branches of the anterior ciliary 
arteries and form the major arterial circle of the iris. This circle is situated just behind the 
root of the iris in front of the radial part of the ciliary muscle (Streeten, 1982). 
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Figure 1.2.1.4.2 Arterial blood supply of the eye (after: Duke-Elder, 1946; Gardner, 1975; 
Ferner and Staubesand, 1978; Longman and Woerdeman, 1978; Schiebler and Schmidt, 1981). 
The iris receives its arterial blood supply from the major arterial circle at the root of the 
iris in the stroma of the ciliary body. Branches of the minor circle also extend backward 
to supply the posterior part of the iris (Rodrigues et al., 1982). 
The veins of the anterior uvea run a relatively straight, and those of the posterior 
pole a tortuous course. The entire choroid as well as a large part of the anterior uvea are 
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drained by the four vorticose veins (Duke-Elder, 1946; Torczynski, 1982) from a well-
circumscnbed segmental distribution of the veins in the choroid, ciliary body and ins 
(Hayreh, 1975). The four vorticose systems are formed by the confluence of choroidal 
veins and are situated in the oblique quadrants, two superior and two inferior, from where 
they curve to a central dilated ampulla Each ampulla narrows at the internal opening of 
the scleral canal and then becomes a vorticose vein. The ampullae and the veins draining 
into them are situated for the greater part in the outermost layer of the choroid and can 
easily be separated from the internal layers of the choroid. Venous anastomoses occur 
frequently 
Part of the uveal blood of the ins and the ciliary body leaves the eye through a 
scleral plexus of anterior scleral (ciliary) veins near the limbus The vorticose veins drain 
into the superior and inferior orbital veins and leave the orbit through the supenor and 
inferior orbital fissures (Duke-Elder, 1946, Rodrigues et al., 1982; Streeten, 1982; 
Torczynski, 1982). These veins debouch into the sinus cavernosus (Jakobiec and Ozamcs, 
1982). 
1.2.2 Pathophysiology of uveal metastases 
A metastasis is a secondary malignant lesion detached from the primary tumour. Virtually 
all malignant tumours have the capacity to metastasize which, however, vanes greatly 
from one tumour to another. This vanabihty is determined inter alia by factors such as 
histological charactenstics, localization and size of the primary tumour Cells within one 
single tumour display a substantial vanabihty This heterogeneity may result in distinct 
cytological differences between the pnmary tumour and the metastases (Spremulli et al., 
1985) 
Metastatic cells may be transported via lymphatic, venous or artenal canals or via 
pleural, pentoneal and cerebrospinal fluids If a tumour is to cause distant metastases, it 
has to have access to one of the above-named systems Malignant cells have to be 
detached and to survive in the transporting medium. Subsequently, they have to be 
arrested in a target organ, become implanted there and be provided with a new blood 
supply (del Regato, 1977, Spremulli et al., 1985). 
Apart from, for instance, local invasion of epitheliomas or melanomas of the 
conjunctiva and of retinoblastomas, secondary tumours of the uvea always have a 
haematogenous pathogenesis. The eye is not included in the lymphatic drainage system 
(Bloom and Fawcett, 1975; Amé and Mathis, 1986) A few authors are of a different 
opinion, however Behr (1922) speaks of the 'Lymphbahnen der Chonoidea' and 
Pressburger (1927) of the lymph flow in the suprachoroidal space. Thomas and Sladden 
(1927) believed that there existed an invasion route along lymphatic canals to the postenor 
pole, which subsequently might extend forward via infiltration. Stuble (1922) descnbed 
lymphatics in the ins, the ciliary body and the choroid. François et al (1967) descnbed a 
canal-like network m the ins connected with the ciliary body and the choroid. Connections 
between the choroid and lymphatics were also postulated by Gruntzig (1982). Nemeth 
(1934) was of the opinion that the choroid is connected by lymphatics with the subclavian 
trunk and the jugular vein and that indal metastases might be caused by a lymphogenous 
pathway. Shields (1983), on the other hand, declares that the intraocular structures possess 
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no lymphatic canals and that the uvea and retina can only be reached by metastases via a 
haematogenous route. 
Two basic hypotheses to explain the pattern of haematogenous metastasization 
exist: the direct hypothesis and the cascade theory. 
The direct hypothesis postulates that spread of neoplastic cells is a process in 
which distant metastases are the result of direct haematogenous dissemination from the 
primary tumour. The cascade theory, on the other hand, premises a process in several 
steps (Spremulli et al., 1985). 
Bross et al. (1975) published a study on the pattern of metastasization in 4728 
patients who had been subjected to autopsy. The findings demonstrated that in metastases 
a cascade process played a part in which in general one or several intermediary sites were 
involved, mostly the lung and the liver. These localizations in their turn might function as 
sources for further metastasization. Every step of the metastatic cascade appears to be a 
highly selective process. Only a small portion of the total number of cells become 
detached from the primary tumour and an even smaller portion of these survive the 
dissemination and are arrested elsewhere in the vascular system. Taking into account the 
interactions of the arrested cells with the local normal tissue, with regard to 
neovascularization and attacks by the defense mechanism of the host tissue, it is not 
surprising that only few of the remaining cancer cells survive and multiply to become 
metastases (Weiss, 1977; Spremulli et al., 1985). Although the localizations of metastases 
vary greatly, typical patterns of spread of various neoplasms can be described 
(Sugerbaker, 1981). 
Different types of cancer cells vary greatly in their capacity of remaining viable at 
a distance from the primary tumour. In addition, certain inconstant immunological factors 
may play a part. Breast cancer cells, which are known to be very hardy, may survive and 
even multiply in circumstances unfavourable for other types of cancer cells (Reese, 1976). 
It is therefore improbable that metastatic cells reach the eye in other ways than via 
the bloodstream (Ewing, 1890; Elschnig, 1891; Ask, 1934; Duke-Elder and Perkins, 
1966; Ferry, 1967; Castro et al., 1982; Shields, 1983; Amé and Mathis, 1986). 
Malignant cells may reach the vascular canals round the primary tumour following 
which they may pass through the pulmonary circulation. Subsequently they may be 
carried, whether or not as tumour emboli, through the heart to the aorta and the common 
carotid artery (Ferry, 1967). Owing to the right angle at which the ophthalmic artery 
arises from the internal carotid artery, it is difficult for metastatic cells in the bloodstream 
to reach the eye (Mullen et al., 1954; Ferry, 1967; Offret and Haye, 1971; Cieplinski et 
al., 1982). The brain and meninges could then be reached easier (Ellett, 1944; Duke-Elder 
and Perkins, 1966). 
Unlike the tumour cells that reach the left common carotid artery, which arises 
directly from the aorta, the tumour cells have to follow a different route to the right 
common carotid artery, namely via the arteria innominata (the brachiocephalic trunk) 
(Ferry, 1967). This anatomical difference between the left and right common carotid 
arteries is regarded by certain authors as the cause of uveal metastases occurring more 
frequently in the left than in the right eye (Sattler, 1926; Ellett, 1944; Stevens and Reeh, 
1958; Eross, 1959; Hart, 1962; Jensen, 1970; Meythaler and Herold, 1979). 
Cieplinski et al. (1982) declare that for uveal metastases to develop tumour emboli 
rather than loose tumour cells are required. For this reason, pulmonary metastases ought 
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to be nearly always present. However, according to several investigators the lungs may be 
bypassed via Batson's plexus (Batson, 1940; Hogan and Zimmerman, 1962; Ferry, 1967; 
Castro et al., 1982). By this route, tumour cells are guided to the above-named vertebral 
system. Via the cranial venous sinuses the vorticose veins are ultimately reached. Batson's 
plexus contains no valves. Reversal of the flow is possible by changes in body posture and 
Valsalva manoeuvres. This might possibly explain the relatively high frequency of 
intraocular metastases of carcinomas of prostate and kidney but fails to account for the 
rarity of metastases of bladder cancer. Possibly, the uvea is not a good nutrient medium 
for bladder cancer (Cieplinski et al., 1982; Dieckert and Berger, 1982). Allegedly, many 
skeletal metastases may also come into being via the paravertebral canals (del Regato, 
1977). 
In haematogenous spread of tumour cells the distribution of the cellular 
agglomerates in the bloodstream may be of decisive importance. The smaller bacterial and 
viral tumour emboli are carried along in the centre of the bloodstream and reach the 
terminal circulation. Therefore, infectious emboli more readily proceed to the retina (Hart, 
1962). Malignant tumour cell emboli, on the other hand, remain at the periphery of the 
bloodstream and tend more to follow the smaller arteries branching off, such as the 
choroidal vessels (Maxwell, 1954; Schiffer et al., 1978). The probability that malignant 
tumour cells reach the iris or the ciliary body is lower because of the flow conditions 
(Adda, 1937). Metastases in muscle tissue are rare, which is probably one of the reasons 
why few metastases are encountered in the ciliary body. Possibly, muscular movements in 
the iris and the ciliary body impede the implantation and growth of metastases (Ask, 
1934). If the ciliary body is reached by tumour cells, the emboli usually are arrested 
there, which allegedly is why metastases occur less frequently in the iris (Sanders, 1938). 
Most uveal metastases are localized in the choroid (Abramson, 1984). Because the 
short posterior ciliary arteries, which supply the posterior pole, are far more numerous 
than the long posterior ciliary arteries, which supply the anterior uvea, most tumour 
emboli pass through the short ciliary arteries and in particular reach the temporal choroid, 
which is supplied by the most numerous and largest blood vessels (Lemoine and McLeod, 
1936; Kreibig, 1937; Duke-Elder and Perkins, 1966; Reese, 1976; Castro et al., 1982; 
Cieplinski et al., 1982; Shields, 1983). Terrien (1929) was of the opinion that the short 
ciliary arteries owing to their smaller calibre were less accessible to metastases and that 
the tumour emboli would already be stopped at the site of penetration of the vessels 
through the sclera. 
Possibly, in many patients with a carcinoma, tumour emboli do reach the eye but 
they do not succeed in multiplying there and clinically no distinct lesions develop (Ferry, 
1967). A tumour embolus which reaches the uvea may block the small blood vessels by 
proliferation of tumour cells. The malignant cells then infiltrate the intervascular space 
and spread in the direction of least resistance (Adda, 1937; Stallard, 1940; 
Leopoldsberger, 1943; Bonnet and Jambon-Genet, 1948; Castro et al., 1982). 
Coman et al. (1951), as part of a study of the mechanism of metastases, carried 
out an experimental investigation in rabbits. They injected malignant tumour cells 
intracardially, following which metastases developed throughout the animal. They 
concluded that the rarity of metastases in certain organs is due not to chemical inhibition 
but to the fact that too few emboli reach these organs. The distribution of metastases could 
be explained by the mechanism of the circulation with the resulting distribution of tumour 
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emboli. 
Basu et al. (1962) injected cell suspensions of a malignant tumour into the right 
common carotid artery in 256 rats. Forty per cent of the animals developed tumours in 
eye or orbit after three to five days. Metastases in the lungs were encountered in 95% and 
in the brain and meninges in 40%. In this connection an agglomeration of more than four 
cells was called a tumour. Unlike the situation in man, however, the rat eye receives its 
blood supply both via the external carotid artery (ocular muscles, orbit, long and short 
ciliary arteries) and via the internal carotid artery (retina, anastomoses with long ciliary 
arteries). Most metastases were encountered in the right orbit and eye. Of the intraocular 
tissues, the uvea was involved most frequently. Basu et al. in this study tested two 
hypotheses: first, the possibility that the implantation of tumour emboli at particular sites 
and their further development into metastases are determined by local biochemical factors 
(the soil theory); second, that the distribution of metastatic tumours depends 
predominantly on the circulation and consequently, on the number of tumour emboli that 
reach the organ in question and are arrested there (the mechanical theory). They preferred 
the latter, mechanical hypothesis: the intra- and extraocular tissues are fairly susceptible to 
metastases. For a metastasis to develop, a tumour embolus of two to four cells suffices. 
Most animals with ocular metastases also had metastases in the brain and meninges 
suggesting that anatomical factors play a part. 
Frank et al. (1987) also injected tumour-cell suspensions into the internal carotid 
artery of 15 rabbits, following which 87% of the animals developed ocular and 93%, 
cerebral metastases. The blood-eye and blood-brain barriers were passed after five to 
seven days. 
Albert et al. (1967b) in an animal experiment studied the fate of circulating tumour 
cells after injecting cells of transplantable tumours into the left ventricle of rabbits. In 20 
of the 33 fully grown animals (61%) metastases developed in 34 eyes. No relationship 
with the age of the animals was found. It was interesting to note that the metastases were 
largely restricted to the iris, ciliary body and anterior part of the choroid (81%) while 
only a small proportion (12%) was localized in the posterior part of the choroid (7% other 
intraocular structures). The development of metastases proved independent of the 
concentration of the cells arrested in the area in question: in 14 grown animals, 173 
arrested clusters of tumour cells and separate cells were encountered, viz. 77 in the 
anterior uvea and 91 in the medial and posterior uvea where, as mentioned, far fewer 
metastases developed (retina and optic nerve: 5). The authors concluded that in this 
experiment far more metastases developed than was known from clinical studies, possibly 
due to the direct injection of tumour cells into the arterial system. 
It is noteworthy that in animals most metastases develop in the anterior uvea (Basu 
et al., 1962; Barron et al., 1963). In humans, on the other hand, metastases are mostly 
encountered in the posterior choroid. Although most tumour emboli get stuck in the 
medial and posterior parts of the choroid, the study of Albert et al. (1967b) revealed only 
few metastases there: the distribution of metastases, therefore, does not completely follow 
the distribution of the tumour emboli. This is in contrast to the studies mentioned earlier. 
Factors concerned with metastases in the eye may be different from those elsewhere in the 
body. Differences in structure and function between the various regions may play a part in 
this connection. For instance, the secretion of aqueous humour might promote the 
development of metastases (Albert et al., 1967b). Jampol et al. (1973) also made 
observations supporting this hypothesis. 
In contrast to clinical studies, Albert et al. (1967b) observed as many metastases in 
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young animals as in fully grown rabbits: intraocular metastases, namely, developed in 12 
of the 16 young rabbits (75%); these were all bilateral and the distribution was the same 
as that in the grown animals. Compared with control (grown) animals, the metastases in 
the young rabbits developed after a significantly shorter interval and the intraocular 
metastases were also larger after an identical interval. 
In 33 animals (17 grown and 16 young ones) a complete autopsy was performed. 
This revealed intraocular metastases in 64% of the animals (21 animals), while 52% had 
metastases in the lungs, 52% in the kidneys, 48% in the liver, 42% in the adrenals, 30% 
in the brain, 12% in the skin, 9% in the mesentery and 3% in the digestive tract. In 
contrast to the other localizations, the eye was rarely found to hold more than three 
metastases. It was concluded that the incidence of metastases in the eye was similar to that 
of metastases in other organs (Albert et al., 1967b). 
From these various experimental studies in animals we may conclude that there are 
indications that both the soil theory and the mechanical theory may play a part in the 
pathogenesis of uveal metastases. After direct injection of malignant tumour cells into the 
bloodstream, most of the test animals developed uveal metastases, which were 
predominantly localized in the anterior part of the uvea. Frequently, pulmonary and 
cerebral metastases were then encountered as well. 
In humans of all ocular tissues the uvea is most frequently affected by metastases. 
However, metastases may also occur in other ocular structures (Table 1.2.2.1). 
Table 1.2.2.1 Localizalion of intraocular metastases 
Localization 
Uvea 
Orbit 
Optic nerve 
Retina 
Sclera 
Extraocular muscle 
Eyelid 
total % exceeds 100 because 
Bloch and 
Gartner, 
N 
22 
4 
6 
4 
3 
1 
-
1971 
% 
78 
14 
21 
14 
11 
4 
-
of multiplicity of sites 
Ferry 
Font, : 
N 
196 
48 
26 
-
-
-
-
and 
1974 
% 
86 
21 
11 
-
-
-
-
in individual eyes 
Hutchison and 
Smith, 
N 
73 
32 
3 
3 
-
-
3 
and patients 
1979 
% 
64 
28 
Castro et 
al., 1982 
Ν % 
80 63 
38 30 
5 4 
4 3 
1 1 
-
3 2 
In ophtha! mological practice metastases in the orbit are the second most frequent, after 
uveal metastases. It is difficult in these cases to determine precisely which tissues in the 
orbit have been infiltrated by malignant cells. In general the bone, the muscles and the 
orbital fat are involved. The ratio of these is approximately 2:2:1. However, the various 
primary tumours show different localizations of predilection. For instance, metastases of 
carcinoma of the prostate are usually localized in the bony orbit, metastases of breast 
cancer in the orbital fat and the muscles and metastases of cutaneous melanoma in the 
muscles (Goldberg et al., 1990). Metastases localized in the extraocular muscles of the 
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eye are гаге (Ashton and Morgan, 1974; Capone and Slamovits, 1990). The survival of 
patients with orbital metastases is usually better than that of patients with uveal metastases 
(Font and Ferry, 1976; Freedman and Folk, 1987). 
The oculomotor nerve, the trochlear nerve and the abducens nerve may be involved 
in a systemic malignancy in the form of meningeal carcinomatosis or a metastasis in the 
apex of the orbit (Bullock and Yanes, 1980). If a metastasis is localized in the optic nerve, 
it usually affects the parenchyma rather than the sheath of the optic nerve (Ginsberg et al., 
1970; Arnold étal., 1981). 
Metastases in the retina occur only rarely and are described virtually exclusively as 
case histories (Klein et al., 1977; Young et al., 1979; Letson and Davidorf, 1982; Leys et 
al., 1990). Metastases in the conjunctiva and sclera are also exceptional (Thiel, 1928; 
Eichholtz, 1971; Radnot, 1977; Daicker et al., 1988). Regarding metastases in the eyelid, 
there have been only sporadic publications (Seddik et al., 1968; Kindermann et al., 1981; 
Shields et al., 1988a). A few times, patients have been described with metastatic cells in 
the vitreous or the anterior chamber without presence of a distinct intraocular tumour 
(Char et al., 1980; Piro et al., 1982). 
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1.3 Epidemiology 
1.3.1 Frequency 
In the first half of this century, uveal metastases were regarded as extremely rare 
(Lagrange, 1901; Sattler, 1926; Casanovas, 1936; Asbury and Vail, 1940; Grecar, 1950; 
Mayer and Nassar, 1958). There were, however, a number of investigators according to 
whom these intraocular metastases occurred more often than reported up to then 
(Devereux Marshall, 1902; Van der Hoeve, 1927; DeLong, 1933; Ask, 1934; Adda, 
1937; Lopes d'Andrade, 1949). 
By the time several hundreds of case reports of patients with intraocular metastases 
had been published, as well as a number of review articles on this subject, it became clear 
that the frequency of uveal metastases was higher than had so far been assumed in the 
literature (Dickson, 1958; Gerhard et al., 1975; François et al., 1976). 
Table 1.3.1.1 presents a survey of a number of publications in which the total 
number of uveal metastases with the preceding primary tumour is stated up to the moment 
of publication of the article in question. 
This table first of all shows that the data in the various articles are incomplete and 
that the authors disagree regarding the condition or the primary tumour. For instance, 
according to Bietti (1938) reports of 28 uveal metastases of pulmonary tumours had been 
published, while Streiff (1949) 11 years later referred to only 18 cases. In addition, it is 
noticeable that the proportion of breast cancer decreased from about 80% in the last 
century to 64% according to the study of Schiffer et al. in 1978. The more patients with 
uveal metastases were described, the more cases were published of patients with 
metastases of primary tumours reported only sporadically or not at all. 
The increased frequency of uveal metastases diagnosed is probably partly due to 
the improvement of the prognosis of patients with a malignancy resulting from, for 
instance, chemotherapy (Alberti and Halama, 1987). The improved recognition of the 
ocular lesion over the years is also of great importance (Brink et al., 1988). Dickson 
(1958) named improved follow-up of oncological patients and closer cooperation between 
the various specialists as additional causes of the more frequent diagnosis of uveal 
metastases. 
It is assumed that 2 to 9% of all intraocular tumours are metastases (Wilder, 1946; 
Spaeth, 1951; Bellone and Cagigrigoriu, 1969; Famarier et al., 1972). Primary 
melanomas of the uvea are encountered more frequently (Hart, 1962; Offret and Haye, 
1971; Aasved and Seim, 1973; Ferry, 1973; Ferry and Font, 1974). In Table 1.3.1.2 the 
numbers of uveal metastases are compared with the numbers of primary malignant 
melanomas of the uvea as reported by several authors. 
The table shows that uveal melanomas occur more often than uveal metastases. In 
clinical studies the proportion of metastases in relation to melanomas is far larger than that 
found at histopathological examination. It should be noted in this connection that the 
histopathological patient material had been largely obtained by enucleation of eyes 
suspected of a malignant uveal melanoma. This obviously influenced the ratio of 
metastases versus melanomas. Although, therefore, melanomas are diagnosed more often 
than metastases of the uvea, various investigators point out that actually, metastases are 
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Tabel 1.3.1.1 Survey of publications on uveal metastases according to the total numbers of patients and the primary tumour 
Total Breast Lung Genital Skin Gastro- Miscel- Unknown 
intestinal laneous 
Author 
Perls, 1872 
Schultze, 1890 
Elschnig, 1891 
Schultœ, 1893 
Lagrange, 1901 
Krukenberg, 1903 
Usher, 1923 
Ask, 1934 
Lemoine and McLeod, 
Bietti, 1938 
Streiff, 1949 
Hollwich and Lemke, 
Seddiketal., 1968 
Schiffer et al., 1978 
, 1936 
1965 
Ν 
1 
5 
8 
16 
25 
37 
90 
211 
231 
267 
300 
530 
752 
745 
Ν 
-
4 
6 
13 
19 
27 
65 
123 
135 
157 
218 
336 
494 
477 
% 
-
80 
75 
81 
76 
75 
72 
67 
67 
66 
73 
63 
67 
64 
Ν 
1 
1 
1 
2 
3 
4 
10 
20 
24 
28 
18 
87 
109 
117 
* 
100 
20 
13 
13 
12 
Π 
11 
И 
12 
12 
6 
16 
15 
16 
Ν 
-
-
-
-
-
-
2 
9 
10 
14 
16 
36 
42 
46 
% 
-
-
-
-
-
-
2 
5 
5 
6 
5 
7 
6 
6 
Ν 
-
-
-
-
1 
-
-
4 
4 
4 
4 
10 
4 
•22 
% 
-
-
-
-
4 
-
-
2 
2 
2 
1 
2 
1 
* 3 
Ν 
-
-
1 
1 
1 
3 
6 
15 
16 
19 
24 
30 
41 
44 
% 
-
-
13 
6 
4 
8 
7 
8 
8 
8 
8 
6 
6 
6 
Ν 
-
-
-
-
1 
2 
7 
12 
14 
17 
20 
31 
43 
39 
* 
-
-
-
-
4 
6 
8 
7 
7 
7 
7 
6 
6 
5 
Ν 
1 
-
28 
28 
28 
-
-
19 
-
% 
* shn and bone 
the most frequent intraocular tumours (Bloch and Gartner, 1971; Ferry, 1973; Ferry and 
Font, 1974; Daicker, 1981; Abramson, 1984). 
Table 1.3.1.2 Frequencies of occurrence of uveal metastases and uveal melanomas 
Uveal metastases Uveal melanomas 
Author N % N % 
Clinically: 
Albert et al., 1967 
Godtfredsen, 1944 
Bnnket al., 1988 
Histopathologically: 
Wilder, 1946 
Heath, 1964 
Ferry en Font, 1974 
Hart, 1962 
Jensen, 1970 
Lommatzsch et al., 1985 
*« 24 
* 6 
* 47 
2 
** 6 
196 
133 
18 
*** з 
28 
25-33 
14 
6 
5 
4.2 
3.2 
1.9 
0.1 
61 
-
-
30 
113 
4500 
4000 
942 
2678 
72 
67-75 
86 
94 
95 
95.8 
96.8 
98.1 
99.9 
* choroid; ** iris; ** intraocular, probably all uveal; 
# according lo Ferry (1967) 24 of the 45 metastases localized in the uvea 
Jensen (1970) reported 18 uveal metastases among 4.3 million inhabitants of 
Denmark over the period 1944-1968: an incidence of 1.7 per 100.000 inhabitants per 
year. François et al. (1976) mentioned a similar incidence, of 2 per 100.000. 
However, according to Nelson et al. (1983) in the United States at least 16.000 
patients who die from a malignancy per year develop intraocular metastases. Breast cancer 
by itself would already account for 10.000 intraocular metastases annually (Abramson, 
1984). Bence (1985) calculated that theoretically ocular and orbital metastases might occur 
in 21.000 to 45.000 patients per year, as against the far smaller number of 1500 to 2000 
uveal melanomas. This would put the incidence figures for uveal metastases between 5 
and 15 per 100.000 inhabitants per year. 
The incidence of malignant uveal melanomas is in the range of 0.4 to 0.9 per 
100.000 inhabitants (Lommatzsch et al., 1985; Egan et al., 1988; Mahoney et al., 1990). 
Establishing the frequency of uveal metastases and comparing it with the frequency 
of other intraocular tumours is very difficult for a number of reasons: 
- The various publications refer to patients from either clinical or histopathological 
populations. The histopathological patient group is characterized by a relatively 
large number of patients with suspicion of a malignant melanoma. Consequently, 
these different patient populations should not be compared with one another just 
like that. 
- The data originate from far-apart years with altered interest in particular diseases 
and with new diagnostic possibilities. 
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- A major problem in establishing the frequency of uveal metastases is due to the 
fact that these tumours do not necessarily cause symptoms, especially when they 
are localized outside the macular area. In that case they might frequently remain 
unnoticed (Aasved and Seim, 1973; François et al., 1976). 
- If the patient's visual acuity is poor due to amblyopia or opaque media, this may 
cause the metastases to escape notice (Thompson et al., 1961). 
- Intraocular metastases occur particularly often in oncological patients in a terminal 
phase (Gillet, 1971). The patient's bad general condition may then render him 
unable to mention any symptoms, or systematical ophthalmological examination 
may no longer be consider«! feasible (Greear, 1950; Hart, 1962; Gillet, 1971; 
Aasved and Seim, 1973; François et al., 1976; Daicker, 1981; Castro et al., 1982; 
Letson et al., 1982; Вепсе, 1985; Amé and Mathis, 1986). Another possibility is 
that the physician in charge underestimates the severity of the possible visual 
symptoms or blames them on the many drugs administered (Thompson et al., 
1961; Viegas Mendonça and Ferraz de Oliveira, 1968; Daicker, 1981; Letson et 
al., 1982). In addition, the physician in charge frequently is not an ophthalmologist 
but a surgeon or internist (Thompson, 1961; François et al., 1976; Reese, 1976). 
- There may be a long interval between the detection of the primary tumour and the 
onset of the intraocular lesion. The uveal metastases may then not be recognized as 
such and the tumour in the eye may not be connected with an earlier malignancy 
(Viegas Mendonça and Ferraz de Oliveira, 1968). 
- Post-mortem examination of a patient with a neoplasm as a rule does not include 
histopathological examination of the eye (Hogan and Zimmerman, 1962; Viegas 
Mendonça and Ferraz de Oliveira, 1968; Aasved and Seim, 1973; François et al., 
1976; Castro et al., 1982). If performed at all, the examination as a rule is 
restricted to the posterior segment of the eye (Reese, 1976). Also, unlike eyes with 
uveal melanomas, eyes with metastases are rarely enucleated, so that no 
pathological examination is performed. As mentioned before, this fact naturally is 
extremely relevant to the patient populations of pathological institutes (Bence, 
1985). 
Table 1.3.1.3 summarizes the data from the literature on the frequency of uveal 
metastases in a patient population with known malignancies. Clinically uveal metastases 
were observed in 0.07 to 2.3% of the patients, and at pathological examination in 0.5 to 
11%. 
Table 1.3.1.4 lists the frequencies of intraocular metastases according to the nature 
of the primary tumours. The data of Godtfredsen (1944) originate from a radiotherapeutic 
institute and represent proportions of all patients known with malignancies. However, 
these patients were not examined systematically, in contrast to the study of Albert et al. 
(1967), in which patients with a malignancy were examined with the specific purpose of 
finding choroidal metastases. 
If the eyes of patients with known malignancies were examined histopathologically, 
metastases were found much more frequently than at clinical examination. According to 
Nelson et al. (1983), 90% of the metastases demonstrated histopathologically are not 
noticed clinically. 
The data in Table 1.3.1.4 show that breast cancer relatively frequently causes 
intraocular metastases. Table 1.3.1.5 presents a survey of the frequency of intraocular 
metastases in patients with breast cancer. 
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Table 1.3.1.3 Frequency of uveal metastases in a patient population with known 
malignancies 
Uveal metastases 
N % Author 
Clinically: 
Number of patients 
with malignancy 
Gailloud, 1975 
Godtfredsen, 1944 
Thompson et al., 1961 
Albertet al., 1967 
Hisiopathologically: 
Guthert et al., 1965 
Kunze and Wurgatsch, 1972 oo 
Nelson et al., 1983 
Bloch and Gartner, 1971 
Timm, 1967 
1500 
8712 
11000 
It 213 
1000 
# 594 
569 
#336 
## 530 
### 376 
230 
80 
** 
* 
* 
* 
* 
* 
* 
* 
1 
6 
11 
5 
5 
5 
8 
8 
15 
15 
22 
9 
0.07 
0.07 
0.1 
2.3 
0.5 
0.8 
1.4 
2.4 
2.8 
4.0 
9.6 
И 
* choroid; ** probably choroid; # patients with disseminated malignancies; tilt malignancy at moment of 
death; tititt died of malignancy; oo all malignancies except bone marrow, lymph nodes and thymus 
Table 1.3.1.5 Frequency of intraocular metastases in patients with breast cancer 
Total number of patients 
with breast cancer 
Author 
Intraocular 
metastases 
Clinically: 
Godtfredsen, 1944 
Thompson et al., 1961 
Thatcher and Thomas, 1975 
Hemmes, 1969 
Schinz, 1939 
Röttingeret al., 1976 
Vanni and Barilla, 1960 
Albertet al., 1967 
Mewis en Young, 1982 
Hisiopathologically: 
Kunze and Wurgatsch, 1972 
Nelson et al., 1983 
Bloch and Gartner, 1971 
1287 
3300 
10592 
*/** 
536 
* 
219 
52 
250 
35 
31 
52 
choroid 
choroid 
choroid 
uvea 
choroid 
choroid 
choroid 
choroid 
choroid 
uvea 
choroid 
eye/orbit 
2 
11 
42 
92 
3 
26 
5 
4 
67 
2 
3 
19 
0.2 
0.3 
0.4 
0.5 
0.6 
2 
2.3 
8 
27 
6 
10 
37 
* total number of patients not mentioned; ** number of deceased patients with breast cancer 
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Tabel 1.3.1.4 
Author 
Clinically: 
Godtfredsen, 1944 
Albert et al., 1967 * 
Frequencies of intraocular metastases according to 
Histopathologically: 
Kunze en Wurgatsch, 1972 *• 
Nelson et al., 1983 *** 
Timm, 1967 
Bloch and Gartner, 1971 
Localization 
choroid 
choroid 
uvea 
choroid 
uvea 
eye/orbit 
Total 
N 
6/8712 
5/213 
8/569 
15/376 
9/80 
28/230 
1 
% 
0,1 
2,3 
1,4 
4,0 
11 
12 
the nature of the primary tumours 
Number of intraocular metastases / number of ] 
Breast 
N 
2/1287 
4/52 
2/35 
3/31 
3/8 
19/51 
% 
0,2 
8 
6 
10 
38 
37 
Lung 
N 
2/156 
1/50 
5/131 
6/89 
2/29 
3/53 
% 
1,3 
2 
4 
7 
7 
6 
Genital 
N 
1/71 
0/8 
0/98 
0/19 
1/14 
3/19 
% 
1,4 
0 
0 
0 
7 
16 
pnmary tumours 
Skin 
N 
-/-
-/-
0/10 
2/25 
-/-
-/-
% 
-
0 
8 
-
-
Gastro-
mtestinal 
N 
-/-
0/30 
1/179 
3/38 
1/17 
1/47 
% 
0 
1 
8 
6 
2 
Miscel-
laneous 
N % 
0/7198 0 
0/73 0 
0/116 0 
1/174 1 
2/12 17 
2/59 3 
* with widespread dissemination; ** excluding localizations in bone marrow, lymph nodes and thymus; *** patients died of maltgnacy 
Godtfredsen (1944), Thompson et al. (1961), Thatcher and Thomas (1975) and Röttinger 
et al. (1976) compared the numbers of known choroidal metastases with all patients with 
breast cancer diagnosed in the same period in the clinics in question. Most of these 
patients with breast cancer had not been subjected to ocular examination. According to 
Thatcher and Thomas (1975) probably not all patients with choroidal metastases were 
recorded so that the actual proportions of patients with metastases will have been larger. 
Albert et al. (1967) and Mewis and Young (1982) in patients with known breast 
cancer searched specifically for choroidal metastases, and their percentages consequently 
are substantially larger than those of the other investigators. Albert et al. (1967) examined 
patients with an already metastasized carcinoma. 
Of the 250 patients examined by Mewis and Young (1982), 98 had no visual 
complaints. Nevertheless, choroidal metastases were diagnosed in nine patients (9%). Of 
the 152 patients with visual complaints, 58 were found to have choroidal metastases, a 
proportion of 38%! 
1.3.2 Primary tumours 
Table 1.3.2.1 surveys, as completely as possible, the various primary tumours reported to 
have caused uveal metastases. For the references, a selection has been made from the 
various case reports and survey articles published on uveal metastases. Mostly, articles 
from authoritative periodicals and publications of recent data were used. 
In establishing the frequency of uveal metastases (see Chapter 1.3.1), it proved 
difficult to compare data from different studies, and the same is true of the literature on 
the nature and localization of the primary tumours. The data relate to periods at long 
intervals, during which changes took place in frequencies of various malignancies and in 
diagnostic techniques, and they concern clinical studies as well as records of pathological 
institutes. Moreover, many publications refer to 'intraocular' metastases, without clearly 
stating the exact localization, or to 'choroidal' metastases, thereby excluding metastases in 
the iris and the ciliary body. 
Tables 1.3.2.2 and 1.3.2.3 survey the primary tumours mentioned in a number of 
original articles from various institutes. Table 1.3.2.2 lists the absolute numbers of 
patients, Table 1.3.2.3 the percentages. A distinction is made between clinical and 
histopathological patient material. 
A number of authors have further subdivided gastrointestinal and genital tumours. 
In such cases, the metastases originating from, for instance, the various genital tumours 
are added up and mentioned in parentheses in the column 'genital'. If in such a column 
numbers of patients are listed without parentheses, the author(s) made no subdivision of 
the various localizations. 
Table 1.3.2.3 shows that the percentages of choroidal and uveal metastases in 
clinical studies match very well. The data from histopathological institutes are divergent. 
They refer to a smaller number of patients from only three institutes. 
37 
Table 1.3.2.1 Survey of malignant tumours reported to have caused uveal 
metastases 
Breast cancer 
female 
male 
Thatcher and Thomas, 1975; Letson et al., 1982; Mewis and Young, 1982 
Lakhanpal et al., 1982; Reynard and Font, 1983; Schlaen and Naves, 1986 
Bronchial cancer 
epithelial carcinoma Wnght and Meger, 1962; Witsche! et al., 1975 
small cell carcinoma (oat cell)Ferry and Font, 1975; Shields, 1983 
adenocarcinoma Walker, 1974 
large cell carcinoma Buys et al., 1982 
carcinoid Bell et al., 1975; Riddle et al., 1982; Balestrazzi et al., 1989 
Gastrointestinal tract 
oesophagus 
stomach 
pancreas 
liver 
ileum carcinoid 
caecum 
colon 
sigmoid 
rectum 
Mullaney, 1970; Mooy et al., 1990 
Rootman and Butler, 1982; Takahashi et al., 1984; Karnad et al., 1986 
Stephens and Shields, 1979; Char and Chnstensen, 1980 
Taake et al., 1963; Yeatts et al., 1982 
Riddle et al., 1982 
Shields, 1983 
Schneider and Bosshard, 1978; Nelson et al., 1983 
Carr et al., 1986 
Ferry, 1973; Cole and Farah, 1985 
Unnary tract 
kidney 
ureter 
bladder 
Voight and Pulhom, 1977; Kindermann et al., 1981; Pau, 1981 
Pe'er and Zimmerman, 1984 
Gordon and Munro, 1974; Resmck et al., 1975; Cieplinski et al., 1982 
Genital tract 
female 
ovary 
uterus 
cervix uten 
vagina 
male 
testis 
seminoma 
embryonal cell 
carcinoma 
teratoma/ 
chonocarcinoma 
epididymis 
prostate 
Seddik et al., 1968; Frank et al., 1979 
Keates and Billig, 1970; Haye and Calle, 1972; Pau, 1979; Planten, 1981 
Kurosawa and Sawaguchi, 1987; Saßmannshausen et al., 1990 
Streiff, 1949 
Hemmes, 1969; Freyler and Egerer, 1977 
Ferry, 1973; Lodato et al., 1983 
Chitwood, 1953; Graether, 1963; Meythaler and Herold, 1979 
Sautter, 1948 
Dieckert and Berger, 1982; Freedman and Folk, 1987; Dobrowsky, 1988 
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to be continued on next page 
Table 1.3.2.1 (continued) 
Nervous system 
neuroblastoma 
adrenal gland 
olfactory nerve 
Hutchison and Smith, 1979; Amé et al., 1983 
Guthert et al., 1965; Alio et al., 1982; Bowns et al., 1983 
Davis and Robertson, 1973; Daicker, 1981 
Bone 
osteosarcoma 
Ewmg sarcoma 
Spaulding and Woodfin, 1968; Jampol et al., 1973; Rossano, 1973 
Jampol et al., 1973 
Skin 
eyelid 
malignant melanoma 
basocellular 
carcinoma 
lip 
cheek (buccal) 
malignant melanoma 
Merkel cell carcinoma 
Adamuk, 1909 
Oksala, 1962 
Goodsitt, 1945; Cury, 1958; Hart, 1962 
Godtfredsen, 1944 
Fishman et al., 1976; Lommatzsch and Tost, 1979; de Bustros et al., 1985; 
Oosterhuis et al., 1987; Eide and Syrdalen, 1990 
Alexander et al., 1989; Small et al., 1990 
Eye 
malignant uveal melanoma 
malignant conjunctival 
melanoma 
retinoblastoma 
Shields et al., 1988 
Andersen, 1947 
Howard, 1962 
Miscellaneous 
atrial myxoma 
larynx carcinoma 
vocal chord 
soft tissue sarcoma 
thyroid 
mediastinum 
thymoma 
adrenal gland 
salivary gland 
parotid gland 
submaxillary gland 
submandibular gland 
Stoweet al., 1979 
Bessieres et al., 1956 
Timm, 1967 
Roolman et al., 1979; Pak et al., 1987 
Gysin and Gloor, 1979; Offret et al., 1979; Daicker, 1981 
Lahav et al., 1978; Tarkkanen et al., 1979 
Tsuboi, 1934 
François et al., 1952 
Lommatzsch, 1989; Saßmannshausen et al. 
Gutman et al., 1986 
Jenrette and Fitzgerald, 1982 
1990 
Unknown 
Miscellaneous 
Carcinoid 
Neuroblastoma 
Skin 
Kidney 
Uterus 
Ovary 
Testis 
Prostate 
Genital tract 
Rectum 
Colon 
Stomach 
Gastrointestinal 
Pancreas 
Thyroid 
Parotid gland 
Lung 
Breast 
Total 
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Table 1.3.2 4 presents a survey of the vanous groups of primary tumours that had 
led to uveal metastases. Here, again, a distinction is made between clinical and 
histopathological studies. 
Clinically * 
N = 530 
% 
72 
12 
3 
2 
2 
4 
5 
Histopathologically ** 
N = 265 
% 
44 
33 
4 
1 
2 
4 
12 
Table 1.3.2.4 Frequency of uveal metastases " according to primary tumours 
Localization primary tumour 
Breast 
Lung 
Genital tract 
Skin 
Gastrointestinal tract 
Miscellaneous 
Unknown origin 
* Van der Hoeve, 1927, Hemmes, 1969, Haye and Calle, 1972, Meythaler and Herold, 1979, Stephens and 
Shields, 1979, Freedman and Folk, 1987, Brink et al , 1988, Saßmannshausen et al , 1990, 
** Jensen, 1970, Ferry and Font, 1974, Castro et al , 1982 
# including publications concerning choroidal metastases only 
It appears that both clinically and histopathologically, breast cancer is the primary tumour 
most frequently diagnosed, followed by lung cancer. There is, however, a sinking 
difference between the percentages of frequency, clinically, 72% of the primary tumours 
are breast cancer as against 44% in the histopathological study group. Lung tumours are 
regarded as primary tumours on clinical grounds in 12% of the patients with uveal 
metastases, as against 33% of the patients from institutes of pathology. 
In the histopathological patient group a higher proportion of unknown primary 
tumours occurs than in the clinical patient group. However, in the patient population of 
histopathological studies many patients are included in whom the eye was enucleated on 
the diagnosis of 'malignant melanoma' and mostly no malignancy elsewhere in the body 
was known. 
In Table 1.3.2.5 the primary tumours are classified according to sex In females, 
88% of the uveal metastases originated from breast cancer clinically and 77% 
histopathologically, while 5% and 13%, respectively, originated from lung cancer. In 
males, lung tumours were clinically regarded as the cause of uveal metastases in 42% and 
histopathologically in 52%, while metastases from other localizations also occurred more 
frequently. 
It is hard to give an unambiguous and satisfactory explanation of the major 
differences between the frequencies of different malignant tumours and the frequencies of 
metastasization of these malignancies to the eye. The very high percentage of intraocular 
metastases of breast cancer is sinking in this respect 
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First of all the frequencies of the various primary tumours themselves should be 
compared (Jensen, 1970). In adults, cancer of breast and lung occur frequently, which 
greatly influences their share in choroidal metastases (Jampol et al., 1973). 
Table 1.3.2.5 Frequency of uveal metastases according to the localization of the 
primary tumour and to sex 
Localization primary tumour 
Breast 
Lung 
Genital tract 
Skin 
Gastrointestinal tract 
Miscellaneous 
Unknown origin 
* Hemmes, 1969; Stephens and Shields, 1979; ** Jensen, 1970; Ferry and Font, 1974 
Table 1.3.2.6 compares the percentages of incidence of different groups of malignancies 
in the United States with the percentual distribution of uveal metastases over the various 
primary tumours. It should be noted that the frequencies of the different malignancies 
have fluctuated over the years. For instance, in the period 1930-1985, the mortality of 
males due to lung cancer has risen by approximately a factor 15, while that of gastric 
cancer decreased by a factor 5. In women, mortality due to uterine and gastric cancer 
decreased and that due to lung cancer increased (Silverberg et al., 1990). 
Сіішсаііу 
Male 
Ν = 36 
3 
42 
6 
11 
3 
17 
19 
% 
Φ 
Female 
Ν = 155 
88 
5 
2 
1 
1 
0 
3 
Histopathologically 
Male 
Ν = 101 
0 
52 
10 
2 
3 
10 
23 
% 
* Φ 
Female 
Ν = ИЗ 
77 
13 
0 
1 
2 
0 
7 
Table 1.3.2.6 Incidence of various groups of malignancies in the United States and 
the distribution of uveal metastases over these various primary 
tumours in terms of percentage 
Localization primary tumour 
Primary tumour * 
total male female 
Uveal metastases 
total male female 
** »** *** 
Breast 
Lung 
Genital tract 
Skin 
Gastrointestinal tract 
Miscellaneous 
16 % 
16 
19 
3 
25 
21 
0 % 
21 
24 
3 
26 
26 
31 % 
11 
15 
3 
24 
16 
76 % 
13 
3 
2 
2 
4 
4 % 
51 
7 
13 
4 
21 
91 
5 
2 
1 
1 
0 
* Silverberg et ai, 1990; ** frequency of occurrence of clinical uveal metastases (after Table 1.3.2.4); 
*** frequency of occurrence of uveal metastases in the sexes (after Table 1.3.2.5) 
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As table 1.3.2.6 shows, breast cancer accounts for 16% of all newly detected 
malignant tumours but is responsible for 76% of the uveal metastases. Other authors also 
state that only 10 to 16% of all cancers in the human body are breast cancer, while 45 to 
80% of all intraocular metastases originate from this tumour (Hollwich and Lemke, 1965; 
Ferry, 1967; Hemmes, 1969; Schiffer et al., 1978). 
Lung cancer accounts for 16% of all primary tumours and for 13% of the uveal 
metastases. Hemmes (1969) gives these proportions as 20% and 11%, respectively. In 
males, 21% of cancers are lung cancer, but this tumour generates 51% of the uveal 
metastases (Table 1.3.2.6). Schiffer et al. (1978) described 22 and 47%, respectively. 
Noticeable is the low proportion (4%) of uveal metastases of tumours of the 
digestive tract, which account for 20% of all primary malignancies (Ferry, 1967). 
According to Schiffer et al. (1978), as many as 15% of the uveal metastases in males 
derive from gastrointestinal tumours while of all malignancies in males, 48% are localized 
in the digestive tract. 
From incidence figures of malignant tumours the distribution of the nature of the 
primary tumours in patients with uveal metastases can only partially be explained. Most 
noticeably, the frequently occurring gastrointestinal and genital tumours rarely metastasize 
to the uvea. 
Ask (1934) believed that the high frequency of breast cancer was caused by the 
already high frequency of this tumour, and its strong tendency to metastasize. Apart from 
the incidence, metastatic characteristics of a tumour are also important (Jensen, 1970). 
Breast cancer tends to haematogenous metastasization and issues a large number of 
malignant cells into the circulation (Lemoine and McLeod, 1936). Although in most 
carcinoma patients some tumour cells will enter the bloodstream, they are only rarely 
viable and, if implantation occurs at all, growth follows only sporadically (Stanford and 
Reese, 1971). Various types of cancer cells differ greatly in their possibilities to remain 
viable distant from the primary tumour. It is known in this connection that the cells of 
breast cancer are very hardy and may survive and even multiply in circumstances 
unfavourable to other types of cancer cells. The large proportion of breast cancer among 
uveal metastases may be attributable to this property (Mullen et al., 1954; Reese, 1976). 
Lemoine and McLeod (1936) postulated that breast cancer cells may have a specific 
affinity for uveal tissue, and particularly for the choroid. 
Furthermore, metastatic cells from breast cancer have only to pass the lung filter to 
cause disseminations in the eye, whereas other tumours, such as gastrointestinal tumours, 
in general first have to pass the liver as well. This might be another reason why breast 
cancer relatively often causes uveal metastases (Schinz, 1939; Gillet, 1971; Schiffer et al., 
1978). Another factor is the anatomically relatively short way from the breast to the eye 
(Schiffer et al., 1978). 
The survival of patients with particular malignant tumours also plays a part 
(Schinz, 1949). The relatively long survival of patients with breast cancer renders distant 
metastases possible (Streiff, 1959; Hollwich and Lemke, 1965; Schiffer et al., 1978). 
Table 1.3.2.7 presents a survey of the survival of patients with various primary 
malignancies. 
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Table 1.3.2.7 Five-year survival of white patients with various primary 
malignancies in the United States in terms of percentage * 
Malignancy 
All malignancies ' 
Breast cancer *** 
Lung cancer 
Stomach cancer 
Colonic cancer 
Rectum cancer 
Prostalic cancer 
Μι 
Cutaneous melanoma 
* Silverberg et al., , ^ 9 0 ; 
1960-1963 
39 
63 
8 
И 
43 
38 
50 
60 
** leukaemia and 
1970-1973 
lymphi 
43 
68 
10 
13 
49 
45 
63 
68 
ama included; 
Period 
1974-1976 
50 
75 
12 
14 
50 
48 
67 
79 
*** females 
1977-1979 
50 
75 
13 
16 
52 
50 
71 
81 
1980-1985 
51 
76 
13 
16 
55 
53 
73 
81 
Patients with breast cancer have a distinctly longer survival than patients with pulmonary 
and gastric malignancies. However, carcinomas of the colon, rectum and prostate and 
malignant cutaneous melanomas also have a relatively long 5-year survival rate, while of 
these tumours, only few intraocular metastases have been reported. 
Therefore, no adequate explanation exists of the differences in frequency of the 
various primary tumours in uveal metastases. 
The interval between the onset of the primary tumour and the intraocular 
metastases varies between detection of the metastasis at the same time as the primary 
lesion and a diagnosis of the metastases only many years later. On average the interval is 
41 to 43 months (Table 1.3.2.8). The interval between breast cancer and the intraocular 
metastases (average 24 to 72 months) is much longer than that in lung tumour cases 
(average interval 1 to 11 months). 
Intraocular metastases from breast cancer are rarely detected within one year after 
the diagnosis of the primary tumour, whereas metastases of lung tumours mostly occur 
within that same period (Jensen, 1970; Aasved and Seim, 1973). The first four years after 
the diagnosis of breast cancer some 80% of the uveal metastases are diagnosed, distributed 
evenly over these years. Thereafter they are rare (Hemmes, 1969). 
Reportedly it is only metastases of breast cancer that may be discovered longer 
than 10 years after the primary tumour (Ferry, 1973). 
Uveal metastases may also develop before a malignancy elsewhere in the body is 
known. This is allegedly the case in 10 to 46% of the uveal metastases (Table 1.3.2.9). 
On average, the primary tumour is then detected after 4 months (0.5 to 30 months) 
(Ferry, 1973). In the literature up to 10% of patients with breast cancer are described in 
whom uveal metastases were detected before occurrence of the primary tumour. 
In patients with lung cancer the primary tumours are mostly diagnosed only after 
uveal metastases have been encountered. In 65 to 90% of the cases the metastases are the 
first sign of a malignancy. 
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Gastrointestinal tumours (Stephens and Shields, 1979; Abramson, 1984; Amé and 
Mathis, 1986) and renal carcinomas (Ferry and Font, 1974) also very frequently cause 
metastases before the primary tumour is known. 
Table 1.3.2.8 Interval between onset of the pnmary tumour and detection of the 
uveal metastasis 
Interval between onset of the 
pnmary malignancy and uveal 
metastasis (months) 
Author Mean Range 
All malignancies: 
Bnnk et al., 1988 
Schiffer et al., 1978 
Stephens and Shields, 1979 
41 
42 
43 
0-156 
Breast cancer: 
Röttingeret al., 1976 
Stolzenbach and von Domarus, 1978 
Thatcher and Thomas 
Meythaler and Herold, 1979 
Hemmes, 1969 
Thompson et al., 1961 
Mewis and Young, 1982 
Ferry and Font, 1974 
Memam, 1961 
Hart, 1962 
Hollwich and Lemke, 1965 
Stephens and Shields, 1979 
Bnnk et al., 1988 
Chu et al., 1977 
Saßmannshausen et al., 1990 
Hutchison and Smith / Castro et al., 1982 
Letson et al., 1982 
24 
24 
26 
30 
33 
36 
36 
39 
42 
42 
42 
46 
46 
48 
53 
61 
72 
0-192 
6-72 
0-114 
-
0-109 
6-89 
6-171 
0-300 
1-120 
-
-
8-240 
-
3-240 
-
0-192 
12-192 
Lung cancer: 
Bnnk et al., 1988 
Saßmannshausen et al., 1990 
Stephens and Shields, 1979 
Ferry and Font, 1974 
1 
2 
6 
11 
-
-
2-15 
0-72 
* median 
Table 1.3.2.9 Uveal metastases diagnosed before or after the primary tumour in 
terms of percentage 
Author 
Diagnosis uveal metastasis 
before after 
primary tumour 
% % 
All malignancies: 
Wilder, 1946 
Meythaler and Herold, 1979 
Saßmannshausen et al., 1990 
Stephens and Shields, 1979 
Ferry and Font, 1974 
10 
10 
11 
31 
46 
90 
90 
89 
69 
** 54 
Breast cancer: 
Meythaler and Herold, 1979 
Ferry and Font, 1974 
Stephens and Shields, 1979 
Abramson, 1984 
0 
9 
9 
10 
100 
• 91 
91 
90 
Lung cancer: 
Ferry and Font, 1974 
Stephens and Shields, 1979 
Abramson, 1984 
65 
70 
90 
*tm 24 
30 
10 
* metastases in eye and/or orbit. It 3 1% at the same moment as the primary tumour, 0.4% unknown; 
## 11 % at the same moment as the primary tumour 
1.3.3 Connection with metastases elsewhere in the body 
A number of authors state that uveal metastases occur more often and possibly exclusively 
in patients with a tumour that has already spread extensively (Adda, 1937; Papolczy, 
1936; Guthert et al., 1965; Kunze and Wurgatsch, 1972; Meur et al., 1974; Nelson et al., 
1983). These patients mostly have reached a terminal stage of their disease (Hart, 1962; 
Gillet, 1971; Daicker, 1981). 
According to Saßmannshausen et al. (1990), 60% of the patients with choroidal 
metastases already have metastases elsewhere in the body; according to Timm (1967), this 
proportion is 82%. Hart (1962) stated that in 12 of the 55 patients with ocular metastases 
no metastases elsewhere in the body were known at the time of the enucleation of the 
affected eye. However, this refers to a histopathological examination of eyes mostly 
enucleated under the false diagnosis of a malignant uveal melanoma. Probably no distant 
metastases were known. 
According to Bullock and Yanes (1980), the interval between the primary tumour 
and metastases not localized in the eye is 49 months on average (varying from 0 to 16 
years), while the interval between the primary tumour and choroidal metastases on 
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average is 72 months (12 months to 16 years) 
Mewis and Young (1982) described nine choroidal metastases in 98 patients with 
breast cancer who had no visual complaints. These nine patients were already known with 
extensive spread of the tumour. In 152 patients who did have visual complaints, 58 
choroidal metastases were established; the ocular metastases occurred at all stages of the 
primary tumour. According to Letson and Davidorf (1982), in 20% of the patients with a 
choroidal metastasis from breast cancer the ocular metastasis was the first sign of systemic 
metastasization, while in 27% of the patients choroidal metastases were discovered at the 
same time as metastases elsewhere in the body Chu et al. (1977) also reported that 20% 
of the choroidal metastases preceded systemic metastases. 
Reportedly, in nearly all cases lung metastases had preceded intraocular 
metastases, thus enabling subsequent spread of tumour cells to the eye (Ask, 1934; Ferry, 
1967; Gillet, 1971, François et al., 1976). Nevertheless, in 15 to 17% of the patients with 
ocular metastases no lung metastases were observed (Lemoine and McLeod, 1936; Ferry, 
1967) Small intraocular metastases can be seen clinically before lung metastases are large 
enough to be visualized radiologically (Mewis and Young, 1982) At autopsy, it is 
possible for small metastases in the lungs to be overlooked (Lemoine and McLeod, 1936; 
Ferry, 1967; Gillet, 1971; Castro et al., 1982). 
Lemoine and McLeod (1936) suggest that tumour cells might pass through the 
lungs without being arrested there. Another possibility is that tumour cells bypass the 
pulmonary circulation and reach the eye via Batson's plexus and the vertebral system (see 
Chapter 1 2) (Ferry, 1967, Gillet, 1971; Castro et al , 1982). 
Mewis and Young (1982) believed that local tissue factors may inhibit the growth 
of metastatic foci. They describe 67 patients with choroidal metastases of breast cancer. In 
40 patients (60%), metastases were observed in the pulmonary parenchyma or the pleura. 
These metastases were diagnosed before choroidal metastases in 27 cases, at the same 
time as the ocular metastases in seven cases and later on, in six cases. If the lung 
metastases were detected before the metastases in the choroid, the interval ranged from 1 
to 39 months (median 13 months). In patients with breast cancer, lung metastases in 
general occur in a proportion of 69% (Haagensen, 1971) 
Since the eye and the brain have the same blood supply, it is assumed that if 
intraocular metastases are encountered, there will be haematogenous cerebral metastases 
as well (Allen, 1968, Jensen, 1970; Abramson, 1984). However uveal metastases arc to 
be considered extracerebral metastases. 
Cerebral metastases occur more frequently than ocular metastases (Cieplmski et 
al,, 1982). According to Guthert et al. (1965), in patients with a malignant tumour 
cerebral metastases are found 12 times as often as intraocular metastases. This is due to 
the extensive ramifications of the vascular system, the size of the brain and the resulting 
greater risk of haematogenous spread. 
Frequently, nevertheless, no cerebral metastases can be demonstrated in patients 
with intraocular metastases; this is due to the fact that very small metastases can be 
diagnosed in the eye while this is not possible in the brain. Still, it is important for 
patients with intraocular metastases to be examined for metastases in the central nervous 
system as well (Abramson, 1984). 
Haagensen (1971) stated that in general, 22% of the patients with breast cancer 
have cerebral metastases. Di Stefano et al. (1979) reported 101 patients with cerebral 
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metastases of breast cancer. In only four patients were choroidal metastases established as 
well. These authors deny a correlation between cerebral metastases and localizations of 
metastases elsewhere in the body. 
Thatcher and Thomas (1975) established cerebral metastases in five out of 42 
patients with choroidal metastases of breast cancer (12%). Mewis and Young (1982) in 30 
out of 67 patients with choroidal metastases of breast cancer found metastases in the 
central nervous system. In two cases, metastases in the nervous system were detected 
earlier than choroidal metastases, in 15 cases they were detected at the same time and 13 
times, choroidal metastases preceded metastases in the nervous system. Accordingly, in 
patients with breast cancer, metastases in the central nervous system appear to manifest 
themselves at the same time as or after the diagnosis of ocular metastases. Choroidal 
metastases may represent the smallest detectable metastatic lesions in systemic 
dissemination of a malignancy (Mewis and Young, 1982). 
1.3.4 Demography 
The age and sex distributions of patients with uveal metastases are influenced greatly by 
the nature of the primary tumour causing the ocular lesion. 
Table 1.3.4.1 presents a survey of the sex distributions in intraocular metastases 
according to various authors. 
Table 1.3.4.1 Sex distribution in patients with intraocular metastases 
Number of Male Female 
metastases 
Aulhor N % N % 
Clinically: 
Brink et al., 1988 
Hemmes, 1969 
Salimannshausen et al., 1990 
Stephens and Shields, 1979 
Freedman and Folk, 1987 
Histopathologically: 
Wilder, 1946 
Castro et al., 1982 
Hutchison and Smith, 1979 
Hart, 1962 
Jensen, 1970 
Ferry and Font, 1974 
* 47 
** 121 
*# 161 
*+ 70 
*** 112 
** 40 
***M 126 
**m 73 
+* 118 
** 18 
** 196 
7 
19 
30 
17 
34 
12 
42 
28 
51 
8 
93 
15 
16 
19 
24 
30 
30 
36 
42 
43 
44 
47 
40 
102 
131 
53 
78 
28 
75 
39 
67 
10 
103 
85 
84 
81 
76 
70 
70 
64 
58 
57 
56 
53 
* choroid; ** uvea; *** eye and/or orbit 
# including two lymphomas; tltt in nine patients sex unknown; ### in six patients sex unknown 
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In the literature the malerfemale ratios are variable. Clinically, the proportions of 
males vary from 15 to 30% and those in females from 70 to 85%. Histopathologically, 
this proportion is 30 to 47% in males and 53 to 70% in females. This is due to the fact 
that most primary tumours causing intraocular metastases are breast cancers and occur in 
females (Bonnet and Jambon-Genet, 1948; Daicker, 1981). Since histopathological 
examinations in particular also reveal uveal metastases in other malignancies, and these 
patients may equally well be males, the emphasis in this group lies less on the female sex. 
The proportion of females among all patients with uveal metastases reported in the 
literature varies between 69 and 79% (Usher, 1923; Ask, 1934; Hollwich and Lemke, 
1965; Schiffer et al., 1978). 
The mean age of patients with intraocular metastases is between 50 and 60 years 
(Table 1.3.4.2). 
Table 1.3.4.2 Age of patients with intraocular 
Author 
All malignancies: 
Meythalerand Herold, 1979 
Jensen, 1970 
Ferry and Font, 1974 
Brink et a!.. 1988 
Saßmannshausen et al., 1990 
Hutchison and Smith, 1979 
Castro et al., 1982 
Breast cancer: 
Hart, 1962 
Stolzenbach and von Domaras, 
Chu et al., 1977 
Mewis and Young, 1982 
Thatcher and Thomas, 1975 
Meythaler and Herold, 1979 
Röttingeretal., 1976 
Hutchison and Smith, 1979 
Lung cancer: 
Hart, 1962 
Hutchison and Smith, 1979 
* clinical; ** histopathological 
# including one leukaemia and > 
1978 
one lymp 
* 
*+ 
** 
Φ 
+ 
+* 
** 
** 
* 
* 
* 
* 
* 
* 
++ 
** 
*+ 
Localization 
choroid 
uvea 
eye/orbit 
choroid 
choroid 
eye/orbit 
eye/orbit 
eye/orbit 
choroid 
choroid 
choroid 
choroid 
choroid 
choroid 
eye/orbit 
eye/orbit 
eye/orbil 
Нота; IM including two 
metastases 
Number of 
metastases 
21 
18 
227 
» 49 
Hit 161 
94 
103 
60 
8 
57 
67 
42 
16 
26 
38 
28 
17 
lymphomas; oo 
mean 
50 
51 
53 
54 
54 
57 
57 
49 
49 
50 
51 
oo 51 
53 
54 
61 
— ^ _ — _ _ _ _ _ _ ^ a 
51 
55 
median 
Age (yr) 
range 
-
-
4-79 
16-79 
-
21-88 
8-88 
33-68 
34-69 
-
28-71 
37-74 
-
35-67 
39-88 
24-72 
28-68 
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Of the patients with metastases, over three-quarters are between the ages of 40 and 
69 years. Fewer than 4% of the patients are younger than 30 years (Table 1.3.4.3). 
Although in children tumour cells have been demonstrated in the peripheral blood 
and even in the choroidal vessels (Bothman and Blankstein, 1942), they hardly if ever 
have ocular metastases (Albert et al., 1967a). It is possible that in children local 
environmental factors render the eye unsusceptible to malignant tumours (Albert et al., 
1967a; François et al., 1967). Such metastases as do occur are mostly disseminations of 
sympathoblastomas (Toppel, 1968). 
In animal experiments, on the other hand, intraocular metastases occur as often in 
young as in fully grown specimens (Albert et al., 1967b). 
The youngest patient with uveal metastases described in the literature was a three-
day-old girl with bilateral iridai metastases of a neuroblastoma detected a few days after 
the iridai tumour (Bowns et al., 1983). Other uveal metastases of neuroblastomas in 
children were described by Bothman and Blankstein (1942), Guthert et al. (1965), 
Hutchison and Smith (1979), Alio et al. (1982), Amé et al. (1983) and Castro et al. 
(1982). Rootman et al. (1979) described a choroidal metastasis of a congenital 
fibrosarcoma in a two-year-old boy. Other primary tumours in children under the age of 
10 to be mentioned are retinoblastoma of the same (Middleton, 1952) or of the other eye 
(Howard, 1962), tumours originating from the testicles (Goldstein and Wexler, 1935; 
Ferry, 1973) and thyroid carcinoma (Stangl, 1977). Between the ages of 10 and 20, uveal 
metastases were described of a bronchial carcinoid (Rosenbluth et al., 1960; Ferry, 1973; 
Fu et al., 1974 and Riddle et al., 1982), a colonie carcinoma (Ferry, 1973), a cutaneous 
melanoma (Font et al., 1967; Spencer, 1986), a choriocarcinoma of the testicle 
(Godtfredsen, 1944a) and a choriocarcinoma of the uterus in a pregnant woman aged 19 
years (Keates and Billig, 1970). 
There are only few known cases of patients over 80 with uveal metastases: the 
oldest patient was a male aged 88 with in his right eye a choroidal metastasis of an 
adenocystic carcinoma of the salivary gland (Gutmann et al., 1986). Kerman and Fishman 
(1987), also, described a male aged 81 with an uveal metastasis of a tumour originating 
from a salivary gland. Other reported cases involved a male aged 82 with an iridai 
metastasis of a thyroid carcinoma (Weisenthal et al., 1989) and a male aged 85 with an 
uveal metastasis of lung cancer (Eichholtz, 1976). 
Geographical position and race possibly play a part in the occurrence of uveal 
metastases. 
Only little is known about the race of patients with intraocular metastases. 
Virtually all publications on uveal metastases originate from European countries or from 
the United States. 
Only a few American authors state the race of their patients (Table 1.3.4.4). They 
fail to state, however, the racial distribution of the population from which these patients 
came. 
It is known that malignant tumours occur in different races in different proportions. 
For instance, in the United States tumours originating from the lung and bronchus are 
encountered far more often among whites, Negroes and inhabitants of Hawai than among 
American Indians and people of Hispano-American extraction (deVita et al., 1989). 
The mortality from malignancies als varies accorcing to geography (Tabel 1.3.4.5). 
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Table 1.3.4.3 
Author 
All malignancies: 
Hemmes, 1969 
Jensen, 1970 
Ferry and Font, 1974 
Age 
Stephens and Shields, 1979 
Total (N) 
(%) 
Breast cancer: 
Meyer and Herold, 1979 
Mewis and Young, 1982 
Total (N) 
(%) 
distribution in 
* 
*+ 
** 
+ 
* 
* 
patients with intraocular metastases 
Localization 
uvea 
uvea 
eye/orbit 
uvea 
uvea 
choroid 
Total numbers 
of patients 
121 
18 
227 
70 
436 
21 
67 
88 
0-9 
-
-
1 
-
1 
0.2 
-
-
. 
-
10-19 
-
1 
2 
-
3 
0.7 
-
-
_ 
-
20-29 
3 
1 
5 
3 
12 
2.8 
1 
1 
2 
2.3 
30-39 
15 
1 
26 
2 
44 
10.3 
3 
8 
11 
12.5 
Age 
40-49 
32 
5 
55 
12 
104 
24.2 
6 
24 
30 
34.1 
50-59 
41 
3 
51 
30 
125 
29.1 
7 
18 
25 
28.4 
60-69 
22 
7 
63 
16 
108 
25.2 
2 
13 
15 
17.0 
70-79 
7 
-
18 
7 
32 
7.5 
2 
3 
5 
5.7 
unknown 
1 
-
6 
-
7 
/ 
-
-
. 
-
* clinically; ** histopathologically 
Table 1.3.4.4 Racial distribution of patients with intraocular metastases 
Author 
Wilder, 1946 
Ferry and Font, 1974 
Stephens and Shields, 1979 
Total number of patients 
and localization 
N 
% 
N 
% 
N 
% 
40 choroid 
227 eye and/or orbit 
Ht 
70 uvea 
white 
40 
100 
196 
91 
65 
93 
Race 
black 
-
0 
17 
8 
5 
7 
yellow 
-
0 
2 
1 
-
unknown 
-
-
12 
-
-
-
* percentage of patients with known race 
Table 1.3.4.5 Age-adjusted death rates per 100.000 population according to 
localization of the primary tumour: 1984-1986 * 
Localization 
All malignancies 
Breast 
Lung 
Colon and rectum 
Stomach 
Netherlands 
male 
271 2 
-
103.8 
25.7 
20.7 
female 
142.8 
32.4 
10.4 
19.6 
8.8 
Country 
Uni 
male 
216.6 
-
73.5 
24.2 
7.4 
ted States 
female 
140.3 
27.4 
26.2 
17.5 
3.4 
male 
198.4 
-
38.2 
18.2 
54.6 
lapan 
female 
104.1 
6 7 
10.5 
12.2 
25.0 
* Silverberg et al , 1990 
Kurimoto and Ito (1970) collected data concerning 21 patients with a choroidal metastasis 
reported in Japan during the period 1957-1970. Fifty-two percent of these metastases were 
caused by lung cancer and only 24% by breast cancer. Ueno et al. (1986) described 165 
Japanese patients with uveal metastases, of which 38.8% originated from lung cancer, 
32.7% from breast cancer and 4.8% from gastric cancer. 
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1.4 Diagnostics 
In this chapter the signs and symptoms that cause a patient with uveal metastases to visit 
the ophthalmologist are described as well as the various diagnostic techniques used for 
making the differential diagnosis of intraocular tumours. 
Conditions that have to be differentiated from uveal metastases are described in 
Chapter 1.5. 
1.4.1 Signs and symptoms 
Choroidal metastases may remain asymptomatic for a long time (François et al., 1976; 
Shields, 1983; Abramson, 1984). As a rule, symptoms manifest themselves if the macula 
is affected or secondary retinal detachment occurs (Lommatzsch, 1989). 
Mewis and Young (1982) carried out ocular examinations in 250 patients with 
breast cancer. Of these patients, 152 had been referred because of symptoms. Choroidal 
metastases were found in 58 patients (38%). Of the 98 patients without ocular symptoms, 
nine women (9%) were found to have metastases in the choroid. 
In most patients with choroidal metastases symptoms have only recently developed 
at the time of diagnosis. Most symptoms have been present for less than 3 months (Hart, 
1962; Jensen, 1970). Jensen (1970) in none of his patients found symptoms that had been 
present for longer than one year. 
In lesions in the macular area, visual acuity deteriorates rapidly (Stevens and Reeh, 
1958) and this also occurs during development of a retinal detachment (Bonnet and 
Jambon-Genet, 1948). If metastases are localized in the peripheral choroid, it takes longer 
for symptoms to appear (Stevens and Reeh, 1958). 
At the first ocular examination, 12 to 13% of the patients have no complaints. 
These asymptomatic choroidal metastases are only detected fortuitously at routine 
ophthalmoscopy (Mewis and Young, 1982; Brink et al., 1988). However, most metastases 
cause signs or symptoms for which the patient seeks medical aid (Tables 1.4.1.1). 
The main complaints at the first ocular examination are decrease of the visual 
acuity and blurred vision (Ferry, 1973; Ferry and Font, 1974; Abramson, 1984; Gartner, 
1985; Brink et al., 1988). They are reported in 66 to 98% of the patients (Table 1.4.1.2). 
Vision may even decrease to no light perception (Reddy et al., 1981). Hart (1962) in 16 
of the 60 patients with choroidal metastases (27%) found only light perception or total 
blindness. Freedman and Folk (1987) in 72 eyes with choroidal metastases found a mean 
visual acuity of 20/70. The cause of this high percentage is the frequent localization in the 
posterior pole of the eye (Goldsmith, 1958; Simpson, 1961; Ferry, 1967). 
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Table 1.4.1.1 Presenting signs and symptoms in uveal metastases * 
Sign/symptom 
Decreased visual acuity 
Pain/headache 
Photopsia 
Red eye 
Floaters 
Field defect 
Photophobia 
Ins lesion 
Metamorphopsia 
Diplopia 
Proptosis 
Ptosis 
Anisocona 
Asymptomatic 
Stephens and Shields, 
Uveal metastases 
N 
56 
10 
9 
5 
5 
2 
1 
1 
-
-
-
-
-
4 
(N 
1979 
=70) 
% 
80 
14 
13 
7 
7 
3 
1 
1 
-
-
-
-
-
6 
Freedman and Folk, 
Intraocular metastases 
N 
57 
9 
-
4 
12 
18 
-
-
3 
3 
1 
1 
1 
1 
(N 
1987 
=58) 
% 
98 
16 
-
7 
21 
31 
-
-
5 
5 
2 
2 
2 
2 
* total % exceeds 100 because some patients had more than one complaint 
Table 1.4.1.2 Frequency of decreased visual acuity and blurred vision in patients 
with uveal metastases at the first ophthalmological examination 
Author 
Mewis and Young, 1982 
Stephens and Shields, 1979 
Hemmes, 1969 
Ferry, 1978 
Gillet, 1971 
Letson, 1982 
Röttingeret al., 1979 
Freedman and Folk, 1987 
Total number of patients 
and localization 
67 
70 
73 
164 
37 
15 
26 
58 
choroid 
uvea 
uvea 
choroid 
choroid 
choroid 
choroid 
choroid 
Decreased visual acuity 
and blurred vision 
N % 
44 66 
56 80 
61 84 
139 85 
32 86 
14 93 
25 96 
57 98 
Hypermetropia may develop due to an elevation of the retina by the underlying tumour. It 
may become manifest by the patient's having to wear increasingly strong positive glasses. 
The hypermetropia as a rule amounts to 1 to 3 diopters, but may increase to 7 diopters 
(Mérigot de Treigny, 1921; Bonnet and Jambon-Genet, 1948; Goldsmith, 1958; Offret and 
Haye, 1971). It may be the earliest sign of a tumour in the eye (Stewart, 1960). In such 
cases, the visual acuity after conection may remain adequate for a long time (Duke-Elder 
and Perkins, 1966). 
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Involvement of the central portion of the choroid may lead to metamorphopsia and 
micropsia (Mérigot de Treigny, 1921; Bonnet and Jambon-Genet, 1948; Goldsmith, 1958; 
Hemmes, 1969; Cole and Farah, 1985; Freedman and Folk, 1987; Brink et al., 1988). 
Visual field defects are usually secondary to a non-rhegmatogenous retinal 
detachment (Allen, 1968; Abramson, 1984; Gartner, 1985; Brink et al., 1988). These 
defects are encountered in variable proportions of the patients, viz. in 3% (Stephens and 
Shields, 1979) to 31% (Freedman and Folk, 1987). 
Patients regularly complain oí floaters (Stephens and Shields, 1979; Freedman and 
Folk, 1987; Wharam and Schachat, 1989). 
Sometimes the patient observes flashes of light (Hemmes, 1969; Stephens and 
Shields, 1979; Wharam and Schachat, 1989). However, according to Stevens and Reeh 
(1958), these occur more frequently in retinal detachments with a rhegmatogenous cause. 
Other infrequent signs and symptoms are diplopia (Hemmes, 1969; Mewis and 
Young, 1982; Cole and Farah, 1985; Freedman and Folk, 1987), photophobia (Stephens 
and Shields, 1979; Mewis and Young, 1982), ptons (Mewis and Young, 1982; Freedman 
and Folk, 1982) and abnormalities of colour vision (Hemmes, 1969). 
Prominent episcleral vessels are seen in 6% of the patients (Stephens and Shields, 
1979). 
Redness of the eye is described repeatedly (Hemmes, 1969; Stephens and Shields, 
1979; Freedman and Folk, 1987). Pain in the eye or periorbital pain may also constitute a 
first symptom (Ferry, 1978; Spencer, 1986; Castro et al., 1982; Letson et al., 1982). In 
10 to 20% of the cases this pain is mentioned as the first symptom (Table 1.4.1.3). 
During the subsequent course this proportion may increase even further (Stephens and 
Shields, 1979; Brasseur et al., 1983). 
Table 1.4.1.3 Frequency of painful eye or periorbital pain in patients with uveal 
metastases at the first ophthalmological examination 
Author 
Hemmes, 1969 
Stephens and Shields, 1979 
Freeman and Folk, 1987 
Hart, 1962 
Ferry, 1978 
Total number of patients 
and localization 
73 
70 
58 
60 
164 
uvea 
uvea 
choroid 
choroid 
choroid 
Ocular and 
periorbital pain 
N % 
7 10 
10 14 
9 16 
11 18 
33 20 
Pain may be due to uveitis which may or may not be associated with a secondary 
glaucoma (Bonnet and Jambon-Genet, 1984; Ferry, 1967/1978; Shields and Young, 1980; 
Shields, 1983). 
Intratumoral necrosis in choroidal metastases may lead to these inflammatory 
alterations that may conceal the clinical picture (Ferry, 1967). Ferry and Font (1974) in 
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16 of 219 patients (7.3%) with metastases in the eye or the orbit described a uveitis, 
associated in most cases with glaucoma. In 15 of these patients (94%) the metastasis was 
localized in the anterior segment of the uvea. 
A choroidal metastasis may present not only as uveitis but also as posterior scleritis 
(Yeoetal., 1983). 
Another cause of pain in the eye may be pressure exerted by the tumour on a 
ciliary nerve (Jaensch, 1950). 
Glaucoma occurs in 5.5% of the patients with a metastasis in eye or orbit (Ferry, 
1973). Possible mechanisms of this glaucoma are increasing pressure due to the size of the 
tumour in a limited space; anterior displacement of the lens causing blockage of the 
anterior chamber; blocking of the angle of the anterior chamber by exfoliated tumour 
cells; pressure of the tumour on the choroidal vessels (De Ocampo, 1961). 
In a group of 227 patients with ocular metastases, the diagnosis of 'glaucoma' was 
made 17 times. It was described as absolute in eight and as secondary in nine cases; in 
three of the latter it was due to iridocyclitis. In none of the 17 cases had the possibility of 
an intraocular tumour been considered. In most patients the uveal metastasis had an 
anterior localization and no primary tumour was known at the time (Ferry and Font, 
1974). 
Shields et al. (1987) reported a secondary increase of the intraocular pressure (over 
23 mm Hg by applanation tonometry) in 12 of 256 eyes with a uveal metastasis (5%). An 
increased pressure was found in only three of the 242 choroidal metastases, in contrast to 
seven out of 11 iridai metastases and two out of three metastases in the ciliary body. Of 
the patients with choroidal metastases, two had metastases of a bronchial carcinoma and 
one, a cutaneous melanoma metastatic to the choroid. In all three cases the angle of the 
anterior chamber was blocked secondary to anterior displacement of the iris-lens 
diaphragm from either choroidal detachment or total retinal detachment (Shields et al., 
1987). 
Stephens and Shields (1979) and De Bustros et al. (1985) reported a patient with 
angle closure glaucoma due to a haemorrhagic detachment of the choroid. 
Stephens and Shields (1979) in one out of 79 eyes with a choroidal metastasis 
described glaucoma as the first symptom. Freedman and Folk (1987) reported increased 
intraocular pressure in two of the 58 patients with a metastasis in the choroid. 
Alterations in the retina, which may or may not be due to a total retinal 
detachment, cause retinal hypoxia and frequently lead to neovascularization of the iris, 
peripheral anterior synechiae and intractible glaucoma (Ferry, 1967/1978). Pain caused by 
this glaucoma is one of the commonest reasons to enucleate an eye with a choroidal 
metastasis (Ferry, 1967; Haye, 1972; Ferry, 1978). As a rule, however, the patient's life 
expectation is too short for development of this final glaucoma (Mérigot de Treigny, 
1921; Ferry, 1967). 
The reason why few choroidal metastases are accompanied by glaucoma is the fact 
that these tumours are frequently localized in the macular area. The consequent loss of 
visual acuity will usually call attention to the tumour before a rise of the intraocular 
pressure takes place (Shields et al., 1987). Because the rise of pressure occurs only late, 
tonometry is of little value for the diagnosis of choroidal metastases (Cohen, 1937). This 
rise of intraocular pressure allegedly appears later in choroidal metastases than in other 
intraocular tumours (Stevens and Reeh, 1958). 
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Metastases in the iris are generally asymptomatic. Sometimes, the iris colour may 
change, especially in blue eyes (Abramson, 1984). 
Ferry (1978) and Ferry and Font (1975) in 60% of the patients with a metastasis 
in the anterior segment reported decreased visual acuity as the first symptom. In the 
longer term, reduced vision was even observed in 80% (Table 1.4.1.4). According to 
other authors, however, visual disorders occur far less often and are usually mild (Shields 
and Young, 1980; Shields, 1983). Tilting of the lens is sometimes observed (Wharam and 
Schachat, 1989). 
Table 1.4.1.4 Presenting signs and symptoms in metastases to the anterior segment 
Ferry and Font, 1975 
Sign/symptom N % 
Decreased visual acuity 
Mass 
Red eye 
Pain 
Iridocyclitis 
Glaucoma 
Hyphaema 
Asymptomatic 1 
15 
15 
12 
11 
10 
7 
1 
58 
58 
46 
42 
38 
27 
4 
* total % exceeds 100 because some patients had more than one sign or symptom 
Metastases in the anterior segment may remain unnoticed until anterior uveitis or 
secondary glaucoma occurs causing pain in the eye (Ferry, 1978; Shields, 1983; Spencer, 
1986; Lommatzsch, 1989; Wharam and Schachat, 1989). Necrosis is the cause of this 
uveitis and secondary glaucoma. Even the comea and sclera may be involved, rendering 
the diagnosis still more difficult (Ferry, 1967; Reese, 1976). This iridocyclitis may be 
accompanied by a hypopyon (Takahashi et al., 1984), by prominent episcleral vessels 
(Stephens and Shields, 1979; Shields, 1983) and by synechiae (Duke and Kennedy, 1958; 
Denslow and Kielar, 1978; Frank et al., 1979). 
Ferry and Font (1975) in ten of the 26 patients with metastases in the iris and the 
ciliary body (40%) described iridocyclitis at the first ophtha!mological examination. 
During the subsequent course, indocyclitis was diagnosed in one other patient. In five 
cases, the eye was enucleated on this diagnosis and presence of a metastasis in the anterior 
uvea was only established at histopathological examination (Ferry, 1973; Ferry and Font, 
1975). 
In uveitis due to metastases in the anterior uvea, breast cancer is only rarely found 
to be the primary tumour, although this is the tumour that most frequently gives rise to 
uveal metastases (inter alia Baudet et al., 1983; Scholz et al., 1983; Woog et al., 1984). 
Iritis is observed particularly often in iridai metastases of malignant skin 
melanomas (Char, 1980; De Bustros et al., 1985). Uveitis may also occur in choroidal 
metastases of skin melanomas (De Bustros et al., 1985). Wormald and Harper (1983) in 
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this connection described a 'black hypopyon' which consists of tumour cells and pigment-
containing macrophages and may give rise to a secondary glaucoma. 
Uveitis is observed with striking frequency in metastases of lung cancer in the iris 
and ciliary body (inter alia Duke and Kennedy, 1958; Talegaonkar, 1969; Reese, 1976) 
and in metastases of clear-cell tumours of the kidney (hypernephroma, Grawitz's tumour) 
(inter alia Chance, 1906; Hird, 1921; Laszczyk, 1975). 
In the presence of uveitis that fails to respond to standard treatments, and of 
symptoms indicative of systemic diseases, such as weight loss and cough, the physician 
should consider the possibility of a pathological condition metastatic to the eye (Scholz et 
al., 1983). 
Rubeosis iridis is regularly described in patients with a metastasis in the anterior 
segment (Duke and Kennedy, 1958; Schulze, 1967). Ferry (1973) described rubeosis in 
ten out of 26 patients with a metastasis in the iris or ciliary body (40%). This rubeosis is 
due to ischaemia of the anterior segment or secondary to a tumour angiogenic factor 
(Gimbrone et al., 1973; Freeman and Friedman, 1975). New blood vessels which form on 
the anterior surface of the iris impair the outflow of the aqueous humour, causing 
glaucoma (Schulze, 1967). However, Shields et al. (1987) never described 
neovascularization in uveal metastases. 
The early necrosis in iridai metastases as mentioned before frequently leads to 
uveitis and secondary glaucoma (Ferry, 1967; Reese, 1976; Meythaler and Barthelmess, 
1980) Other possible causes of glaucoma are tumorous infiltration of the trabecular 
meshwork and closure of the angle of the anterior chamber by the tumour mass (Daicker, 
1981). 
In the study of Ferry and Font (1975), a glaucoma was the first sign of an 
intraocular tumour in seven out of 25 patients with metastases in the anterior segment 
(28%). In the longer term, they described a rise of the intraocular pressure in 14 patients 
(56%). Glaucoma, therefore, is one of the symptoms with which an iridai metastasis may 
present (Castro et al., 1982; Abramson, 1984; Takahashi et al., 1984; Lommatzsch, 
1989). 
Duke-Elder and Perkins (1966) report increased intraocular pressure in 20% of the 
iridai metastases while Char (1989) did so in one-half of the cases. 
Shields et al. (1987) established a secondary rise of the intraocular pressure to over 
23 mm Hg in seven out of 11 patients with an iridai metastasis (64%) and in two out of 
three patients with metastases in the ciliary body. In eight of these nine patients either 
tumour invasion or angle closure was the cause of the glaucoma. 
Open as well as closed angle mechanisms may occur in glaucoma. In some patients 
with an open angle, the trabecular meshwork is covered by a sheet of tumour cells, 
causing the socalled malignant epithelialization of the angle (Ferry and Font, 1975). In 
other patients with an open angle, the trabecular meshwork and the emissary veins may be 
infiltrated by neoplastic cells. The angle may also be closed by tumour lobules that have 
broken through the boundaries of the uvea or by peripheral anterior synechiae (Ferry, 
1967; Ferry and Font, 1975). 
Chapter 1.4.2 deals with intraocular haemorrhages and retinal detachments which 
may occur as complications in uveal metastases. 
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1.4.2 Ophthalmoscopy and slit lamp examination 
Metastases have a characteristic ophthalmoscopic image. Gass (1974) describes choroidal 
metastases in his book 'Differential diagnosis of intraocular tumours' as '... typically 
amelanotic, white or cream-colored, slightly elevated lesions with ill-defined margins'. 
Amé and Mathis (1986): 'Certain caracteres sont en faveur du diagnostic de métastases 
choroldiennes: tumeurs volontiers bilatérale ou multiples, siégeant avec prédilection au 
pôle postérieur, peu saillantes, поп-pigmentées, à bords irréguliers'. In 'Tumors of the 
eye' (1976), Reese describes choroidal metastases as follows: '... examination reveals a 
more or less solid-appearing detachment of the retina, invariably in the posterior pole. 
The elevated area is pinkish white, fading off into the normal-appearing surrounding 
retina. The tumor surface is frequently mottled. An occasional hemorrhage and some slight 
pigmentary changes may be seen over the involved area. Such lesions are often pale gray, 
pale yellow or yellowish gray. Multiple tumor foci are in some instances noted throughout 
the fundus. ' Shields in 'Diagnosis and management of intraocular tumors' (1983): 
Ophthalmoscopic examination of a choroidal metastasis characteristically reveals a 
creamy yellow placoid lesion in the posterior choroid. Tumors that are slightly more 
elevated frequently produce a serous detachment of the fovea and alterations in the retinal 
pigment epithelium. The retinal pigment epithelium changes can be rather marked, 
appearing as well-delineated clumps of golden brown pigment on the surface of the 
tumor. ' To conclude, Lommatzsch's description of choroidal metastases in 'Intraokulare 
Tumoren' (1989): 'Ophthalmoskopisch sieht man gelbliche fleckige, oft nur gering 
prominente Bezirke. Typisch ist die begleitende seröse Ablatio retinae, die manchmal den 
gesamten Tumor verdeckt und Anlaß zur Fehldiagnose geben kann. Die Veränderungen im 
Pigmentepithel über einer solchen Metastase sind charakteristisch und fuhren zu einer 
leopardenfellartigen goldbraunen Pigmentierung der Tumoroberfläche. Manche Metastasen 
wachsen aber auch kugelförmig und sind ophthalmoskopisch dann nicht von einem 
amenalotischen Melanom zu unterscheiden. Finden sich jedoch mehrere Tumorknoten am 
Fundus, so spricht dies mit großer Wahrscheinlichkeit für eine Metastase. ' 
The principal ophthalmoscopic features of choroidal metastases, therefore, are the 
shape, delineation, colour and localization of the lesion, together with their bilateral or 
multiple occurrence and any secondary alterations. These, accordingly, will be discussed 
in succession. 
Shape: the first ophthalmoscopic sign of a choroidal metastasis is a colour change 
of a small, well-delimited zone of the retina as a more or less pale yellow diffuse area of 
retinal oedema (Gilbert, 1939). These round or oval foci are typically very flat or only 
slightly elevated without much displacement of the overlying retinal vessels (Sattler, 1926; 
Stevens and Reeh, 1958; Gass, 1972; Gartner, 1985). A latent choroidal metastasis is also 
described as nodular miliary (Bonnet and Jambon-Genet, 1948). In the initial phase the 
tumour is not more than a few disk diameters wide (Stevens and Reeh, 1958; Ferry, 
1967). The elevation as a rule amounts to less than 6 diopters (Stevens and Reeh, 1958). 
At successive examinations a number of changes are seen and the lesion in only a 
few weeks' time assumes a different aspect (Bonnet and Jambon-Genet, 1948; Albert et 
al., 1967b). The tumour in general grows diffusely laterally of the choroid with only a 
minimal increase in thickness, because it chooses the line of least resistance (Ferry, 1967; 
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Gass, 1974). Separate foci may fuse into a large placoid tumour (Sattler, 1926). 
Homogeneous solitary tumours also occur (Pau, 1979). In case of a nodular miliary 
lesion, increase of volume occurs and the lesion runs into a dome-shaped elevated mass. 
The tumour extends to the vitreous, bringing about an oval little-elevated tumour 
which grows more convex (Bonnet and Jambon-Genet, 1948). Sometimes, the tumour is 
irregular and multinodular (Stephens and Shields, 1979; Shields, 1983). 
In a number of patients, the tumour is markedly elevated and dome-shaped as in a 
primary melanoma (Shields, 1983). Such an elevated, localized growth reportedly occurs 
in tumours at the periphery, in contrast to the natter lesions with a broad base in the 
posterior pole (Simpson, 1961). Metastases of breast cancer are said to grow without 
much elevation (Simpson, 1961), but exceptionally may be very large (Char, 1989). This 
in contrast to metastases of lung cancer (Norton, 1969). Other authors state that 
metastases of breast cancer on the contrary are mostly more elevated than metastases of 
lung cancer (Freedman and Folk, 1987). 
It is rare for metastases to break through Bruch's membrane (Gass, 1974). The 
mushroom shape, typical of large melanomas, therefore almost never occurs and is 
described only sporadically (Friedenwald et al., 1957; Howard, 1965; Regan, 1966; 
Ferry, 1967; Shields, 1983; Gartner, 1985; Spencer, 1986; Kerman and Fishman, 1987; 
Char, 1989). Mostly, these metastases are mistaken for primary malignant melanomas of 
the choroid. If the eye is enucleated, histopathological examination reveals a lesion of 
metastatic nature, often a metastasis of a bronchial carcinoma (Jarrett, 1976) or 
sometimes, of a clear cell tumour of the kidney (hypernephroma, Grawitz tumour) (Hart, 
1962). 
The delineation of the lesion is described by a number of investigators as ill-
defined without sharp or discrete margins (Stevens and Reeh, 1958; Gillet, 1971; Gass, 
1974). Other authors describe the edges of the tumour as well-delineated and abrupt 
(Sattler, 1926; Gilbert, 1939; Shields, 1983). 
The colour of the tumour is described as amelanotic, yellowish, pinkish, greyish-
white to white or yellowish-grey (Table 1.4.2.1). 
Table 1.4.2.1 Colours of choroidal metastases 
Colour Author 
Amelanotic Gass, 1974; Stephens and Shields, 1979; Shields, 1983 
Yellow (pale-yellow, yellowish-white, Sattler, 1926; Gilbert, 1939; Bonnet and Jambon-Genet, 
yellowish-brown, yellowish-pink, 1948; Simpson, 1961; Gass, 1974; Hayreh, 1974; Maor et 
creamy) al., 1977; Shields, 1977b; Schiffer et al., 1978; Shields, 
1983; Gartner, 1985 
Pinkish Norton, 1969; Haye, 1972; Reese, 1976 
Greyish-white or white Bonnet and Jambon-Genet, 1948; Norton, 1969; Gass, 1974 
Grey or yellowish-grey Stevens and Reeh, 1958; Simpson, 1961; Schiffer et al., 
1978; Pau, 1979 
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In spite of this range of colouring, a choroidal metastasis as a rule is described as 
light in colour. Metastases have no intrinsic tumour pigment. Exceptions to this rule are 
metastases of malignant skin melanomas, which are often pigmented (Shields, 1976/1983; 
Char, 1989). However, owing to the mostly rapid growth, secondary alterations occur in 
the retinal pigment epithelium. These consist in general of depigmentation, degeneration, 
mobilization and destruction of the pigment epithelium. Sometimes, spotty lumps of dark 
grey or orange pigment are seen on the tumour surface. These pigmentary changes may be 
interpreted as proof of production of pigment by the tumour. Biomicroscopy is of great 
value for the differentiation of this surface pigment from the intrinsic pigment of 
melanomas (Gass, 1972). 
The pigment changes lead to the mottled aspect, so characteristic of metastases, 
with depigmentation on the tumour surface (Gilbert, 1939; Stevens and Reeh, 1958; 
Norton, 1969; Hayreh, 1974; Reese, 1976; Maor et al., 1977). Shields (1983) and 
Lommatzsch (1989) described this as golden-brown leopardskin-like. The cause of this 
mottled aspect is proliferation of the retinal pigment epithelium; it is independent of 
whether the tumour is or is not pigmented (Wallow and Ts'o, 1972). 
The ill-defined margin of the lesion may be slightly pigmented (Gillet, 1971) and 
fades into the surrounding normal-appearing retinal colour (Reese, 1976). 
Shields et al. (1976) in all patients with a choroidal metastasis of an 
adenocarcinoma described lumps of lipofuscin on the tumour surface as reddish-brown or 
dull brown pigment. According to Smith and Irvine (1973) this never occurs in 
metastases. 
Damage to the pigment epithelium leads to a cystoid oedema of the overlying 
retina which turns more or less cloudy. This cloudiness therefore is not due to invasion of 
the tumour into the retina. The area of retinal oedema as a rule is much larger than the 
area of the underlying choroidal lesion (Simpson, 1961; Ferry, 1967). Restriction of the 
lesion to the choroid without involvement of the overlying retinal pigment epithelium is 
also possible, however (Gass, 1972). 
A serous exudation occurs in the subretinal space and less often in the subpigment 
epithelial space (Simpson, 1961; Ferry, 1967; Gass, 1972; Schatz et al., 1978). In the 
process, the subretinal humour increases and the cloudy exudates may mask the 
underlying tumour picture and give it a white appearance (Stevens and Reeh, 1958; 
Simpson, 1961; Ferry, 1967; Norton, 1969; Gass, 1974). The cloudy-turbid, flatly 
detached retina fairly often bulges markedly (Ferry, 1967; Pau, 1979). This serous retinal 
detachment occurs frequently in the macula (Gass, 1972; Shields, 1983). 
A retinal detachment occurs often in choroidal metastases and is a typical feature. 
It may be observed even in the earliest phases of the tumour (Witmer, 1967). In general, 
the retina] detachment is flat; it reportedly occurs in 90% of all choroidal metastases 
(Norton, 1969; Reese, 1976; Shields, 1976/1977b; Pau, 1979; Stephens and Shields, 
1979; Freedman and Folk, 1987). No retinal breaks are seen in the process (Albert et al., 
1967), although Howard (1968) reports a retinal break in 5 to 10% of retinal detachments 
secondary to tumours. 
A choroidal metastasis may also be accompanied by a choroidal detachment, just as 
may occur in malignant melanomas. This is rare, however (Sneed et al., 1991). 
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Table 1.4.2.2 Localization of uveal metastases 
Author 
Hemmes, 1969 
Ferry and Font, 1974 
Stephens and Shields, 
Castro et al., 1982 
1979 
Total number of 
patients/eyes 
oo 121 patients 
196 patients 
oo oo 83 eyes 
94 eyes 
Choroid 
* 
N 
HI 
170 
78 
80 
Choroid 
% 
92 
87 
94 
85 
Choroid 
only 
N 
109 
140 
77 
80 
1 
% 
90 
71 
93 
85 
Ciliary body 
Ciliary body 
+* 
N 
7 
II 56 
3 
9 
% 
6 
It 29 
4 
10 
Ciliary body 
only 
N 
2 
0 
3 
9 
% 
2 
0 
1 
10 
Ins 
**+ 
N 
7 
И 56 H 
4 
5 
% 
6 
29 
5 
5 
Ins 
Ins 
only 
N 
4 
6 
3 
5 
% 
3 
3 
4 
5 
* oho a localization in the ciliary body and/or ¡he ins; ** also a localization in the choroid and/or the ins; +** also a localization in the choroid and/or the 
ciliary body; H 56patients (29%) metastases in the 'anterior segment' and also in the choroid, 23 patients (12%) metastases in the 'anterior segment' only; 
oo six patients uveal localization unknown; oo oo two patients uveal localization unknown 
Localization: metastases are localized in the uvea more often than in any other 
ocular structure (Simpson, 1961; Jensen, 1970; Shields, 1976; Hutchison and Smith, 
1976; Castro et al., 1982; Shields, 1983). Ferry (1973) and Ferry and Font (1974) 
reported a proportion of 86.3%. 
The frequent involvement of the uvea in metastatic processes is due to its relatively 
extensive vascularization and to the fact that it constitutes a nutritional condition suitable 
for metastases (see Chapter 1.2) (Lemoine and McLeod, 1936). 
Within the uvea, the choroid is involved most frequently (Sanders, 1938; Ferry and 
Font, 1975) (Table 1.4.2.2). The proportions mentioned vary between 85 and 94%. Only 
few uveal metastases are localized in the anterior segment: 4 to 10% in the ciliary body 
and 5 to 6% in the iris (Hemmes, 1969; Ferry, 1973; Ferry and Font, 1974/1975; 
Stephens and Shields, 1979; Castro et al., 1982). Ferry and Font (1975) reported a larger 
proportion of disseminations in the anterior segment, viz. 29% of all patients with uveal 
metastases. In 13% of the patients, only the anterior segment is affected, without 
involvement of the choroid. 
Most metastases in the posterior pole have a temporal localization (Duke-Elder and 
Perkins, 1966; Ferry, 1967; Ferry and Font, 1973; Meythaler and Herold, 1979; Castro 
et al., 1982; Gartner, 1985; Amé and Mathis, 1986; Freedman and Folk, 1987; Brink et 
al., 1988; Hoogenhout et al., 1989). This predilection for the temporal choroid is also 
mentioned in older literature on uveal metastases (Lagrange, 1901, Maggiore, 1922). The 
macula is said to be involved in about 15% (Brink et al., 1988; Hoogenhout et al., 1989) 
or in 40% of the cases of choroidal metastases (Freedman and Folk, 1987; Wharam and 
Schachat, 1989). However, choroidal metastases may also occur outside the posterior pole 
(Bonnet and Jambon-Genet, 1948). Proportions vary from 8% (Freedman and Folk, 1987) 
to 19% (Hoogenhout et al., 1989), 55% (Pau, 1979) and even 67% (Saßmannshausen et 
al., 1990). 
The predilection of uveal metastases for the posterior pole is related to the 
distribution of the supplying vessels. The ciliary arteries arise from the ophthalmic artery 
less sharply than its central branch (DeLong, 1933). The posterior segment of the uvea 
receives its blood supply from 20 short posterior ciliary arteries, the anterior segment 
from 2 long posterior and 7 short anterior ciliary arteries. Most thrombi of tumour cells 
land in the posterior short ciliary arteries and are carried to the choroid, especially to the 
area temporal of the optic disk where the supply vessels have the largest number and 
diameter (Lagrange, 1901; Duke-Elder and Perkins, 1966; Gillet, 1971; Reese, 1976; 
Meythaler and Herold, 1979; Castro et al., 1982; Gartner, 1985). 
A lower frequency of metastases in the iris and the ciliary body might also be 
connected with the muscles in this region, the movements of which might impair the 
implantation of metastases (Ask, 1934; Schlagenhauff, 1950). Moreover, inflammatory 
reactions in metastases in the anterior segment might mask the tumour, causing it to be 
diagnosed less readily (Duke-Elder and Perkins, 1966) (see Chapter 1.2.2). 
In older literature on uveal metastases it is generally assumed that metastases occur 
more often in the left than in the right eye. This was supposed to be due to the fact that 
the left carotid artery branches off from the aorta more at right angles than the right one, 
and is larger as well. As a consequence, tumour emboli would be carried sooner to the 
left eye (Lagrange, 1901; Sattler, 1926). Usher (1923), on the other hand, was of the 
opinion that metastases are distributed equally over both eyes. 
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Recent literature shows that there is no clear predilection for the right or the left 
eye (Table 1.4.2.3). 
Table 1.4.2.3 Laterality of uveal metastases in terms of percentage 
Author 
Pau, 1979 
Stephens and Shields, 1979 
Hutchison and Smith, 1979 
Castro et al., 1982 
Mernam, 1961 
Mewis and young, 1982 
Ferry and Font, 1974 
SaHmannshausen et al., 1990 
Hoogenhoutet al., 1989 
François et al., 1976 
Total number of 
eyes * 
25 
78 
94 
118 
27 
82 
196 
214 
39 
50 
Localization 
choroid 
uvea 
eye/orbit 
intraocular 
choroid 
choroid 
uvea 
choroid 
choroid 
choroid 
Right eye 
% 
36 
42 
44 
46 
48 
48 
50 
51 
55 
56 
Left eye 
% 
64 
58 
56 
54 
52 
52 
50 
49 
45 
44 
* eves ич/Л known localization 
Table 1.4.2.4 Bilateral ocular metastases 
Author Total number Localization 
of patients 
Bilateral metastases 
N % 
Ferry and Font, 1974 
Jensen, 1976 
Maggiore, 1922 * 
Саыго el al., 1982 
Hutchison and Smith, 1979 
Stephens and Shields, 1979 
Lemoine and McLeod, 1936 * 
Hemmes, 1969 
Usher, 1923 * 
Freedman and Folk, 1987 
SaHmannshausen et al., 1990 
François et al., 1976 
Brink et al., 1988 
Mewis and Young, 1982 
Memam, 1961 
Meythaler and Herold, 1979 
186 
18 
70 
101 
78 
70 
229 
121 
98 
58 
160 
37 
49 
67 
35 
21 
uvea 
eye 
choroid 
eye/orbit 
eye/orbit 
uvea 
uvea 
choroid 
choroid 
choroid 
choroid 
choroid 
choroid 
choroid 
choroid 
choroid 
10 
1 
12 
17 
14 
13 
48 
32 
30 
17 
54 
13 
17 
27 
20 
12 
5 
5 
17 
17 
18 
19 
21 
25 
30 
30 
34 
35 
35 
40 
57 
57 
* review of literature 
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Ocular metastases occur bilaterally in 20 to 40% of the cases (Table 1.4.2.4). A 
lower proportion, of 5%, is reported by Ferry (1973), Ferry and Font (1974) and Jensen, 
1976). Meythaler and Herold (1979) indicate a larger proportion, of 57%, while according 
to Bonnet and Jambon-Genet (1948) bilateral metastases are even found in as many as 
75 % of the patients. 
Thorough examination will in the long run reveal metastases in both eyes in the 
majority of the patients (Gillet, 1971). 
Multiple lesions in one or both eyes occur often in choroidal metastases and are 
characteristic of the metastatic origin of the tumours (François and De Vos, 1958; Norton, 
1969; Theodossiadis, 1978; Shields and Young, 1980; Shields, 1983; Amé and Mathis, 
1986). If multiple lesions are observed, a metastatic process is practically certainly 
involved (Gartner, 1985). Ferry (1969), however, is of the opinion that multiple 
metastases in one eye occur only occasionally. 
As Table 1.4.2.5 shows, the proportions of multiple choroidal metastases in one 
eye vary from 15 to 36%. The study of Mewis and Young (1982) was exclusively 
concerned with patients with breast cancer. Their proportion of multiple lesions is 
distinctly higher than in the other three study groups, with a more mixed population of 
malignancies. 
Table 1.4.2.5 Frequency of occurrence of multiple choroidal metastases in one eye 
Author 
Brink et al., 1988 
Stephens and Shields, 1979 
Freedman and Folk, 1987 
Mewis and Young, 1982 
Total number 
of eyes 
66 
83 
77 
67 
Multiple metastases 
N 
10 
14 
17 
24 
% 
15 
17 
22 
36 
Number of lesions 
2 - 4 
2 - 6 
* 
3 - 1 6 ** 
number of lesions not mentioned; ** total number of lesions in both eyes 
In uveal metastases, haemorrhages may sometimes occur as the first sign of an intraocular 
malignancy. This may render the diagnosis more difficult (Maxwell, 1954; Evans et al., 
1971; Castro et al., 1982; Gartner, 1985). The localizations of these haemorrhages may 
be on the tumour surface and retinal (Vanni and Barilla, 1960; Thompson et al., 1961; 
Reese, 1976), beneath the pigment epithelium (Gass, 1974), or subhyaloidal (Evans et al., 
1971) and they may also occur as a haemorrhagic retinal detachment masking the tumour 
(Gass, 1967; De Bustros et al., 1985). Vitreous haemorrhages are also possible in 
choroidal metastases (Koenig et al., 1963; Font et al., 1966; Ginsberg et al., 1970). 
However, occurrence of haemorrhages in intraocular metastases is rare. Freedman and 
Folk (1987) at the first ocular examination of 58 patients with an intraocular metastasis 
found a retinal haemorrhage in only one patient and vitreous haemorrhages in only two. 
Uhthoff (1891), on the other hand, was of the opinion that choroidal carcinomas 
have a distinct tendency to bleed. The alleged cause of this was erosion of the vessel 
walls. Together with developing necrosis, these haemorrhages would explain 
inflammation-like abnormalities and attacks of serious pain. 
Castro et al. (1982) attributed the presence of haemorrhages to small choroidal 
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vessels being blocked by tumour cells. This may lead to a rupture and subsequently, to a 
haemorrhage in the choroid. These haemorrhages may cause the charactenstic mottled 
aspect of the tumour surface. 
At histological examination, fresh or older haemorrhages are often encountered in 
the cell nests, often associated with necrosis (Sattler, 1926; Ginsberg, 1928; DeLong, 
1933) 
Ferry (1967) described iridai metastases as follows: 'In a typical case metastatic 
carcinoma of the ins appears clinically as a nodular lesion at the antenor surface of the 
ins with fairly well-defined borders. More than one nodule may be present, and any part 
of the ins may be involved. Most often the color of the tumor is gray or light brown, and 
the tumor often contains very prominent blood vessels. ' 
The shape of the lesion is also described as diffuse or diffuse nodular (Gartner, 
1985, Char, 1989). Several lesions of different sizes may be present. Sometimes, indal 
metastases are very subtle and only to be observed with the slit lamp (Shields, 1983). The 
pupils may be irregular (Gartner, 1985). 
Just as in choroidal metastases the colour is highly variable. Indal metastases are 
nearly always amelanotic (Stephens and Shields, 1979, Shields, 1983; Char, 1989) 
Occasionally, a grey, red or reddish brown colour is descnbed (Gartner, 1985). 
According to certain investigators, indal metastases show no predilection for any 
particular quadrant (Usher, 1923; Shields, 1983). However, Ferry and Font (1975) in 26 
patients with metastases only in the antenor segment found a predilection for the 
honzontal over the vertical mendian. 
The consistency of the tumour is gelatinous (Shields, 1983; Lommatzsch, 1989) or 
fleshy (Stephens and Shields, 1979). 
On the tumour surface vessels are often seen (Shields, 1983; Gartner, 1985). A 
hyphaema may be present (Duke and Kennedy, 1958; Shields and Young, 1980). Ferry 
and Font (1975) in six out of 26 patients (29%) with a metastasis in the ins and 
sometimes in the ciliary body as well, encountered a hyphaema In case of a recurrent 
hyphaema the possibility of indal metastases should be considered (Smith, 1976). The 
hyphaema often causes an indal metastasis to go unnoticed (Dhermy, 1979, Castro et al., 
1982; Abramson, 1984) 
In addition, there may be signs of inflammation, with or without a hypopyon 
(Kanski, 1984). 
Metastases in the ciliary body are rare (Ferry, 1973; Ferry and Font, 1975). They 
are hardly distinguishable from amelanotic melanomas (Shields, 1983; Lommatzsch, 
1989) In general they start in the antenor part of the ciliary body, in the area of the angle 
of the antenor chamber, and invade both the angle and the base of the ins. They occur 
more rarely in the pars plana and the postenor part of the ciliary body (Hogan, 1964). 
Sometimes, prominent episcleral vessels indicate the presence of a tumour (Shields, 1983). 
Regarding multiple lesions in the ciliary body no literature is available. A hyphaema may 
be present (Kreibig, 1936; Schlagenhauff, 1950; Font et al., 1967). 
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1.4.3 Fluorescein angiography 
Fluorescein angiography is a technique of sequentially visualizing the fluid dynamics 
within the vascular system of the retina and uvea and the perfusion of the tissue which it 
supplies (Federman and McGuire, 1989). The first ophthalmological description of this 
technique dates from 1961 (Novotny and Alvis, 1961). 
Sodium fluorescein is highly water soluble and in blood is partly bound to albumin. 
It is excreted rapidly, mostly by the liver and the kidney. In the bloodstream, fluorescein 
is excited by light with a wavelength of 465 nm; it has an emission spectrum of 525 nm. 
Following injection into an arm vein, the area to be examined is illuminated and after 
filtration, photographed (Federman and McGuire, 1989; Richard, 1989). 
In particular, angiography with use of indocyanm green under infrared illumination 
renders the deeper vascularization (choroid) clearly visible (Bacín et al., 1981; Bisschoff, 
1985) 
The commonest side effect of fluorescein angiography is transient nausea, 15 to 20 
seconds after injection. Some patients complain of itching. Anaphylactic shock has been 
described but is a highly exceptional complication (Bresnick, 1969; Stein and Parker, 
1971; Federman and McGuire, 1989) 
Technique- at angiographic examination of the fundus, two separate vascular 
systems are to be distinguished, the superficial retinal circulation and the choroidal 
vasculature situated beneath the retinal pigment epithelium (RPE) (Bresnick, 1969). In 
lightly pigmented fundi the fluorescein staining of the large choroidal vessels can be 
observed, following which the chonocapillans fills in irregular patches, just before the 
retinal artenes (Federman and McGuire, 1989). 
After injection fluorescein reaches the retinal vessels in 8 to 10 seconds. The 
fluorescein study can be divided into an arteria], artenovenous and venous phase 
(Bresnick, 1969). The capillaries of the retina are not fenestrated and in normal 
circumstances show no leakage, in contrast to the fenestration of the endothelium of 
choroidal vessels through which fluorescein rapidly escapes into the extracellular space 
(Federman and McGuire, 1989). Owing to this leakage and because of staining of the 
collagen tissue of the sclera, the fluorescence persists for a long time even after the 
fluorescein has left the retinal vessels (Bresnick, 1969) 
The degree of pigmentation and pathological alterations of the RPE have great 
influence on the angiographic features of the choroid. In normal circumstances the RPE 
constitutes a bamer to leakage or transportation of fluorescein. 
Compared with the normal fluorescence of the fundus, hyper- and 
hypofluorescence are distinguished. Hyperfluorescence occurs owing to the abnormal 
presence of fluorescein in a location, a higher-than-normal concentration of dye in any 
location where it is also observed under normal circumstances or increased transmission of 
fluorescence from an area of normal dye concentration and distribution due to a 
pathological overlying condition. Hypofluorescence occurs because of decrease of 
fluorescence in a region where it is normally found and by block of the transmission of 
fluorescence caused by overlying pathological alterations. 
Tumour cell masses are in general associated with increased vascularization, 
resulting in more fluorescein in the area. This fluorescein probably leaks rapidly into the 
stroma, which results in hyperfluorescence. Hyperfluorescence may also be caused by 
transmission through defects in the RPE and by presence of the substance in cystic retinal 
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spaces (Federman and McGuire, 1989). 
The earliest descnptions of fluorescein angiography in uveal metastases date from 
1964 (Norton et al.). In metastases no pathognomonic image is seen. The fluorescence 
vanes greatly in dependence on changes of the RPE, tumour pigment and tumour vessels, 
vascular permeability, secondary degeneration and necrosis and haemorrhages in the lesion 
(Wessing, 1968, Famaner et al., 1973; Fishman, 1977, Schiffer et al., 1978; Dams, 
1979). The image is independent of the histology of the primary tumour (Kolin, 1969; 
Hayreh, 1974; Amaine, 1979). 
In the early vascular phase, choroidal metastases are desenbed as invisible or 
hypofluorescent (Norton et al , 1964, Gass, 1972). If fluorescence is seen at all, it occurs 
only in the arteriovenous phase (Offret and Haye, 1971) or in the venous and late phases 
(Orsoni, 1968, Tanev and llieva, 1980; Bonnin, 1986, Lommatzsch, 1989). Sometimes, 
early iluorescence is observed, as in haemangiomas (Schiffer, 1978) 
The fluorescence in metastases is usually spotty and not very pronounced; it is 
distnbuted fairly evenly and renders the tumour homogeneously fluorescent, with a poorly 
delineated margin (Wessing, 1977; Bonnin, 1986). A secondary detachment of pigment 
epilhchum or retina is of great importance. In case of destruction of the RPE, 
hyperiluorescence occurs (Gass, 1972; Kelley, 1977, Wharam and Schachat, 1989). An 
extensive detachment frequently causes a mottled aspect in the artenovenous phase 
(Norton, 1969) As a rule any subretinal fluid becomes fluorescent at the same time as or 
after the tumour, due to accumulation of fluorescein (Norton, 1969; Gass, 1974; Bonnm, 
1986) Owing to the subretinal fluid, the retinal capillaries in the early phase are clearly 
visible but not abnormal (Bonmn, 1986) or only dilated without microaneurysms or 
leakage (Wessing, 1977), although Karel and Peleska (1972) desenbed a patient with 
microaneurysms Sometimes, cystoid retinal oedema is present owing to damage to the 
RPE (Schatz et al , 1978), while according to other authors this argues against a 
metastasis (Davis and Robertson, 1973, Fishman, 1977, Schiffer et al., 1978). 
In metastases, hyperfluorescent spots are desenbed which are particularly clear in 
the venous phase (Famaner et al , 1973, Scheffer, 1973, Shields, 1983; Turut et al., 
1987) These spots are brought about by drusen in Bruch's membrane and by multiple 
defects of the RPE (Voigt and Pulhorn, 1977). 
Regarding the presence of large vessels in the tumour there is no consensus in the 
literature. According to certain authors, these are nol present in metastases (Davis and 
Robertson, 1973; Hayreh, 1974, Fishman, 1974, Schiffer et al., 1978, Dams, 1979; 
Lommatzsch, 1989), but other investigators do desenbe them, especially in sphencal 
tumours (Gass, 1974, Voigt and Pulhorn, 1977, Wessing, 1977; Shields, 1983). 
Orange or brown pigment on the tumour surface remains hypofluorescent (Schatz 
et al., 1978; Shields, 1983). Socalled 'multilake' areas argue against a metastasis (Hayreh, 
1974; Schiffer et al., 1978, Shields, 1983) 
A number of authors have attempted to distinguish patterns in the fluorescein 
angiography of choroidal metastases. Davis and Robertson (1973) desenbed three types: 
the most frequent was a generally early, artenal or artenovenous, increasing fluorescence; 
less often, a blockage of the background fluorescence was observed against which the 
entire tumour stood out as a dark or irregular spotty area with only artenovenous and late 
but progressive and diffuse staining. In one patient an early artenovenous fluorescence 
was seen which decreased in the course of the examination with only punctate 
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fluorescence in the late phase. The authors emphasize that no single pattern is 
characteristic of metastases. 
Hayreh (1974) distinguished four groups. In flat mottled, yellowish-brown tumours 
progressive fluorescence in the arterial or arteriovenous phases is described with late 
staining. In moderately elevated localized uniformly yellowish-brown tumours, masking of 
the choroidal fluorescence in the early phase was seen, with a slowly diffusing staining in 
the arteriovenous and late phases. In large yellowish-white lesions, no fluorescence was 
seen. This is rare. Finally, the least common, lesions which fluoresce in the arterial and 
the arteriovenous phases and which fluorescence fades as the choroidal fluorescence 
decreases, which indicates an unmasking of the choroidal staining. The late fluorescence is 
restricted to spots. Hayreh found no typical pattern of metastases, either. Consequently, 
the diagnosis of a choroidal metastasis cannot be made solely on the basis of the 
fluorescein angiogram (Schiffer et al., 1978). 
Owing to the anterior location the vascular structure of the ins is in part 
immediately visible. Iridai capillaries normally do not leak. An iridai tumour standing out 
as a dark spot is regarded as benign. Mottled or diffuse leakage and weak fluorescence at 
the central margin of the tumour indicate malignancy (Demeler, 1981). 
Iridai metastases are more vascularized than can be established clinically and cause 
leakage of fluorescein (Freeman and Friedman, 1975). A network of vessels is seen, 
which fill in early phases and leak profusely. This leakage is not restricted to the margin 
of the mass, as in melanomas, but also occurs at the pupillary margin or other not 
tumour-related iridai structures (Kottow, 1978). According to Demeler (1981), marginal 
fluorescence occurs only in melanomas. In metastases he also did not observe the 
fluorescence at the tumour base, as seen in peripherally localized, highly prominent 
melanomas of the root of the iris. 
In connection with technical problems, fluorescein angiography in tumours of the 
ciliary body has been described only sporadically (Federman and McGuire, 1989; Fries 
and Cher, 1990). Obtaining data is possible if the iris also is involved in the process 
(Brovkina and Chichua, 1979). 
1.4.4 Echography 
Echography (ultrasonography, USG) plays an important part in the diagnostics of 
intraocular tumours, particularly in case of opaque media (cataract, vitreous 
haemorrhages) and in bullous retinal detachments with cloudy subretinal fluid 
(Lommatzsch, 1989). 
In 1956, echographic ocular examination was applied for the first time to patients 
with an intraocular tumour (Mundt and Hughes, 1956; Oksala and Lehtinen, 1957). 
Initially, only solid processes could be detected and no conclusion could be drawn 
regarding the histological nature (Buschmann, 1966; Bellone and Cagigrigoriu, 1969). 
Coleman in 1973 was the first to succeed in differentiating between benign and malignant 
lesions. Subsequently, more sophisticated echographic diagnostic criteria for the various 
intraocular tumours were laid down (Coleman et al., 1974; Ossoinig and Biodi, 1974). 
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Technique: the patient is preferably examined in the supine position. The comea 
and conjunctiva are anaesthetized locally and after application of a contact fluid 
(methylcellulose 2%), the transducer is placed in direct contact with the globe. The eye is 
then examined systematically in all quadrants. Any abnormalities found may be 
photographed or stored in a computer. Echographic examination gives the patient no 
discomfort (Jakobiec, 1978; Verbeek, 1985). 
At echographic examination tissue is scanned with a piezoelectric resonator crystal: 
the transducer. It emits pulses of ultrasound and is altematingly transmitter and receiver. 
After the sound emitted has engaged in interaction with the tissue (reflection, absorption, 
scattering) it is received back by the transducer. In ophthalmology, use is made of sound 
waves with frequencies from 8 to 12 MHz. The reflected sound energy is converted into 
an electronic signal and visualized by means of an oscilloscope or TV monitor. 
These echoes are reproduced unidimensionally by means of the A- (Amplitude) 
scan and bidimensionally by means of the B- (Brightness) scan. The amplitude of the 
echoes provides quantitative information on the acoustic properties of the tissues. The grey 
tone of the B-scan is a more qualitative measure of these properties. The anatomical 
morphological information in the Α-scan is limited to distances and dimensions of 
reflecting structures. The B-scan gives a bidimensional image the topography of which is a 
faithful representation of the anatomy. 
Membranes present in the vitreous humour can be differentiated with quantitative 
(Α-scan) and kinetic criteria. Solid lesions with a prominence of at least 0.5 mm can be 
detected by means of echography. However, for further differentiation of the pathology by 
means of the echogram several echo spikes, and consequently a longer tract, are required 
because it is necessary to evaluate degree of reflection, homogeneity, vascularity and 
attenuation. To be considered for echographic differential diagnostics, therefore, tumours 
must have a prominence of 2 to 2.5 mm or more. For this purpose the A- and B-scans 
supplement one another. This implies that a series of criteria are used in which both 
imaging techniques play a part. 
The height or amplitude of the echo spikes from the infrastructure of the tumour 
which are brought about by tissue inhomogeneities, vacuoles, necrotic zones, etcetera, is 
compared with the retinal reflectivity. With marked variations in the socalled acoustic 
impedance (product of sound velocity and mass density) these tumour echoes are relatively 
high, while they have a low amplitude in tissues composed of relatively small structures. 
In homogeneous tissues, with tightly packed cells, a relatively low degree of absorption 
will occur, which results in a gradual decrease of the amplitude of the echo spikes. It 
should be noted that the representation of this decrease in the Α-scan depends on the type 
of amplifier in the echo apparatus and on its adjustment. Numerous and irregular tissue 
interfaces in the tumour render the echographic image inhomogeneous (Coleman et al., 
1974; Ossoinig and Biodi, 1974). 
The attenuation of the ultrasound can be measured by means of an absorption 
coefficient, called the kappa angle, which is determined by the decrease of the amplitude 
of the echoes by the tumour mass (Ossoinig and Biodi, 1974; Verbeek, 1985). 
With the aid of the bidimensional B-scan it is possible to determine the shape of 
the lesion and the size of the tumour base. In choroidal melanoma, the choroid is 
infiltrated completely by homogeneous tumour tissue. In the echogram this leads to an 
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acoustic gap in the reflectivity pattern of the choroid. This is called the choroidal 
excavation, a term comparable to the papillary abnormality in glaucoma: the glaucomatous 
excavation. In melanomas this choroidal excavation is observed with a variable frequency 
(Coleman et al., 1974; Poujol, 1986). Incompletely known influences of the apparatus are 
undoubtedly involved here. 
From the infrastructure of the tumour fast, spontaneous movements can be 
recorded (vascularity) which are caused by the bloodstream in the tumour vessels. 
In large, prominent tumours attenuation of the ultrasound by the tumour mass is 
established; this is depicted as a shadowing in the orbital fat behind the tumour. Between 
the tumour mass and the orbital shadow the orbital fat pattern is intact (Coleman, 1975). 
Any penetration of the tumour through the sclera into extraocular structures can be 
established if the reflectivity of the tumour tissue is different from that of the surrounding 
orbital fat. In the low-reflective choroidal melanoma, a clear spot in the high-reflective 
orbital fat contiguous to the tumour is detected then. 
Apart from contact echography, immersion B-scan echography may be used. This 
method permits good examination of the anterior segment. When the transducer is applied 
directly to the globe, the region immediately behind the transducer lies in a dead zone (5 
mm large). This zone is followed by an area in which structures can only poorly be 
assessed. As a consequence, the first 5 to 8 mm of the eye cannot be inspected accurately. 
With the aid of a perspex cylinder (diameter 18 to 22 mm, height 20 mm) filled with 
methylcellulose 2% placed on the anaesthetized cornea, the comea, anterior chamber, iris, 
ciliary body and lens can be imaged adequately (Verbeek, 1990; Verbeek and 
Mitropoulos, 1991). An older immersion method uses a waterbath applied to the eye 
(Ossoinig, 1972). 
Uveal metastases at echographic examination as a rule show up as flat solid lesions 
with a relatively broad base (Coleman, 1973; Brink et al., 1988; Guthoff, 1988). More 
convex or lobular tumours are also observed (Coleman et al., 1974; Shields and Tasman, 
1977). The mushroom shape, typical of melanomas, is described only sporadically 
(Kerman and Fishman, 1987). The prominence of metastases is usually less than 7 mm 
(Poujol, 1986). 
A high initial echo, originating from the tumour surface and caused by the 
interface between the vitreous humour and the retina is followed subretinally by spikes of 
high reflectivity bunched closely together (Coleman, 1973; Chang et al., 1978; Poujol and 
Chaintron, 1988). The tumour is delimited posteriorly by a high scleral spike. The 
relatively high tumour echoes are caused by the numerous interfaces between groups of 
tumour cells and tissue partitions, intercellular substances and areas with necrosis 
(Ossoinig and Biodi, 1974). Owing to this non-homogeneous tissue structure, the internal 
tumour echoes of metastases form an irregular picture (Goes, 1981; Verbeek, 1985; 
Poujol, 1986; Bigar, 1988). When the intensity of the transmitted energy is reduced, the 
image of a metastasis remains solid, in contrast to melanoma (Coleman et al., 1974). 
A choroidal excavation is observed either not at all (Coleman et al., 1974; Gonvers 
et al., 1979; Kerlen, 1980) or only rarely (Neetens et al., 1984). Only Poujol (1986) 
described such an excavation in 42% of the patients. Vascularity is observed only 
sporadically (Ossoinig and Biodi, 1974; Neetens et al., 1984; Freedman and Folk, 1987). 
Neetens et al. (1984) and Coleman and Abramson (1989) described an orbital shadow in 
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large metastases. 
A few investigators point out that metastases may sometimes show a low 
reflectivity. These are tumours with closely packed, evenly distributed cells such as 
metastases of an oatcell carcinoma, seminoma, thyroid carcinoma and malignant skin 
melanoma, which as a rule have a regular infrastructure (Freyler and Egerer, 1977; 
Ossoinig and Harrie, 1983; Doro et al., 1984; Kerman and Findl, 1984; Verbeek, 1985; 
Brink et al., 1988; Guthoff, 1988). In these tumours, vascularity is often observed 
(Verbeek, 1985; Freedman and Folk, 1987). 
In metastases different malignancies are described as the primary tumours. This is 
the cause of the histological diversity of tumours that may metastasize to the choroid and 
of the fact that their echograms are less clear-cut than those of the malignant choroidal 
melanoma. For this reason, in the clinical and echographic diagnostics of tumours, the 
metastasis should always be differentiated from the homogeneous melanoma (Coleman, 
1973; Verbeek, 1985; Brink et al., 1988). 
Computer analysis of the spectral data of a solid process is a recent development 
in echography. It allows a quantitative analysis of echograms as obtained with the B-scan. 
This might allow a differential diagnosis between spindle В melanomas and mixed-
epithelioid melanomas and metastases (Thijssen and Verbeek, 1981; Reibaldi et al., 1988). 
According to Coleman and Lizzi (1983), this can even be done with 98% reliability. 
1.4.5 Computed tomography (CT scan) 
With the aid of computed tomography (CT scan), the eye can be examined in its relation 
to other structures in the orbit. The retina, choroid and sclera are depicted as one layer. 
Excentric thickening of this layer without inflammatory changes, associated masses, nerve 
thickening or muscle enlargement may be a sign of a neoplasm of the choroid (Bernardino 
et al., 1978). In tumours with a prominence less than 3 mm, echography is superior to CT 
scanning (Desjardins, 1986a; Peyman and Mafee, 1987). For examination of lesions of the 
ciliary body the CT scan is reported to be more suitable (Damato and Foulds, 1986). 
Computed tomography is said to be the examination of first choice for the 
detection of extrascleral growth (Peyster et al., 1985; De Keizer et al., 1986; Desjardins, 
1986a) and to be a good method for in-vivo determination of the size of the tumour 
(Peyster et al., 1985). 
In metastases, variable images of elevated or flat and diffuse masses are described 
(Mafee et al., 1985; Desjardins, 1986a; Peyman and Mafee, 1987). The tumours can be 
visualized better after contrast enhancement (Desjardins, 1986a; Yeo et al., 1983). An 
associated retinal detachment is observed frequently (Bellamy and Husband, 1985). 
Differentiation between metastases and melanomas of the choroid by means of the 
CT scan may be difficult (Mafee et al., 1985; Peyman and Mafee, 1987). 
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1.4.6 Magnetic resonance imaging (MRI) 
Magnetic resonance imaging (MRI) is based on manipulation of protons in tissues which 
may be regarded as elementary magnets. They may be aligned in parallel to the permanent 
magnetic field of the examination apparatus. Under the influence of high-frequency 
impulses the elementary magnets take up energy, which causes the net magnetization to 
turn to a direction perpendicular to the main magnetic field. After cessation of the 
impulses an alternating current is induced in the receptor coil: the MR signal (Guthoff and 
Seiler, 1989). The intensity of the signal depends on the proton density of the tissue, on 
the Tj relaxation time (the return of the protons to their original state), the T2 relaxation 
time (the description of the phase cohesion loss) and on the movements of the hydrogen 
nuclei (Chambers et al., 1987; Guthoff and Seiler, 1989; Kolodny et al., 1989). Higher 
resonance frequencies give MR images with a better signal-noise ratio (Kolodny et al., 
1989). 
MRI shows a clear distinction of an intraocular tumour from the vitreous humour, 
the sclera and the ciliary body. For this reason, MRI appears to be a more sensitive 
method for demonstration of extraocular growth than echography (De Keizer et al., 1989). 
Like the CT scan, however, MRI requires a minimal prominence of 3 mm for good 
visualization (Chambers et al., 1987; Mafee et al., 1987). 
Metastases display variable intensities at both ^ and Tj weighted images. The 
causes of this may be an accompanying haemorrhage, exudation, necrosis and the quantity 
of melanin (Haik et al., 1987b). In general, a hyperintensity is described in T, and T2 
weighted images of metastases (Chambers et al., 1987; Mafee et al., 1987; Peyman and 
Mafee, 1987; Guthoff and Seiler, 1989). For further contrast enhancement Gadolinium 
DTPA (Brab et al., 1991) or 31P (De Potter et al., 1991) may be used. 
1.4.7 Perimetry 
The visual field is that portion of space in which to the steadily fixating eye several 
objects are visible simultaneously. Small objects are perceived only if they are localized 
close to the visual axis of the eye. Larger and brighter stimuli are required to be perceived 
in the peripheral visual field. The purpose of perimetry is to perform a quantitative 
examination of the visual acuity in all parts of the visual field. Defects in the normal 
visual fields may be detected, quantified and plotted as contour lines, isopters, within 
which an identical object is observed (Harrington, 1956). 
A scotoma is an area of decreased visual acuity within an area of (relatively) 
normal visual acuity. It is called absolute if at the site of the scotoma no stimuli at all, 
regardless of size or brightness, are perceived. The site of the optic nerve constitutes such 
an absolute scotoma in the visual field. If a larger or brighter test object is observed, the 
scotoma is called relative (Harrington, 1956). 
In tumours changes in the visual field are caused by involvement of the retina and 
by the associated retinal detachment. The defect corresponds to the site of maximal 
damage to the retina. If the tumour breaks through into the vitreous, the neurofibrils 
appear to be forced aside rather than destroyed. In the latter event, there ought to be a 
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peripheral loss of function of the retinal area from which these fibres originate, which is 
not the case (Scott, 1957). Choroidal tumours situated anteriorly cause peripheral 
depression or sector defects in the visual field. Tumours in the posterior pole may cause 
scotomata. If ал associated retinal detachment is present, the visual field may assume 
some of its characteristics. In general, the deeper parts of the scotoma or the sector 
defects then correspond to the portion of the retina that is in contact with the tumour or 
that is situated at the site of the highest part of the tumour mass. This is surrounded by a 
zone of retinal detachment which causes a defect with sloping margins, not to be 
distinguished from a simple retinal detachment. For this reason, perimetry is of limited 
value for the differential diagnosis of retinal detachments and choroidal tumours with a 
secondary retinal detachment. However, in case of a tumour in the posterior pole, 
relatively often a visual field defect without breakthrough to the periphery occurs. This is 
rare in a simple retinal detachment. In case of a tumour such a breakthrough can only take 
place in case of a secondary retinal detachment situated inferiorly (Harrington, 1956; Reed 
and Drance, 1972). 
In metastases, defects in the visual field, next to blurred vision constitute the main 
symptoms (Abramson, 1984). Freedman and Folk (1987) established a defect of the visual 
field in 18 out of 58 patients with choroidal metastases (31%). The defect is described as 
either relative (Harrington, 1971) or as absolute in over half the cases (Van Dijk, 1978; 
Brink et al., 1988). Especially if the tumour invades the choriocapillaris an absolute 
central scotoma occurs due to early degeneration of rods and cones (Ferry, 1967). In most 
cases, such a scotoma rapidly increases in size. 
Sometimes, small tumours in the contralateral eye escape notice. Early detection 
may be possible by means of an accurate bilateral examination of the visual field (Manor 
et al., 1978). 
Successive perimetric examinations may be useful for the differential diagnosis of 
metastases and melanomas, because the size of the defect in most cases increases more 
slowly in melanoma cases (Manor et al., 1978). However, in general perimetric 
examination contributes little to the diagnosis of uveal metastases or to the determination 
of the extent of choroidal or retinal involvement. 
The correlation of the lesion with alterations of the visual field is not strong. This 
is probably due to the fact that in early phases the nutrition of the external retinal layers is 
not severely affected by the choroidal lesion. In later stages there is no good correlation 
because of the frequent occurrence of an associated retinal detachment (Thompson et al., 
1961). 
1.4.8 Electrophysíology 
1.4.8.1 Electro-oculography (EOG) 
Between the comea and the back of the eye a difference in electrical potential of 6 mV 
exists with the cornea positive to the posterior pole. This is called the standing potential. 
By applying electrodes near the canthus on both sides of the eye potential differences 
caused by eye movements can be registered indirectly. This registration is called the 
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electro-oculogram (EOG). The EOG consists of at least two independent potentials: a 
light-independent potential, the above-named standing potential, and a light-dependent one. 
Electro-oculography measures changes in potential caused by alterations in the adaptation 
state of the eye. During dark adaptation, the light-dependent potential decreases slightly. 
The lowest value, the socalled dark trough, is measured (Dt: the mean of the 
measurements at the 6th, 8th, 10th and 12th minutes). After illumination this potential 
increases slowly and reaches a peak: the light peak (Lp: the mean of the maximum values; 
if no real Lp is present the mean of the registrations between the 19th and 22th minutes is 
taken). After the light peak, the corneal positive oscillations vary in voltage in a damped 
sinusoidal manner (François et al., 1957; Pinckers, 1979; Berson, 1981). 
The pigment epithelium is probably responsible for the light-independent 
component of the EOG. The light-sensitive part depends on the activity of the 
photoreceptors and the inner nuclear layer of the retina (Berson, 1981). 
An important EOG criterion is the Arden ratio, which is defined as the quotient of 
light peak and dark trough. This Lp/Dt ratio in general is higher than 1.8 in normal test 
subjects (Arden et al., 1962; Pinckers, 1979). 
Very little is known about the EOG in metastases. It is mentioned only incidentally 
in a few published case histories as one of the examinations performed (Ponte and 
Lauricella, 1977; Hayreh et al., 1982; Lodato et al., 1983). We ourselves have 
constructed a diagram to differentiate with the aid of the EOG alone between lesions 
suspected of being a malignant melanoma of the choroid or the ciliary body, choroidal 
naevi, choroidal metastases and rhegmatogenous retinal detachments. We concluded that 
no correct classification of metastases is possible with this method. As a rule, a lowered 
Lp/Dt ratio with a normal dark trough was found in metastases (Brink et al., 1989/1990). 
1.4.8.2 Electroretinography (ERG) 
Illumination of the retina is followed by hyperpolarization of the sensory elements in the 
retina, causing a change in electric potential. This mass response is called the 
electroretinogram (ERG). 
The ERG consists inter alia of an early cornea-negative a-wave and a comea-
positive b-wave. The a-wave is composed of a rod and a cone component. The b-wave is 
largely determined by the Müller fibres but the bipolar cells also play a part. The 
receptors are dependent on the choroidal circulation. If this is impaired, the a- and fa-
waves decrease. The Müller fibres are supplied by retinal vessels. Impairment of this 
circulation leads to a decreasing b-wave. 
ERG components registered at the retina can also be measured at the comea with a 
similarly shaped wave. The ERG is usually recorded by means of a contact lens electrode 
on the anaesthesized comea. The patient is seated in front of an illuminated sphere and 
various light stimuli are offered during different adaptation conditions. Separate 
stimulation of the rods and of the cones is possible (François and De Rouck, 1973; 
Berson, 1981). 
In the literature, ERG data of patients with metastases are described only very 
summarily. The recordings are generally described as subnormal or abnormal (Sundmark, 
1958; Straub, 1961; Famarier et al., 1972; Ponte and Lauricella, 1977; Hayreh et al., 
1982; Lodato et al., 1983). 
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1.4.9 Biopsies and punctures 
Various methods of establishing a cytological or histological diagnosis of an intraocular 
lesion without sacrificing the eye exist. Ophthalmological biopsy was performed as early 
as 1895 (von Grosz, 1929). 
The biopsy method currently most widely used is fine needle aspiration biopsy. 
Cytopathological techniques have played an important part in the diagnostics of 
ocular diseases (Green, 1984). According to a number of authors, fine needle aspiration 
biopsy of solid intraocular tumours may be regarded as a reliable and relatively safe 
diagnostic technique. Owing to lack of large groups and long follow-up, it cannot yet be 
applied as a routine examination. Its diagnostic use is considered to be restricted to the 
following indications: 
1. patients with a possible neoplastic intraocular lesion with major diagnostic 
uncertainties; 
2. patients who clinically have an intraocular metastasis without a primary non-ocular 
malignancy being known and without another metastasis accessible to biopsy being 
present; 
3. patients who desire a histopathological confirmation of the clinical diagnosis before 
agreeing to the treatment proposed (Augsburger and Shields, 1984). 
Biopsy should only be performed if it affects the therapeutic management (Jakobiec et al., 
1979). 
At needle biopsy the approach to an intraocular tumour depends inter alia on the 
localization of the lesion. Mostly, a 22 to 30 gauge needle is used which is attached to an 
aspiration syringe. For iridai and iridociliary tumours shorter and finer needles are used 
than for lesions of the posterior segment. 
When the media are clear, the tumour is punctured with direct visualization, with 
or without use of an operation microscope, indirect ophthalmoscopy and fundus contact 
lens. In case of opaque media echography is used. 
In posterior uveal melanomas and sometimes in choroidal metastases the pars plana 
over 90° outside the tumour quadrant is used as the puncture site. The vitreous humour 
situated between the pars plana and the tumour then acts as a buffer to stop any tumour 
cells on the biopsy needle. In choroidal metastases, if tumour dissemination in the orbit is 
not a matter of concern, the tip of the needle is sometimes introduced directly into the 
tumour tissue from the scleral side after preparing a lamellar scleral bed at the tumour 
site. In iridai and iridociliary tumours, the chosen puncture site is the limbus, 30 to 45° 
removed from the tumour quadrant. In this case, the aqueous humour serves as a buffer 
zone. A limbal route is also used in ciliary melanomas in aphakic eyes. 
After the needle tip is inserted into the tumour, cells are aspirated by abruptly 
retracting the piston of the syringe. Apart from tumours with a liquid consistency, as a 
rule no tissue is seen in the syringe. The entire specimen is localized inside the needle. 
The piston is released, the needle is introduced farther into the tumour and another 
aspiration is carried out. This procedure may be repeated several times. Subsequently, the 
needle is retracted slowly in a straight line. If the puncture site bleeds, the bleeding is 
stopped by means of digital pressure on the globe. The puncture opening in the sclera is 
closed with a pre-placed suture, a lamellar scleral bed with interrupted sutures. 
In preparation for the cytological examination, a new syringe is attached to the 
used needle and 1-2 ml of a sterile saline solution or 50% alcohol is aspirated. In this way 
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the cellular specimen is sucked into the lumen of the syringe and small aspirations may 
become visible. This syringe is sent immediately to the pathologist (Jakobiec et al., 1979; 
Augsburger and Shields, 1984; Karcioglu et al., 1985). 
The evaluation of the biopsy specimen requires not only an ophthalmologically 
specialized pathologist but also an experienced cytopathological team (Jakobiec et al., 
1979). 
The cytological diagnosis of malignancy or benignancy made by means of this 
needle biopsy method can be confirmed histologically in 94.3% of the cases. The cytology 
in metastases is often insufficiently clear to indicate the precise nature of the primary 
tumour. In melanomas, the cell type of the punctures may not correspond well with the 
histology (Augsburger et al., 1985). 
At aspiration biopsy, some intraocular bleeding virtually always occurs after 
withdrawal of the needle. It is always mild and clears up spontaneously. A 
rhegmatogenous retinal detachment caused by the hole in the retina is never observed, nor 
has traction on the retina ever been described (Jakobiec et al., 1979; Augsburger and 
Shields, 1984). Dissemination along the needle tract, subconjunctival tumour growth or 
growth in the orbit was not observed by Augsburger and Shields (1984), nor were 
systemic metastases. After enucleation and histological examination, Augsburger (1985) 
found tumour cells along the needle tract in only a few cases. Karcioglu et al. (1979), 
however, encountered clusters of tumour cells in the tract in one-half and Glasgow et al. 
(1988) even in over one-half of the cases. To what extent this also meant tumour growth 
was not clear. Tumour cells in the needle tract were found in a larger percentage of the 
cases after transscleral needle biopsy than after indirect biopsies (Glasgow et al., 1988). 
Tumour growth was then also observed more often (Jensen and Andersen, 1959). 
Decrease of the visual acuity due to the biopsy was never described (Augsburger et 
al., 1985). 
In tumours with subretinal fluid, aspiration of the subretinal fluid can be 
performed by puncture of the fluid space after scleral depression. This is considered to be 
a good examination method in case of doubt concerning the nature of the tumour 
(Sternberg et al., 1984). Meisner used this technique as early as 1923. Bee (1968) advised 
against this technique in connection with the risk of implantation metastases, but other 
investigators did not encounter this complication (Sternberg et al., 1984). In choroidal 
metastases, this method has been applied successfully several times (Rathschuler and 
Romanelli, 1971; Sternberg et al., 1984). 
In tumours of the anterior uvea with cells in the aqueous humour, vitrectomy or 
puncture of the anterior chamber or vitreous humour may be useful (Font et al., 1967). 
This method has been used a few times in metastases (Char et al., 1980; Engel et al., 
1981; Scholz et al., 1983). So far, however, insufficient data are available to establish the 
usefulness and safety (Char et al., 1980). 
Iridectomy or iridocyclectomy may be useful in visible iridai lesions (Sanders, 
1952; Font et al., 1967; Вес, 1968; Barbee et al., 1971). 
Transscleral incision biopsies of posterior uveal tumours directly through the 
sclera result in a good histological diagnosis (Sanders, 1952). However, tumour 
dissemination at the biopsy site and in the orbit occurs frequently (Bee, 1968; Augsburger 
and Shields, 1984). 
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Constable et al. (1980) described chorioretinal biopsy under hypotension. 
However, this entails a considerable risk of an intraocular haemorrhage with all its 
consequences (Foulds et al., 1985). 
1.4.10 Radioactive phosphorus (32P) and other isotopes 
In ophthalmological tumour diagnostics, radioactively labelled phosphorus ("P) is the 
principal isotope used (Desjardins, 1986). The examination is based on the principle that 
malignant tumour cells take up and incorporate more 32P than normal tissue. The beta-
radiation at the site of the tumour can be quantified with a counter and compared with a 
control site (Shields, 1983). Only metabolically active tumours give a positive test result. 
Thomas et al. (1952) were the first to apply this method for the diagnosis of 
intraocular tumours. Using a small Geiger counter, measurements were carried out at the 
tumour site and in other parts of both eyes, 30, 60 and 90 minutes after intravenous 
injection of 32P. The eye was then enucleated and the measurement repeated. They 
concluded that with this method, identification of intraocular tumours could be improved. 
The examination was limited to tumours situated anteriorly in the eye (Thomas et al., 
1952; Dunphy, 1957). 
Since a number of non-malignant conditions such as inflammatory lesions also 
showed an increased uptake of the isotope, the test was modified by also measuring 24 
hours after administration of 32P. A relative decrease was then established in inflammatory 
processes, an increase in malignant lesions (Eisenberg et al., 1954; Temer et al., 1956). 
The 32P test fell into disuse because of inaccuracy in posteriorly located tumours. 
Hagler et al. (1970) modified the test. In tumours of the posterior pole, they opened the 
conjunctiva and carried out transscleral measurements instead of measuring 
transconjunctivally, as was usual. They once more emphasized the importance of correct 
localization of the lesion before the measurement. This requires a diameter larger than 6 
mm (Ruiz and Howerton, 1975; Desjardins, 1986). In opaque media, echography may be 
applied for correct localization of the lesion (Shields, 1978). 
The indication for the 32P uptake test is differentiation between benign and 
malignant lesions and especially the differential diagnosis of melanoma versus naevus and 
melanoma versus haemangioma. Differentiation between melanomas and metastases is not 
possible (Ruiz and Howerton, 1975; Shields, 1978; Gysin, 1979; Desjardins, 1986). 
The accuracy of the differentiation between benign and malignant lesions is high, 
over 95% (Jarrett, 1976; Shields, 1978; Goldberg et al., 1980; Desjardins, 1986). 
A transconjunctival measurement is regarded as positive if the increase amounts to 
over 30%; with transscleral measurement, the increase has to be over 60% (Hagler et al., 
1970; Chua, 1974). Other investigators apply other limits, e.g. a lower limit of 40% 
(Lommatzsch et al., 1984), of 50% (Shields, 1978) or of 100% (Ruiz and Howerton, 
1975). The transscleral method therefore is more sensitive than the transconjunctival one. 
An increase of over 100% occurs only in malignancies. 
The measurement at the site of the lesion is compared with a control site where no 
lesion is present. Initially, the other eye was used for this purpose (Eisenberg et al., 
1954a) but later, use was made of a normal part of the same eye (Ruiz and Howerton, 
1975). 
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For 6 weeks after an operation the test is unreliable and may give a false-positive 
result, especially with transconjunctival measurement This occurs in inflammations and, 
less frequently, in haemorrhages and haemangiomas (Eisenberg et al., 1954, Hagler et al , 
1970, Chua, 1974, Lommatzsch, 1977, Shields, 1977b/1978, Van Dijk, 1978, 
Lommatzsch et al , 1984) 
False-negative results as a rule are to be attributed to technical errors such as 
incorrect localization of the tumour and poor standardization of the equipment (Chua, 
1974) When the tumour is in the resting phase or if there are benign cells, haemorrhages 
or necrosis between the tumour and the probe, a false-negative test result may also be 
obtained False-negative values are found particularly often in malignant lesions of the 
ciliary body, probably owing to the thick tissue layer between the tumour and the probe 
(Goldberg et al , 1980) For iridai tumours, also, the method is not suitable (Hagler et al , 
1970, Gysin, 1979, Lommatzsch et al , 1984) 
No major complications of the 32P uptake test are known Theoretically, spread of 
tumour cells is possible due to manipulation during the measurement This has not been 
demonstrated (Shields, 1978, Desjardins, 1986) Retinal and vitreous haemorrhages may 
occur, as may occlusion of the central retinal artery (Kanski, 1984) No oncogenic side 
effects on haematological cells are known (Shields, 1978) 
The first description of the 12P uptake test in metastases was published by Thomas 
et al (1952) As mentioned before, differentiation from melanomas is not possible 
Slowly growing and relatively acellular tumours such as metastases of a scirrhous 
breast carcinoma may give a negative or unclear result (Chua, 1974) Larger numbers of 
patients with metastases were described by Jarrett (1976), Lommatzsch (1977), Shields 
(1978), Lommatzsch et al (1984) and Desjardins (1986) 
Use of gamma cameras for the diagnosis of intraocular tumours has the advantage 
that the technique concerned is noninvasive, that images are obtained rather than counts, 
and that the test can be repeated and may have prognostic value (Packer, 1984) The 
isotopes used include quinohne labelled with Iodine-125 and Iodine-123, which have an 
affinity for pigmented structures An amelanotic melanoma cannot be localized with these 
isotopes and heavily pigmented benign lesions show a positive uptake Moreover, they 
have short half-lives (Leopold et al , 1964, Packer et al , 1977) 
Localization of tumours with labelled melanin precursors could make an important 
contribution Although in that case amelanotic melanomas would show no uptake, and 
benign proliferative lesions would give a false-positive value, it is possible to differentiate 
between uveal melanomas on the one hand and metastases and haemangiomas on the 
other Metals prove to have an affinity for melanin Therefore radioactive indicum-111 
bleomycin, gallium-67 citrate, lead-203 tns and technetium-99 ferroascorbate inter alia 
have been tested as isotopes for tumour diagnostics However, these isotopes in general 
showed insufficiently selective uptake and the success was limited (Wilson and Boyd, 
1976, Packer et al , 1977, Van Dijk, 1978, Packer, 1984) 
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1.4.11 Transillumination 
Transillumination may provide useful information for the evaluation of suspected 
intraocular tumours. The principal techniques are: 
- transpupillary transillumination: the light source is placed in the conjunctival cul-
de-sac at the level of the tumour. It is then determined ophtha!moscopically 
whether or not the lesion is pervious to light; 
- transscleral transillumination: the light source is held against the sclera across from 
the tumour. This method is used for exact determination of the tumour base for, 
inter alia, the "P uptake test. In tumours situated posteriorly, a conjunctival 
incision is necessary; 
- transillumination with ophthalmoscopy: the light source is placed at the site of the 
lesion which is then inspected with the ophthalmoscope. 
The transmission of light is in principle blocked by pigmented lesions or blood. Non-
pigmented tumours and serous detachments allow light to pass (Shields, 1983; Amé and 
Mathis, 1986). 
In the differential diagnosis of uveal melanomas, a diaphanous lesion is suggestive 
of a metastasis. A lightly pigmented melanoma, however, may present the same image 
(Ferry, 1967; Reese, 1976; Ferry, 1978; Amé and Mathis, 1986). In smaller tumours, 
also, a normal transmission of light may occur (Dunphy et al., 1958). 
1.4.12 Immunological techniques 
Char and Christensen (1980) determined the level of immune complexes in the serum of 
patients with a choroidal tumour. Values higher than 25 μg/ml were classified as 
abnormal. Such high values were measured in nine out of 11 patients with choroidal 
metastases and in ten out of 43 patients with a choroidal melanoma (of whom six patients 
also suffered from an autoimmune disease, which affects the immune complex level). 
They concluded that immune complexes cannot be used as the sole diagnostic criterion, 
but that combination with a carcinoembryonic antigen (CEA) assay is useful for the 
diagnosis of intraocular tumours. 
Char (1977) described a number of immunological techniques. Leukocyte 
migration inhibition assay (a test for cell-mediated immunity) in vitro gave a distinctly 
different result in metastases than in melanomas. With delayed hypersensitivity skin tests 
with a soluble melanoma antigen, the results were significantly more often positive in 
melanomas than in metastases of the uvea. The rosette assay is an immunological test for 
T-cellular immunity. This test, also, gave distinctly different values in metastases than in 
melanomas. 
Donoso et al. (1984) in a patient with a histologicaly confirmed choroidal 
metastasis without a known primary tumour used monoclonal antibodies that bound 
selectively to the tumour tissue. 
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1.4.13 Histological examination 
The group of patients with uveal metastases in which histopathological examination was 
performed constitutes a selected population. Often, enucleation was performed because of 
complications, for example in the form of unbearable pain in secondary glaucoma, or on 
the erroneous diagnosis of malignant melanoma (Ferry, 1973). 
Tumour emboli reach the eye via branches of the ophthalmic artery. Histological 
examination sometimes reveals malignant cells in the blood vessels (Castro et al., 1982). 
Uveal metastases arise as emboli of malignant tumour cells that get stuck in the 
small blood vessels of the choroid. These cells appear primarily to proliferate in the 
venules. Once the vessel is blocked, a further increase of cells takes place, which cells 
break through the vessel wall and invade the perivascular space. From here, the cells may 
invade other vessels. When the perivascular space is reached, the tumour infiltrates further 
between the layers of the choroidal stroma, choosing the line of least resistance (Cordes, 
1944; Duke-Elder and Perkins, 1966) (see Chapter 1.2.2). 
The fast growth of cells round the blood vessels may cause erosion and lead to a 
haemorrhage in the metastasis and the environment of the lesion (Cordes, 1944). 
Consequently, there are many reports of recent or old haemorrhages found at histological 
examination (Sattler, 1926). 
The impairment of the circulation may cause necrosis through ischaemia (Cordes, 
1944). It may be due to an intratumoral haemorrhage or to excessive growth of malignant 
tumour cells (Castro et al., 1982). Jensen (1970) reported necrosis at histological 
examination in one-half of the patients with a uveal metastasis. The necrotic areas are 
usually sharply delimited (Sattler, 1926). 
Only a moderate lymphocytic infiltration occurs in the choroid directly adjacent to 
the lesion (Sattler, 1926). Polymorphonuclear leukocytes may be encountered at the 
margin of the area with necrotic tumour cells (Castro et al., 1982). In the metastatic tissue 
many choroidal vessels are destroyed (Sattler, 1926). 
A desmoplastic reaction may be observed in the stroma of certain metastases and is 
particularly distinct in scirrhous breast carcinoma. Calcifications of blood vessel walls are 
sometimes striking phenomena (Castro et al., 1982). 
Sometimes, miliary metastatic deposits are encountered in the choriocapillaris. 
Small diffuse tumours appear to infiltrate the normal choroid and to displace it; 
histologically there are then often multiple foci (Shields, 1983). Bruch's membrane as a 
rule remains intact. The overlying retina is involved only rarely (Cordes, 1944; Duke-
Elder and Perkins, 1966). 
Jensen (1970) described rupture of Bruch's membrane in four out of 19 patients 
with a uveal metastasis. In melanomas, a rupture is described more frequently (Castro et 
al., 1982). 
In iridai metastases, malignant cells sometimes tend to grow along the anterior 
edge of the iris. Such diffuse tumours may constitute a lesion that is only one or two cell 
layers thick (Shields, 1983). 
A choroidal metastasis may invade the optic nerve and the sclera and perforate to 
extraocular structures (Sattler, 1926; Cordes, 1944; Ginsberg et al., 1970; Daicker and 
Gysin, 1980; Gartner, 1985). Episcleral expansion of uveal metastases is rare, however, 
and described only incidentally (Corrado, 1928; Hoffmann, 1933; Cohen, 1937; Cordes, 
1944; Maxwell, 1954; Casanovas, 1966). Jensen (1970) described scleral invasion in three 
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out of 19 patients with uveal metastases The extraocular extension often takes place via 
blood vessels and nerves (Sattler, 1926). Ginsberg et al. (1970) collected data from the 
literature on 117 patients with metastatic infiltrations of the optic nerve In 39% of the 
cases infiltration in the optic nerve was caused by growths from choroidal and retinal 
metastases 
The histopathological picture of a metastatic uveal lesion depends on the primary 
tumour which has generated the metastasis. However, just as in metastases elsewhere in 
the body, lack of cellular differentiation may result in loss of charactenstic features of the 
tumour type in question In such cases it is frequently impossible to determine the primary 
cancer solely on the basis of the histopathological examination of the ocular metastasis 
(Hogan and Zimmerman, 1962; Duke-Elder and Perkins, 1966, Castro et al., 1982, 
Spencer, 1986) 
Better-differentiated metastatic lesions may retain certain histological and 
histochemical features of the primary tumour Special staining methods or electron 
microscopy may be necessary (Shields, 1983) 
Many metastases produce intracellular mucus If this cannot be demonstrated with 
routine haematoxylin or eosin staining, use of vanous histochemical dyes may render 
further diagnostics possible in many cases As a rule the mucus production is minimal, but 
sporadically it may be massive (Jakobiec et al , 1987) 
The growth pattern and the cellular characteristics of metastases are often identical 
to those of the primary tumour (Ferry, 1967) 
Metastases of breast cancer are in general reasonably well differentiated and retain 
features of an adenocarcinoma Typical aspects are solid epithelioid nests or glandular 
structures As a rule there are alveoli of different sizes with large round or polygonal cells 
with a large nucleolus The stroma between the alveoli is sometimes scarce In other 
cases, however, big masses of fibrous tissue are present (Duke-Elder and Perkins, 1966; 
Shields, 1983, Spencer, 1986) 
Some lesions produce mucus, which can be demonstrated using alcian blue, 
colloidal iron and mucicarmine (Spencer, 1986). 
The choroidal tissue is compressed and atrophic Degenerative changes of the 
stroma manifest themselves with disintegration of chromatophores and release of tumour 
pigment (Sattler, 1926, Cordes, 1944; Duke-Elder and Perkins, 1966; Castro et al., 
1982) 
Uveal metastases of bronchial carcinomas are often not differentiated, but 
exceptionally they may show an epithelioid appearance (Spencer, 1986). Metastases of 
oatcell carcinomas contain small, closely packed anaplastic cells without an alveolar 
pattern (Shields, 1983). Sometimes, a biphasic pattern of large and small cells may be 
present (Spencer, 1986) Bronchial adenomas (carcinoid) may have a glandular structure 
(Shields, 1983) 
Malignant cutaneous melanomas which metastasize to the uvea may sometimes be 
difficult to differentiate from primary malignant melanomas of the uvea. However, unlike 
the primary uveal tumours in which different cell types may be found, metastases as a rule 
consist entirely of epithelioid cells Also, naevus cells at the tumour base are rarely 
described in metastases. Tumour cells in the uveal vessels are never encountered in 
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primary melanomas, but are sometimes found in metastases (Font et al., 1967; Albert et 
al., 1972). 
Although metastases of a malignant cutaneous melanoma frequently are not 
pigmented, microscopy as a rule will reveal signs of pigment production (Spencer, 1986). 
In uveal metastases, mitoses are usually more abundant and there is a more 
pronounced stromal reaction than in the primary uveal melanoma. An important feature of 
metastases is the large amount of connective tissue that may be present (Hogan and 
Zimmerman, 1962; Jensen, 1970). 
Metastases from the digestive tract produce much mucus. Metastases of a 
carcinoma of the prostate often retain an adenoid or glandular pattern (Spencer, 1986). 
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1.5 Differential diagnostics 
1.5.1 Introduction 
The diagnostics of uveal metastases is complicated. Even before a primary malignancy 
elsewhere in the body is known, an intraocular metastasis may have occurred, and this 
tumour may assume different forms (Hutchison and Smith, 1979; Amé and Mathis, 1986). 
The clinical context and the course of the condition are of great importance for the correct 
diagnosis (Amé and Mathis, 1986). If in a patient with an ocular tumour a malignancy 
elsewhere in the body is known, the physician should be alert to the possibility of ал 
intraocular metastasis (Shields, 1983, Hunyor, 1984). 
As described in the preceding chapter, in the diagnostics of uveal metastases use is 
made of a large number of examination techniques because there exists no single method 
with which the ophthalmological diagnosis can be made with 100% certainty. It is only by 
histopathological examination of the tumour tissue that the clinical diagnosis can be 
confirmed. However, pigmentation of the uvea and compression of the tumour tissue may 
mask characteristic cellular patterns in metastases (Jensen, 1970). The cytological picture 
of metastases of a bronchial carcinoid may be similar to that of an amelanotic melanoma 
(Font et al., 1966) and the histological differentiation between primary uveal melanomas 
and uveal metastases of a malignant cutaneous melanoma is difficult (Font et al , 1967). 
Consequently, the diagnosis of uveal metastases may pose a problem not only to the 
clinician but sometimes to the pathologist as well An extensive description of the 
differential diagnostics is therefore necessary. 
What conditions have to be considered concerning the differential diagnosis of 
uveal metastases depends on the localization of the tumour in the eye (Michelson et al., 
1979; Shields, 1983). Where choroidal metastases are concerned, differential diagnosis of 
(amelanotic) malignant melanoma, (amelanotic) naevus, haemangioma and posterior 
sclentis is of particular importance. Choroidal metastases have also to be differentiated 
from other multifocal little-pigmented lesions (Arne and Mathis, 1986). Table 1.5.1.1 
presents a survey of some conditions that are mentioned in the differential diagnosis of 
choroidal metastases 
Metastases of the ins and of the ciliary body have to be differentiated, apart from 
inflammatory conditions such as tuberculosis, sarcoidosis and syphilis from, in particular, 
other, benign and malignant tumours of the ins (Mayer and Nassar, 1958). The most 
relevant in the differential diagnosis are amelanotic melanoma, leiomyoma, granulomatous 
inflammation and endophthalmitis (Shields, 1983: Table 1.5.1.2). In older literature 
emphasis is laid on inflammatory processes, particularly tuberculosis (Méngot de Treigny, 
1921; Lopes d'Andrade, 1949). 
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Table 1.5.1.1 Differential diagnostics of choroidal metastases 
Stephens and Shields, 1979 
Amelanotic and pigmented melanoma 
Haemangioma 
Choroiditis with retinal detachment 
Cytomegalic inclusion retinitis 
Lymphoid hyperplasia of the uvea 
Leukaemia 
Lymphoma 
Reticulum cell sarcoma 
Shields, 1983 
Amelanotic naevus 
Amelanotic melanoma 
Haemangioma 
Postenor sclentis 
Osteoma 
Retinitis and choroiditis 
Rhegmatogenous retinal detachment 
Harada's disease 
Uveal effusion syndrome 
Central serous chorioretinopathy 
Amé and Malhis, 1986 
Amelanotic naevus 
Amelanotic melanoma 
Haemangioma 
Posterior sclentis 
Osteoma 
Viral and mycotic infections 
Rhegmatogenous retinal detachment 
Harada's disease 
Congenital hypertrophy of pigment epithelium 
Toxic retinopathy 
Diffuse lymphoid hyperplasia of the uvea 
Reticulum cell sarcoma 
Leukaemia 
Multiple uveal melanocytomas 
Wharam and Schachat, 1989 
Melanoma 
Osteoma 
Haemangioma 
Postenor sclentis 
Harada's disease 
Uveal effusion syndrome 
Disciform scar 
Suhretinal haemorrhage 
Table 1.5.1.2 Differential diagnostics of iridai metastases (Shields, 1983) 
Amelanotic melanoma 
Leiomyoma 
Granulomatous intis 
Endophthalmitis 
Ectopic lacnmal gland 
Juvenile xanthogranuloma 
Foreign body 
The diagnosis of uveal metastasis is often erroneously not made. Ferry (1973) and Ferry 
and Font (1974) described 227 patients with histologically confirmed metastases to the eye 
and orbit. In only 82 patients (36.1%) the clinical diagnosis, made preoperatively or prior 
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to autopsy, proved to be correct. In 57 of these patients the primary tumour was known. 
In 127 patients (55.9%) a different diagnosis was made, including 'intraocular tumour' 43 
times and malignant melanoma 31 times (Table 1.5.1.3). 
Table 1.5.1.3 
Diagnosis 
Preoperative or ante mortem clinical diagnosis in 227patients with 
metastases to ophthalmic structures * 
N 
82 
43 
31 
17 
13 
5 
18 
Number of patients 
% 
36.1 
18.9 
13.7 
7.5 
5.7 
2.2 
7.9 
Metastasis 
Intraocular tumour 
Malignant tumour 
Glaucoma 
Orbital mass 
Retinal detachment/tumour 
Miscellaneous 
Not stated 18 7 9 
* Ferry, ¡973; Ferry mul Font, ¡974; three paliems (1.3%) metastasis m optic nerve only; 28 patients 
(12.3%) metastasis m orbit only; 30 patients (13.2%) apart from uveal metastasis abo metastasis in optic 
nerve and/or orbit 
In a study by the same authors, regarding iridai metastases, the clinical diagnosis was 
correct in only ten out of 26 patients (38%) (Ferry, 1973; Ferry and Font, 1975). In nine 
of these ten patients the presence of a primary tumour elsewhere in the body was known 
(Table 1.5.1.4). 
Table 1.5.1.4 Preoperative or ante mortem clinical diagnosis in 26 patients with 
metastases to the anterior segment * 
Diagnosis Number of patients 
Metastasis 
Iridocyclitis with secondary glaucoma 
Malignant melanoma 
Intraocular tumour 
Chronic glaucoma 
10 
5 
4 
4 
1 
38 5 
19.2 
15.4 
15.4 
3.8 
Not stated 7.7 
* Ferry, 1973; Ferry and Font, 1975 
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In case of intraocular tumours, the possibility of uveal metastases should always be 
kept in mind. However, several intraocular conditions may mistakenly be regarded as 
metastases. Michelson et al. (1979) described 13 such pseudometastases of the choroid, 
including six inflammatory processes (Table 1.5.1.5). In nine of the 13 patients, a 
malignancy elsewhere in the body was known, and this constituted the main cause of the 
erroneous diagnosis, as also mentioned earlier by Algan et al. (1965). 
Table 1.5.1.5 Conditions mistaken for uveal metastases (Michelson et al., 1979) 
Clinical diagnosis 
Malignant choroidal melanoma 
Choroidal haemangioma 
Subretinal granuloma (possible sarcoidosis) 
Subretinal granuloma (rubella retinopathy) 
Cytomegalic inclusion retinitis (twice) 
Presumed ocular histoplasmosis syndrome 
Serous detachment of the retinal pigment epithelium 
Excentnc haemorrhagic exudative chorioretinopathy (disciform) 
Choroidal effusion secondary to sclentis 
Subfoveal haemorrhage secondary to thrombocytopenic purpura 
Aphakic choroidal detachment 
Myelinated nerve fibers 
Accordingly, the diagnosis of uveal metastases is frequently missed but also erroneously 
made in a number of cases. The differential diagnosis of metastases of the uvea is 
therefore very important. In this chapter a number of conditions that have to be 
differentiated from uveal metastases will successively be described. Extensive attention 
will be paid to the findings in the principal differential-diagnostic conditions: melanomas, 
naevi and haemangiomas of the uvea. The aetiology and therapy of these conditions will 
also briefly be discussed. 
The discussion of a number of other lesions will be restricted to their main 
differential-diagnostic features. A subdivision is made into lymphoproliferative conditions, 
other intraocular tumours, inflammatory diseases, intraocular haemorrhages, detachments 
of the retina, pigment epithelium and choroid and miscellaneous symptoms and disorders. 
1.5.2 Malignant melanoma 
The amelanotic malignant melanoma of the uvea is the main lesion that has to be 
differentiated from a uveal metastasis (Shields, 1983). 
In 1 to 2% of the patients of whom an eye was enucleated on the diagnosis of 
malignant melanoma, histopathological examination proved the lesion to be an intraocular 
metastasis (Ferry, 1964; Howard, 1969; Shields and Zimmerman, 1973; Colombo and 
Carnevali, 1985). Zero to 2% of the iridai 'melanomas' prove to be metastases (Ferry, 
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1965; Shields, 1983). On the other hand, 4% of all metastases reportedly are mistakenly 
enucleated as melanomas (Shields and McDonald, 1973). 
Metastases of breast cancer are correctly diagnosed in 93% of the cases. 
Metastases of a pulmonary carcinoma, on the other hand, are mistaken for a melanoma in 
59% of the patients. In most patients of whom an eye with an intraocular metastasis is 
enucleated on the erroneous diagnosis of melanoma, the lesion proves to be a metastasis 
of a pulmonary carcinoma. This holds particularly true of mushroom-shaped tumours 
(Jarrett, 1976; Ossoimg and Hame, 1983; Verbeek, 1985). 
The incidence of uveal melanomas is four to nine per 1.000.000 of the population 
(Lommatzsch et al., 1985; Egan et al., 1988; Mahoncy et al., 1990). The sex distribution 
is approximately 1:1 (Wilder and Paul, 1951; Paul et al., 1962) although sometimes a 
slightly higher incidence in females (Bonmn, 1986) or in males (Mahoney et al., 1990) is 
reported Among non-white races the condition is rare (Wilder and Paul, 1951; Paul et 
al., 1962, Scotto et al , 1976, Margo and Mclean, 1984) The melanoma is diagnosed as 
a rule in the sixth and seventh decades and occurs rarely in children and adolescents 
(Wilder and Paul, 1951, Paul et al , 1962; Barr et al , 1981, Egan et al., 1988). Patients 
with iridai melanomas are on the whole 10 to 20 years younger than patients with 
choroidal melanomas (Duke and Dunn, 1958, Rones and Zimmerman, 1958; Geisse and 
Robertson, 1985). 
Uveal melanomas reportedly rarely coexist with other extraocular malignancies 
(Algan et al , 1965; Lischko et al , 1989) Jensen (1963) in 4 to 6% of the patients 
described a second independent malignancy in addition to the uveal melanoma, which is 
higher than the frequency of multiple malignancies in other tumours Char (1989) 
describes a percentage of 6 to 10% in melanomas, and Hart (1962) even of 14%. In one 
case, the malignant uveal melanoma was described as a third (Morgan et al., 1973) and in 
one other case as a fourth primary tumour (Pheasant et al , 1979) 
Turner et al. (1989) believed that the prevalence of malignancies was increased in 
patients with a melanoma, that gynaecological tumours, in particular, occur more 
frequently and that a connection may exist between cutaneous and uveal melanomas. A 
common aetiological factor for the occurrence of uveal and cutaneous melanomas may 
exist (Gilbert el al , 1987, Lischko et al., 1989). According to other authors, however, 
this association is unusual (de Bustros et al., 1985) In patients with cutaneous 
melanomas, uveal naevi, on the other hand, are said to occur more frequently (Albert et 
al., 1983). Oosterhuis et al (1982) described the 'familial atypical multiple mole 
melanoma syndrome' (FAMMM syndrome) which occurs very rarely. 
In some articles, an association of uveal melanoma with breast cancer is described 
(Algan et al., 1965, Hcnkind and Roth, 1971). Holly et al. (1991), however, were unable 
to demonstrate a connection between earlier malignancies and a possibly increased risk of 
uveal melanomas. 
Histologically, uveal melanomas are subdivided into spindle cell, epithelioid and 
mixed cellular tumours (Jakobiec, 1978) In older literature necrotic and fascicular 
tumours are distinguished as well (Callender, 1931; Wilder and Paul, 1951). Mixed 
cellular and spindle cell В melanomas are the most frequent forms (Paul et al., 1962). 
In one-half of the patients with uveal melanomas, histological examination shows a 
tumour invasion of the sclera to be involved (Jensen, 1963). Extraocular extension is 
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descnbed in 10 to 23% of the patients (Byers and MacMillan, 1935; Stair and 
Zimmerman, 1962; Jensen, 1963; Shammas and Biodi, 1977). 
Metastasization is mainly to the liver and, less frequently, to the bone, the lungs 
and the subcutaneous tissue and occurs in one-half of the patients. If metastases develop, 
the average survival is less than one year (Einhorn et al., 1974; Lommatzsch and 
Dietrich, 1976; Char, 1978; Bedikian et al., 1981; Jensen, 1982). At the time of 
enucleation of the affected eye, metastases elsewhere in the body are descnbed in 0.5% of 
the patients (Zimmerman and McLean, 1979). 
The reported survival of patients with uveal melanomas vanes considerably. The 
prognosis depends strongly on the cell type and the tumour size. The 10-year survival rate 
is 50 to 70% (Wilder and Paul, 1951; Packard, 1980; Jensen, 1982; McLean et al., 
1982). The nature of the treatment (in the form of brachytherapy or enucleation) is 
reported not to affect the survival rate (Augsburger et al., 1986; Adams et al., 1988). 
There are several therapeutic possibilities in malignant melanoma of the uvea. The 
main ones are enucleation in tumours with postenor localization (Zimmerman and 
McLean, 1979; Manschet, 1980), local resection, particularly in lesions of the ciliary 
body (Peyman et al., 1984; Damato and Foulds, 1986), mdectomy in mdal melanomas 
(Rones and Zimmerman, 1958), irradiation, either by means of radioactive plaques 
(brachytherapy): Ruthenium-106 (Lommatzsch, 1986), Cobalt-60 (Zografos et al., 1988; 
Augsburger et al., 1990) and Iodine-125 (Packer et al., 1984) or with protons (Gragoudas 
et al., 1985) or helium ions (Char et al., 1990) and photocoagulation in very small 
tumours (Meyer-Schwickenrath, 1980; François, 1982). 
Signs and symptoms. The principal complaint of patients with uveal melanomas is 
detenoration of the visual acuity. Defects in the visual field are described frequently. 
Sometimes, metamorphopsia, micropsia, photopsia, anisocona, muscae volitantes or veils 
occur (Jensen, 1963; Gailloud, 1975; Amé and Mathis, 1986). 
In 67% of the patients with an uveal melanoma loss of visual acuity, mostly 
pronounced, is reported" 19 to 38 5% are said to have no more light perception and only 
27 to 37% a visual acuity better than finger counting (Martin-Jones, 1946; Jensen, 1963; 
Kanckhof, 1967). According to Augsburger et al. (1990), 60% of the patients have a 
visual acuity over 5/10. In 21% of the patients visual field defects constitute the initial 
complaint. In combination with detenoration of the visual acuity this occurs in 77 to 
100% of the patients (Kanckhof, 1967; Mosselman, 1975). 
Only 3 % of the patients with uveal melanomas are reported to have no complaints, 
the tumour being a fortuitous finding (Jensen, 1963). However, in more recent literature it 
is stated that the melanoma is a fortuitous finding in 17% of the patients (Augsburger et 
al., 1990). 
In choroidal melanomas the symptoms as a rule have been present for longer than 
in choroidal metastases. Of the patients with melanomas, 40% have had symptoms for 
longer than one year, which never occurs in metastases (Jensen, 1970). 
Melanomas of the ciliary body cause symptoms such as metamorphopsia and visual 
field defects only when the tumours are large (Alberti and Halama, 1987). Loss of vision 
is caused by displacement or deformation of the lens. Foos et al. (1969) described a 
shallow anterior chamber and unilateral cataract in these patients. 
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Melanomas of the ms are detected either fortuitously (20%: McGalhard and 
Johnston, 1989) or as the result of a unilateral glaucoma or inflammation (Dhermy, 1979). 
The pigmented indal lesion often has been known for years Visual acuity is usually 
normal- 74% have an eyesight of 20/20 or better (Duke and Dunn, 1958). Cataract is 
reported to occur in 66% of the melanomas, as against only 12% of the metastases 
(Jensen, 1970) 
Pain occurs in 12 to 24% of the patients with uveal melanomas and is a first 
symptom in 6% (Jensen, 1963; Mosselman, 1975) Pain is said to be more frequent in 
choroidal metastases than in choroidal melanomas (Ferry, 1978; Gartner, 1985). 
Shields et al (1987) desenbed elevation of the intraocular pressure in only 3% of 
all uveal melanomas. Other authors, however, report glaucoma in 20 to 48% of the 
patients Risk factors mentioned are a localization in the ins, with or without involvement 
of the ciliary body, and in melanomas localized posteriorly, the size of the tumour (Kirk 
and Petty, 1956, Duke and Dunn, 1958; Jensen, 1963; Yanoff, 1972; Foulds and Lee, 
1983, Rohrbach et al , 1988, McGalhard and Johnston, 1989) Melanomas of the ciliary 
body frequently cause ocular hypotension (Foos et al , 1969) 
Diffuse uveal melanomas cause glaucoma in 61% of the patients, while 9% have a 
red eye and 15%, an inflammation (Font et al , 1967) 
Almost all melanoma patients with glaucoma are reported to have uveitis, and 
closure of the angle of the antenor chamber by postenor penpheral synechiae (Kirk and 
Petty, 1956) Fraser and Font (1979) report an inflammation in 4 9% of the patients with 
a melanoma of the ciliary body or choroid, in ciliary body tumours this was usually 
episclentis, in necrotic choroidal melanomas, panophthalmitis Although necrosis 
frequently occurs in mdal metastases, it is rare in melanomas of the ins (Mayer and 
Nassar, 1958) 
In 3 to 10% of the patients with a choroidal melanoma, a vitreous haemorrhage is 
described This is said to be charactenstic of a melanoma (Noble and Marsh, 1984; 
Bonnin, 1986, Gragoudas et al , 1987) In case of sudden loss of visual acuity due to a 
vitreous haemorrhage, the possibility of this tumour should be considered (Gass, 1963). 
Fraser and Font (1979) desenbed a hyphaema and subretinal haemorrhages. 
Prominent episcleral vessels are described in 5 to 25% of the patients with a uveal 
melanoma (Jensen, 1963, Dams, 1979) In melanomas of the ciliary body this 
phenomenon is sani to occur nearly always (Foos et al., 1969). 
Rubeosis ir dis is observed in 5% of the choroidal melanomas (Schulze, 1967). 
Ophthalmoscopy and slit lamp examination. Malignant melanoma of the choroid 
may manifest itself in vanous ways (Shields, 1985). 
Jensen (1963) reported that 93% of the uveal melanomas onginated from the 
choroid, 4% from the ciliary body and 3% from the ins. 
Melanomas may be encountered throughout the eye, unlike choroidal metastases 
which are frequently limited to the macular area (Hungerford, 1985; Augsburger et al., 
1990) Nevertheless, most choroidal melanomas are said also to be localized temporally in 
the postenor pole (Jensen, 1963, Shields and Young, 1980, Shields, 1983). In contrast to 
choroidal metastases, melanomas are rarely observed round the optic disk (Hart, 1962; 
Howard, 1965; Augsburger et al., 1990). 
Bilateral melanomas are very rare (Lerman, 1966; Shammas and Watzke, 1977; 
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Shields and Young, 1980; Shields, 1983). Multiple melanomas in one eye, also, have 
virtually never been described (Kreibig, 1935; Rosen and Moulton, 1953). 
According to Jensen (1963) 5% of the melanomas have a flat shape, 64% are 
dome-shaped, 24% are mushroom-shaped and 2%, diffuse (other shapes 5%). 
Choroidal melanomas in general have a prominence of 5 to 8 mm with a base of 
12 mm on average (Peyster et al., 1985; Poujol and Chaintron, 1988; Augsburger et al., 
1990). Mostly, melanomas are more elevated than metastases (Bonnet and Jambon-Genet, 
1948; Slezak, 1966, Ferry ,1978; Gartner, 1985). However, in metastases the base of the 
tumour is relatively larger than in melanomas with a simular prominence (Poujol and 
Chaintron, 1988). Dome-shaped metastases may be difficult to differentiate from 
amelanotic melanomas (Gass, 1974; Amé and Mathis, 1986). 
Breakthrough of Bruch's membrane and protrusion into the vitreous may bring 
about the mushroom shape that is typical of melanomas. In such cases even the retina may 
be perforated (Norton, 1969; Scheffer, 1973; Gass, 1974; Char, 1989). With the passage 
of time such mushroom shapes occur more frequently, especially in amelanotic or slightly 
pigmented choroidal melanomas (Hayreh, 1974, Shields, 1985). 
Melanomas are more sharply delimited than metastases (Bonnet and Jambon-Genet, 
1948, Ferry, 1978) Flat melanomas may sometimes be delineated poorly (Hayreh, 1974). 
Norton (1969), Scheffer (1973) and Hunyor (1984) described a flat greyish-brown 
marginal zone round the tumour or a kind of halo In mushroom-shaped tumours the 
central, most protruding part is not or only slightly pigmented, while the peripheral 
portion contains more pigment (Hayreh, 1974). 
The pigmentation of the melanoma varies, but most lesions are pigmented to some 
extent (Reese, 1951; Bonnin,1986). Jensen (1963) described the melanoma as white to 
yellowish in 15% of the cases, as grey in 20%, as yellowish-brown in 13%, as brown or 
dark in 26% and as spottily pigmented in 26%. Twenty-five per cent of the melanomas 
reported are relatively amelanotic (Char, 1989) Prominent tumours, in particular, display 
much pigment (Shields, 1976). The tumour surface may be white, sometimes with grey 
pigment patches, or have a pink haze due to vascularization (Hayreh, 1974). 
Suggestive of a melanoma are widespread alterations of the overlying pigment 
epithelium with areas of orange pigment deposits on the tumour surface (Gass, 1974). 
Histologically, these are predominantly lipofuscin pigment-laden cells (macrophages or 
pigment epithelium cells· Gass, 1974; Shields et al , 1976). In melanomas this is 
described in 47 to 85% of the cases (Smith and Irvine, 1973; Shields, 1976), especially in 
flat lesions (Hayreh, 1974). 
During growth of the melanoma, large dilated blood vessels may become visible on 
the tumour surface, especially in little-pigmented tumours (Reese, 1951; Norton, 1969; 
Gass, 1972/1974, Hayreh, 1974) These vessels are described less frequently in metastases 
(Gass, 1974). 
Melanomas even at an early stage show alterations in the pigment epithelium. 
These lesions are associated with a variable degree of exudation between the tumour and 
the retina (Gass, 1972). Cystoid oedema of the retina is sometimes desenbed (Scheffer, 
1973, Gass, 1974; Schatz et al , 1978). 
A retinal detachment is observed in 25 to 87% of the tumours (Jensen, 1963; 
Kanckhoff, 1967; Font et al., 1968; Schatz et al., 1978; Peyster et al., 1985; Augsburger 
et al., 1990). Sometimes, a bullous retinal detachment is described (Norton, 1969). 
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Retinal breaks are very rare (Peyman et al , 1976). According to Shields (1976), the 
extension of the retinal detachment is usually larger in metastases. 
Haemorrhages in uveal melanomas are reported to be observed only rarely (Dams, 
1979). In 3 to 10% of the melanomas an intraocular haemorrhage is reported, usually in 
the form of a vitreous haemorrhage, sometimes as a hyphaema or subretinal haemorrhage 
(Martin-Jones, 1946, Jensen, 1963; Noble and Marsh, 1984). The cause of a vitreous 
haemorrhage may be invasion of the retina by the tumour (Gass, 1974). Massive 
haemorrhages may occur in necrotic tumours (Shields and Young, 1980). Sub- or 
intraretmal haemorrhages are sometimes observed (Hunyor, 1984) and may be due to 
haemorrhages from the chonocapillans or from the large vessels on the tumour surface 
(Zimmerman, 1963; Scheffer, 1973; Gass, 1974). A haemoirhagic retinal detachment may 
mask the tumour Haemorrhages are observed particularly often in melanomas localized in 
the macular area (Gass, 1974) Although a spontaneously recurring hyphaema is said to be 
almost pathognomonic of iridai metastases, it is also encountered in melanomas of the ins 
(Ferry, 1973) 
Three per cent of all uveal melanomas are situated in the ins (Jensen, 1963; Noor 
Sunba el al., 1980) They are predominantly solitary and may or may not be pigmented. 
Frequently, an ectropion uveae is present with distortion of the pupil (Foulds, 1985; 
Shields, 1985) The lesion is predominantly present in the inferior or infero-temporal 
region of the ins (Jensen, 1963, Dhermy, 1979, Ternto et al , 1988), but it may be found 
in any part (Zimmerman, 1963) 
The lesion is generally small and placoid The margin may be sharply or poorly 
defined The degree of pigmentation is highly variable (Zimmerman, 1963; Foulds, 1985): 
58% have a pale colour and 42% are darkly pigmented (Foulds, 1985) Heterochromia of 
the ins is often present (Shields and Young, 1980, Shields, 1983) In 58% of the tumours, 
abnormal vessels are observed (Foulds, 1985) 
Melanomas of the ciliary body in an early phase are difficult to discern (Naumann, 
1980). Mostly they are detected by accident (Shields, and Young, 1980) At the time of 
presentation they are usually large (Gass, 1974; Shields, 1985). Frequently, part of the 
choroid or the ins is also involved in the process (Gass, 1974). The iris may be pushed 
forward by the tumour and the root of the ins may be displaced (Foulds, 1985). 
The shape is generally convex, but a diffuse ring melanoma has sometimes been 
desenbed (Gass, 1974, Lommatzsch, 1989). The surface is smooth, sometimes irregular 
(Gass, 1974) Ciliary melanomas are often dark or of a mottled greyish-brown colour. 
Abnormal vessels are desenbed, sometimes with blood on the tumour surface (Foulds, 
1985) A retinal detachment occurs only at a late stage and in that case the choroid is 
often also involved in the process (Gass, 1974). 
A metastasis of the ciliary body may show great similarity to a diffuse melanoma 
(Foulds, 1985). 
Suckling and Donaldson (1970) state that melanomas and metastases may be 
distinguished from each other with the aid of infrared photography. According to Sautter 
et al. (1974), however, this is not possible. 
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Fluorescein angiography. The fluorescence of choroidal melanomas is 
indistinguishable in timing and progression pattern of the patterns seen with choroidal 
metastases (Davis and Robertson, 1973). The fluorescein-angiographic picture of 
melanomas is variable (Oosterhuis and Van Waveren, 1968; Wessing, 1968; Gass, 1972). 
In general, melanomas stain in the arterial or arteriovenous phase in vague confluent 
patches, sometimes even before the retinal arteries. In late phases, diffuse staining takes 
place. Atrophy of the retinal pigment epithelium causes hyperfluorescence. The fluid 
beneath the retinal detachment, if present, stains to a greater or lesser extent. Areas with 
hyperpigmentation and lipofuscin remain dark (Norton et al., 1964; Wessing, 1968/1977; 
Gass, 1974; Hayreh, 1974; Fishman, 1977; Theodossiadis et al., 1978; Bonnin, 1986). 
Necrotic areas are hypofluorescent but some staining occurs later (Wessing, 1977). Large 
blood vessels in the tumour, separate from the retinal circulation, the socalled 'double-
blood supply', are seen more often than in metastases (Gass, 1972; Davis and Robertson, 
1973; Wessing, 1977). Hyperfluorescent spots are observed in late phases, especially at 
the margin of the tumour. 
Cystoid degeneration and oedema of the retina which stain with fluorescein are 
sometimes described. Occasionally, dilatation of the retinal capillaries with micro-
aneurysms is established. The tumour is frequently surrounded by a hypofluorescent 
margin. If breakthrough of Bruch's membrane occurs, the protruding part of the tumour 
remains hypofluorescent with clearly staining tumour vessels and leakage in the vitreous. 
An amelanotic melanoma is usually large and mushroom-shaped, with prominent 
vessels. The pink pigmented parts stain more than the white areas. The fluorescence is 
progressive and in the late phases diffuse. The greyly pigmented parts of the tumour mask 
the background fluorescence (Gass, 1972/1974; Davis and Robertson, 1973; Hayreh, 
1974; Fishman, 1977; Wessing, 1977; Schatz et al., 1978; Theodossiadis et al., 1978; 
Danis, 1979). 
For the diagnosis of melanomas of the ciliary body, fluorescein angiography is not 
very useful, because of the peripheral localization of the tumour (Fries and Char, 1990). 
Melanomas of the iris show an early, mottled fluorescence in the direct vicinity of 
the lesion. Leakage occurs from the central margin and from the otherwise normal radial 
iridai vessels (tumour iritis). Leakage at the pupillary margin is frequently described. Such 
fluorescence is reported never to occur in iridai metastases (Demeler, 1981). However, 
Kottow (1978) does describe a fluorescence at the tumour margin in metastases. In 
melanomas the blood vessels run in a crisscross fashion. Parts of the iris that are not 
affected by the tumour show no fluorescence. 
Echography. Echographically, a melanoma displays a dome-shaped tumour or a 
characteristic mushroom shape. The initial retinal spike is followed by lower regular 
internal echoes brought about by the densely packed cellular structure and are frequently 
accompanied by an orbital shadow. Tumour infiltration in the choroid causes a choroidal 
excavation. Large tumour vessels cause echographic vascularity (Ossoinig and Biodi, 
1974; Ossoinig and Harrie, 1983; Coleman et al., 1974; Verbeek, 1985; Poujol, 1986). 
If necrosis or haemorrhage occurs in the tumour, a higher and more irregular echo 
pattern appears (Verbeek, 1985). 
Extraocular extension of the melanoma may be established by means of echography 
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(Ossoinig and Harne, 1983; Guthoff, 1988). 
The differential diagnostics of choroidal metastases may be difficult in individual 
cases, especially in metastases of oatcell carcinomas of the lung (Verbeek, 1981/1985). 
According to several authors, computer echography renders possible the 
differentiation of spindle cell В and mixed epithelioid melanomas (Thijssen and Verbeek, 
1981; Coleman and Lizzi, 1983). 
Computed tomography. The melanoma is characterized by an elevated, 
hyperdense, sharply delimited lesion with, as a rule, a slight to moderate enhancement 
after administration of contrast (Mafee et al., 1985; De Keizer et al., 1986; Desjardins, 
1986). Making the differential diagnosis between melanoma and metastasis by means of 
the CT scan may be difficult (Alsbirk and Halaburt, 1983). 
Magnetic Resonance Imaging (MRI). Melanomas in general are hyperintense in 
relation to the vitreous in T, weighted images and hypointense in Т
г
 weighted images 
because of the relative short T, and T, relaxation times. However, melanomas which 
remain hypointense in T, weighted images have also been reported (Sobel et .al., 1985; 
Chambers et al., 1987; Haik et al., 1987; Mafee et al., 1987; Wollensak et al., 1988). 
The image is probably brought about by the paramagnetic properties of melanin. An 
increase of pigment leads to short T, and Tj relaxation times. Consequently, a melanoma 
containing little pigment may show a different image. In such cases, differentiation from 
metastases may be a problem (Gomori et al., 1986). Unlike melanomas, metastases 
display an hyperintensive image in T2 weighted images (Chambers et al., 1987). 
Perimetry. Jensen (1963) reports visual field defects in 64% of patients with a 
uveal melanoma. According to Van Dijk (1978), the visual field defect is absolute in 86% 
of the cases. In large tumours with a secondary serous retinal detachment, perimetry is of 
limited value. It is considered quite useful, on the other hand, for the diagnosis of small 
pigmented tumours with little prominence. The melanoma, namely, rapidly causes 
destruction of the sensory cells and of the deeper layers of the choroid (Oosterhuis et al., 
1981). According to Flindall and Drance (1969), the visual field defect in melanomas 
often extends to the periphery owing to rupture of the neurofibrils. This is in contrast to 
what Scott (1957) observed in choroidal tumours. Characteristic of melanomas are the 
intensity and the steep margin of the visual field defect. This in contrast to the relative 
scotoma and the sloping edge in a simple retinal detachment (Harrington, 1956; Aulhom, 
1966; Amé and Mathis, 1986). 
According to Gass (1977) and Shields (1977), perimetry is of limited value for the 
differentiation of melanomas from naevi. While a visual field defect is frequently 
encountered in a melanoma, exceptions are possible and defects are frequently described 
in naevi as well. 
The progression of the visual field defect in general is less rapid in melanomas 
than in metastases (Manor et al., 1978). 
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Electro-oculography (EOG). An abnormal EOG with a low ratio is frequently 
described in melanomas. According to most authors, the EOG registration is independent 
of the size of the tumour (Staman et al., 1980; Markoff et al., 1981; Brink et al., 
1989/1990), although according to Jones et al. (1981), the ratio is inversely proportional 
to the prominence. Differentiation from naevi and retinal detachments is possible (Bohar 
and Parkas, 1976; Staman et al., 1980; Graniewski-Wijnands and Van Lith, 1981; 
Markoff et al., 1981; Ulrich et al., 1981; Brink et al., 1989/1990; Thaler et al., 1989). 
The EOG does not contribute to the differential diagnostics of melanomas from metastases 
of the choroid (Brink et al., 1989/1990). 
Electroretinography (ERG). The ERG in melanomas of the choroid is subnormal 
to abnormal. The a- and b-waves are distinctly lower in the eye containing the tumour 
than in the normal eye. The larger the tumour, the more the amplitude is decreased. In 
tumours without associated retinal detachment, the ERG is described as normal to 
subnormal. In a large retinal detachment, the ERG is absent (Sundmark, 1958; Straub, 
1961; Bohar and Parkas, 1976; Ponte and Lauriceila, 1977; Ulrich et al., 1981). 
Biopsies and punctures. In melanomas, use is made of biopsy methods as 
mentioned in Chapter 1.4.9. In most cases differential diagnosis from metastases is 
possible. In metastases of malignant cutaneous melanomas and of bronchial carcinoids, 
assessment of the biopsy may give problems, however (Font et al., 1966; Font et al., 
1967). 
32P and other isotopes. The diagnostics of melanoma constitutes one of the main 
indications for the "P uptake test (Jarrett, 1976; Lommatzsch, 1977; Shields, 1977/1978; 
Goldberg et al., 1980; Lommatzsch et al., 1984; Desjardins, 1986). Cell typing by means 
of this test is not possible (Temer et al., 1956; Gysin, 1979). 
No distinction of metastases from melanomas is possible by means of the 32P 
uptake test (Van Dijk, 1978; Gysin, 1979). Of tumours in an anterior position, metastases 
in general present lower values than melanomas (Thomas et al., 1954). 
Uveal melanomas can be distinguished from metastases with the aid of labelled 
melanin precursors. In amelanotic tumours, however, no differentiation is possible (Packer 
et al., 1977). 
Monoclonal antibodies against cutaneous melanomas labelled with radioactive 
technetium ("mTc) have been used in the diagnostics of uveal melanomas. The specificity 
is high but the sensitivity depends on the tumour size, the site of the lesion and the 
proportion and amount in which the antibody is incorporated (Bomanji et al., 1987). 
Transillumination. In melanomas, a shadow or a reduced transparancy to light is 
virtually always described (Van Dijk, 1978; Jensen, 1963). However, in little-pigmented 
melanomas, diaphanous tumours are also described and differentiation from metastases is 
not possible (Jensen, 1963; Ferry, 1967/1978; Amé and Mathis, 1986). 
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Immunological techniques. In melanomas, extensive research has been carried out 
into immunological techniques for tumour diagnostics. Their use, however, is still in a 
phase of development (Cochran et al., 1985; Folberg et al., 1985; Dieckhues, 1986; 
Damato et al., 1987; Ringens et al., 1989; Scheiffarth et al., 1989). 
1.5.3 Naevus 
The terms naevus and benign melanoma are synonyms for benign melanocytic tumours of 
the uvea (Zimmerman, 1965; Gass, 1974). Naevi may be present from birth and rarely 
grow faster than the normal uveal tissue, and therefore they may be regarded as 
hamartomas (Gass, 1974). 
Histologically, naevi are aggregations of melanocytes (Gass, 1974). Cytologically, 
naevoid cells are identical to cells normally present in the choroid. Plump polyhedral cells 
and spindle cells are observed in particular. Differentiation from spindle cell A melanomas 
is not always possible (Gass, 1974). Melanomas are said to originate from pre-existent 
naevi (Yanoff and Zimmerman, 1967), although the transformation of naevi into malignant 
melanomas has only rarely been described clinically (Gass, 1974). 
Choroidal naevi are observed clinically in 1 to 5% of normal eyes, and at 
histopathological examination, in 10 to 20% (Hale et al., 1965; Gass, 1974). Naevi of the 
ciliary body are clinically rare and histologically occur in 3% of the normal population 
(Gass, 1974). 
Naevi are described more frequently in females than in males. In Negroes, they are 
observed less frequently than in Caucasians, but the difference is less than for malignant 
melanoma. The incidence of naevi increases from the fourth decade and the age is 59 
years on average at the time of detection (Tamler and Maumenee, 1959; Naumann et al., 
1966; Gass, 1977). In young patients, choroidal naevi often contain little pigment, so they 
are rarely detected. The growth is probably maximal in the prepubertal years. In adults 
there occurs no or only a very slow increase in size and marked growth suggests a 
malignant melanoma (Tamler, 1970; Gass, 1974). 
The differentiation of iridai naevi from iridai melanomas is often difficult. Naevi 
may remain stationary in size for years and then begin to grow (Gass, 1974). Of 
pseudomelanomas of the uvea, one-quarter of the cases prove to be naevi (Shields et al., 
1980a), of iridai lesions this proportion is 31% (Shields et al., 1983). 
Treatment is necessary only if serous detachments of pigment epithelium or retina, 
which sometimes occur, fail to disappear spontaneously. Areas of leakage may be treated 
with laser photocoagulation (Gass, 1974; Folk et al., 1989). 
Signs and symptoms. Naevi in general cause no symptoms. Symptoms manifest 
themselves when a serous retinal detachment occurs in naevi localized in the macular area 
(Gass, 1974). However, Karickhoff (1967) described a decrease of visual acuity in 21% of 
the patients with naevi. A defect in the visual field was present in 7.5% of the patients. 
Naevi of the iris are nearly always asymptomatic (Dhermy, 1979). 
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Ophthalmoscopy and siti lamp examination. Choroidal naevi are flat or slightly 
elevated oval or round grey tumours with well-defined, although not sharply delimited 
margins (Gass, 1974, Hayreh, 1974). They are in general 1 to 3 disk diameters large with 
a prominence of 0.05 to 1 mm. Diameter and elevation of the lesions may vary greatly. 
They may be so elevated that a suspicion of malignant melanoma arises (Naumann et al., 
1966; Gass, 1974/1977). 
The typical colour of a naevus is slate-grey, but it may vary markedly, depending 
on the thickness of the lesion, the amount of melanin, pigment characteristics of the 
patient and changes of the overlying pigment epithelium. The lesion may be completely 
pigmented or only partly and have a dark centre with a light margin or vice versa. 
Mostly, naevi are evenly coloured. Focal areas of pigment loss and clustering of pigment, 
either in the form of dark patches or as orange pigment, do occur but are rare. 
Sometimes, whitish granular material is observed on the surface of the lesion (Smith and 
Irvine, 1973; Gass, 1974/1977; Oosterhuis and Von Winning, 1979). If naevi are 
amelanotic and multiple, as in neurofibromatosis, differentiation from metastases may be 
difficult (Font and Ferry, 1972). 
Drusen occur frequently in choroidal naevi (in about one-quarter to one-half of the 
cases); they are described particularly often in larger and more prominent lesions. These 
drusen become confluent to form large areas of exudative detachment of the pigment 
epithelium. Leakage of serous fluid may lead to a limited serous retinal detachment which 
may resolve spontaneously. Cystoid retinal degeneration and oedema are rare (Naumann et 
al., 1966/1977; Gass, 1972/1974; Hayreh, 1974). Ruptures may develop in Bruch's 
membrane which may be associated with formation of neovascularization membranes in 
the sub-pigment epithelial space. Especially when located in the macular area these may 
give nse to haemorrhages and localized or disciform haemorrhagic detachments of 
pigment epithelium and retina. In the early phases, haemorrhages may look black and be 
mistaken for fast-growing malignant melanomas (Gass, 1974). 
Naevi may occur throughout the fundus, but are encountered particularly often in 
the postenor pole. They are described with the least frequency in the anterior part of the 
choroid and the ciliary body (Reese, 1951; Naumann, 1966; Gass, 1974). Amé and 
Mathis (1986) stated that 90% of the naevi were situated behind the equator. Thirty per 
cent of the patients have one naevus in one eye, 3.5% more than one lesion in both eyes 
and 7%, multiple lesions in one eye (Gass, 1977). 
Naevi of the ciliary body are discovered only rarely. In general they are relatively 
flat or slightly elevated (Gass, 1974). 
Naevi of the ins are usually slightly elevated tumours situated in the antenor iridai 
stroma They only become visible at the young adult age because of the pigmentation 
developing at that time. As a rule, no changes of the shape of the pupil develop, although 
this has been descnbed in large naevi. Indal naevi may be multiple (Gass, 1974). 
Fluorescein angiography. The fluorescence depends on the localization of the 
naevus. More superficially localized lesions cause an early shadowing of the choroidal 
staining which disappears with complete staining of the choroid. Naevi in the deeper 
layers of the choroid are poorly visible and only show the late masking of the background 
fluorescence in a vanable degree. The size of the area of hypofluorescence roughly 
corresponds to that of the tumour. Hayreh (1974), however, reported that in the preretinal 
arterial phase a much larger area was seen than at ophthalmoscopical examination. This 
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area rapidly grew smaller after complete filling of the choroidal vasculature. Naevi have 
no vascularization of their own (Gass, 1972/1974; Hayreh, 1974; Fishman, 1977; 
Wessing, 1977; Bischoff, 1985; Bonnin, 1986). 
Drusen frequently become visible in the first few minutes of staining and then stain 
progressively more. Retinal cysts may be present. They show no leakage, disappear with 
the retinal vascular fluorescence and are specific of naevi in older patients (Gass, 
1972/1974; Wessing, 1977). 
Choroidal neovascularizations may be visible in the form of intensely staining 
membranes (Gass, 1974). 
Sometimes, a spotty or granular staining resembling that of a melanoma is 
observed in the arterial or arteriovenous phase. Possibly, only part of the pigmented area 
stains (Rubinstein, 1967; Wessing, 1977). Areas with whitish pigmentation remain non-
fluorescent (Oosterhuis and Von Winning, 1979). 
In naevi of the iris only minimal changes develop in the normal vascular pattern 
and permeability of the iris (Gass, 1974). 
Echography. For echographic differentiation of intraocular lesions a prominence of 
2 to 2.5 mm is necessary (Coleman et al., 1974; Ossoinig and Biodi, 1974). Since uveal 
naevi are less than 2 mm prominent, echography is of very limited value (Gass, 1977). A 
choroidal excavation has been described occasionally (Fuller et al., 1979). 
Because CT scanning and MRI require a minimal prominence of 3 mm for 
visualization of the lesion, these examination techniques are not suitable for the 
differential diagnosis of naevi (Chambers et al., 1987; Mafee et al., 1987; Wollensak et 
al., 1988). In exceptional cases naevi are imaged, however. Liu et al. (1989) described a 
patient with a choroidal lesion with a prominence of 2.3 mm that was visible in the CT 
scan. At MRI, a hyperintense image was seen in T, weighted images, and the intensity 
decreased in T2 weighted images. Consequently, the lesion was mistaken for a malignant 
melanoma; it proved to be a naevus, however. 
Perimetry. According to certain investigators, defects in the visual field are 
encountered only rarely in naevi. They only develop when the choroidal nutritional supply 
of the retina is affected. If a scotoma develops, the depth is virtually always relative and it 
is localized at the site of the lesion (Reese, 1951; Karickhoff, 1967; Van Dijk, 1978). 
Some authors described a relative scotoma in 38 to 85% of the patients with a 
naevus of the choroid. These defects are observed in particular in elevated lesions, and 
they are associated with visible changes of the pigment epithelium. If a retinal detachment 
is or has been present, the defect of the visual field may be larger than the size of the 
lesion (Tamler and Maumenee, 1959; Flindall and Drance, 1969; Gass, 1974). Absolute 
scotomas have been reported in naevi but they occur only rarely (Naumann et al., 1966a; 
Flindall and Drance, 1969; Oosterhuis and De Wolff-Rouendaal, 1981). 
According to Gass (1977) and Shields (1977), perimetry is of limited value for the 
differentiation of a naevus from a melanoma. While in melanoma a visual field defect is 
usually established, exceptions are possible, and in naevi defects are also observed 
frequently. An absolute scotoma is more indicative of a melanoma, a relative scotoma of a 
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naevus (Oosterhuis et al., 1981). 
Electro-oculography (EOG). In general, the light peak/dark trough ratio is normal 
in naevi cases (Staman et al., 1980; Jones et al., 1981; Markoff et al., 1981). The dark 
trough is not abnormal. Differentiation from melanomas, metastases and retinal 
detachments solely by means of EOG is possible in 73% of the cases (Brink et al., 
1989/1990). 
31P uptake test. In 98 to 100% of naevi, the 32P uptake test gives a negative result. 
If the result is positive, a melanoma with a low degree of malignancy may be involved 
(Shields, 1978, Van Dijk, 1978, Oosterhuis et al , 1980). 
Transillumination. At diaphanoscopy, naevi show the same image as melanomas 
(Van Dijk, 1978) Hale et al (1965) performed transillumination in 200 eyes with a uveal 
naevus and reported sharply delimited, opaque lesions 
1.5.4. Haemangioma 
The cavernous haemangioma of the choroid is a benign hamartoma which manifests itself 
either as a solitary tumour in patients without other vascular malformations, or as a 
diffuse thickening of the choroid in the Sturge-Weber syndrome (Gass, 1974). For the 
differential diagnostics of uveal metastases, the solitary haemangioma is of particular 
importance 
Uveal haemangiomas do not occur frequently (MacLean and Maumenee, 1960) 
Haemangiomas of the ciliary body and of the ins are rare (Reese, 1951, Duke Elder and 
Perkins, 1966a) 
At histopathological examination large, dilated, thin-walled vessels are observed 
which at the edges blend into the normal choroidal tissue (Gass, 1974). The tumour 
contains hardly any connective tissue. Between the tumour and the retina a membrane may 
be present which contains calcifications Ossification is frequent (Reese, 1951). Jones and 
Cleasby (1959) and Gass (1974) describe an extensive proliferative change of the pigment 
epithelium, and metaplasia and cystoid degeneration of the retina 
Growth of the tumour is probably maximal during the normal growth period of the 
individual. In adulthood, the size of the lesion shows hardly any change (Gass, 1974). In 
case of rapidly growing and multiple localizations, the possibility of uveal metastases 
should be considered (Chisholm and Blach, 1973, Hutchison and Smith, 1979). 
Although according to a number of authors haemangiomas are rarely detected 
before the third decade, and the patients are between 40 and 59 years old in 85% of the 
cases (Gass, 1974; Jarrett et al , 1976), according to other authors they are diagnosed 
more often in young people (Reese, 1951; Jones and Cleasby, 1959). The mean age is 48 
to 51 years (Gass, 1974; Anand et al., 1989) Patients with haemangiomas of the Sturge-
Weber syndrome are much younger, 8 years old on average (Witschel and Font, 1976). 
Interestingly, haemangiomas in 70% of the cases are observed in males (Gass, 1974; 
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Jarrett et al., 1976; Anand et al , 1989) and particularly in Caucasians (Gass, 1974). 
Witschel and Font (1976) described an equal distribution over the sexes in solitary 
tumours, but a larger proportion of males in diffuse haemangioma. 
If a haemangioma is detected fortuitously, without retinal detachment or signs of 
an earlier retinal detachment, it requires no treatment. If the tumour is situated outside the 
fovea and a retinal detachment is present, the tumour may be treated with laser 
photocoagulation at the site of diffuse leakage on the tumour surface. This will nearly 
always result in absorption of the subretinal fluid and correction of the retinal detachment. 
The treatment does not affect the tumour size (Jarrett et al., 1976; Gass, 1974; Bonnin, 
1986). Sanborn et al., (1982), Greber et al. (1985) and Zografos et al., (1989) describe 
various radiotherapeutic techniques used in the treatment of uveal haemangiomas. 
Signs and symptoms. Ninety per cent of the patients with a choroidal 
haemangioma have symptoms varying from blurred vision and metamorphopsia to severe 
deterioration of the visual acuity or blindness Ten per cent of the patients are 
asymptomatic. As a rule, symptoms only develop when, at an older age, a serous retinal 
detachment occurs which extends from the margin of the lesion to the macular area In 
haemangiomas situated in the macular area or in large tumours symptoms are reported 
earlier If the tumour is localized in the macular area, a disturbance of the central visual 
acuity sometimes occurs before significant alterations manifest themselves in the overlying 
pigment epithelium or retina. The visual acuity varies from 20/15 to no light perception 
and on average is 6/30 (Gass, 1974; Anand et al , 1989). Witschel and Font (1976) report 
total blindness in 60% of the patients. 
Glaucoma, uveitis, cataract, corneal degeneration and intraocular haemorrhages 
have been desenbed as well as dilated episcleral vessels (Reese, 1951; Jones and Cleasby, 
1959) Hayreh (1974), however, denies that uveitis and cataract occur. Witschel and Font 
(1976) report an increased intraocular pressure in 40% of the solitary and 76% of the 
diffuse haemangiomas. 
In haemangiomas of the ciliary body a hyphaema is sometimes described (Daily, 
1931; Reese, 1951). 
Ophthalmoscopy and slit lamp examination. Characteristic of the choroidal 
haemangioma is a round or oval, slightly elevated, orange-red tumour with a vague 
margin (Gass, 1974) 
Most haemangiomas are located in the macular area or close to the optic disk and 
then may cause early symptoms (Reese, 1951, Gass, 1974; Jarrett et al., 1976; Witschel 
and Font, 1976, Bonnm, 1986, Anand et al., 1989) 
Haemangiomas are distributed evenly over the right and left eyes (Gass, 1974; 
Witschel and Font, 1976), although Anand et al (1989) report a predilection for the nght 
eye and Bottom et al. (1990) one for the left eye. A bilateral solitary haemangioma is 
encountered only sporadically (Schepers and Schwart, 1958; Shields, 1983). Multiple 
haemangiomas in one eye have been desenbed only rarely (Shields, 1983; Zografos et al., 
1989). 
The tumour is usually less than 4 to 5 disk diameters large. Large haemangiomas 
may be difficult to distinguish from amelanotic melanomas and metastases (Gass, 
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1972/1974; Jarrett et al., 1976). Haemangiomas are said never to show the mushroom 
shape typical of melanomas (Shields, 1983). Amé and Mathis (1986) described 
haemangiomas with a multifocal appearance. The margins of the lesion are blurred and 
poorly delimited (Bonnin, 1986). The colour is pinkish, orange-red or fleshy. There may 
be small pigment patches on the tumour surface (Gass, 1974; Jarrett et al., 1976; Amé 
and Mathis, 1986). Orange lipofuscin pigment is not observed in haemangiomas (Smith 
and Irvine, 1973). Because the colour often resembles that of the surrounding normal 
fundus and the lesion is usually only slightly elevated, choroidal haemangiomas are easily 
overlooked if no use is made of binocular indirect ophthalmoscopy. If there are no or only 
minimal signs of change of pigment epithelium or retina, the tumour is detected only by 
accident (Gass, 1974). Some haemangiomas may blanch on manual compression of the 
eye (Gass, 1974). 
Biomicroscopy is important for the perception of changes of pigment epithelium 
and retina. In adults, the retina is typically thickened and cystoid and retinoschisis may be 
present. The mottled yellow material that accompanies the cystoid alterations lies in the 
depth or beneath the degenerated retina (Gass, 1974). Retinal oedema is frequently 
observed, usually at a distance from the tumour. Presence of cystoid macular oedema in a 
nasally localized tumour according to a number of authors indicates a haemangioma 
(Jarrett et al., 1976; Bonnin, 1986). Approximately one-third of the patients have a 
permanently damaged macula owing to the cystoid retinal degeneration and oedema, 
circinate retinopathy, distinct pigment disturbances and sometimes, a macular pucker 
(Gass, 1974). Serous detachment of the surrounding retina is often present (Gass, 1972; 
Jarrett et al., 1976). A retinal detachment is described in 76 to 78% of the patients and is 
total in 7%. This retinal detachment is rarely bullous and almost never separated from the 
tumour. Sometimes, there are signs of previous retinal detachment (Gass, 1974; Anand et 
al., 1989). The retinal detachment may mask the tumour (Bonnin, 1986). 
Intraretinally, haemorrhages may develop. Reportedly, small calcifications in the 
retina occur in 20% of the haemangiomas (Reese, 1951; Witschel and Font, 1976; 
Bonnin, 1986). Bonnin (1986) describes the frequent development of alterations of the 
retinal capillaries. Prominent choroidal vessels, as in melanomas, are not observed in 
haemangiomas (Hayreh, 1974). The choroidal vascular pattern (Karel and Peleska, 1972) 
and dilatation of the retinal or choroidal vessels may be visible (Jones and Cleasby, 1959). 
Haemangiomas of the ciliary body or the iris are uncommon (Daily, 1931; Keller, 
1962; Heath, 1964; Oksala et al., 1964; Duke-Elder, 1966; Brück, 1969). 
Fluorescein angiography. Characteristic aspects of the haemangioma are a coarse 
vascular fluorescence pattern in the pre-arterial and arterial phases corresponding to the 
location of the tumour, the extensive areas of fluorescence secondary to the diffusion of 
the dye from the surface and the multiloculated pattern of fluorescein accumulation in the 
outer retina, characteristic of polycystic degeneration and oedema, during later stages. In 
the absence of visible cystoid retinal oedema, the diagnosis of haemangioma allegedly is 
doubtful (Norton and Gutman, 1967; Gass, 1974; Hayreh, 1974; Schatz, 1978). 
The tumour as a rule stains even before the retinal arteries, simultaneously with the 
surrounding choroid (Hayreh, 1974; Wessing, 1977; Schatz, 1978; Wessing and Foerster, 
1983; Bonnin, 1986). For a few seconds there occurs a sponge-like configuration of areas 
that do or do not stain. This fades because of the fluorescein leaking into the perivascular 
space, which stains the entire tumour (Wessing and Foerster, 1983). In the venous phase, 
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a uniform fluorescence of the entire tumour is described (Bottoni et al., 1990). Pink areas 
stain more than white areas (Hayreh, 1974). 
Dilated vascular canals fill in early phases (Rosen, 1969; Fishman, 1977; Schatz, 
1978; Bottoni et al., 1990), but according to other authors they are not visible (Hayreh, 
1974). Gass (1974) describes the separate vascular structures with clearly frayed vascular 
walls, unlike the smooth vascular walls in melanomas. The delimitations in the fluorescein 
angiographic image are far sharper than in the ophthalmoscopic image (Bonnin, 1986) 
although, according to Wessing (1977), there is, on the contrary, a smooth blending into 
the normal choroid. Frequently, a hypofluorescent zone at the margin of the lesion is 
observed. This might be caused by the common proliferative changes in the pigment 
epithelium (Gass, 1974) or by displacement of the normal choroidal melanocytes (Bonnin, 
1986). 
In haemangioma, hyperfluorescent spots may be seen which accordingly are not 
characteristic of melanomas but only of prominent choroidal tumours (Bonnin, 1986) and 
which, according to other authors, do not occur in metastases (Fishman, 1977). 
Sometimes there are signs of changes of the permeability of the retinal capillaries at the 
margin of the lesion (Gass, 1974; Hayreh, 1974), although according to Loewer-Sieger 
and Oosterhuis (1971) these constitute an argument against the diagnosis of haemangioma. 
Multilake areas, as in haemangiomas, and late fluorescence in areas with cy¡stoid retinal 
oedema, as also seen in melanomas, are said not to be described in metastases (Davis and 
Robertson, 1973). 
The early pre-arterial fluorescence brought about by the large vascular canals and 
the later multilocular staining due to cystoid degeneration of the overlying retina have 
rarely been described in other tumours (Gass, 1972/1974). 
Echography. Haemangiomas have a broad base and are mostly 0.5 to 3 mm 
prominent. They are rarely larger than 5 to 6 mm (Chang et al., 1978; Anand et al., 
1989). Allegedly, a mushroom shape never occurs (Shields and Tasman, 1977). 
The large congested vessels with intervascular septa, owing to the large tissue 
interfaces, give a high reflectivity, of 95 to 100%. Because of the predominantly regular 
tissue structure, the infrastructure of the tumour is usually regular (Ossoinig and Harrie, 
1983; Neetens et al., 1984; Verbeek, 1985; Poujol, 1986; Bigar, 1988). Sporadically, the 
reflectivity is described as relatively low (Coleman, 1973). 
Since the haemangiomatous tissue echographically is highly similar to the normal 
surrounding choroid, a choroidal excavation will almost never occur (Chang et al., 1978; 
Neetens et al., 1984; Poujol, 1986), but it has occasionally been described (Fuller et al., 
1979). Echographic vascularity is hardly ever seen, probably because there is no blood 
flow in the tumour or the lesions are too small (Neetens et al., 1984; Verbeek, 1985; 
Guthoff, 1988). However, Ossoinig and Biodi (1974) frequently describe a distinct 
vascularity. 
In haemangiomas of longer standing calcium deposits may be demonstrated, owing 
to which the lesion echographically is sometimes no longer to be distinguished from an 
osteoma (Guthoff, 1988). 
Computed tomography. Haemangiomas can be visualized by means of the CT scan 
only after administration of contrast medium (De Keyzer et al., 1985; Mafee et al., 1985). 
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Roentgen examination may be useful because of possible calcifications which, however, 
are only present in tumours of long standing (MacLean and Maumenee, 1960). 
Magnetic Resonance Imaging (MRI). In haemangiomas a hypodense tumour is 
described in T, weigthed images as against a hyperdense lesion m Tj weighted images 
(Haik et al., 1987b; Mafee et al., 1987). Anand et al. (1989) in these cases describe a 
hyperdense image in T, and an isodense image in T2 weighted images. 
Perimetry. A haemangioma with cystoid retinal alterations causes a defect in the 
visual field at the site of the tumour and when a retinal detachment is present, at the site 
of the detachment. Defects of nerve fibre bundles secondary to a choroidal haemangioma 
have rarely been described (Gass, 1974). If a haemorrhage occurs in the nerve fibre layer 
of the retina it may cause a sector defect (Reese, 1951). According to MacLean and 
Maumenee (1960), visual field defects occur frequently in haemangiomas and are more 
extensive than the size of the tumour itself. The scotoma is usually relative but sometimes 
absolute (Witschel and Font, 1976). 
Electro-oculography (EOG). A low ratio and a normal dark trough are described 
at EOG examination (Gramewsky-Wijnands et al , 1981). 
32P uptake test. The 32P uptake test usually, but not always, gives a negative result 
(Gass, 1974). A positive result is described in 8 to 10% of the haemangiomas (Van Dijk, 
1978; Shields, 1978; banning and Shields, 1979; Oosterhuis et al., 1980; Desjardins, 
1986). 
Transillumination. Choroidal haemangiomas allow easy passage to light. 
Sometimes there is a vague circular defect in the transillumination at the tumour margin. 
This corresponds to a comparable zone of hypofluorescence at fluorescein angiography 
(Gass, 1974; Jarrett et al., 1976). 
1.5.5 Lymphoproliferative diseases 
Practically all parts of the eye and the ocular adnexa may be involved in lympho-
proliferative diseases. Most frequently, lesions are encountered in the orbit and 
conjunctiva. The intraocular structures are only sporadically affected clinically (Shields, 
1983). Lymphoid tumours may resemble amelanotic melanomas, metastases or intraocular 
infections (Shields, 1983). Uveal localizations are seen more frequently m patients with 
leukaemia than in patients with a malignant lymphoma (Gass, 1974). 
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1.5.5.1 Leukaemia 
In patients with leukaemia the eye may be involved in the pathological process through 
infiltration of tissue by leukaemic cells or through secondary complications such as 
haemorrhages and infections (Allen and Straatsma, 1961; Kincaid and Green, 1983; 
Nelson et al., 1983; Shields, 1983; Leonardy et al., 1990). Ocular abnormalities occur 
about as often in acute as in chronic leukaemia (Allen and Straatsma, 1961; Schachat et 
al , 1988; Leonardy et al., 1990). However, according to Gass (1974), the most evident 
lesions are seen in the acute forms. 
Histopathologically, the choroid is infiltrated in 66% of the patients, the ciliary 
body in 13% and the ins in 3% (Leonardy et al., 1990). Clinically, however, infiltration 
of ocular structures is established in only 3% of the patients with leukaemia (Schachat et 
al , 1989). 
Histopathologically, variable numbers of neoplastic cells are observed in the uvea, 
with separation of choroidal vessels and thickening of the choroid, most pronounced in the 
posterior pole. If the ciliary body is involved in the disease process, it shows only slight 
thickening and the architecture little abnormality (Shields, 1983; Leonardy et al., 1990). It 
has been asserted that a relationship exists between the ophtha!mological involvement on 
the one hand and the leukocyte count and severity of the systemic disease on the other 
(Leonardy et al , 1990). 
Ocular signs and symptoms may constitute the first indications for the diagnosis of 
leukaemia. In the majority of the patients this diagnosis is already known, however. If the 
choroid is affected, blurred vision is an important symptom. Although histopathologically, 
infiltrates occur frequently in terminal stages of leukaemia, it is doubtful whether they also 
frequently cause symptoms (Gass, 1974; Shields, 1983; Abramson, 1984; Stewart et al., 
1989; Leonardy et al., 1990). 
If the ins is involved, complaints about blurred vision, photophobia and pain are 
frequent Conjunctival and episcleral injection can regularly be observed. Indal infiltrates 
may have features in common with granulomatous iritis, endophthalmitis or indal 
metastases. The ins may show diffuse thickening, often with small poorly delimited 
nodules extending to the pupillary margin. Diffuse infiltrations cause discolouring of the 
ins and heterochromia. 
Vascular congestion may cause a vascular rupture and consequently, a hyphaema. 
The infiltration may be so extensive that tumour cells layer out into the antenor chamber 
and there form a pseudohypopyon. Infiltrates of the angle of the antenor chamber may 
lead to a secondary glaucoma. An increased intraocular pressure occurs in 9% of the 
patients with leukaemia (Johnston and Ware, 1973; Gass, 1974; Kincaid and Green, 1983; 
Shields, 1983; Shields et al., 1987, Schachat et al., 1988). 
Ophthalmoscopically, well-defined white preretinal lumps and masses may be 
observed. Secondary leukaemic alterations such as haemorrhages and cottonwool spots due 
to anaemia and thrombocytopenia are described more frequently than in infiltrates 
(Schachat et al., 1989). Intraocular haemorrhages develop in 11 to 45% of the patients 
with leukaemia (Leonardy et al., 1990). Although in many patients the uvea is involved in 
the process, the alterations are often not visible at ophthalmoscopy. In extreme cases, the 
fundus at the site of the infiltration may have an intensive yellow-pink colour (Gass, 1974; 
Naumann, 1980). Sporadically, alterations occur in the retinal pigment epithelium in the 
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form of focal areas of brown pigment. At ophthalmoscopy this may give a leopardskin-
like image as described in choroidal metastases and uveal effusion. Apart from choroidal 
infiltrations, the disk and retina are also sometimes involved. The infiltrate may grow so 
large that it becomes a localized or diffuse choroidal tumour. This occurs most frequently 
in acute lymphatic leukaemia. A serous retinal detachment is described regularly (Gass, 
1974; Kincaid and Green, 1983; Shields, 1983; De Laey and De Gersem, 1989). 
Fluorescein angiography may be useful for the detection of areas of damage to the 
pigment epithelium situated beneath a serous retinal detachment. No characteristic 
fluorescein angiographic image exists. If the pigment epithelium is affected, mottled 
irregular areas may be present which cannot be differentiated from inflammatory choroidal 
cellular infiltrations with multiple sites of leakage from the underlying choroid (Gass, 
1972/1974). In leukaemic infiltration of the choroid, multiple fluorescent spots are 
described which then fade again and progressive diffusion occurs which in late phases 
delimits an extensive area of serous detachment. The image may greatly resemble that of 
Harada's disease, sympathetic ophthalmia, toxicosis or other signs of occlusion of the 
choriocapillaris (De Laey and De Gersem, 1989). 
Echographically, a thickening of the uvea is described in leukaemia, often with a 
high reflectivity (Poujol and le Roy, 1983). 
Puncture of the anterior chamber and other techniques of obtaining cellular ocular 
material may be of diagnostic importance (Shields, 1983; Schachat et al., 1988). 
Ophthalmological therapy consists of atropine and steroids to combat the symptoms 
in case of involvement of the anterior segment and radiotherapy of the eye for local 
tumour treatment (Johnston and Ware, 1973; Shields, 1983; Schachat et al., 1988). 
1.5.5.2 Lymphoma 
Apart from reticulum cell sarcoma, lymphomas of intraocular structures are rare (Shields, 
1983). Forms described include intraocular Hodgkin lymphoma (Primbs et al., 1961) and 
the Burkitt lymphoma (Karp et al., 1971). Choroidal infiltration by malignant lymphocytic 
lymphomas is rarely observed (Weisenthal et al., 1988). Raised intraocular pressure is 
described in 27% of the patients (Shields et al., 1987). 
Reticulum cell sarcoma (RCS, diffuse histiocytic lymphoma, non-Hodgkin 
lymphoma) is probably less rare than is assumed. Intraocular manifestations may occur 
isolatedly but in most cases are associated with involvement of the central nervous system 
and less often with visceral lymphomas. The mean age is about 60 years. The condition is 
said to occur more frequently in females (Freeman et al., 1987). The interval between the 
earliest symptoms and the diagnosis is two years in general. The condition is often 
bilateral (Shields, 1983; Freeman et al., 1987; Siegel et al., 1989; Schachat, 1990). 
The clinical picture of RCS depends on whether the vitreous humour, the retina, 
the papilla or the choroid is affected most. Ophthalmological symptoms may precede other 
symptoms. A painless deterioration of the visual acuity is frequent. Slit lamp examination 
reveals characteristic corneal precipitates and retrolental vitreous cells, probably secondary 
to the retinal involvement. The vitreous cells may be so dense that ophthalmoscopy is not 
possible. If the retinal or choroidal involvement is more pronounced and there is little 
reaction of the vitreous, the picture may give the impression of retinitis or posterior 
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uveitis. In that case, yellow infiltrates may be observed that appear to lie deep in the 
retina (Shields, 1983; Schachat, 1990). Sometimes, instead of more diffuse lesions, 
solitary subretinal or choroidal masses are seen. These lesions may be mistaken for 
choroidal metastases (Barr et al., 1975; Stephens and Shields, 1979; Raju and Green, 
1982; Shields, 1983; Strempel, 1983; Siegel et al., 1989). Several authors describe a large 
serous retinal detachment in RCS (Barr et al., 1975; Simon and Friedman, 1980; Char et 
al., 1988/1988a). In general, choroidal lesions are observed more often in systemic RCS 
(with lymphadenopathy and visceral involvement). If the central nervous system is 
involved in the disease, the optic nerve and retina are affected more frequently (Klingele 
and Hogan, 1975; Shields, 1983). 
Extensive affection of the iris occurs less frequently. It may resemble 
granulomatous iritis or an iridai metastasis. Iridai lymphomas may sometimes 
spontaneously bring about a hyphaema. Closure of the angle of the anterior chamber may 
lead to a secondary glaucoma (Collyer, 1972; Shields, 1983). 
Needle biopsy of the vitreous humour to obtain cellular material may be of 
diagnostic importance in RCS (Shields, 1983; Freeman et al., 1987; Char et al., 
1988/1988a). Echographically, a patient with a solitary low-reflective tumour of an RCS, 
with 6.5 mm prominence, has been described with choroidal excavation, vascularity and 
orbital shadow suggestive of a malignant melanoma (Fredrick et al., 1989). Sullivan and 
Dallow (1989) described an echographic image of a ring/annular tumour in the ciliary 
body. 
In uveitis of unknown origin in patients of more advanced age, the possibility of 
RCS should be considered (Shields, 1983; Siegel et al., 1989). 
The treatment of RCS consists of radiotherapy, possibly corticosteroids and 
systemic chemotherapy (Margolis et al., 1980; Shields, 1983; Freeman et al., 1987; Char 
et al., 1988/1988a). 
1.5.5.3 Benign reactive lymphoid hyperplasia 
Benign reactive lymphoid hyperplasia (BRLH) is a pseudotumour which may affect the 
uvea with or without simultaneous involvement of the conjunctiva or the orbit. In case of 
uveal localization the diagnosis is sometimes difficult because the lesion may resemble a 
diffuse choroidal neoplasm or an inflammatory process. For the differential diagnosis a 
diffuse malignant melanoma, metastasis, reticulum cell sarcoma, leukaemia, sympathetic 
ophthalmia and posterior scleritis should be considered (Crookes and Mullaney, 1967; 
Gass, 1967; Ryan et al., 1972; Shields, 1983; Ben-Ezra et al., 1989; Verbeek et al., 
1990). 
Although initially a reactive inflammatory genesis was postulated (Hogan and 
Zimmerman, 1962), it is currently believed that the condition is a low-grade tumour with 
diffuse infiltrates of mature lymphocytes with lymphoblastic features. (Uveal) lymphoid 
infiltration accordingly would be a more appropriate name (Jakobiec et al., 1987a). 
In general the condition occurs in middle-aged persons (average 55 years). BRLH 
is described more frequently in Caucasians and in males, and is mostly unilateral (Ryan et 
al., 1971/1972). 
A characteristic element is a mostly painless deterioration of the visual acuity. If 
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the orbit is also involved, ocular protrusion may develop Glaucoma is reported in 67% of 
the cases, iridocyclitis in 57% (Ryan et al , 1972) 
In involvement of the ins, a diffusely thickened iridai stroma is described, 
sometimes associated with Tyndall's phenomenon, cells in the aqueous humour and 
keratitic precipitates Occasionally, a spontaneous hyphaema is reported The picture may 
show similarity to a granulomatous inflammation or a diffuse indal neoplasm Sometimes, 
a localized nodular mdal tumour is described, as in an indal melanoma or metastasis At 
fluorescein angiography, a non-specific early vascularization and late hyperfluorescence 
are seen Needle or excision biopsy may be necessary before a definite diagnosis can be 
made (Shields et al , 1981, Shields, 1983) 
BRLH of the ciliary body rarely occurs as a solitary lesion It is usually described 
as part of a panuveal involvement In extensive infiltrates a narrow-angle glaucoma may 
develop The lesion may show similarity to chronic cyclitis or a ring melanoma of the 
ciliary body (Gass, 1967, Shields, 1983) 
A BRLH of the postenor uvea is characterized by a diffuse or nodular amelanotic 
thickening of the choroid In one-half of the patients a serous retinal detachment is present 
with displacement of the subretinal fluid at movements of the head (Gass, 1967, Ryan et 
al , 1972, Shields, 1983) Changes of the pigment epithelium are possible Ophthalmo-
scopy then reveals golden-brown foci on the amelanotic tumour surface, which foci 
contain macrophages with lipofuscin and melanin (Shields et al , 1976, Shields, 1983). 
Jakobiec et al (1987a) desenbed BRLH cases with multifocal, sometimes confluent, 
cream-coloured choroidal infiltrates with an indistinct margin without changes of the 
pigment epithelium or retinal detachment At fluorescein angiography, staining of the 
lesions was seen without leakage into the sub-pigment epithelial or subretinal space 
Shields (1983) describes fluorescein-angiographic images with early mottled hyper-
fluorescence of the choroidal mass with late staining and many aspecific hyperfluorescent 
foci 
Desroches et al (1983) described echographic images with an elevated mass in the 
postenor pole without choroidal excavation or vascularity with a low regular reflectivity 
In other cases, thickening of the choroid was observed with sometimes, an episcleral 
extension (Jakobiec et al , 1987a) At CT scanning, a thickened choroid may be imaged 
(Desroches et al , 1983, Jakobiec et al , 1987a) 
Treatment consists of systemic and sometimes, retrobulbar corticosteroids. 
Radiotherapy is also possible (Shields, 1983, Jakobiec et al , 1987a, Ben-Ezra et al , 
1989) Given early diagnosis and treatment, the prognosis of the visual acuity is excellent 
as is the prognoses quoad vitam (Shields, 1983) 
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1.5.6 Other intraocular tumours and related tumour-like lesions 
1.5.6.1 Leiomyoma 
Leiomyomas of the uvea are rare tumours derived from smooth muscle tissue. Probably, 
all uveal leiomyomas are of mesectodermal origin. Clinically, the differentia] diagnosis, 
especially from malignant melanomas and metastases, is extremely difficult or impossible. 
By optic microscopy, the cells frequently cannot be distinguished from melanoma cells, 
either. Electron microscopy is then required for a definite diagnosis (Reese, 1963; 
Jakobiec et al., 1977; Ishigooka et al., 1989; Shields et al., 1989; White et al., 1989). 
With regard to many tumours described in the literature as leiomyomas, the correctness of 
the diagnosis is doubted (Reese, 1963). Of all iridai tumours, 9 to 14.5% reportedly are 
leiomyomas (Reese, 1963; Ashton and Wybar, 1966). Brovkina and Chichua (1979) 
described 30 out of 55 surgically removed iridai tumours as leiomyomas. Shields et al. 
(1983) diagnosed only one out of 158 pseudomelanomas of the iris as a leiomyoma. 
Jakobiec et al. (1976) described an extremely rare choroidal leiomyoma which had 
been enucleated on the erroneous diagnosis of malignant melanoma. 
Leiomyomas of the ciliary body are encountered nearly exclusively in females. The 
mean age is 31 years. Patients over 50 are rarely described (Burk et al., 1989; Shields et 
al., 1989). At slit lamp examination, dilated episcleral vessels, uveitis, neovascularization 
of the iris, pupillary deformations, lens dislocations, cataractogenous opacities and a 
tendency to rapid growth can be observed (Ishigooka et al., 1989). A retinal detachment 
may develop. 
At fluorescein angiography, hyperfluorescence in the venous phase with late 
irregular fluorescence or a diffuse staining of the tumour is observed. At echography, a 
low-reflective spherical tumour is described with a choroidal excavation, similar to a 
melanoma. The tumours are generally large: on average with a prominence of 6 mm and a 
base of 9 mm. The CT scan may display a solid ciliary mass, MRI shows a slight 
hyperdensity in relation to the vitreous humour in T, and hypo- or hyperdensity in T2 
weighted images. Of the 32P uptake test, pathological results are regularly described. 
A noticeable aspect of leiomyomas of the ciliary body is the fact that at 
diaphanoscopy the site of the lesion transilluminates more clearly than the vicinity of the 
tumour. This has also been described in an adenoma of the non-pigmented ciliary 
epithelium and in a nodular posterior scleritis. 
With the various examination techniques, differentiation of the leiomyoma from 
other tumours is not possible. The occurrence at an early age and the diaphanoscopical 
image, however, are possibly pathognomonic of leiomyomas (Dunbar, 1956; Jakobiec et 
al., 1977; Burk et al., 1989; Ishigooka et al., 1989; Mafee et al., 1989; White et al., 
1989). 
Leiomyomas of the iris are flesh-coloured, yellowish-pink or brown, but nearly 
always unpigmented. The lesions are often prominent with a sharp delimitation from the 
normal iridai tissue. On the tumour surface blood vessels may be discerned. Some 
ectropion uveae is regularly described. The tumours may be localized anywhere in the 
iris, but there is a predilection for the lower, especially the temporal part of the iris and 
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the iridociliary zone. The tumour may be a localized lesion or infiltrate the iridai stroma 
as far as the angle of the anterior chamber (Erdbrink and Harbert, 1955; Reese, 1963; 
Ashton and Wybar, 1966; Duke-Elder, 1966; Brovkina and Chichua, 1979; Waubke, 
1983; Shields et al., 1989). 
At fluorescein angiography, usually at the same time as the iridai vessels, a spotty 
staining of the lesion is observed and sometimes, a vascular tumour network, without 
diffuse staining. Fluorescence at the pupillary margin as a rule is only seen opposite to the 
tumour (Brovkina and Chichua, 1979). 
The treatment of leiomyoas of the iris and the ciliary body consists of local 
excision of the tumour. Metastases have not been described. The prognosis quoad vitam is 
excellent (Ashton and Wybar, 1966; Waubke, 1983; Ishigooka et al., 1989; Jakobiec et 
al., 1989). 
1.5.6.2 Tumours of the non-pigmented ciliary epithelium 
Tumours of the non-pigmented epithelium of the iris and the ciliary body are rare (Shields 
et al., 1983). The neuroepithelial tumours and tumour-like lesions are subdivided into 
congenital and acquired tumours. The medullo-epithelioma belongs to the congenital 
tumours and is subdivided in its turn into the primary and the teratoid tumours, of which 
both benign and malignant forms exist. The acquired, more differentiated tumours include 
the adenoma and the adenocarcinoma (Zimmerman, 1971; Andersen et al., 1982). 
Medulloepüheliomas are гаге, slowly growing tumours of the non-differentiated 
unpigmented epithelium of the ciliary body and very rarely of the optic nerve or retina. 
The mean age is 5 to 7 years and the patients are practically never older than 14 years. 
The tumour occurs with equal frequency in both sexes and is always unilateral. 
Deterioration of the visual acuity is described in 25 to 40% of the patients, pain in 
30%. About 30 to 50% of the patients have cataract and 32 to 50%, glaucoma. Rubeosis 
iridis is observed in over 80% of the patients, although Broughton and Zimmerman (1978) 
reported this only a few times. A retinal detachment is seen in 5 to 10% of the patients 
and 18% have a leukokoria. Occasionally, a hyphaema or vitreous haemorrhage is 
described (Broughton and Zimmerman, 1978; Canning et al., 1988). The tumour may fill 
the entire ovular cavity (Sirsat et al., 1972). The diagnosis can be made after aspiration of 
vitreous humour containing free-floating cysts (Orellana et al., 1983). 
In general, medullo-epitheliomas grow slowly. Locally, however, they may show a 
malignant behaviour. Allegedly, two-thirds of the tumours are benign, most of them 
containing keratoid elements (Canning et al., 1988). Broughton and Zimmerman (1978), 
however, classified two-thirds of the tumours as malignant. All these tumours contained 
cells that resembled cells as encountered in retinoblastoma. An extraocular extension is 
described in 18 to 25% of the tumours. The tumour is said to behave more malignantly in 
adults. Distant metastases develop rarely and occur only in patients with extrascleral 
spread (Orellana et al., 1983). Treatment consists of enucleation or, in localized tumours, 
local excision. The prognosis quoad vitam generally is excellent (Canning et al., 1988). 
In young children with poor eyesight, a mass in the ciliary body, unilateral 
glaucoma and/or cataract, a medullo-epithelioma has to be considered for the differential 
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diagnosis. 
The tumour is also sometimes called diktyoma (Orellana et al., 1983). 
Adenomas of the non-pigment ed ciliary epithelium cannot be distinguished from 
malignant melanomas of the ciliary body and are often enucleated on that clinical 
diagnosis. The tumour is also sometimes called benign epithelioma. Although the tumour 
is cytologically benign, it may grow slowly and cause subluxation of the lens, cataract or 
secondary glaucoma (Reese, 1976; Shields et al., 1983). The mean age of the patients in 
whom the tumour is observed is 43 years (Andersen, 1962; Shields et al., 1983). The 
tumour may be accompanied by decrease of the visual acuity, pain and mild iridocyclitis 
(Fanta, 1977). 
Echography shows a solid mid-reflective tumour (Shields et al., 1983). The 3 2P 
uptake test may be positive (Lommatzsch et al., 1979). Patrinely et al. (1983) described 
an adenoma at the site of an iridocoloboma in a child aged 2.5 years. This was probably a 
hamartomous tumours. 
Adenocarcinomas of the поп-pigmented ciliary epithelium, also sometimes called 
malignant epitheliomas, are very rare slowly growing tumours. They are diagnosed at the 
mean age of 59 years and are distributed equally over the sexes. Forty per cent of the 
patients have an ophtha!mological anamnesis of injury or inflammation. Malignant 
transformation of a reactive hyperplasia may have occurred. Subluxation of the lens and 
glaucoma may be observed (Kuchynka, 1979; Dryja et al., 1981; Rodrigues et al., 1988; 
Grossnikiaus et al., 1990). The tumour has to be differentiated from a metastasis of a 
carcinoma of the prostate and from colloid breast cancer. Histologically, this distinction is 
difficult to make (Jakobiec et al., 1987; Grossnikiaus et al., 1990). The treatment consists 
in enucleation or local excision. The prognosis is unknown. Extraocular extension is 
regularly observed, metastasization may occur (Grossniklaus et al., 1990). 
1.5.6.3 Tumours and tumour-like lesions of the pigment epithelium of the iris, 
ciliary body and retina 
Hypertrophy, hyperplasia and benisn melanoma of the pigment epithelium according to 
Gass (1974) are different names for one and the same condition which is probably 
congenital and should be regarded as a hamartoma of the pigment epithelium. Amé and 
Mathis (1986), on the other hand, make a clear distinction between hypertrophy and 
hyperplasia. 
The hypertrophic lesions of the retinal pigment epithelium may occur at any age 
and in both sexes. They cause no symptoms, are mostly unilaterally located and situated 
temporally in 70% of the cases. Defects in the visual field develop only rarely. These are 
mostly absolute in older and relative in young patients (Buettner, 1975). The lesions are 
fiat, sharply delimited and pigmented, brown, greyish-brown or black. The pigmentation 
may be irregular and a hypopigmented halo is often present. The overlying retina as a rule 
shows no abnormalities. In larger lesions hypopigmentation occurs. In contrast to 
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metastases of the choroid, hypertrophic lesions are less numerous, flat, display no growth 
and may show the above-mentioned halo. Hyperfluorescence is caused by pigment defects 
and the halo. No leakage is observed. The EOG and ERG are normal, as is the 32P uptake 
test. There is no connection with systemic diseases or ophtha!mological pathology 
(Buettner, 1975; Purcell and Shields, 1975; Arne and Mathis, 1986). 
Hyperplasia of the retinal pigment epithelium nearly always develops as a reaction 
to an earlier inflammation. The condition appears as solitary or multiple, heavily 
pigmented and sometimes elevated lesions with irregular margins (Arne and Mathis, 
1986). At fluorescein angiography, a well-delimited masking of the background 
fluorescence is observed (Hayreh, 1974; Bonnin, 1986). 
Hypoplasia of the retinal pigment epithelium is probably congenital and is 
characterized by a flat, sharply delimited lesion which is usually round to oval in shape, 
of a white colour with focal hypopigmentation. Histopathologically, pigment granules are 
absent in a predominantly normal but somewhat flattened pigment epithelium. The lesion 
may be confused with unpigmented naevi, metastases or other nodular lesions of the 
choroid (Gass, 1974). 
The adenoma of the pigment epithelium (benign epithelioma) is described as 
accounting for 1.4% of all primary tumours of the iris (Ashton and Wybar, 1966). It may 
also be present in the ciliary body (Lieb et al., 1990). It presents as a predominantly black 
mass in the iridai stroma, which causes slight deformation of the iris without an ectropion 
of the pigment epithelium. The pupillary reactions are mostly unimpaired. Pale lesions 
may occur. In general there is only little melanin production. Inflammation in the affected 
area is observed frequently, lenticular opacities are sometimes seen (Garner, 1970; Lowe 
and Greer, 1971). 
Patients with an adenocarcinoma of the retinal pigment epithelium (malignant 
epithelioma) on the whole are older than patients with benign epitheliomas. The condition 
is divided equally over both sexes. It is a rare low-grade malignant tumour which almost 
never causes metastases and as a rule does not cause infiltration outside the choroid or the 
lamina cribrosa. There is only little inflammation and nearly always there is production of 
melanin so that the fundus is heavily pigmented. The fluorescein angiogram reveals 
mottled fluorescence. Echographically, an elevated low- to mid-reflective lesion is 
described with a distinct choroidal excavation without vascularity. The tumour may show 
great similarity to a melanoma (Garner, 1970; Minckler and Allen. 1970). 
1.5.6.4 Combined hamartoma of the retina and retinal pigment epithelium 
The combined hamartoma of the retina and the retinal pigment epithelium is a rare, 
benign, congenital lesion. It may represent an ocular manifestation of a phakomatosis 
(Font et al., 1989; Palmer et al., 1990). The hamartoma grows endophytically and is 
variably pigmented with abnormal-appearing retinal blood vessels due to contraction of the 
inner surface of the lesion, leading clinically to distortion of the retina. The lesion occurs 
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as often in females as in males The patients are mostly adolescents or young adults, with 
a mean age of 15 years Juxtapapillary lesions are said to develop mostly at older ages. 
Multiple and bilateral tumours are rarely observed. 
Sixty per cent of the patients expenence a painless loss of visual acuity. In 
numerous patients the eyesight is poorer than finger counting Strabismus is present in 
18% of the patients, in 10% the lesion is detected fortuitously Most of these tumours are 
situated round the disk and macula Peripherally localized lesions are rarely encountered 
The colour is greenish-blue, grey or black Nearly all patients have tortuosity of the 
retinal vessels in and round the lesion The majority of the patients show some 
depigmentation and elevation and vitreoretinal alterations or formation of an epiretinal 
membrane A subretinal or vitreous haemorrhage may develop At fluorescein angio-
graphy, an early hypofluorescence, depending on the degree of pigmentation, is seen with 
tortuosity and abnormal retinal capillaries In the majority of the patients, accumulation of 
dye and leakage from tumour vessels are observed (Gass, 1973, McLean, 1976, Laqua 
and Wessing, 1979, Schachat et al , 1984, Font et al , 1989) 
1.5.6.5 Retinoblastoma 
The retinoblastoma is a malignant congenital tumour arising from the nuclear cell layers 
of the retina Sixty per cent of the tumours occur sporadically and are unilaterally located 
Forty per cent is autosomal dominant hereditary and nearly always bilateral (Sanders et 
al , 1988) The incidence in the Netherlands is 1 15 560 inhabitants (Schipper, 1980) 
Virtually all tumours are diagnosed before the fifth year of life (Tamboli et al , 1990), the 
mean age is 17 to 20 months Retinoblastoma is the most frequent malignant intraocular 
tumour in children (Howard and Ellsworth, 1965, Pendergrass and Davis, 1980, 
Fllsworth, 1989) Sex and race do not atfect the frequency of occurrence (Ellsworth, 
1989, Tamboli et al , 1990) 
The first sign of retinoblastoma is usually a white pupillary reflex (leukokona) 
Strabismus is seen in 20% of the patients Depending on the site in the retina where the 
tumour develops, either a tumour bulging into the vitreous is observed or a subretinally 
growing lesion which causes a retinal detachment A retinoblastoma has a creamy-pink 
colour, often with neovascularization on the tumour surface The tumour stroma is 
frequently found to contain microaneurysms and teleangiectatic vessels Large afferent 
vessels to the tumour have been described, as well as exudates on the tumour surface or in 
the macular area An atrophic pigment ring round the tumour is seen in 10% of the 
patients In retinoblastomas, a spontaneous hyphaema, superficial haemorrhages and 
vitreous haemorrhages have been described Necrosis may cause inflammation (Howard 
and Ellsworth, 1965, Schipper, 1980, Ellsworth, 1989) Clinical glaucoma is reported in 
23% of the patients (Yoshizumi et al , 1978) In 84% of the patients there are several 
tumours per eye, with an average number of five Cell clusters may detach themselves 
from the tumour and be found floating in the vitreous or as implantation metastases 
Together with intratumoral calcifications, they are pathognomonic of retinoblastoma 
(Schipper, 1980, Ellsworth, 1989) 
Fluorescein angiography reveals a capillary network permeable to fluorescein 
Within the depth of the tumour, vessels may be observed (Gass, 1974). Echographically, 
either a solid tumour is described or, in extensive necrosis, a more cystic lesion A 
retinoblastoma is markedly high-reflective and produces strong shadowing. Intratumoral 
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calcifications and vascularity may be observed. A choroidal excavation is not described 
(Shields et al., 1976a, Chang et al , 1978; Ossoimg, 1974; Ellsworth, 1989). Kerman and 
Fishman (1987) described mushroom-shaped retinoblastomas. Calcifications may also be 
seen in the CT scan (Char et al., 1984; Haik et al., 1987a; Mafee et al., 1989). With 
MRI the tumour can be demonstrated and differentiated well; a hyperdense lesion is 
described in T, and a hypodense lesion in T2 weighed images (Mafee et al., 1989). Of the 
32P uptake test, pathological results are described (Ellsworth, 1989) 
Ingrowth into the choroid is practically always present. Expansion via the optic 
nerve to the meninges is possible and cames a poor prognosis. Metastasization is to the 
brain and bone marrow, not to the lungs (Schipper, 1980, MacKay et al., 1984; 
Ellsworth, 1989, Kopelman et al., 1987) The five-year survival rate is 91% (Tamboh et 
al., 1990). A retinoblastoma may be accompanied by osteosarcomas elsewhere in the body 
(Sanders et al., 1988) 
The treatment of the retinoblastoma is irradiation, either external or by 
brachytherapy, which may or may not be combined with chemotherapy. Enucleation is 
indicated in a limited number of cases About 1% of the tumours show spontaneous 
regression (Schipper, 1980, Ellsworth, 1989). 
1.5.6.6 Osteoma 
The osteoma is a benign tumour of the choroid which histopathologically shows bone 
formation The pathogenesis is not completely known. There are indications that the 
tumour anses from an embryonal tumour remnant and is primarily congenital. Bilateral 
tumours may occur familially Osteoma-hke lesions may also develop due to secondary 
calcification of haemangiomas, inflammatory lesions, injuries and Harada's disease 
(Cunha, 1984; Gass, 1979/1987, Shields et al , 1988; Noble, 1990). The tumour is 
encountered with equal frequency in both eyes Virtually all the patients are females of 
about 20 years of age (Gass, 1979; Shields, 1983) The osteoma has also been described 
in older patients, however (Wiesner et al., 1987; Menchini et al., 1990). Hormonal 
factors may play a part in the growth of the lesions (McLeod, 1988, Noble, 1990). 
Symptoms are blurred vision, metamorphopsia and paracentral scotomas. Most 
patients have a good visual acuity (Gass, 1979). 
Clinically, an osteoma is a sharply delimited, sometimes lobulated lesion with a 
scalloped or geographic border. The size at the base ranges from 1.5 to 15 disk diameters 
and the prominence from 0 5 to 2 mm Osteomas are typically solitary with a para-
papillary localization; they may surround the optic nerve head completely. Extension to 
the macular area is nearly always present. The colour depends on the degree of thinning 
and depigmentation of the pigment epithelium If the epithelium is affected only slightly, 
the colour is orange-red Mostly, however, depigmentation of the overlying pigment 
epithhum develops and then the tumour has a yellowish-white appearance often with 
orange pigment on the surface. Bundles of vascular branches across the lesion have been 
described which resemble those of choroidal neovascularizations. A retinal detachment is 
frequently encountered Cystoid oedema or degeneration of the retina is not observed. 
Sometimes, drusen or a haemorrhagic macular detachment are described (Gass, 1979). 
At fluorescein angiography, if the pigment epithelium is affected only little, a 
normal or only slightly masking of the choroidal fluorescence is observed. However, in 
yellowish-white tumours, there is hyperfluorescence due to prompt perfusion of the 
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capillary network. In late phases the fluorescence fades. A spotty staining sometimes 
occurs. Choroidal neovascularization, if present, causes early leakage. On the tumour 
surface hyperfluorescent drusen may be observed. The retinal circulation is normal (Gass 
et al., 1978; Gass, 1979). Echographically, a highly reflective, irregular tumour with a 
marked orbital shadow is described (Gass, 1979; Ossoinig and Harrie, 1983; Shields et 
al., 1988; Cennamo et al., 1990). 
At roentgen examination, CT scanning of the orbit and MRI, the calcified tumour 
may be visualized (Shields et al., 1988; DePotter et al., 1991). 
The 32P uptake test gives a pathological result (Costón and Wilkinson, 1978; Gass, 
1979). 
Spontaneous decalcification of the lesions is possible (Trimble et al., 1988). Sites 
of leakage of exudates may, if desired, be treated with laser photocoagulation (Gass, 
1979; Rose et al., 1991). 
Osteomas owing to their colour and the occasionally multifocal appearance may 
resemble metastases, but they are more sharply delimited from the environment (Gass, 
1979; Amé and Mathis, 1986; Menchini et al., 1990). 
1.5.6.7 Melanocytoma and other melanocytic uveal tumours 
Melanocytomas (magnocellular naevi) are benign tumours. They may develop wherever in 
the eye there are melanocytes present, inter alia in the iris, the ciliary body and the 
choroid. The most frequent localization is on or immediately adjacent to the optic nerve 
head (Reidy et al., 1985). Melanocytomas of the uvea are rare and difficult to distinguish 
from other pigmented naevi. Sometimes they are mistaken for a melanoma (Zimmerman, 
1965; Howard and Forrest, 1967). 
Unlike melanomas, melanocytomas are reported with a high frequency in ethnic 
groups with hyperpigmentation of ocular structures such as Negroes. Mostly they are 
discovered at routine examinations of middle-aged people, without a distinct sex 
predilection. Characteristically they are unilaterally located, but sometimes bilaterally 
(Frangieh et al., 1985; Reidy et al., 1985). 
Melanocytomas are asymptomatic unless the lesion is large and/or shows necrosis. 
However, perimetry in the majority of the cases reveals an enlarged blind spot (Reidy et 
al., 1985). Eckhardt and Hutz (1990) describe a large absolute scotoma. Sometimes there 
is an afferent pupillary defect in the affected eye, probably due to compression of the 
nerve fibre layer by the tumour. The tumour is ink-black, flat and mostly localized 
excentrically on the optic nerve head. The margins of the tumour frequently show a fuzzy 
aspect due to infiltration into the surrounding nerve fibre layer, but they may also be 
sharp. Growth is usually absent (Joffe et al., 1979; Reidy et al., 1985). If progressive 
increase of the tumour size occurs, it may be mistaken for a melanoma (Mansour et al., 
1989). 
At fluorescein angiography, hypofluorescence is observed, probably brought about 
by the pigmentation of the tumour. No pathognomonic image exists (Reidy et al., 1985). 
Echographically, a solid tumour with a smooth surface and about 2 mm prominence which 
was highly reflective has once been described (Lauritzen et al., 1990). 
The management of this benign tumour is observation. Malignant degeneration has 
been described (Reidy et al., 1985). 
Melanocytomas of the iris may undergo malignant transformation. Pigmentation of 
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the angle of the antenor chamber may lead to a secondary glaucoma (Cialdmi et al., 
1989). At fluorescein angiography, no stajmng of the lesion is observed (Shields et al., 
1977; Hodes et al., 1979, Cialdmi et al., 1989). 
Melanocytomas of the ciliary body show no preference for any particular quadrant 
and, although benign, they may infiltrate adjacent tissues. Fluorescein angiography, 
echography and the 32P uptake test do not contribute to the differential diagnosis. Shields 
et al. (1980) desenbed a melanocytoma of the ciliary body which showed growth but 
caused no complaints about visual acuity. At echography, a low- to mid-reflective tumour 
was observed which was compatible with the diagnosis of melanoma. The 32P uptake test 
gave a pathological result. 
The literature contains reports of a few cases of bilateral diffuse benign 
melanocytomas of the uvea in association with a systemic malignancy. Such lesions may 
be mistaken for intraocular metastases (Barr et al , 1982, Mullaney et al., 1984; De 
Wolff-Rouendaal, 1985, Arné and Mathis, 1986). In all probability, a syndrome is 
concerned here in which the uvea shows a reaction to the malignancy elsewhere in the 
body or to the same 'oncogenous' stimulus which causes that malignancy (Barr et al., 
1982). The patients' ages range from 57 to 78 years. In most patients there is loss of 
visual acuity and bilateral diffuse darkly pigmented lesions are described. A nodular shape 
is also possible, however No lesion has a prominence of over 3 mm. A serous retinal 
detachment and cataract occur very frequently Dilatation of episcleral vessels is desenbed 
regularly and glaucoma may also develop. At fluorescein angiography in the artenovenous 
phase, multiple irregular areas of hyperfluorescence are observed which correspond to 
small orange spots on the tumour surface. Echography reveals a thickening of the uvea or 
a highly reflective nodular tumour with a choroidal excavation. Histopathologically, a 
diffuse flat infiltration of the uvea is described with polygonal and spindle-shaped naevus 
cells and intrascleral spread Sometimes, atypical cells are encountered. As a rule there is 
focal necrosis Most patients die shortly after the ophthalmological diagnosis, probably 
due to the systemic malignancy elsewhere in the body. This malignancy may be of vanous 
types, such as a carcinoma of the lung, ovary, pancreas, colon, uterus or gall bladder 
(Machemer et al., 1966, Curtin, 1974; Font, 1976; Ryll et al., 1980, Barr et al., 1982; 
Mullaney et al., 1984, De Wolff-Rouendaal, 1985; Gass et al , 1990). 
1.5.7 Inflammatory disorders 
On the one hand, uveal metastases may be associated with inflammatory phenomena, 
especially if the metastasis is localized in the ins (Duke and Kennedy, 1958; Ferry, 1967; 
Reese, 1976; Stephens and Shields, 1979) Ferry and Font (1975) desenbed iridocyclitis 
in 40% of the patients with metastases in the anterior segment. The inflammation may be 
so pronounced that endophthalmitis develops (Levine and Williamson, 1970; de Bustros et 
al , 1985). 
On the other hand, vanous inflammatory disorders may resemble uveal metastases 
(Shields, 1983, Amé and Mathis, 1986, Wharam and Schachat, 1989). It is especially in 
the older literature that inflammations are frequently mentioned in this connection. Sattler 
(1926), for instance, lists tuberculosis, foci of choroiditis and septic metastases in his 
differential diagnostics of choroidal metastases. Michelson et al (1979) desenbed a patient 
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with a possible focus of toxoplasmosis in the choroid and a patient with a subretinal 
granuloma in rubellar retinopathy as pseudometastatic lesions. Endophthalmitis in rare 
cases may resemble an iridai metastasis, and create a hypopyon similar to the pseudo-
hypopyon that may be formed by metastatic cells (Shields, 1983). If a uveitis fails to 
respond to treatment, the possibility of intraocular metastases should be considered, at any 
rate if weight loss or coughing is also involved (Scholz et al., 1983). 
1.5.7.1 Uveitis 
Choroiditis with ал exudative retinal detachment is part of the differential diagnosis of 
choroidal metastases (Daicker, 1981; Shields, 1983). Granular lesions in particular may 
show distinct similarities to an intraocular tumour (Keller, 1962). If no primary tumour or 
metastases elsewhere are known, the differential diagnosis may be difficult (Takahashi et 
al., 1984). 
In case of suspicion of tuberculosis or sarcoidosis, an iridai metastasis may not be 
diagnosed correctly (Bonamour and Bonnet, 1956; Abramowicz, 1969; Talegaonkar, 
1969; Scholz et al., 1983; Spencer, 1986). 
Tuberculosis of the choroid is rare nowadays. Clinically, its distinction from 
tumours such as metastases or malignant melanomas may be difficult. Ophthalmoscopy, 
fluorescein angiography, echography and '-'P uptake testing frequently leave uncertainty 
(Gulhoff, 1988). Jaensch (1951) was of the opinion that the ophthalmoscopic image of a 
choroidal metastasis resembled that of disseminated tuberculosis of the choroid. Poujol 
and le Roy (1983) described a choroidal tuberculoma which echographically showed 
similarities to a melanoma with choroidal excavation. 
Granulomatous sarcoidosis of the choroid is rare. At ophthalmoscopy, a non-
pigmented yellowish subretinal mass is seen with an overlying retinal detachment which 
causes decrease of the visual acuity. The intraocular lesion is usually solitary and may be 
the first sign of sarcoidosis. However, bilateral and multiple localizations are also 
described. Especially if the choroidal infiltrates are situated in the macular and 
paramacular regions, subretinal fluid is present and the visual acuity is decreased, the 
differential diagnosis of choroidal metastases may be difficult. At perimetry, a scotoma 
may be found (Wessing, 1968; Michelson et al., 1979; Marcus et al., 1982; Oik et al., 
1983; Campo and Aabcrg, 1984; Ryckewacrt et al., 1988). 
At fluorescein angiography in the early phases a block of the choroidal 
fluorescence is observed. In the arteriovenous phase, a minimal abnormal hyper-
fluorescence is seen at the site of the lesion followed by hyperfluorescent spots on the 
surface. In the late phases the choroidal mass beneath the retinal detachment stains 
intensely and homogeneously. The retinal vasculature is normal (Marcus et al., 1982; Oik 
et al., 1983). The fluorescein-angiographic image in sarcoidosis may show similarities to 
that of choroidal metastases. The echographic finding of a homogeneous mid-reflective 
tumour is also described both in metastases and in sarcoidosis (Campo and Aaberg, 1984). 
Oik et al. (1983) reported that a lesion in sarcoidosis may be visualized by means of CT 
scanning with image intensifying after administration of contrast medium. 
Treatment consists of systemic administration of corticosteroids (Marcus et al., 
1982; Campo and Aaberg, 1984). 
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In syphilis, also, a lesion suggestive of an intraocular tumour is possible (Tamesis 
et al., 1990). 
In cryptococcosis discrete yellow choroidal or chorioretinal lesions can be observed 
(Clarkson and Green, 1989; Holland, 1989). 
The juvenile xanthogranuloma, a chronic granulomatous inflammatory reaction of 
unknown aetiology, is a rare benign intraocular tumour. It may be accompanied by yellow 
skin lesions. Ophthalmologically, an involvement of the iris and the ciliary body occurs 
most frequently. The condition is distributed evenly over both sexes and nearly all patients 
are young children, most of them younger than one year (Sanders, 1962; Zimmerman, 
1965a; Treacy et al., 1990). However, juvenile xanthogranuloma has been described in 
adults between 26 and 38 years (Zimmerman, 1965; Smith et al., 1969; Brenkman et al., 
1977; Bruner et al., 1982). The lesions develop virtually always unilaterally (Zimmerman, 
1965; Hadden, 1975). A localization of juvenile xanthogranuloma in the iris may lead to 
an opacification of the cornea and cause complaints such as photophobia and epiphora. In 
involvement of the ciliary body a red eye and signs of inflammation have been described 
(Dhermy, 1979). Minckler et al., (1978) described a pathological result of the 32P uptake 
test. 
In young children the possibility of juvenile xanthogranuloma has to be considered 
in the presence of an asymptomatic diffuse or localized iridai tumour, unilateral glaucoma, 
spontaneous hyphaema, a red eye with signs of uveitis or iridai heterochromia (Sanders, 
1962; Zimmerman, 1965). 
Treatment consists in corticosteroids or radiotherapy (Treacy et al., 1990). 
Harada's syndrome involves an inflammation of inter alia the uvea, retina and 
meninges. It is part of the Vogt-Koyanagi-Harada syndrome in which lesions of ears and 
skin are also described. In Harada's syndrome, uveitis with exudative retinal detachment 
is predominant. The condition may have a viral aetiology and is probably a cell-mediated 
autoimmune process (Ohno et al., 1977; Lubin et al., 1981). 
Harada's syndrome usually develops between the ages of 20 and 40 years, occurs 
as frequently in males as in females and is observed particularly in patients with marked 
pigmentation. Inflammation of the anterior segment and vitreous opacities are encountered 
virtually always and cataract and glaucoma are described frequently. In 96% of the cases 
both eyes are involved (Ohno et al., 1977; Perry and Font, 1977). 
The principal complaint is deterioration of the visual acuity, followed by headache, 
tinnitus, metamorphopsia, photophobia, vertigo and depigmentations of the skin (Shimizu, 
1973). 
Ophthalmoscopically, the condition is characterized by diffuse bilateral 
granulomatous uveitis with involvement of the choriocapillaris. Focal areas of 
chorioretinal scarring develop with a distinct reaction of the retinal pigment epithelium. 
Depigmentation of the retinal pigment epithelium and the choroid causes the ophthalmo-
scopical image of a 'sunset glow fundus'. A retinal detachment develops from the macular 
area and extends towards the periphery. Many bullous detachments may occur. There is 
hyperaemia of the optic nerve head with subretinal fluid in the peripapillary space. 
Progressive signs of inflammation of the vitreous humour may develop (Lubin et al., 
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1981). The picture may be deceptive, owing especially to choroidal detachment (Amé and 
Mathis, 1986). In addition, subretinal neovascularization is possible (Ober et al., 1983). 
The ophthalmoscopic image may greatly resemble that of choroidal metastases (Gass, 
1987; Wharam and Schachat, 1989). 
At fluorescein angiography in the arteriovenous phase, many discrete fluorescent 
dots are seen at the level of the retinal pigment epithelium. These dots increase in number 
but their size does not change. Dye accumulates beneath the pigment epithelium. In the 
venous phases, a diffuse background fluorescence develops. There is an increased 
permeability of the optic disk capillaries. The retinal vessels, on the other hand, appear 
normal (Shimizu, 1973; Lubin et al., 1981). 
The condition responds well to administration of corticosteroids (Lubin et al., 
1981). 
Acute multifocal ischaemic choroidopathy (AMIC), also called acute multifocal 
posterior placoid pigment epitheliopathy (AMPPPE), is a primary affection of the choroid 
with obstruction of precapillary choroidal arterioles which is probably caused by a 
vasculitis (Deutman, 1983). Its aetiology is not known but may be viral (Deutman et al., 
1972; Ryan and Maumenee, 1972). The condition should be included in the differential 
diagnostics of choroidal metastases (Daicker, 1981). AMIC develops at an average age of 
31 years, independently of sex or race and often bilaterally. The symptoms consist of 
acute painless deterioration of visual acuity without photopsia. The eyesight ranges from 
finger counting to 20/20 and in practically all cases returns to normal after 2 to 12 weeks, 
with or without treatment with corticosteroids. Frequently, cells in the vitreous humour or 
iritis are observed (Annesley et al., 1973; Tessler and Schlaegel, 1989; Williams and 
Mieler, 1989). 
At ophthalmoscopy, yellowish-white placoid lesions, about one disk diameter in 
size, are observed at the level of the choroid and the pigment epithelium. The macula in 
particular is affected, but the lesions may extend farther to the periphery and fuse. 
Sometimes retinal oedema, small retinal haemorrhages, anterior uveitis or diffuse 
episcleritis develop (Gass, 1968; Annesley et al., 1973; Tessler and Schlaegel, 1989; 
Williams and Mieler, 1989). At fluorescein angiography in the early phases, hypo-
fluorescent spots are seen similar to the cream-coloured lesions at ophthalmoscopy which 
in later phases show hyperfluorescence. There is a sharp delimitation between fluorescent 
and non-fluorescent areas. Filling defects of the choriocapillaris may be demonstrated 
(Annesley et al., 1973; Deutman and Lion, 1977; Tessler and Schlaegel, 1989). 
The EOG and the ERG are abnormal at early stages (Deutman et al., 1972). 
1.5.7.2 Retinitis 
Patients with a malignancy often have reduced resistance and are more susceptible to 
infections. 
Michelson et al. (1979) described two patients with cytomegalovirus retinitis in 
whom the lesions were suspected of being metastases. In contrast to metastases of the 
choroid, cytomegalovirus retinitis, as its name indicates, involves the retina in particular. 
Multiple and bilateral yellowish-white areas of retinal necrosis may be present. The 
lesions have irregular margins and often exhibit retinal haemorrhages. 
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Fungal retinitis may also resemble a choroidal metastasis, but is usually 
accompanied by signs of inflammation (Shields, 1983, Arne and Mathis, 1986). Crypto-
coccosis has already been discussed in the chapter on uveitis (Chapter 1.5 7.1). 
1.5.7.3 Posterior scleritis 
Postenor sclentis is an uncommon condition. Existing signs of antenor sclentis or a 
history of collagen and vascular diseases may constitute indications for the diagnosis. The 
main cause of posterior sclentis is rheumatoid arthritis Postenor sclentis occurs twice as 
frequently in females as in males This applies in particular if an exudative macular 
detachment has developed or a circumscribed area of swelling is established. Annular 
cihochoroidal effusion and choroidal folds are observed more often in males Postenor 
sclentis occurs at an average age of 38 years If a circumscribed mass is present, the age 
is 47 years on average Posterior sclentis occurs bilaterally in 10 to 33% of the cases 
(Benson, 1988) 
The main symptoms are pain, deteriorating eyesight and a red eye and, in severe 
cases, proptosis and diplopia The patient may also be asymptomatic, however. Most 
patients have some degree of antenor sclentis Watson (1982) and Benson (1988) in one-
quarter of the cases describe cells in the anterior chamber or the vitreous humour due to 
uveitis, and an increase in the intraocular pressure may also be observed 
A local posterior sclentis may present the ophtha!moscopical picture of a choroidal 
tumour (Chang et al , 1978, Arne and Mathis, 1986, Bonnin, 1986) The similarities may 
be very pronounced in metastases with intrascleral or even extrascleral spread (Bailliart ct 
al , 1968, Yeo et al , 1983) In posterior sclentis the lesion shows the same orange-red 
colour as the surrounding normal retinal pigment epithelium and a normal choroidal 
vascular pattern The swelling is surrounded by concentric choroidal folds or retinal 
stnae Cystoid macular oedema, an exudative macular detachment, a bullous and/or 
penpheral retinal detachment and an annular choroidal detachment may be encountered 
(Benson, 1988) 
If the sclentis leads to a retinal detachment, a defect in the visual field related to 
this detachment may be recorded (Harper, 1960) If subretinal fluid is present, this may at 
fluorescein angiography bnng about a mottled choroidal background fluorescence, 
following which bright multiple pinpoint areas of hyperfluorescence develop that grow 
larger In later phases leakage of dye is observed The same pattern may also be observed 
in choroidal metastases However, characteristic features of postenor sclentis are the 
choroidal folds observed at angiography (Bonnin, 1986, Benson, 1988). 
At echography, a flattening of the postenor pole is observed with a diffuse 
thickening of the posterior coats of the eye and retrobulbar oedema (Benson, 1988) The 
differentiation from malignant tumours is difficult The sclentis may exhibit pronounced 
prominence with the same acoustic properties as a melanoma (Chang et al , 1978, Finger 
et al., 1990) or a highly reflective lesion with an irregular ultrastructure which may be 
mistaken for a metastasis (Ossomig and Harne, 1983, Benson, 1988). 
In the CT scan a scleral thickening may be established which grows more 
pronounced after administration of contrast medium (Benson, 1988). The 32P uptake test 
may give positive as well as negative results (Chang et al., 1978; Shields, 1978; Benson, 
1988). 
Thus, postenor sclentis may present a picture like that of a choroidal metastasis 
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and vice versa. Signs of intraocular inflammation may be useful for the differentia] 
diagnosis (Chang et al., 1978; Amé and Mathis, 1986; Bonnin, 1986). Important 
indications of posterior scleritis are pain, cells in the anterior chamber or vitreous 
humour, the orange colour, choroidal folds and retinal striae as well as the presence of a 
retrobulbar oedema at echography indicative of oedema (Benson, 1988). 
Treatment consists of systemic or retrobulbar corticosteroids or antiprostaglandins 
such as aspirin (Benson, 1988). 
1.5.8 Intraocular haemorrhages and detachments of the retina, retinal pigment 
epithelium and choroid 
1.5.8.1 Vitreous haemorrhage 
A vitreous haemorrhage, whatever its cause, sometimes assumes a globular configuration 
and may then show the appearance of a melanoma. Ophthalmoscopically, the haemorrhage 
is mobile and the correct diagnosis can as a rule be made without difficulty (Shields, 
1977b). 
An organized haemorrhage may show the echographic image of an acoustically 
dense mass. However, there is no connection of the lesion with the sclera. The reflectivity 
is very low (Neetens et a]., 1984). 
1.5.8.2 Retinal detachment, subretinal haemorrhage and retinoschisis 
Retinal detachments are predominantly of rhegmatogenous origin. Ophthalmoscopically, 
they can as a rule be recognized easily by the break in the retina, the folded aspect of the 
retina and the absence of displacement of subretinal fluid during movements of the head. 
In intraocular tumours and also in choroidal metastases in which retinal detachments are 
frequently described, breaks in the retina occur rarely (Albert et al., 1967; Howard, 1968; 
Shields, 1977b; Pau, 1979; Stephens and Shields, 1979; Amé and Mathis, 1986; 
Freedman and Folk, 1987). If the subretinal fluid is cloudy, the lesion may be mistaken 
for an amelanotic tumour (Gass, 1972). 
The defect in the visual field in retinal detachment is nearly always relative, has a 
sloping edge and is reasonably uniform in density. In bullous detachments a sharp edge is 
possible. The scotoma as a rule shows an extension to the periphery (Harrington, 1956; 
Reed and Drance, 1972). 
At fluorescein angiography, some hypofluorescence is sometimes seen, due to 
masking of the background fluorescence. As a rule no hyperfluorescence or late staining 
of the lesion is seen. In retinal detachments of longer standing some hyperfluorescence 
may be observed due to secondary defects in the retinal pigment epithelium (Gass, 1972; 
Fishman, 1977). 
In bullous retinal detachments, echography shows a highly reflective membrane 
that is connected with the disk or the ora serrata. The surface is smooth and concave. The 
subretinal space is acoustically empty except if a haemorrhagic detachment has occurred. 
If the haemorrhagic detachment was caused by a tumour, this tumour may be difficult to 
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distinguish from an organizing haemorrhage (Coleman and Jack, 1973; Shields and 
Tasman, 1977; Chang et al., 1978; Verbeek, 1985). 
Electro-oculographically, both a low dark trough and a low ratio are reported in 
retinal detachment (François et al., 1957; Brink et al., 1989). The retinal detachment can 
be clearly distinguished from melanomas and metastases, even if these tumours are 
associated with a similar secondary detachment (Brink et al., 1989/1990). 
An organized subretinal haemorrhage may present as an elevated lesion which, 
because of its shape, may be mistaken for a haemangioma or neoplasm. At echography in 
the early phase a low-reflective irregular tumour is observed. With time the lesion 
becomes more highly reflective. Since in general the haemorrhage does not displace the 
choroid, no choroidal excavation develops (Chang et al., 1978). 
With MRI shorter T2 relaxation times are observed than in choroidal metastases 
(Wollensak et al., 1988). The 32P uptake test shows no abnormalities (Shields, 1978). 
In retinoschisis a peripheral splitting of the retina without a break is observed. A 
schisis constitutes a smooth thin-walled bullous lesion with extensive peripheral cystic 
degeneration. Bilateral presence has been described. The schisis is most frequently 
localized peripherally in the inferotemporal quadrant (Shields, 1977b). 
A schisis is regularly mistaken for a melanoma or a slightly pigmented tumour, 
especially if the condition is accompanied by retinal cysts, intraretinal haemorrhage and 
proliferations of the pigment epithelium, or if the lesion contains cloudy fluid (Gass, 
1972; Amé and Mathis, 1986). 
At fluorescein angiography, some hypofluorescence is sometimes observed due to 
masking of the choroidal staining. If a break is present in the outermost layer of the retina 
with a retinal detachment of long standing, hyperfluorescence may occur secondarily to 
loss of pigment from the pigment epithelium. As a rule, however, fluorescein angiography 
shows no hyperfluorescence or late staining (Gass, 1972; Fishman, 1977). 
At echography, a linear echo is obtained extending from the ora serrata. Unless a 
secondary retinal detachment occurs, it rarely reaches the optic nerve. The space behind 
this echo is acoustically clear (Shields and Tasman, 1977). 
1.5.8.3 Detachment of the retinal pigment epithelium, haemorrhage below the 
pigment epithelium and age-related disciform macular degeneration 
A detachment of the retinal pigment epithelium varies in size from a minimal lesion to a 
detachment that extends over nearly the entire posterior pole. Only large lesions cause 
diagnostic problems and then have to be included in the differential diagnosis of choroidal 
metastases (Shields, 1977b; Michelson et al., 1979; Amé and Mathis, 1986). Character-
istic features of detachments of the pigment epithelium are sharply delimited round or 
kidney-shaped elevations with a smooth surface. The colour varies from orange to yellow 
or white, depending on the loss of pigment from the pigment epithelium. On the surface, 
pigment clumps may be present. Large detachments in general occur in older patients with 
intraocular drusen which can then be observed in the other eye as well. Gass (1972), 
122 
Shields (1977b) and Amé and Mathis (1986) described the rarely observed detachment of 
the pigment epithelium as a complication after choroiditis due to a suspected 
histoplasmosis. 
At fluorescein angiography, a pathognomonic image is observed. In the early 
phases, the dye diffuses beneath the detached pigment epithelium and stains the underlying 
fluid. This causes an area of hyperfluorescence which corresponds exactly to the 
detachment. This staining persists long. Sometimes, there is a diffuse leakage of dye into 
the subretinal space through a rupture in Bruch's membrane (Gass, 1972; Fishman, 1977). 
A central serous chorioretinopathy (retinitis or retinopathia centralis serosa) may 
cause blurred vision and metamorphopsia such as may also occur in choroidal metastases. 
Usually the visual acuity is not severely affected. Ophthalmoscopically, only serous fluid 
below the fovea is observed without signs of a choroidal tumour. Rarely, a large bullous 
retinal detachment is described. This may be accompanied by a creamy-white detachment 
of the retinal pigment epithelium. Its appearance may show clear similarities to that of a 
metastasis. Neovascularization may occur directly below or in the immediate vicinity of 
the central fovea. These abnormal vessels may pierce Bruch's membrane and pass into the 
subretinal space. At fluorescein angiography one or several small foci of leakage of 
fluorescein may be observed, probably due to increased capillary permeability and/or a 
defect in Bruch's membrane. EOG is normal (Deutman, 1971; Gass, 1973a; Shields, 
1983; Abramson, 1984; Watzke, 1989). 
Vitelliform dystrophy of the fovea (Best's disease) is an autosomal dominant 
inherited usually bilateral macular condition affecting the retinal pigment epithelium. 
Predominantly a gradual decrease of visual acuity occurs. Classically an egg-yellow round 
slightly elevated lesion surrounded by a dark border is described. Multiple structures in 
the posterior pole can occasionally be observed. At fluorescein angiography hypo-
fluorescence at the site of the lesion is observed. In case of atrophy of the pigment 
epithelium areas of hyperfluorescence occur. EOG is almost always subnormal (Deutman, 
1971/1989). 
A haemorrhage below the pigment epithelium in most cases presents with a 
sudden loss of visual acuity (Reese, 1961). A haemorrhagic detachment of the pigment 
epithelium and retina may be brought about by a rupture of neovascular structures in the 
subpigment epithelial space, such as occurs in patients with age-related macular 
degeneration or early degenerative alterations of the choroid (Gass, 1972). In the posterior 
pole, a generally unilateral, dark round thickening is seen which may resemble a 
melanoma. After about two weeks, a red halo of subretinal blood develops at the margin 
of the lesion (Reese, 1961; Gass, 1972). At fluorescein angiography, a hypofluorescence 
is observed, the fluorescein being absorbed by the extravascular haemoglobin. As a rule, 
absorption takes place after 10 days to 2 weeks (Fishman, 1977; Shields, 1977b). The 
lesion may be difficult to distinguish from a tumour (Silva and Brockhurst, 1976; Shields, 
1977b; Amé and Mathis, 1986). 
Age-related macular degeneration (Kuhnt Junius) is the principal cause of 
blindness in the Western world and should be included in the differential diagnosis of 
choroidal metastases (Daicker, 1981; Michelson et al., 1987). About its aetiology only 
little is known. The patients are mostly over 50 years of age and the disorder frequently 
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occurs bilaterally. Most patients exhibit only drusen in the fundus. Decrease of visual 
acuity is caused by subretinal neovascularizations and the resulting serous and 
haemorrhagic detachment of pigment epithelium and retina at the site of the macula. A 
choroidal neovascularization membrane presents the image of a round to oval grey-green 
lesion. The ultimately formed fibrovascular disciform scar may be mistaken for a tumour 
(Gass, 1987; Bressler et al., 1988). 
At fluorescein angiography a hypofluorescence at the site of the lesion is observed 
in all phases as well as an intense late hyperiluorescence that corresponds to the 
neovascularization membrane beneath the retinal pigment epithelium and retina (Shields, 
1983). 
If collagenous tissue has formed between the retina and the choroid, this 
homogeneous mid-reflective tissue may echographically resemble a melanoma (Bigar, 
1988). A choroidal excavation may be present (Shields, 1983). Guthoff (1988) described 
this pseudotumour as a lesion with an irregular infrastructure, with areas of both low and 
high reflectivity. The prominence rarely exceeds 3 mm. 
The 32P uptake test gives a normal result (Van Dijk, 1976; Shields, 1983a). 
1.5.8.4 Choroidal detachment and choroidal haemorrhages 
A choroidal detachment frequently occurs after an injury or intraocular surgery with low 
intraocular pressures, but it may also be associated with uveitis or a retinal detachment or 
as part of a uveal effusion (Fishman, 1977; Shields, 1977b·, Chang et al., 1978; Amé and 
Mathis, 1986). A choroidal detachment has to be distinguished from choroidal metastases 
(Michelson et al., 1979). 
At ophthalmoscopy, a smooth round or lobulated brown mass is seen at the 
periphery which may present as a tumour. As a rule it does not extend farther back than a 
few millimeters behind the equator, and the detachment is frequently annular. 
Differentiation from a tumour is more difficult in a haemorrhagic detachment. An 
overlying detachment of the pigment epithelium may make the lesion appear to be solid 
(Gass, 1972; Fishman, 1977; Kelley, 1977; Shields, 1977b; Amé and Mathis, 1986). 
At fluorescein angiography a shadow at the site of the lesion may be observed. 
Neither in serous nor in haemorrhagic detachment is hyperfluorescence, abnormal 
permeable vessels or staining observed (Gass, 1972; Fishman, 1977; Kelley, 1977). 
Echography as a rule shows a convex elevation of the retina and choroid delimited 
anteriorly by the ciliary body and posteriorly by the site of the vortex ampullae. The 
suprachoroidal space is acoustically empty or, in case of a haemorrhagic detachment, 
shows diffuse echoes (Shields and Tasman, 1977; Chang et al., 1978). 
MRI in a serous detachment shows a hyperintensity in T, weighted images and a 
moderately hyperdense image in T2 weighted images (Mafee et al., 1987). The 32P uptake 
test is normal (Shields, 1978). A serous detachment of the choroid is diaphanous, a 
haemorrhagic detachment gives a shadow (Gass, 1972; Fishman, 1977; Amé and Mathis, 
1986). 
A choroidal detachment disappears spontaneously, although this may take several 
months (Kelley, 1977). 
If an exudative detachment of the choroid and ciliary body occurs without a clear 
cause, this is called an idiopathic ciliochoroidal effusion. This condition frequently 
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develops bilaterally and in healthy subjects, mostly in middle-aged males. The aetiology is 
probably an anomaly of the sclera with hypotrophy of the vorticose veins impainng 
outflow from the uvea (Schepens and Brockhurst, 1963; Gass and Jallow, 1982; Gass, 
1983). 
The uveal effusion syndrome, which may include increased albumin in the 
cerebrospinal fluid and a raised intracranial pressure, has to be differentiated from 
choroidal metastases (Schepens and Brockhurst, 1963; Kreiger et al., 1969; Michelson et 
al., 1979; Gass and Jallow, 1982; Wharam and Schachat, 1989). 
Frequently, gradual loss of the superior field of vision is noticed, sometimes 
blurred eyesight and metamorphopsia. Dilated episcleral vessels and cells in the vitreous 
humour are observed often. The ocular pressure is normal (Gass and Jallow, 1982). 
Clinically, a partial or circular flat or bullous choroidal detachment with an 
exudative retinal detachment is observed. The serous fluid is displaced by movements of 
the head. Frequently, a separate clumping of brown pigment is seen in the retinal pigment 
epithelium and on the surface of the detachment orange pigment may be present. Oedema 
of the optic nerve occurs in 10 to 20% of the patients (Schepens and Brockhurst, 1963; 
Shields, 1977b, Gass and Jallow, 1982) 
At fluorescence angiography, a retarded perfusion of the choroid is often 
described The above-mentioned depigmentation of the pigment epithelium and 
leopardskin-hke clumping of pigment may be demonstrated (Gass and Jallow, 1982). 
Owing to the serous nature of the detachment, echographic differentiation from a 
choroidal tumour is possible. A thickening of the choroid is observed, or a smooth 
circumferential convex elevation of the choroid and ciliary body (Coleman and Jack, 
1973; Gass and Jallow, 1982, Guthoff, 1988) 
The ERG is subnormal (Gass and Jallow, 1982), the 32P uptake test gives a normal 
result (Shields, 1983a). 
In localized suprachoroidal haemorrhages, ophthalmoscopy reveals a darkly 
pigmented lesion in the posterior pole, localized in the suprachoroidal space. No vitreous 
haemorrhage or retinal detachment occurs, choroidal vessels run a normal course and the 
intraocular pressure is normal. Choroidal folds are observed, however. The condition is 
encountered rarely, mostly shortly after intraocular surgery and especially in myopic 
patients, it may present as a melanoma 
Fluorescein angiography reveals a pattern that resembles that of the surrounding 
choroid with relative hypofluorescence at the margins and choroidal folds. There is no 
block of the choroidal fluorescence or double circulation (Hoffman et al., 1984, 
Augsburger et al., 1990a). At echography an acoustically very low-reflective lesion is 
observed without choroidal excavation, vascularity or orbital shadow (Neetens et al., 
1984). At echography, the base of the lesion ranges from 7 to 14 millimeters and the 
prominence from 1.5 to 5.5 millimeter (Augsburger et al., 1990a). 
An intrachoroidal haemorrhage of recent date gives a hypodense image in both T, 
and T2 weighted images. A chronic haemorrhage is hyperdense in T, and T2 weighted 
images (Mafee et al , 1987). 
The lesion disappears spontaneously after one to two months (Augsburger et al., 
1990a). 
A subfoveal haemorrhage due to thrombocytopenic purpura may be mistaken for a 
choroidal metastasis (Michelson et al., 1989). 
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1.5.9 Miscellaneous disorders and phenomena 
Cysts and pseudocysts of the iris and ciliary body may be mistaken for an intraocular 
malignant tumour (Reese, 1950; Yanoff and Zimmerman, 1965; Duke-Elder and Perkins, 
1966b; Shields et al., 1984). 
Shields (1983) mentions a foreign body in the differential diagnosis of iridai 
metastases. Upper et al., (1981) described a patient with a painful eye and a large yellow 
choroidal mass with exudates and a flat retinal detachment. At fluorescein angiography, an 
early staining was observed followed by a distinct hyperfluorescence and leakage into the 
retina. Echography showed a low-reflective tumour. The eye was enucleated on the 
diagnosis of malignant melanoma. At histopathological examination it proved to be a 
chorioretinal inflammatory process due to a foreign body. Ferry (1964) also described 
such a pseudomelanoma. 
A toxic retinopathy may be the consequence of protracted treatment with, for 
instance, thioridazine hydrochloride (Mellaril") and manifests itself as depigmented zones 
(Meredith et al., 1978). These more or less characteristically alternating zones of 
pigmentation and thinning have to be differentiated from choroidal metastases (Amé and 
Mathis, 1986). 
Simpson (1961) described a retinal vascular occlusive image characterized by acute 
impairment of the central and paracentral visual acuity with retinal oedema as a 
differential diagnosis from choroidal metastases. 
A chorioretinal coloboma is a predominantly congenital defect in the eye and is 
rarely mistaken for an intraocular tumour (Pagon, 1981; Brown, 1989). 
A vorticose vein in an area of a delimited choroidal detachment echographically 
may show a low-reflective tumour, with the rapid movements of the spikes being mistaken 
for vascularity (Till and Hauf, 1981). Buettner (1990) described a patient in whom a varix 
of a vorticose vein was taken for a melanoma. 
Michelson et al. (1987) in their article on pseudometastases refer to a woman with 
breast cancer in whom myelinated nerve fibres were mistaken for a choroidal metastasis. 
Finally, according to Shields (1983), an ectopic lacrimal gland should be included 
in the differential diagnosis of iridai metastases. Such an aberrant lacrimal gland may 
present as a cystic lesion of the iris and the ciliary body (Hunter, 1960) or as a solid mass 
(Christensen and Anderson, 1952). 
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1.5.10 Conclusions 
Many examination techniques are used for the differential diagnosis of uveal metastases. 
Although the differentiation of a metastasis with a more or less typical appearance from, 
for instance, a characteristic melanoma as a rule causes no problems, it is the atypical 
lesions that render the diagnosis difficult. With no single examination technique is the 
correct diagnosis to be made with 100% certainty and histopathologically, also, the 
diagnosis can sometimes only be made with difficulty. 
Since uveal metastases may be detected before a primary tumour elsewhere in the 
body is known, assumed absence of a systemic malignancy does not exclude the diagnosis 
of intraocular metastasis. Furthermore multiple and bilateral localizations are not limited 
to metastases. Complications such as retinal detachment and inflammatory reactions may 
further impede the differentiation. 
Metastases of lung tumours, in particular, may cause diagnostic problems. 
The principal lesions from which choroidal metastases have to be differentiated are 
(amelanotic) malignant melanoma, naevus and haemangioma. The various lesions are 
surveyed in Table 1.5.10.1. 
The melanoma, the most often diagnosed intraocular tumour, can often be 
differentiated from a metastasis on the basis of its unilateral and solitary occurrence, the 
pigmentation and the echographic characteristics. The differentiation of small and 
amelanotic melanomas from, especially, choroidal metastases of lung tumours may be 
extremely difficult. 
Naevi of the choroid are flat and usually darkly pigmented and show no growth. At 
fluorescein angiography, no leakage is observed and electro-oculographically, also, naevi 
can be distinguished from choroidal metastases. 
Haemangiomas of the choroid are unilateral and solitary, with an orange-red 
colour, with in most cases a typically thickened and cystoid retina and a characteristic 
fluorescein-angiographic pattern. At echography and CT scanning, calcifications may be 
observed. 
Clinically, intraocular structures are only sporadically involved in lympho-
proliferative diseases. Uveal infiltration in leukaemia is mostly diffuse, with presence of 
intraocular haemorrhages and cottonwool spots. The reticulum cell sarcoma, which often 
occurs bilaterally, is characterized in general by corneal precipitates and cells in the 
vitreous humour. A nodular lesion in benign reactive lymphoid hyperplasia of the uvea 
may give rise to diagnostic problems. 
Posterior localized tumours such as leiomyomas, adenomas and adenocarcinomas 
of the retinal pigment epithelium are extremely rare. Hypertrophy and hyperplasia of the 
pigment epithelium can as a rule be differentiated from metastases owing to the marked 
pigmentation. Combined hamartomas of the retina and retinal pigment epithelium develop 
at younger ages than choroidal metastases and can also be differentiated adequately 
because of the retinal tortuosity and the distorted retina. Osteomas occur predominantly in 
young adults. Calcifications give a characteristic image at echography and CT scanning. 
Unlike metastases, retinoblastomas develop at very early ages. Melanocytomas of the uvea 
are heavily pigmented and occur only exceptionally. Bilateral diffuse benign 
melanocytomas show similarities to choroidal metastases. 
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Table 1.5.10.1 Differential diagnosis of choroidal metastases 
Malignant melanoma 
Naevus 
Haemangioma 
Lymphoproli ferali ve diseases 
Leukaemia 
Lymphoma (in particular reticulum cell sarcoma) 
Benign reactive lymphoid hyperplasia 
Other intraocular tumours and related tumour-like lesions 
Leiomyoma 
Tumours and tumour-like lesions of the retinal pigment epithelium 
Hypertrophic lesions of the retinal pigment epithelium 
Hyperplasia of the retinal pigment epithelium 
Hypoplasia of the retinal pigment epithelium 
Adenocarcinoma of the retinal pigment epithelium 
Combined hamartoma of the retina and retinal pigment epithelium 
Retinoblastoma 
Osteoma 
Melanocytoma 
Inflammatory disorders 
Endophthalmitis 
Uveitis 
Tuberculosis 
Sarcoidosis 
Syphilis 
Cryptococcosis 
Toxoplasmosis 
Harada's syndrome 
Acute multifocal ischaemic choroidopathy (AM 1С) 
Retinitis 
Cytomegalovirus retinitis 
Fungal retinitis (cryptococcosis) 
Subretinal granuloma in rubella retinopathy 
Posterior sclentis 
Intraocular haemorrhages and detachments of the retina, retinal pigment epithelium and choroid 
Vitreous haemorrhages 
Serous and haemorrhagic retinal detachments 
Retinoschisis 
Serous and haemorrhagic detachments of the retinal pigment epithelium 
Age-related macular degeneration (Kuhnt Junius) 
Central serous chorioretinopathy 
Vitelliform fovea! dystrophy 
Serous and haemorrhagic detachment of the choroid 
Uveal effusion syndrome 
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Table 1.5.10.1 (continued) 
Reactive Fibrosis due to a foreign body 
Toxic retinopathy 
Retinal oedema 
Chonoretinal coloboma 
Vortex vein 
Myelinated nerve fibres 
In inflammatory disorders the signs of inflammation in general point in the right direction, 
but these signs may also be observed in metastases. If inflammatory signs are less 
pronounced and a granulomatous lesion is observed, which occurs, for instance, in 
tuberculosis or sarcoidosis, the differential diagnosis may be difficult. Harada's syndrome 
and acute multifocal ischaemic choroidopathy may ophthalmoscopically resemble choroidal 
metastases as well as certain forms of retinitis. The diagnosis of posterior scleritis is often 
clear owing to the pain and the redness of the eye. If there are only few symptoms in the 
presence of an intraocular swelling, the differentiation from metastases may be difficult. 
However, characteristic features of posterior scleritis are the choroidal folds and the 
retrobulbar oedema that can be demonstrated by means of echography. 
Differentiation of metastases from serous and haemorrhagic detachments of the 
retina, retinal pigment epithelium or choroid as a rule is not difficult with echography. An 
intraocular haemorrhage may resemble a tumour, but can nevertheless be distinguished 
adequately from it. 
The other lesions, such as reactive fibrosis in foreign body, toxic retinopathy, 
oedema in retinal vascular occlusion, dilated vorticose veins and myelinated nerve fibres 
are only mistaken for choroidal metastases in highly exceptional cases. 
Metastases of the ciliary body occur extremely rarely. Since only a few patients 
have been described, establishing an adequate differential diagnosis for these lesions is 
difficult. The principal tumour in this connection is the malignant melanoma, which as a 
rule can be differentiated well owing to its colour, shape and echographic features. 
Patients with a leiomyoma or a medulloendothelioma in the ciliary body are far younger 
than patients with metastases. Also, the leiomyoma shows a characteristic image at 
diaphanoscopy. Naevi, reactive fibrosis and the other tumours in the ciliary body are 
particularly rare (Table 1.5.10.2). 
Iridai metastases occur infrequently and have to be differentiated from amelanotic 
melanoma, leiomyoma and a number of inflammatory disorders (Table 1.5.10.3). 
Melanomas of the iris are solitary and at fluorescein angiography show leakage of 
dye at the pupillary margin. Since these lesions are treated with local excision, a possible 
fault in the diagnosis is mostly rapidly cleared up. 
Naevi of the iris in general have been known for years to the patient as well as his 
environment, they show no growth and are mostly flat and pigmented. 
If in leukaemia infiltration of the iris occurs, a diffuse image is seen. As a rule, 
signs and symptoms of inflammation are present. 
The other tumours in the iris are extremely rare. 
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Iridai metastases are frequently accompanied by iridocyclitis. For this reason, 
inflammatory disorders such as tuberculosis and sarcoidosis have to be included in the 
differential diagnosis. The juvenile xanthogranuloma is characterized by its onset at a very 
early age. 
A reactive fibrosis round a foreign body may sometimes be mistaken for a tumour. 
Table 1.5.10.2 Differential diagnosis of ciliary metastases 
Malignant melanoma 
Naevus 
Lymphoproliferative diseases 
Leukaemia 
Lymphoma 
Benign reactive lymphoid hyperplasia 
Other tumours 
Haemangioma 
Leiomyoma 
Medulloendothelioma 
Adenoma of the non-pigmented ciliary epithelium 
Adenocarcinoma of the non-pigmented ciliary epithelium 
Juvenile xanthogranuloma 
Cysts and pseudocysts 
Table 1.5.10.3 Differential diagnosis of iridai metastases 
Malignant melanoma 
Naevus 
Lymphoproliferative diseases 
Leukaemia 
Lymphoma (in particular reticulum cell sarcoma) 
Benign reactive lymphoid hyperplasia 
Other tumours 
Leiomyoma 
Adenoma of the pigmented epithelium of the ins 
Adenocarcinoma of the pigmented epithelium of the ins 
Inflammatory disorders 
Endophthalmitis 
Intis 
Tuberculosis 
Sarcoidosis 
Syphilis 
Juvenile xanthogranuloma 
Reactive fibrosis due to foreign body 
Cysts and pseudocysts 
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1.6 Treatment and prognosis 
1.6.1 Treatment 
The treatment of uveal metastases is virtually always palliative. According to Daicker 
(1981), in some cases, with a curable primary tumour and a solitary intraocular 
metastasis, treatment of the ocular tumour may be curative. Treatment aimed at the 
primary tumour, such as surgical resection and radiotherapy of this malignancy, appear to 
have little or no effect on the metastases in the choroid (Gillet, 1971). It is therefore 
necessary to treat the uveal metastases selectively. The choice of treatment depends on the 
symptoms, the localization and the extension of the intraocular metastasis, the nature of 
the primary tumour and the chemotherapeutic possibilities (Ferry, 1967; Shields, 1983) 
Char (1989) emphasizes the importance of the patient's general condition and of the 
presence or absence of metastases in the central nervous system. 
It is the ophthalmologist's duty to endeavour to preserve good visual acuity and to 
treat complications such as pain and secondary glaucoma (Ferry, 1967). 
Although the life expectation of patients with uveal metastases is mostly poor, 
treatment should be considered to maintain visual function (Gass, 1974). 
Therapeutical decisions have to be made in consultation with the medical oncologist 
in charge. According to Char (1989), treatment should only be decided upon after 
complete evaluation including CT or MRI examination of the brain 
In this chapter, the vanous possibilities of treatment will be discussed. Reference 
will be made to the nature and indications of the treatment, the therapeutic effect and the 
possible complications. 
1.6.1.1 Observation 
If a patient in whom metastases in the uvea are detected is in a terminal phase of the 
disease, no treatment should be instituted (Ferry, 1978). Observation is also often 
indicated in small metastatic lesions (Brady et al , 1982). Stephens and Shields (1979) 
recommended an expectative policy if the fovea is not threatened by the tumour or a 
secondary retinal detachment. B^ady et al. (1982) desenbed regression of a uveal 
metastasis m an untreated patient. 
If observation of an intraocular tumour is advocated, examinations such as 
ophthalmoscopical photography, fluorescein angiography and echography may be valuable 
for determination of alterations of the lesion (Shields, 1983). 
If metastases cause visual symptoms or threaten the macula or disk, treatment is 
necessary (Wharam and Schachat, 1989). Untreated uveal metastases may rapidly increase 
in size and, partly through the accompanying retinal detachment, may lead in a few days 
or weeks to severe loss of visual acuity (Orenstem et al., 1972; Brink et al., 1988). 
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1.6.1.2 Chemotherapy 
If intraocular metastases are discovered in cancer patients, this usually also indicates 
progression of the disease elsewhere in the body. Therefore, systemic treatment is 
frequently necessary (Aasved and Seim, 1973, Mewis and Tang, 1982). 
Choroidal metastases, being localized extracerebrally, may be as sensitive to 
chemotherapy as other metastases (Orenstem et al , 1972; Char, 1989). A favourable 
response of the primary tumour to chemotherapy is usually accompanied by regression of 
coexistent intraocular metastases (Abramson, 1984). Chemotherapy of uveal metastases 
may therefore be useful (Focosi and Salvi, 1961, Smith, 1976; Turut et al., 1987). 
Especially if the primary tumour is breast cancer, chemotherapy might be the treatment of 
first choice (Char, 1989). Gailloud (1975/1978) and Bnnkley (1980) also stated that 
combination chemotherapy may be an alternative for irradiation of the intraocular 
metastases. 
According to Shields (1983) asymptomatic intraocular metastases that can be 
observed adequately require no specific ophthalmological treatment It is then necessary 
carefully to check the patient every two to four months for tumour growth and visual loss 
Saßmannshausen et al (1990) are also of the opinion that in some cases, in peripherally 
localized metastases, the effect of systemic treatment may be awaited provided 
ophthalmological follow-up is possible during chemotherapy. If tumour growth occurs 
during systemic therapy, these authors consider radiotherapy necessary in all cases. 
Muller-Grotjan and Liegi (1966) recommend, in the presence of choroidal 
metastases and metastases elsewhere, to start with cytostatic therapy. If this remains 
without effect, the chemotherapy should be changed (Kaiser-Kupfer, 1978) According to 
Meythaler and Herold (1979), multiple-drug chemotherapy is to be preferred in rapidly 
growing metastases. Stolzenbach and von Domarus (1978) treat patients with uveal 
metastases from breast cancer and metastases elsewhere with a combination of hormonal 
and chemotherapy. If this has no effect, treament is changed to radiotherapy of the uvea 
and combination chemotherapy of second choice. Rottinger et al. (1979) believe that in 
minimal clinical symptoms and under continuous ophthalmological control the choroidal 
metastases may be used as a parameter of the efficacy of the chemotherapy. However, 
most patients develop choroidal metastases during such systemic therapy and therefore are 
probably resistant to this treatment. 
While, therefore, on the one hand there is no consensus on whether the effect of 
systemic treatment on choroidal metastases should (Stolzenbach and von Domarus, 1978, 
Shields, 1983, Char, 1989) or should not be awaited (Thatcher and Thomas, 1975; Chu, 
1980), on the other hand investigators who, in a number of situations treat uveal 
metastases with chemotherapy alone, differ on the policy to be conducted. 
According to Brady et al (1982), systemic therapy may be followed by 
stabilization or regression of uveal metastases According to these authors, 50% of the 
eyes show no progression when the patient receives chemotherapy. 
Letson and Davidorf (1982) described six patients with a choroidal metastasis from 
breast cancer in eight eyes who were treated with chemotherapy alone. Chemotherapy 
consisted of cyclophosphamide and fluorouracil, often in combination with other 
cytostatics Eight other patients received radiotherapy alone. The patients treated with 
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chemotherapy alone had a more generalized metastasization and a poorer prognosis than 
those subjected to radiotherapy. All patients on chemotherapy showed regression of the 
tumour with improved visual acuity in five eyes and stabilization of the acuity in the three 
eyes with normal visual acuity pnor to therapy. The mean visual acuity before treatment 
in eyes with a metastasis was 0.39 (finger counting to 0.8) while after treatment it was 
0.58 (0.2 to 1.0). Five of the six patients died after a mean interval of 12 months. No 
effect of the chemotherapy on the duration of survival was established. In all eight 
irradiated patients a decrease of the tumour size was observed and in seven patients, 
improvement of the visual acuity. Letson and Davidorf conclude that chemotherapy alone 
is as effective as radiotherapy in the treatment of choroidal metastases from breast cancer, 
without the risk of irradiation cataract. According to these authors, therefore, radiotherapy 
is indicated only when no stabilization is achieved with chemotherapy (Davidorf et al., 
1982). The possibility exists that owing to the effective use of chemotherapy of metastases 
elsewhere, still undiscovered choroidal metastases are not progressive and escape notice 
(Letson and Davidorf, 1982). 
In a comment on this article by Letson and Davidorf, Mewis and Tang (1982) 
pointed out that the group of patients treated with chemotherapy alone cannot simply be 
compared with the irradiated patients. The mean visual acuity before treatment, namely, 
was 0 39 in the chemotherapy group as against only 0 04 in the radiotherapy group. Of 
the nine patients with breast cancer whom Mewis and Tang examined themselves and who 
received chemotherapy alone, five in 6 months showed an increase in size or number of 
metastases. In three of these patients radiotherapy was necessary to treat (imminent) loss 
of visual acuity. In four other patients, no progression of the choroidal metastases was 
observed during chemotherapy. Improvement of visual acuity was reported in only one 
patient. However, this patient had also been irradiated for an occipital cerebral metastasis. 
Mewis and Tang accordingly conclude that chemotherapy alone is inadequate for the 
treatment of choroidal metastases. 
Stolzenbach and von Domarus (1978) treated eight patients with choroidal 
metastases of breast cancer with a combination of hormonal and chemotherapy. These 
patients had known metastases elsewhere as well. In six of the eight patients a decrease in 
size of the metastasis was observed and in five patients, improvement of the visual acuity 
was achieved. The mean visual acuity in the nine eyes of the six patients in whom the 
metastases went into remission was 0.65 (1/40 to 1 0) before treatment and 0.92 (0.5 to 
1.0) after the systemic therapy. An accompanying retinal detachment went into regression 
in all cases. Other authors also reported positive results of such combined therapy (Aasved 
and Seim, 1973, Farnaner et al., 1973). 
Other authors who reported a positive effect of chemotherapy alone on uveal 
metastases from breast cancer are Liegi (1960), Günther (1961), Todter (1961), Schmelzer 
(1963), Muller-Grotjan and Liegi (1966), Orenstein et al (1972), Bnnkley (1980) and 
Brasseur et al. (1983). 
According to Wharam and Schachat (1989), patients with lung cancer as a rule at 
the time of occurrence of choroidal metastases have already received chemotherapy. 
Mostly, then, no effect of resumed chemotherapy is to be expected. If the patient has not 
yet received chemotherapy, the effect of such therapy may be awaited. This applies 
exclusively to metastases of small cell pulmonary tumours and not to metastases of 
squamous cell, adeno or large cell tumours of the lung. 
Sierocki et al. (1980) had to alter the chemotherapy before remission of ins 
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metastases and increase of the visual acuity could be achieved in a patient with oat cell 
carcinoma of the lung. Lloyd (1968) reported a patient with a metastasis of oat cell 
carcinoma in whom on cyclophosphamide the uveal metastases went into regression 
although the existing visual field defect remained unchanged. Later on, some growth of 
the metastasis was observed again. Castro et al. (1982) described a patient with a 
choroidal metastasis of an oat cell carcinoma in whom the metastasis grew larger and the 
visual acuity decreased during chemotherapy. By means of radiotherapy, an improvement 
of the visual acuity could be obtained. 
Finally, positive results of chemotherapy have been reported in patients with a 
choroidal metastasis of a cutaneous melanoma (Stark et al., 1971; Engel et al., 1981), in a 
patient with a choroidal metastasis of a choriocarcinoma (Keates and Billig, 1970), and in 
a neonate with iris metastases of a neuroblastoma (Bowns et al., 1983). 
In a patient with a metastasis from a thyroid carcinoma, chemotherapy proved 
ineffective (Famarier et al., 1973), just as in a patient with a metastasis of a bladder 
carcinoma (Resnick et al., 1975). 
Chemotherapy for uveal metastases may only be administered in consultation with 
the oncologist and when the patient's general condition is known (Daicker, 1981). 
In the discussion of the effect of chemotherapy it should further be kept in mind 
that use of cytostatics in the treatment of uveal metastases may lead to various side effects 
and ophthalmological complications (Haye, 1986). On this aspect, several survey articles 
have been published (Vizel and Oster, 1982; Fraunfelder and Meyer, 1983; Zaal and 
Polak, 1985; Imperia et al., 1989). Table 1.6.1.2.1 presents a survey of these side effects. 
Ferry (1972) described a patient with a choroidal metastasis from a cutaneous 
melanoma in whom a major inflammatory reaction developed after administration of 
cytostatics. The probable cause was massive necrosis and haemorrhage in the intraocular 
tumour. Cytostatic treatment of uveal metastases therefore entails the risk of permanent 
loss of eyesight and possibly even loss of the eye. 
With respect to the complications of simultaneous use of chemotherapy and 
radiotherapy, the reader is referred to the chapter on radiotherapy of uveal metastases 
(1.6.2.4). 
If in patients with a malignancy which is being treated with cytostatics 
ophthalmological complaints occur, these may be the consequence of metastases in the 
uvea as well as of side effects of the systemic cytostatic therapy. 
To recapitulate, there is no consensus in the literature on the efficacy or inefficacy 
of chemotherapy for treatment of uveal metastases or on the policy to be conducted when 
cytostatic treatment is instituted. Only a few studies on the use of cytostatics in uveal 
metastases have been published. In general these concerned small groups of patients with 
breast cancer as the primary tumour. 
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Table 1.6.1.2 1 Ophthalmological side effects of commonly used cytostatics * 
Blurred vision 
Keratoconjunctivitis sicca, hyperpigmentation of the eyelids and conjunctiva, 
cataract, blurred vision 
Hyperpigmentation of the eyelids and conjunctiva, necrotizing uveitis 
Keratitis, retinopathy and retinal haemorrhages, papilloedema, oculomotor 
disturbances with diplopia 
Retinopathy, papilloedema, retrobulbar neuritis, ERG abnormalities, colour 
blindness, cortical blindness, blurred vision 
Keratoconjunctivitis sicca, blepharoconjunctivitis, hyperpigmentation of the 
eyelids, pinpoint pupils, accommodation disorders, blurred vision 
Keratitis, conjunctivitis, decreased visual acuity 
Conjunctivitis, epiphora 
Papilloedema, optic neuritis, cortical blindness 
Cicatricial ectropion, hyperpigmentation of the eyelids, hyperaemia, 
ankyloblepharon, blepharospasm, blepharitis, keratoconjunctivitis, epiphora, 
chronic canahculitis, dacryostenosis and fibrosis, epiphora, photophobia, 
ocular pain, optic neuropathy, circumorbital oedema, nystagmus, oculomotor 
disturbances, accommodation disorders, blurred vision 
Blurred vision 
Blepharoconjunctivitis, conjunctival hyperaemia, depigmentation or 
hyperpigmentation of the eyelids, keratitis, epiphora, cataract, penorbital 
oedema, optic neuropathy, photophobia, ocular pain, blurred vision 
Blurred vision 
Cataract, retinopathy and retinal haemorrhages, papilloedema, diplopia, 
blurred vision 
Corneal opacification and oedema, conjunctival hyperaemia, secondary 
glaucoma, vitreal opacities, retinitis, retinopathy, retinal infarction, optic 
neuroretinitis, optic atrophy, extraocular muscle fibrosis, internal 
ophthalmoplegia, diplopia, orbital arteriovenous shunts, orbital pain, blurred 
vision 
Periorbital pallor 
Hyperpigmentation of the eyelids and conjunctiva, purpura, retinopathy, 
retinal haemorrhages, nystagmus, accommodation disorders, papilloedema, 
photophobia, diplopia 
Ptosis, lagophthalmos, corneal hypaesthesia, optic atrophy and neuropathy, 
extraocular muscle paralysis and cranial nerve palsies with diplopia, 
hemeralopia, cortical blindness, tapetoretinal degeneration, ocular pain 
* Dralands, 1972, Fraunfelder, 1976, Griffin and Garmck, ¡981; Vizel and Osler, ¡982, Fraunfelder and 
Meyer, 1983, Zaal and Polak. 1985, Imperia el al , ¡989, Farmacotherapeutisch Kompas ¡990-¡99¡ 
Amsacnne 
Busulfan 
Chloromethme 
Chlorambucil 
Cis-platinum 
Cyclophosphamide 
Cytarabine 
Doxorubicin 
Fludarabine 
Fluorouracil 
Ifosfamide 
Methotrexate 
Mitomycin-C 
Mitotane 
Nitrosoureas 
Plicamycin 
Procarbazine 
Vincristine and vinblastine 
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1.6.1.3 Hormonal treatment 
Uveal metastases occur most frequently in patients with breast cancer. In these patients 
endocrine therapy is possible (Abramson, 1984). 
If in patients with breast cancer specific receptors for oestradiol can be 
demonstrated, a favourable effect of hormonal treatment may be expected in 50% of the 
cases. If no such receptors can be demonstrated, only up to 10% of the patients respond. 
If in addition to the oestradiol receptors the progesterone receptors are also present, the 
probability of positive effect increases further. 
Endocrine treatment may consist inter alia of ovariectomy or antioestrogenic agents 
such as tamoxifen. More recent methods of treatment are large doses of oestrogens or 
progestative agents, or of aminoglutethimide. Adrenalectomy and hypophysectomy, 
formerly widely used, are rarely recommended nowaways because of the pharmaceutical 
alternatives available. 
Hormonal treatment can be combined with chemotherapy. Although combinations 
of hormonal and chemotherapy lead to higher percentages of remission than single 
therapies, no evident benefit to the patient in the sense of a longer total duration of 
remission or longer survival is demonstrable. For this reason, the palliative combination 
of hormonal and chemotherapy is not a standard treatment (Beex, 1987; Rose and 
Mouridsen 1984; Lippman et al., 1988). 
A few patients have been described with a good response of uveal metastases to 
systemic hormonal treatment. Cogan and Kuwabara in 1954 published the first positive 
results of diethylstilboestrol. Other authors also have used such additive therapy in a few 
cases with good results (Goldmann, 1957; Aasved and Seim, 1973; Famarier et al., 1973; 
Meythaler and Herold, 1979). 
Hormonal treatment of uveal metastases may be combined with chemotherapy with 
a positive result (Farnarier et al., 1973; Stolzenbach and von Domarus, 1978). Wharam 
and Schachat (1989) recommended that if a patient with a choroidal metastasis is not yet 
receiving systemic treatment, a cytostatic or hormonal therapy may be given, which may 
have an adequate effect on the eye. 
A number of authors stated that for the treatment of uveal metastases hormonal 
therapy should be combined with radiotherapy (François et al., 1976; Ferry, 1978). About 
hormonal treatment of patients with breast cancer it may be stated, just as about 
chemotherapy, that most patients had already been subjected to it, and had developed 
uveal metastases in spite of this treatment (Thatcher and Thomas, 1975). Thompson et al. 
(1961) are also of the opinion that hormonal treatment alone of breast cancer metastases in 
the eye causes no dramatical regression of the lesions. 
Just as during chemotherapy it is possible, according to Röttinger et al. (1979), in 
case of minimal clinical symptoms and under continuous ophthalmological control to use 
the choroidal metastasis as a parameter of the efficacy of the hormonal treatment. 
Ablative endocrine therapies to combat uveal metastases such as surgical or 
radiological ovariectomy, adrenalectomy or hypophysectomy are reported mainly in older 
literature; the results varied (Ellis and Scheie, 1952; King, 1954; Blondel et al., 1957; 
Hotz, 1957; Beringer et al., 1961; Fanta, 1961; Lemke, 1965; Hollwich, 1966; Klien, 
1966; Hamer et al., 1967; Kai ser-К up fer, 1978; Meythaler and Herold, 1979). 
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The only publication on the effect of hormonal treatment on choroidal metastases 
from breast cancer not confined to case histories was a brief comment by Vesterdal (1973) 
on an article by Aasved and Seim (1973). Vesterdal described 14 choroidal metastases, all 
treated with large doses of glucocorticoids. In addition, in seven premenopausal women 
the ovaries were irradiated and five patients were given androgens. Twelve of the patients 
retained a visual acuity of 6/6 in at least one eye until death. In one patient, the visual 
acuity was 6/12 owing to an age-related macular degeneration and another patient had a 
visual acuity of 6/36 due to, as Vesterdal put it, 'too late ovarial X-ray treatment'. His 
conclusion was that owing to a late diagnosis the prognosis of the first-affected eye was 
poor in some cases but the visual acuity in the second eye was preserved in all eyes until 
the time of death, without cytostatic treatment being necessary. 
Ophthalmological side effects of tamixofen are increased corneal opacities and 
retinopathy (Griffin and Garnick, 1981; Imperia et al., 1989). 
Corticosteroids have many possible ophthalmological side effects including 
discolouring of the sclera, cataract, glaucoma, visual field defects, diplopia, 
exophthalmos, ocular infections and blurred eyesight (Griffin and Garnick, 1981; Imperia 
et al., 1989). 
To recapitulate, there are major differences of opinion among the various 
investigators with respect to the indication and the use of hormonal treatment to combat 
uveal metastases of breast cancer. Both ablative (surgical and physical) and additive 
(pharmaceutical) hormonal treatments have been applied. On this subject only a few, 
mostly older, publications are known. 
Another tumour metastasis that might be treated hormonally is a choroidal 
metastasis of prostatic carcinoma (Saraux and Biais, 1969). Dieckert and Berger (1982) 
described a patient whom they treated with orchidcctomy and oestrogens, following which 
the metastasis disappeared in two months and visual acuity improved from 6/60 to 6/6. 
They are consequently of the opinion that for an initial choroidal metastasis of a prostatic 
carcinoma, hormonal treatment is to be preferred. François et al. (1976) recommended 
both endocrine and radiotherapeutic treatment of this metastasis. 
1.6.1.4 Radiotherapy 
As far back as the thirties radiotherapy was used in the treatment of uveal metastases 
(Lemoine and McLeod, 1936; Evans, 1937; Cordes, 1944) and nowadays is generally 
regarded as an efficacious therapy (Thatcher and Thomas, 1975; Stephens and Shields, 
1979; Brady and Shields, 1982; Letson and Davidorf, 1982; Mewis and Young, 1982; 
Hoogenhout et al., 1989; Lommatzsch, 1989). 
This chapter contains a review of the literature on the indications, irradiation 
schedules, irradiation techniques, effects of irradiation and side effects in radiotherapy of 
uveal metastases. 
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Classification of ionizing radiation 
There is no essential qualitative difference in the biological efficacies of the various types 
of ionizing radiation whatever their form or energy (Tables 1.6.1.4.1 and 1.6.1.4.2). 
There are only quantitative differences in penetrating power and in density of the 
ionizations brought about. These ionizations are caused by the inelastic scattering of 
electrons or, in the case of neutron radiation, by collisions with hydrogen nuclei. 
Quantitative differences depend on the energy. As to roentgen and gamma radiation 
(photon radiation), the penetrating power is less and the dose in the superficial layers 
larger when the energy is lower (Duke-Elder, 1972; Lerman, 1980). In high energy 
electrons, the penetrating depth is directly correlated with the energy [penetrating depth 
(cm) = energy (MeV)/2] (Khan, 1984). 
Table 1.6.1.4.1 Classification of ionizing radiation * 
Electromagnetic radiation: - Roentgen radiation (Bremsstrahlung): produced by an electron beam in an 
X-ray unit or linear accelerator 
- Gamma radiation: emitted spontaneously by decay of unstable nuclei 
Subatomic particles: - a particle decay (Helium nuclei) 
- ß particle decay (electrons) 
- Neutrons 
- Protons 
• T-mesons 
- Heavy ions 
* Duke-Elder, 1972; Khan, ¡984; Richter et al., 1985 
The advantages of use of megavoltage X-ray or gamma-ray beams over low energy 
roentgen irradiation are the relatively low skin dose with a large dose at greater depth, 
and the equal degrees of absorption in soft tissues and bone (Tapley, 1973; Lerman, 1980; 
Khan, 1984). 
The density of ionization depends on the type of radiation. Roentgen and gamma 
radiation deliver energy to the tissue through a large number of ionizations over a large 
area. High energy electrons deliver their energy by ionizations, the ionization density 
being of the same magnitude as that of roentgen or gamma radiation. Alpha particles 
cause tracks of high-density ionizations. Indirectly neutrons cause ionizations through 
collisions with hydrogen nuclei. Since the biological damage increases with the density of 
the ionizations produced, alpha radiation is the most effective form. However, its range is 
small so that this type of radiation has no applications in radiotherapy (Duke-Elder, 1972; 
Lerman, 1980). 
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Table 1.6.1.4.2 Classification of ionizing radiation 
Energy (MV/MeV) Photons Electrons 
100 
10 
0.1 
0.01 
4-30 MV 
1.25 MV 
500-1000 kV 
660 kV 
150-500 kV 
50-150 kV 
40-50 kV 
<20 kV 
Megavoltage therapy 
(linear accelerator, betatron, 
microtron) 
Co-60 gamma radiation 
Supervoltage therapy 
Cs-137 gamma radiation 
Orthovoltage therapy 
(deep X-ray therapy) 
Superficial X-ray therapy 
Contact therapy 
Grenz ray therapy 
4^5 MeV Betatron 
Microtron 
Linear accelerator 
* Khan. 1984; Richter et al., 1985 
Indications 
Radiotherapy of intraocular metastases is necessary if the visual acuity is threatened or if 
secondary complications such as an accompanying retinal detachment or secondary 
glaucoma are to be expected (Stephens and Shields, 1979; Mewis and Young, 1982; 
Shields, 1983; Alberti and Halama, 1987). In addition, irradiation may alleviate ocular 
pain (de Bustros et al., 1985). 
According to Dollfus (1954), metastases from breast and lung cancer are 
particularly to be considered for radiotherapy. Jaeger et al. (1971) and Lommatzsch 
(1989) also report that breast cancer metastases respond well to irradiation. Allen (1968) 
is of the opinion that metastases from primary malignancies sensitive to radiation may be 
irradiated. However, according to de Bustros et al. (1985) radiotherapy is also used 
successfully for uveal metastases of primaries less sensitive to radiotherapy, such as 
malignant melanoma of the skin. 
Radiotherapy may also be of diagnostic value: Dickson (1958) described a patient 
with a uveal 'metastasis' that failed to respond to irradiation. After enucleation it was 
found to be a melanoma. 
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Time of irradiation 
No consensus exists about the time when radiotherapy should be applied. Some authors 
state that to begin with, the effect of systemic hormonal or chemotherapy may be awaited 
(Stolzenbach and von Domarus, 1978; Shields, 1983; Char, 1989). According to Chu 
(1980), however, postponement of irradiation of ocular metastases may lead to retinal 
detachment and permanent blindness. Radiotherapy should therefore be administered 
without delay. Thatcher and Thomas (1975) believe that awaiting the effect of hormonal 
or chemotherapy leads to unnecessary delay of irradiation. It should be noted in this 
connection that the two last-mentioned publications originated from radiotherapeutic 
clinics. 
Occasionally, radiotherapy is started only when growth of the metastases is 
established photographically or echographically (Alberti and Halama, 1987). 
As mentioned before, the effect of cytostatic or hormonal therapy may be awaited 
at first. Breast cancer patients, however, in general have already received hormonal or 
chemotherapy or a combination of these. Radiotherapy of the uveal metastases is then 
indicated since a protracted secondary remission with second-line systemic treatment is 
compromised by the earlier hormonal or chemotherapy. If no systemic therapy has been 
administered in the past, the effect of such therapy on the uveal metastases may be 
awaited (Wharam and Schachat, 1989). If no effective cytostatic therapy is available, 
however, or if uveal metastases have developed during chemotherapy, radiotherapy of the 
uveal metastases should be instituted (Mewis and Young, 1982; Alberti and Halama, 
1987; Char, 1989; Wharam and Schachat, 1989). 
According to some authors, examination of the orbit and brain is necessary before 
starting irradiation. A second course of radiation for initially unsuspected orbital or 
cerebral metastases, causing additional exposure of the eye, can then be avoided (Haik et 
al., 1983; Char, 1989). 
According to several authors, the length of the interval between the initial 
symptoms and the treatment does not influence the effect of irradiation (Thatcher and 
Thomas, 1975; Röttinger et al., 1976). 
Brachytherapy 
For radiotherapy of the eye two methods may be used: irradiation via an external beam or 
irradiation by means of local application of a radioactive source in a scleral plaque 
(brachytherapy). 
Brachytherapy has been applied sporadically in uveal metastases. In the thirties, 
this was done for instance with radon seeds with a reasonable effect on prominence and 
visual acuity (Ask, 1936; Evans, 1937/1938; Cordes, 1944; Hoffman, 1959). This method 
was abandoned, however, because of the rapid dose reduction and the exposure to 
radiation of the normal tissues (Alberti and Halama, 1987). 
According to some authors, irradiation with a radioactive applicator may be 
considered in patients with a solitary metastasis (Gerhard et al., 1975; de Bustros et al., 
1985). Busse and Muller (1983), for instance, irradiated two uveal metastases with 
application of Ruthenium-106 with a scleral dose of 400-800 Gy. In one patient the visual 
acuity improved, in the other it decreased. No scleral necrosis developed. Metastases 
responded to Rhutenium-106 irradiation far sooner (after 6 to 8 weeks) than uveal 
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melanomas (12 to 36 months). Haye and Calle (1972) treated three patients with a Cobalt-
60 plaque. This method gave poorer results than conventional external irradiation (Haye, 
1972). Shields (1983) had better expenence with this method. Newell and Harper (1957) 
treated a patient with local Iodine-131, with good results. 
Since metastases often have diffuse or multiple localizations, application of 
brachythcrapy is not indicated (Char, 1989) Also there may be small, as yet 
imperceptible foci, while the margins of the metastasis often cannot be determined with 
sufficient exactitude to justify such a taxing treatment (Daicker, 1981). Local application 
with a radioactive source on the sclera, namely, necessitates surgical interventions to 
introduce and to remove the plaque (Shields, 1983) 
A different form of irradiation, namely by administration of radioactive iodine (I-
131), was described by Weisenthal et al (1989) in a patient with an ins metastasis from a 
thyroid carcinoma. During this treatment the ins tumour and visual acuity remained 
stable. 
External irradiation 
In most cases, photons or electrons are used for irradiation of uveal metastases 
Photon irradiation can be performed by means of orthovolt or megavolt techniques. 
The megavolt technique (linear accelerator) gives a sharply defined beam so that good 
localisation of the high-dose area is possible Owing to the minimal lateral scattering, the 
lateral damage is minimized. In this way, a high depth dose with a low skin dose can be 
administered with a high dose rate and consequently, a short duration of the irradiation so 
that the effect of movements of the patient is limited (Orenstem et al , 1972; Shields, 
1983) A disadvantage of megavolt photons is that, because of the high penetrating 
capacity, the normal tissue in front of and behind the target volume receives an 
undesirably high dose Electrons have the advantage of a high dose reduction in depth. By 
optimal adjustment of the electron energy the tissue situated behind the target volume can 
be spared (Chu et al , 1977). 
The use of radiation with high ionization density, as that of protons is distinguished 
from photon and electron radiation by its high biological activity Compared with photons 
and electrons, this type of radiation offers the advantage of a favourable dose distribution 
with a well-defined range and little scattering The depth dose of these heavy particles 
gives a typical dose plateau This renders possible a high tumour dose with low exposure 
of surrounding structures (Alberti and Halama, 1987) 
Gragoudas and Carroll (1979) treated a patient with multiple choroidal metastases 
from a bronchial carcinoid with proton irradiation combined with laser treatment Char 
(1989) considered this proton treatment to be of little value since metastases frequently are 
diffuse or multiple. 
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Irradiation schemes 
In the literature the various authors recommend different schemes (Table 1.6.1.4.3). The 
total doses in choroidal metastases range from 20 to 56 Gy. 
Table 1.6.1.4.3 
Author 
Haye and Calle, 1972 
Reddy et al , 1981 
Memam, 1961 
Ferry, 1967 
Mewis and Young, 1982 
Maor et al., 1977 
Shields and Augsburger, 
Dobrowsky et al., 1987 
Recommended total and fraction dose in irradiation 
metastases 
1983 
Thatcher and Thomas, 1975 
Jaeger et al., 1971 
Shields, 1983 
MacComb and Fletcher, 
Orenstein et al., 1972 
Letson et al., 1982 
Bnnketal., 1988 
Hoogenhoutet al., 1989 
Saßmannshausen et al., : 
Röttingeret al., 1976 
Haik et al., 1983 
Chu, 1980 
1967 
1990 
Stephens and Shields, 1979 
Alberti and Halama, 1987 
Brady et al , 1982 
Char, 1989 
Lommatzsch, 1989 
Chu et al., 1977 
Haye, 1986 
Dobrowsky, 1988 
Zografos and Gailloud, 1 1983 
Total dose 
(Gy) 
20^0 
21-30 
24-32 
25-30 
25-30 
25-30 * 
25-40 
25-50 
28 
30 
30 
30 
30 
30 
30 
30 
30 
3040 
30-40 
30-40 
3048 
30-50 
30-56 
3540 
40 
40 
40 
40-50 
45 
Fraction dose 
(Gy) 
-
3 
-
2.5-3 
2.5-3 
3-5 
-
-
2.8 
-
-
-
-
3 
3 
3 
3.3 
2 
-
-
-
-
-
2 
2 
-
3.3 
-
of choroidal 
Overall time 
(weeks) 
3 
1.5-2 
2-3 
2 
2 
1-2 
-
2 5-5 
2 
3 
3 
2 
2 
2 
2 
2 
3 
4-5 
2-4 
2-3 
-
3 4 
3-5 5 
3 
5 
3 
4 
3-5 
-
* doses used most often 
The recommended dose depends on the patient's prognosis quoad vitam. For instance, if 
metastases refractory to treatment are present outside the eye, 30 Gy suffices. For patients 
with a reasonable life expectation 50 Gy is advised (Alberti and Halama, 1987). Char 
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(1989) recommends irradiation of terminal patients with deteriorating eyesight due to 
uveal metastases with up to about 35 Gy with high fraction doses. This would result in a 
lower percentage of remissions and more long-term complications, but it may be 
administered in a shorter time with little risk of side effects during the patient's remaining 
days. Brady et al. (1982) recommend doses of at least 30 Gy in 3 weeks or 56 Gy in 5.5 
weeks. If there is a good chance of survival and metastases are present exclusively in the 
choroid, it is attempted to prevent complications. Char (1989) for such cases advises a 
dose of 35 to 40 Gy in fractions of 2 Gy three times per week. More than three sessions 
per week would be too taxing for the patient (Alberti and Halama, 1987). 
Dobrowsky (1988) used electrons (42 MeV betatron) or high-energy photons 
(Cobalt-60) with a dose of 40 to 50 Gy in three to five weeks. When a lower dose is used 
the metastases may grow back. MacMichael (1969) treated a number of patients with a 
single dose of 10 to 15 Gy. Mostly, however, a total dose of 30 Gy is administered 
(Jaeger et al., 1971; Brasseur et al., 1983). A dose of 30 Gy in 10 fractions in two weeks 
is the most widely accepted irradiation schedule (MacComb and Fletcher, 1967; Orenstein 
et al., 1972; Letson et al., 1982; Haik et al., 1983; Brink et al., 1988; Hoogenhout et al., 
1989). 
In metastases in the iris, also, a dose of 30 Gy is recommended (Stephens and 
Shields, 1979). 
Allegedly, above 30 Gy there is no correlation between the total dose administered 
and the response to the irradiation (Thompson, 1961; Thatcher and Thomas, 1975; 
Rôttinger, 1976; Brink et al., 1988; Hoogenhout et al., 1989). In Thatcher and Thomas, 
the total dose in all patients with a complete response to irradiation was minimally 32.5 
Gy. If irradiation is administered, they recommended a dose of 28 Gy minimally. 
The schemes of 30 Gy in two weeks and of 40 Gy in four weeks have the same 
effect with respect to improvement of visual acuity or tumour decrease, while the 30 Gy 
scheme is less of a burden to the patient (Brink et al., 1988; Hoogenhout et al., 1989). 
Irradiation technique 
In unilateral choroidal metastases a lateral beam will in general be opted for. The anterior 
delimitation of the irradiation field is situated at the outer bony canthus of the lateral 
orbital wall so that the anterior chamber can be shielded (Thatcher and Thomas, 1975). If 
possible, the comea and lens should not be included in the irradiation volume. However, 
most patients do not survive long enough for late radiation damage to occur (Daicker, 
1981). To protect the lens of the contralateral eye the beam is directed 5 to 10° occipitally 
or a half field tecnhique is used (Dickson, 1958; Merriam, 1961; Ferry, 1967; MacComb 
and Fletcher, 1967; Haye, 1968; Haye and Calle, 1972; Orenstein et al., 1972; Thatcher 
and Thomas, 1975; Rôttinger et al., 1976; Chu et al., 1977; Maor et al., 1977; Reddy et 
al., 1981; Brady et al., 1982; Mewis and Young, 1982; Haik et al., 1983; Shields and 
Augsburger, 1983; Alberti and Halama, 1987; Hoogenhout et al., 1989; Lommatzsch, 
1989; Saßmannshausen et al., 1990). Sometimes an angle of 20° occipitally is applied 
(Dobrowsky et al., 1987). In case of a lateral beam, when electron irradiation is ad-
ministered, the dose distribution will be markedly influenced by the bone (MacComb and 
Fletcher, 1967; Hoogenhout et al., 1989). If no electron beams are available, Cobalt-60 
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may also be used (Haik et al., 1983; Hoogenhout et al., 1989). Chu et al. (1977) 
recommend that small temporally situated lesions should be irradiated with 10 MeV 
electrons, protecting the lens. Owing to a rapid dose reduction the exposure of the 
surrounding tissue remains limited. In case of a larger tumour volume, the same technique 
is applied but use is made of a higher electron energy (15 MeV) (Chu et al., 1977). 
Sometimes use is made of a ventral beam (Brady et al., 1982) for instance in 
metastases localized in the lateral or medial part of the choroid; the patient is then asked 
to look in the contralateral direction to protect the lens (MacComb and Fletcher, 1967). In 
equatorially situated metastases, the lens and the lacrimal gland can be shielded 
(Dobrowsky et al., 1987; Hoogenhout et al., 1989). Haye and Calle (1972) recommend a 
ventral beam in multiple metastases or poor general condition of the patient. It is then not 
necessary to shield the lens. In lesions situated on the nasal side in the posterior pole, 
preference is sometimes given to a ventral beam laterally shielded. During the irradiation 
the patient is made to look away from the radiation beam so that the nasal side of the 
posterior pole turns forward, toward the beam, and the lens away from the beam (Chu et 
al., 1977). 
The entry field as a rule measured 4x4 sq.cm (Orenstein et al., 1972; Thatcher and 
Thomas, 1975; Chu et al., 1977; Maor et al., 1977; Hoogenhout et al., 1989). Dickson 
(1958) used a beam with a diameter of 2.5 cm. The lateral beam was then combined with 
a medial oblique beam through the bridge of the nose from the other side. This technique 
made possible an improved depth dose with better protection of the skin. However, there 
was a higher risk of lens damage. Jaeger et al. (1971) used a circular beam with a 
diameter of 3 cm, one-half of which was shielded to spare the lens. They combined a 
lateral beam with the eye looking straight forward with a ventral-medial oblique beam 
with the eye looking in the lateral direction. 
In bilateral metastases, two parallel opposed lateral beams are used (Maor et al., 
1977; Alberti and Halama, 1987; Hoogenhout et al., 1989; Saßmannshausen et al., 1990). 
A ventral and a lateral beam may also be combined to obtain an optimal dose distribution. 
If a metastases develops in the contralateral eye, the same technique may be applied with 
minimal overlapping of the area irradiated previously. The anterior radiation field in this 
case is delimited by the medial canthus; the lateral field of 3x4 sq.cm at the external 
canthus is directed 70° posteriorly in relation to the anteroposterior radiation beam, 
without shielding the lens (Chu et al., 1977). 
In a very extensive lesion, also, combination of a ventral and a lateral beam may 
be opted for (Chu et al., 1977; Alberti and Halama, 1987). 
In extraocular spread of the choroidal metastasis the field size may be adjusted to 
the size of the extraocular extension (Alberti and Halama, 1987). 
In metastases in the iris, the anterior segment has to be irradiated as well (Shields, 
1983). Tumours of the iris may be irradiated with a ventral or a lateral beam. Preference 
is given to a ventral beam although no protection of the lens is possible (Alberti and 
Halama, 1987; Lommatzsch, 1989). Char (1989) advises treating iris metastases in the 
same way as metastases localized in the posterior segment. 
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Effect of irradiation on visual acuity 
The effect of radiotherapy on uveal metastases can be evaluated in various ways. 
Preservation or, if possible, improvement of the visual acuity is the principal objective. 
Other important elements are the effect on tumour size and on the secondary retinal 
detachment, as well as prevention of complications such as secondary glaucoma. 
In literature concerning irradiated uveal metastases, authors often omit to mention 
how they define a positive or negative result after irradiation. Haik et al. (1983) and 
Abramson (1984) reported that 75% of the irradiated choroidal metastases responded well, 
without defining this response. Brady et al. (1982) desenbed a positive objective response 
in nearly 90% of the irradiated eyes, by which they probably meant the effect on tumour 
size. 
A uveal metastasis may go into complete remission due to radiotherapy. The 
treatment is also successful, however, if regression of the tumour takes place so that a 
secondary retinal detachment returns to normal and improvement of the visual acuity is 
accomplished, although the metastasis is still partly present (Ferry, 1967). Stephens and 
Shields (1979), for instance, described regression of the metastasis after radiotherapy with 
reduction of the subretinal fluid and improved visual acuity. In small metastases, in 
particular, complete normalization of visual acuity may be expected (Chu, 1980). 
Table 1.6.1.4.4 presents a survey of publications regarding the effect of 
radiotherapy on the patient's visual acuity A change of the visual acuity is defined as an 
improvement if an increase of the visual acuity by at least two lines on Snellen's chart was 
determined occurred or if this change is described as 'distinct' or 'substantial'. 
Stabilization of the visual acuity is defined as the fact that no effect of the radiotherapy on 
the visual acuity is observed or that an improvement, if any, amounts to less than two 
lines on Snellen's chart or is desenbed as 'slight' or as 'some' improvement of the visual 
acuity. Deterioration of the visual acuity means a decrease of the acuity by at least two 
lines on Snellen's chart or a description as 'decrease'. 
As this table shows, improvement of the visual acuity was reported in proportions 
ranging from 27 to 90%. The visual acuity of 1.0 before and after radiotherapy should 
also be regarded as a positive result, however. Considered from this point of view, 
radiotherapy has been successful in the vast majonty of the patients. 
The mean visual acuity before irradiation in the 15 patients of Gillet (1971) was 
0.64 (20/200-20/20). After irradiation, the mean visual acuity was 0.82 (20/30-20/20). Of 
the 71 patients of Saßmannshausen et al. (1990) in whom the effect of the irradiation on 
the visual acuity was known, 61% retained a visual acuity of at least 0 40. After 
successful irradiation, it took eight months on average (1 to 24 months) before a stable or 
increased visual acuity was desenbed (Hoogenhout et al., 1989). 
Detenoration of the visual acuity is usually the consequence of tumour growth 
(Saßmannshausen et al., 1990). 
MacComb and Fletcher (1967) desenbed preservation of functional visual acuity in 
eight of the 10 irradiated patients with improvement of the visual acuity for the rest of 
these patients' lives. Memam (1961) recorded preservation of adequate visual acuity until 
death in 14 of the 27 irradiated eyes (duration of survival 1 month to 3 years, median 8.5 
months). All the patients of Rottinger et al. (1976) in whom radiotherapy led to improved 
visual acuity retained this for good (duration of survival 0 to 44 months, median: 8 
months). 
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Irradiation scheme Visual acuity after irradiation 
Author 
MacComb and Fletcher, 1967 
Maor et al., 1977 
Letsonetal., 1982 
Dobrowsky, 1988 
Röttmgeret al., 1976 
Haye and Calle, 1972 » η 
Dobrowsky et al., 1987 
Gillet, 1971 
Memam, 1961 
Brink et al., 1988 
Hoogenhoutetal., 1989 
Chu et al., 1977 
Orenstein et al., 1972 
Jaeger et al., 1975 
Thompson et al., 1961 
Saßmannshausen et al., 1990 
Thatcher and Thomas, 1975 
Mewis and Young, 1982 
Number of * 
patients/eyes 
10 
42 
β 
20 
22 
22 
16 
15 
27 
33 
45 
57 
6 
21 
14 
71 
49 
52 
patients 
patients 
patients 
eyes 
patients 
patients 
eyes 
eyes 
eyes 
patients 
eyes 
eyes 
patients 
eyes 
eyes 
eyes 
eyes 
eyes 
Localization 
primary tumour 
breast 
breast 
breast 
mainly breast 
breast 
mainly breast 
breast 
mainly breast 
breast 
mainly breast <*> 
mainly breast oo 
breast 
breast and lung 
mainly breast 
breast 
mainly breast 
breast 
breast 
Total 
dose 
(Gy) 
30 
25-30 
30-35 
40-50 
30-40 
20->25 
25-50 
30^*0 
30-40 
30^0 
30^10 
25-50 
30 
14.6-54 
30 
30-50 
25-30 
Fraction 
dose 
(Gy) 
3 It 
2.5-5 
3 
2-2.5 If 
2 
1.3-2 # 
2 « 
not stated 
2-3 0 
2-3 
2-3 
2 # 
2-3 » 
2 » 
3 # 
3.3 
2 
2.5-3 
Overall 
time 
(wk) 
3 
1-2 
2 
3-5 
3-4 
3 
2.5-5 
2-3 
2-4 
2-4 
3-4 
3 
3 
1-3.5 
3 
3-5 
2 
Increase 
% 
90 
89 
88 
85 
82 
59 
56 
53 
52 
48 
38 
35 
33 
33 
33 
28 
27 
27 
No 
change 
% 
10 
11 
12 
15 
14 
41 
44 
47 
48 
36 
33 
65 
67 
67 
42 
55 
73 
69 
Decrease 
% 
-
-
-
-
5 
-
-
-
-
15 
29 
-
-
-
25 
17 
-
4 
Metastases from breast cancer in general show a dramatic response to radiotherapy 
with reduction of tumour size, disappearance of the retinal detachment and improvement 
of the visual acuity. The response of metastases from other primaries is mostly less 
dramatic but nevertheless always positive (Shields, 1983). 
Effect of irradiation on prominence and secondary retinal detachment 
The effect of irradiation on tumour size and retinal detachment is recapitulated in Table 
1.6.1.4.5. In 57 to 80% of the irradiated metastases regression of the tumour was 
observed. Growth of the metastasis after irradiation was described sporadically. Only 
Saßmannshausen et al. (1990) observed further tumour growth in 11% of the irradiated 
eyes. 
De Bustros et al. (1985) in two out of five successfully irradiated uveal metastases 
of cutaneous melanomas, nevertheless reported resumed growth later on. Jaeger et al. 
(1971) in three out of seven patients with preserved visual acuity or tumour regression 
after irradiation, reported a recurrence within 7 months. 
After radiotherapy an increase of pigment clumping in the retina in the tumour 
region was observed, and ultimately a flat chorioretinal scar with yellowish white mottled 
pigmentation remained (Jaeger et al., 1971; Pau, 1979; Shields, 1983; Zografos and 
Gailloud, 1983; Lommatzsch, 1989; Saßmannshausen et al., 1990). Reddy et al. (1981) 
described the ophtha! moscopical effect as fragmentation of the tumour with necrosis and 
pigment migration. 
According to Chu et al. (1977), the effect of irradiation depends on the size of the 
intraocular metastatic lesion: metastases which occupy less than half a quadrant of the 
fundus and are not accompanied by a retinal detachment, they state, always show a 
positive response. In metastases of larger size and with no or only minimal retinal 
detachment, this was 77%. If the retinal detachment was larger, the probability of 
improvement was reduced to only 32%. An early diagnosis is therefore necessary. 
Accordingly, if no improvement of the visual acuity is obtained, the most frequent 
cause of this is a secondary retinal detachment already known prior to treatment (Duke-
Elder and Perkins, 1966). Zografos and Gailloud (1983) are of the opinion that if a retinal 
detachment disappears after irradiation, some loss of visual acuity nevertheless frequently 
persists. Although a retinal detachment has a poor prognosis, this does not constitute a 
contraindication to radiotherapy (Chu et al., 1977). Small tumours, namely, sometimes 
fail to respond to irradiation while irradiation of a large lesion with a retinal detachment 
may give a good result (Jaeger et al., 1971). A retinal detachment, therefore, may respond 
well to the treatment (Reddy et al., 1981). According to some authors, presence of a 
secondary retinal detachment is irrelevant for the prognosis of the visual acuity after 
irradiation (Merriam, 1961; Thatcher and Thomas, 1975). 
When an eye that has been irradiated because of a uveal metastasis is examined 
histologically, viable neoplastic cells can still be demonstrated in spite of proved 
symptomatic efficacy (Lemoine and McLeod, 1936; Duke-Elder and Perkins, 1966; Jaeger 
et al., 1971; Witschel et al., 1975). Necrosis is reported more frequently in irradiated 
metastases than in irradiated melanomas and retinoblastomas (Goder and Lommatzsch, 
1965; Lommatzsch and Goder, 1965). 
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Table 1.6.1.4.5 Effect of external beam irradiation on tumour prominence and secondary retinal detachment in uveal 
metastases 
Author 
Gillet, 1971 
Saßmannshausen et al., 1990 
Hoogenhoutet al., 1989 
Brinketal., 1988 
Chu et al., 1977 
Orenstem et al., 1972 
Number of * 
patients/eyes 
15 
71 
45 
35 
57 
7 
eyes 
eyes 
eyes 
patients 
eyes 
patients 
Localization 
primary tumour 
mainly breast 
mainly breast 
mainly breast oo 
mainly breast oo 
breast 
breast and lung 
Total 
dose 
(Gy) 
30 
30-40 
30-40 
30-40 
25-50 
Irradiation scheme 
Fraction 
dose 
(Gy) 
not stated 
3.3 It 
2-3 
2-3 
2 tt 
2-3 # 
Overall 
time 
(wk) 
3 
гл 
3-4 
з^ 
3 
Prominence after irradi 
Decrease No 
% 
80 
80 
78 
69 
63 
57 
change 
% 
20 
8 
22 
31 
27 
29 
ation ** 
Increase 
% 
-
11 
-
-
-
14 
* number of patients or eyes in which the effea of radiotherapy on prominence was stated; ** in patients or eyes in which the effect of radiotherapy on the 
tumour prominence and/or retinal detachment was known; tt fraction dose, assuming five fractions a week; oo one patient acute lymphatic leukaemia; oo oo 
three patients brachytherapy 
By application of radiotherapy the nsk of development of a secondary glaucoma 
caused by the intraocular tumour may be reduced (Ferry, 1967). Even if no improvement 
of the visual acuity can be achieved, enucleation may be avoided (Thatcher and Thomas, 
1975). 
According to several authors the duration of the interval between observation of the 
initial symptoms and the treatment does not influence the effect of the irradiation. In 
Thatcher and Thomas (1975) this interval ranged from 0.5 to 59 weeks and in Rottinger et 
al. (1976) from 3 to 26 weeks. 
The localization of the metastasis, the distance to the macula (Thatcher and 
Thomas, 1975), the patient's age and the menopausal state in patients with breast cancer 
(Memam, 1961) do not affect the result of irradiation, either. 
The earliest effect of irradiation is to be expected two to four weeks after the start 
of the radiotherapy (Memam, 1961; Duke-Elder and Perkins, 1966; Thatcher and 
Thomas, 1975, Brasseur et al., 1983; Haye, 1986) If the effect fails to occur after this 
length of time, this may be due to exudative macular lesions (Brasseur et al , 1983). The 
long-term result of irradiation is difficult to assess since most patients are reported to have 
died within six months after treatment (Haye and Calle, 1972). Most investigators, 
however, report the mean or median duration of survival after treatment to have been 8 to 
20 months (Memam, 1961; Rottinger et al., 1976; Chu et al., 1977; Maor et al., 1977; 
Brady et al , 1982; Dobrowsky et al., 1987; Bnnk et al , 1988; Dobrowsky, 1988). 
interactions of chemotherapy and radiotherapy 
Because of possible interactions of cytostatics with radiotherapy, combinations of these 
according to Alberti and Halama (1987) should only be used on urgent indications and 
under thorough ophthalmological control The authors regard cytostatic treatment with 
adnamycin during radiotherapy as contraindicated because a potentiating action on side 
effects of this drug during irradiation of other tumours is known. 
Chan and Shukovsky (1976) described patients who were irradiated for malignant 
tumours of the nasal cavities or paranasal sinuses with the eye lying in the radiation field. 
If fluorouracil was administered simultaneously with irradiation, a significant decrease of 
the visual acuity was observed. Corrected for duration of survival, blindness after three 
years developed five times as often after use of fluorouracil during irradiation. This was 
brought about by corneal lesions, phthisis bulbi and optic neuntis. Moreover, cataract was 
encountered five times as often when fluorouracil was used. Chronic conjunctivitis 
developed in 75% of the patients (as against 25% of the patients given radiotherapy alone) 
and in all patients a corneal lesion occurred within two years after treatment (irradiation 
alone: 15%). 
Mostly, however, patients with uveal metastases that were irradiated received 
chemotherapy at the time of the irradiation (Thatcher and Thomas, 1975; Stephens and 
Shields, 1979, Dobrowsky, 1988). For instance, Saßmannshausen et al. (1990) desenbed 
56 patients, and Thatcher and Thomas (1975) 40 patients who developed uveal metastases 
in spite of earlier systemic treatment. In addition, many patients had received such 
treatment pnor to the irradiation (Thatcher and Thomas, 1975; Reddy et al., 1981; Letson 
et al., 1982). 
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Side effects of radiotherapy 
Unfortunately, in radiation therapy the surrounding normal tissue may be damaged during 
its administration. Both normal and pathological tissues vary greatly in degree of 
sensitivity to radiation. Fractionation of the irradiation provides a possibility to influence 
the biological effects of the irradiation on the different tissues (Haik et al., 1983). 
Side effects of radiotherapy depend on the total dose, fractionation, overall time 
and the ophthalmological structures situated in the irradiation volume. Literature data on 
side effects of radiotherapy on ocular structures are limited. No more than an indication 
can therefore be given of the total doses that will cause side effects. The side effects can 
be subdivided into acute and late effects. Different tissues have different sensitivities to 
radiation (Duke-Elder, 1972; Haik et al., 1983; Alberti and Halama, 1987). Acute side 
effects of fractionated irradiation are listed in Table 1.6.1.4.6, late side effects in Table 
1.6.1.4.7. 
Table 1.6.1.4.6 Acute side effects (within six weeks of irradiation) of radiotherapy 
with a fraction dose of 2 Gy, 5 fractions a week * 
Tissue Side effect Total dose (Gy) 
Skin/eyelids 
Conjunctiva 
Comea 
Ins 
Retina 
* MacFaul and Bedford, 1970; Duke-Elder, 1972; Memam el al., 1972; Haik et al., 1983; Alberti and 
Halama, 1987; Dobrowsky, 1988; Hoogenhout et al., 1989 
Regarding late side effects of radiotherapy, only limited data from a few authors are 
available in the literature. The doses listed in Table 1.6.1.4.7, therefore, are only an 
indication of the total dose of which such side effects may be expected. 
The ocular structure most sensitive to radiation is the lens. Mitotic lens epithelium 
is damaged, ultimately leading to cataract (Haik et al., 1983). For irradiation to cause 
lenticular damage a total dose of only 4 Gy may suffice. With a total dose of over 11.5 
Gy cataract develops in all cases. The higher the dose, the sooner it will develop. Thus, 
the latency time after irradiation with a dose of 4 to 10 Gy will be 6.5 years on average, 
with 10 to 20 Gy, 5 years and 2 months, with 20 to 40 Gy two years and 8 months and 
with doses of over 40 Gy 2.5 years on average (Merriam and Focht, 1957). 
Radiation optic neuropathy, which may lead to major loss of visual acuity, is 
characterized by a typical acute swelling of the disk with surrounding exudate, 
haemorrhages and subretinal fluid and is probably secondary to vascular damage. Such 
damage may occur after a dose of over 36 Gy and on average manifests itself after 19.3 
Erythema 
Moist desquamation 
Epilation (temporanly) 
Hyperaemia 
Conjunctivitis 
Punctate keratitis 
Oedema 
Intis 
Oedema 
20-30 
50-60 
30-40 
20-30 
30-40 
30-50 
40-50 
60 
40-50 
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months (S to 36 months). Recuperation of visual acuity is possible after a few months 
(Brown et al., 1982a). 
Radiation retinopathy manifests itself ophthalmoscopically with hard exudates, 
haemorrhages, microaneurysms, cotton-wool spots and teleangiectases. This damage is 
caused by capillary non-perfusion. Such abnormalities are described after irradiation with 
a mean dose of 49 Gy (35 to 72 Gy) in fractions of 2 Gy over a period of one to two 
months. The retinopathy then develops after an average of 18.7 months (7 to 36 months) 
(Brown et a]., 1982b). 
Use of orthovolt equipment owing to the unfavourable depth dose distribution and 
marked scattering of radiation will lead to more cataract, retinopathy, optic nerve damage 
and neovascularization glaucoma than use of megavolt techniques (Alberti and Halama, 
1987). 
Table 1.6.1.4.7 Late side effects (more than six months after irradiation) of 
radiotherapy with a fraction dose of 2 Gy, 5 fractions a week * 
Tissue Side effect Total dose (Gy) 
TD 5/5 ** 
Skin/eyehds 
Lacrimal gland 
Conjunctiva 
Comea 
Lens 
Uvea 
Retina 
Optic nerve 
* MacFaul and Bedford, 1970; Duke-Elder, 1972, Memam et al., 1972; Brown et al., I982ab; Haik et al., 
1983; Parsons et al., 1983; Alberti and Halama, 1987; Dobrowsky. 1988 
** Tolerance dose 5/5 is defined as the dose which under standard conditions results in no more than 5% 
severe side effects within five years after treatment 
Side effects of radiotherapy on the lens and retina in patients with intraocular metastases, 
who have a relative short duration of survival, have a different meaning than in patients 
with a primary ocular tumour in whom treatment mostly has a curative intention. Since 
cataract and radiation retinopathy as a rule only occur after a latency period of one year 
after radiotherapy, the radiation tolerance of these structures may, if necessary, be 
exceeded (Alberti and Halama, 1987). 
Most authors observed no or no significant side effects of the irradiation (Dickson, 
1958; Orenstein et al., 1972; Thatcher and Thomas, 1975; Maor et al., 1977; Stephens 
and Shields, 1979; Brady et al., 1982; Mewis and Young, 1982) especially when the total 
Pigmentation 
Teleangiectasis 
Epilation (permanently) 
Atrophy 
Teleangiectasis 
Atrophy 
Keratinization 
Vascularization 
Ulcération/perforation 
Cataract 
Uveitis 
Retinopathy 
Neuropathy 
40-50 
40-50 
40-50 
50-60 
40-50 
40-50 
50 
50 
60 
4-6 
40-50 
40-50 
50-60 
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dose did not exceed 30 Gy (Char, 1989). Irradiation cataract is uncommon owing to the 
frequently brief duration of survival and to shielding of the lens (Merriam, 1961; 
MacComb and Fletcher, 1967; Jaeger et al., 1971; Thatcher and Thomas, 1975; Röttinger 
et al., 1976; Brink et al., 1988; Dobrowsky, 1988; Hoogenhout et al., 1989). Chu et al. 
(1977) described one patient among 57 irradiated eyes with a cataract within one year, 
Saßmannshausen et al. (1990) one among 152 irradiated eyes, three months after 
radiotherapy. Letson et al. (1982) in two out of eight irradiated patients subsequently saw 
deterioration of visual acuity due to development of cataract. If cataract occurs, this is 
acceptable in relation to the result obtained (Haik et al., 1983). 
The most acute side effect is conjunctivitis, which responds well to treatment 
(Jaeger et al., 1971; Röttinger et al., 1976; Haik et al., 1983; Brink et al, 1988; 
Dobrowsky, 1988; Hoogenhout et al., 1989). Transient erythema of the skin (grade 1) 
also occurs frequently, more often with use of orthovolt equipment than with irradiation 
with high-energy photons or electrons (Jaeger et al., 1971; Röttinger et al., 1976; Chu et 
al., 1977; Haik et al., 1983; Dobrowsky, 1988). Dobrowsky (1988) in one out of 16 
irradiated patients described substantial oedema with erythema of the skin which 
responded well to oral corticosteroids. 
We ourselves after irradiation once observed acute glaucoma due to massive 
tumour necrosis of a metastasis from a thyroid carcinoma (Brink et al., 1988; Hoogenhout 
et al., 1989). Pau (1979) also described a patient in whom choroidal and retinal necrosis 
developed. The lesion was a metastasis from a uterine carcinoma. Saßmannshausen et al. 
(1990) described two patients with complications of radiotherapy, viz. once a cataract 
(three months after irradiation) and once, radiation retinopathy (after five months). Three 
out of 152 irradiated eyes were enucleated because of secondary glaucoma or necrosis 
which was not definitely attributable to the irradiation. 
Brown et al. (1982ab) described a patient with radiation optic neuropathy and two 
patients with radiation retinopathy. 
1.6.1.5 Other methods of treatment 
Enucleation of an eye with a uveal metastasis early in this century constituted the usual 
treatment of this lesion (Giri, 1939). Although according to some authors indications for 
enucleation in the treatment of uveal metastases still exist at present, most enucleations are 
performed under the false diagnosis of 'malignant uveal melanoma' (Ferry and Font, 
1975; Colombo and Carnevali, 1985). 
Enucleation is indicated only if an eye is painful (Allen, 1968; Shields et al., 1983; 
Char, 1989). Inflammation and glaucoma may render enucleation unavoidable 
(Leubuscher, 1927; Bonnet and Jambon-Genet, 1948; Ferry, 1967; Offret and Haye, 
1971; Haye and Calle, 1972; Ferry and Font, 1975; Stephens and Shields, 1979; Shields, 
1983; De Jong et al., 1985; Lommatzsch, 1989; Saßmannshausen et al, 1990). A number 
of authors in patients with uveal metastases mention as an indication for enucleation, apart 
from a painful eye due to glaucoma, also blindness of the affected eye (Castro et al., 
1982; Shields, 1987). A persistent secondary glaucoma should be treated pharmaceutically 
as long as possible (Shields, 1987). 
In other intractible complaints due to the local tumour an indication for enucleation 
may also be present (Daicker, 1981). In a metastasis larger than 15 mm in prominence the 
eye should be enucleated according to Haye (1986). A painful eye in patients in a terminal 
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phase of the disease may also be treated with retrobulbar injection of alcohol (Ferry, 
1967). 
Some investigators are of the opinion that in a solitary metastasis in the uvea, e g 
a metastasis of a carcinoid, enucleation may be useful to prolong the duration of survival 
(Hart, 1962; Font et al., 1966; Font and Ferry, 1976; Schreck, 1980; Daicker, 1981). 
However, according to Hemmes (1969), enucleation of eyes with uveal metastases affected 
the prognosis unfavourably 
A number of investigators state that enucleation is sometimes necessary if local 
symptoms indicate a primary uveal melanoma and no primary tumour is known (Hart, 
1962, Daicker, 1981) De Jong et al (1985), however, point out that the localization of a 
primary tumour can only rarely be identified by histological examination of a uveal 
metastasis Shields (1983) also regards such a diagnostic enucleation as controversial. 
Just as enucleation, local excision of ins and ciliary body metastases of a carcinoid 
may sometimes be advisable (Archer and Gardiner, 1982; Shields, 1983; Lommatzsch, 
1989) Since these tumours are radioresistant, local excision is justified in case of rapid 
growth (Rodngues and Shields, 1978). Malbran et al (1979) point out the possibility of 
local excision if the primary tumour is unknown. 
Photocoagulation or laser therapy has been applied in a limited number of patients 
with small uveal metastases (Wevc, 1960, Raverdino, 1960, Moura Brazil and Rezende, 
1961, Daicker, 1981, Brady et al , 1982) For multiple or diffuse choroidal lesions this 
treatment is rarely suitable, however (Char, 1989) In the literature, only sporadic 
reference is made to photocoagulation of multiple small lesions (Eide and Syrdalen, 1990). 
Meyer-Schwickerath (1959) reported that in three small penpheral metastases of 
breast cancer a completely flat scar resulted after one or two photocoagulation sessions A 
fourth, larger metastasis could not be destroyed and was subsequently treated with 
irradiation. 
François and Weckers (1965) noticed that because of the rapid growth of 
metastases photocoagulation does not result in destruction of the lesions while meanwhile 
new metastases develop For these reasons they earned out no more laser treatment of 
uveal metastases unless the outflow of aqueous humour was blocked and a painful 
secondary glaucoma developed. 
Gragoudas and Carroll (1979) obtained good results with xenon lamp 
photocoagulation of a tumour rest persisting after proton irradiation of a metastasis of a 
bronchial carcinoid 
Cryocoagulation of uveal metastases is only described exceptionally (Brady et al., 
1982) 
Daicker and Gysin (1980) desenbed a patient with a thyroid carcinoma in whom 
two choroidal metastases in the left eye were treated with transscleral cryocoagulation. 
Three months postoperatively a total retinal detachment developed. Subsequently, several 
metastases were also discovered in the other eye; these were treated with a combination of 
cryo- and photocoagulation after which complete scanfication of the tumours occurred 
with preservation of visual acuity until the moment of death. At autopsy, a metastasis in 
the left eye was found to have broken through the sclera at the site of the cryo-apphcation. 
Lmcoff et al. (1967) treated four patients with a choroidal metastasis by means of 
cryocoagulation. However, two patients with a metastasis from lung cancer developed a 
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retinal detachment. One patient with breast cancer showed few complications but there 
was rapid regrowth of the choroidal metastasis. In a fourth patient with a metastasis of 
breast cancer, the treatment was unsuccessful due to exudation, vitreous traction, cystic 
abnormalities of the macula and progressive tumour growth at the margin of the lesion. 
1.6.2 Prognosis 
Detection of uveal metastases means a poor prognosis quoad vitam (Cordes, 1944; 
Jaensch, 1950; Maxwell, 1954; Stevens and Reeh, 1958; Duke-Elder and Perkins, 1966; 
Ferry, 1967; Gartner, 1985). In Chapter 1.3 (Epidemiology), the connection of uveal 
metastases with metastases elsewhere in the body is described. At the moment of 
ophthalmological diagnosis, 60 to 82 % of the patients with uveal metastases were already 
known to have a disseminated malignancy (Timm, 1967; Chu et al., 1977; 
Saßmannshausen et al., 1990). Most of these patients are described as being in a terminal 
phase of their disease (Hart, 1962; Gillet, 1971; Röttinger et al., 1979; Daicker, 1981; 
Castro et al., 1982; Abramson, 1984). Accordingly, uveal metastases are indicative of 
advanced dissemination of the malignancy (Giri, 1939; Bonnet and Jambon-Genet, 1948; 
Greear, 1950; Jaensch, 1950; Stevens and Reeh, 1958; Asseman et al., 1964; Casanovas, 
1966; Orenstein et al., 1972). 
Hemmes (1969) established that patients with a uveal metastasis from breast cancer 
had a worse prognosis than patients without ocular metastases. He believed that this was 
due to metastases elsewhere in the body the activity of which was influenced among other 
things by the presence or absence of uveal metastases. In agreement with Greear (1950) 
he is therefore of the opinion that a patient with a malignancy should not be subjected to 
operation of the primary tumour before uveal metastases are excluded. 
Of all patients with uveal metastases 43 to 78% die within one year after the 
ophthalmological diagnosis and 75 to 94% within two years (Table 1.6.2.1). Survival for 
over two years is exceptional but will become more frequent owing to improved treatment 
of the primary tumour (Ferry, 1967). Ferry and Font (1974) reported that all patients with 
metastases in the iris had died within two years after the diagnosis. 
Table 1.6.2.1 Mortality in patients with uveal metastases after ophthalmological 
diagnosis in terms of percentage 
Author 
Ferry and Font, 1974 
Saßmannshausen et al., 1990 
Hemmes, 1969 
Meythaler and Herold, 1979 
after 
43 
50 
68 
78 
one year 
Mortali ity W 
after two years 
79 
75 
90 
94 
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The duration of survival after the ophthalmological diagnosis in patients with uveal 
metastases according to most authors is 7 to 9 months. Some authors report a substantially 
shorter duration of survival, of 3 months (de Bustros et al., 1985) or a longer survival, of 
14 months (Brink et al., 1988) (Table 1.6.2.2). 
Table 1.6.2.2 Patient survival after detection of metastases to ocular structures 
Author 
de Bustros et al., 198S 
Ferry and Font, 1975 
Ferry and Font, 1974 
Usher, 1923 
Meythaler and Herold, 1979 
Orenstein et al., 1972 
Brink et al., 1988 
Number of patients 
and localization 
9 
26 
192 
90 
18 
7 
49 
uvea 
ins en ciliary body 
eye and orbit 
choroid * 
choroid 
choroid 
choroid 
Survival (months) 
Mean 
3.0 
-
-
8 
9 
9.3 
14 
Median 
2.4 
5.4 
7.4 
-
-
9 
-
' survey of the literature 
It is noticeable that in the course of this century the prognosis has failed to improve. The 
longest duration of survival of a patient with a choroidal metastasis was described by 
Ferry (1973). It was a male who was originally described by Rosenbluth (1960). In this 
patient an eye with a metastasis from a carcinoid was enucleated. In spite of metastases 
elsewhere in the body, the patient was still alive 15 years later. Ferry described another 
patient, a female, who died 13 years and 2 months after enucleation of an ocular 
metastasis of breast cancer. 
The nature of the primary tumour influences the duration of survival (Table 
1.6.2.3). Patients with a metastasis of lung cancer after diagnosis of a uveal metastasis 
have a mean duration of survival of 5 to 6 months as against 8.5 to as long as 23 months 
in patients with a metastasis from breast cancer. Stephens and Shields (1979) established 
that patients with intraocular metastases of a carcinoma of the stomach, pancreas or 
kidney had a prognosis quoad vitam of 3 to 6 months. The mean duration of survival of 
patients with a uveal metastasis of a cutaneous melanoma was 2.2 months and that of 
patients with metastases of an unknown primary tumour 3.7 months. A very poor 
prognosis was described in patients with a choroidal metastasis of a chorionic epithelioma 
of the testis. Chitwood (1953) reports a mean duration of survival of these patients of only 
5 weeks. Patients with a metastasis from a carcinoid tumour, on the other hand, have a 
very favourable prognosis (Rodrigues and Shields, 1978). In general, the median duration 
of survival of patients with uveal metastases is markedly shorter than the mean duration of 
survival. 
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Table 1.6.2.3 
Author 
Breast cancer: 
Memam, 1961 
Dickson, 1958 
Hart, 1962 
Maoret al., 1977 
Freedman and Folk, 
Meur étal. , 1974 
Stephens and Shields, 
Letsonetal., 1982 
Lungcancer: 
Stephens and Shields, 
Hart, 1962 
Gartner, 1985 
Patient survival after detection 
breast 
1987 
1979 
1979 
or lung cancer 
Number of patients 
and localization 
20 
7 
25 
42 
28 
5 
29 
8 
10 
28 
choroid 
choroid 
eye and orbit 
choroid 
choroid 
choroid 
uvea 
choroid 
uvea 
eye and orbit 
not stated 
of metastases to ocular structures of 
Survival (months) 
Mean 
8.5 
10 
10 
-
-
13 
13.4 
23 
5.2 
6 
6 
Median 
-
-
-
10 
10.5 
9 
8 
15 
3.3 
-
-
Freedman and Folk (1987) established in patients with a choroidal metastasis a longer 
median duration of survival for those with stage 1 or 11 breast cancer than for those with 
stage 111 or IV breast cancer. Older patients had a better prognosis than younger ones. The 
median duration of survival of patients with an orbital metastasis was significantly better 
than with choroidal metastases, independently of the stage of the breast cancer. However, 
patients with orbital metastases were mostly older. After correction for age, there was no 
longer a statistical difference in duration of survival between patients with choroidal or 
with orbital metastases. 
Hemmes (1969) was of the opinion that patients with bilateral uveal metastases of 
breast cancer had a longer duration of survival than patients with unilateral metastases. 
According to Stevens and Reeh (1958), however, the reverse was true. 
Enucleation of an eye with a uveal metastasis allegedly has an adverse influence on 
the patient's prognosis quoad vitam (Hemmes, 1969). 
The interval between the diagnosis of the primary tumour and the detection of the 
uveal metastasis does not influence the duration of survival of the patient (Stephens and 
Shields, 1979). 
If a patient is irradiated for the intraocular metastasis and is not treated by means 
of chemotherapy, this allegedly does not influence the duration of survival (Letson et al., 
1982). 
Possibly, some relationship exists between the duration of survival and the 
localization of the uveal metastasis. Ferry and Font (1975) in patients with a metastasis in 
the posterior segment reported a median duration of survival of 7.2 months as against 5.4 
months for patients with anterior segment metastases. De Bustros et al. (1985) also report 
a shorter duration of survival for patients with iris metastases. 
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Colour plates 
Colour plate 1. External photograph of a grey-coloured slightly elevated iridai metastasis from 
lung cancer in a painful right eye. Note the hyperaemia of the conjunctiva. At ophthalmoscopy a 
choroidal metastasis was observed as well. 
Colour plate 2. External photograph of a ciliary tumour in the right eye which has broken 
through the iris. One month after diagnosis of an iridocyclitis a glassy white-coloured iridai 
tumour was observed. Ten days later a pulmonary carcinoma was diagnosed. Note the dilated 
episcleral vessels and the pigment coating on the lens. Clinical diagnosis: ciliary metastasis. 
Colour plate 3. Fundus photograph of a yellowish-orange choroidal 
metastasis in the posterior pole of the left eye in a patient with breast 
cancer. 
Colour plate 4. Fundus photograph of the right eye of a patient with breast 
cancer showing three cream-coloured choroidal metastases. 


Colour plate 5. Fundus photograph of the left eye showing a yellowish-grey 
choroidal metastasis with a mottled appearance, originating from breast 
cancer. 
Colour plate 6. Fundus photograph of the right eye showing a yellowish-
white choroidal metastasis temporal of the macular area originating from 
lung cancer. 
Colour plate 7. Fundus photograph of a yellowish-orange slightly elevated 
choroidal metastasis with a mottled brownish pigmentation in the right eye 
in a patient with breast cancer. 
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Colour plate 8. Fundus photograph of a predominantly grey-coloured 
malignant melanoma in the lefi eye with areas of orange pigment on the 
tumour surface. 


Colour plate 9. Fundus photograph of a salmon-pink 
haemangioma located nasally to the optic disk in the lefi eye. 
choroidal 
Colour plate 10. Fundus photograph of a grey-coloured choroidal naevus 
with multiple drusen in the right eye. 
Colour plate 11. Fundus photograph of three yellowish-cream coloured 
choroidal metastases from breast cancer in the left eye one week before 
radiotherapy. Visual acuity: 0.4. Visual acuity in the right eye with two 
choroidal metastases: 1.0. 
Colour plate 12. Fundus photograph of the same eye as colour plate 11, 
four months after start of radiotherapy: in the superiorly and temporally 
located metastases a positive reaction was observed. However, the inferiorly 
located metastasis had increased in size round the optic disk and the 
macula. Visual acuity: 2/60. Visual acuity in the irradiated right eye: 1.0. 


Colour plate 13. Stereo fundus photographs of a predominantly cream-
coloured choroidal metastasis in the right eye from a seminoma (with 
elements of teratoma) of the testis, one week before radiotherapy. Visual 
acuity: 0.8. 
ч 
Colour plate 14. Stereo fundus photograph of the same eye as colour plate 
13, eight weeks after radiotherapy showing disappearance of the tumour 
resulting in an atrophic, partly pigmented scar. Visual acuity: 0.8. 

Part 2 
Retrospective study 

2.1 Aims of the study and study design 
2.1.1 Aims of the study 
By collecting and processing all available demographic, anamnestic, diagnostic and 
therapeutic data on patients with uveal metastases known in the Ophthalmological Clinic 
of Nijmegen University Hospital, it is attempted to obtain as detailed as possible a clinical 
picture of this condition. The first objective is to establish in this manner which tumours 
metastasize to the uvea, and consider what the diagnosis of uveal metastases means for the 
patient's prognosis quoad vitam. 
Differentiation of uveal metastases from other intraocular tumours is highly 
important. Regularly, in a patient with an intraocular lesion with suspicion of a tumour, 
no primary tumour elsewhere in the body is known. Conversely, the presence of such a 
primary malignancy does not exclude the presence of a melanoma or haemangioma in the 
eye. Furthermore, frequently lesions are encountered in which the various diagnostic 
techniques give no uniform results. Evaluation of these diagnostic possibilities is therefore 
important. Differentiation of uveal metastases from other intraocular tumours evidently 
has considerable consequences. If the tumour is found to be a metastasis of a malignancy 
already known elsewhere in the body, this indicates dissemination of the tumour which has 
substantial therapeutic and prognostic consequences. If, on the other hand, no malignancy 
is known and the ophthalmological findings are nevertheless strongly suspicious of an 
intraocular metastasis, extensive examination will as a rule be performed in order to 
discover a primary tumour. Since the various intraocular tumours require also different 
methods of treatment, an accurate differential diagnosis of these lesions is of major 
importance. 
The last objective of this retrospective study is evaluation of the treatment. Patients 
with a malignancy carry a heavy burden in any case. The life expectation is limited. 
Preservation of visual acuity is therefore of great importance for an optimal quality of life. 
To sum up, the objectives of this retrospective study are: 
- to determine the nature of the primary tumours metastatic to the uvea and the 
meaning of these metastases for the prognosis; 
- to relay a detailed description of the results of the various examination techniques 
in uveal metastases and their contribution to the diagnostics; 
- to define the differential-diagnostic features of uveal metastases; 
- to evaluate the methods of treatment applied in uveal metastases. 
2.1.2 Study design 
The Ophthalmological Clinic of Nijmegen University Hospital is, owing in particular to 
echographic experience and skill, a regional and extraregional centre to which a relatively 
large number of patients with suspicion of malignant intraocular tumours are referred. 
For about 25 years now the findings in patients with an intraocular tumour have 
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been recorded photographically. The pictures in question are fundus, slit lamp and 
external photographs and fluorescence angiograms. The conditions are coded according to 
the probability diagnosis at initial examination which occasionally is adjusted later. 
The patients of this retrospective study were collected through the coding systems 
of the department of photography, echography and electrophysiology. Also, the protocols 
of histologically examined eyes were searched for patients with intraocular tumours. The 
latter yielded no new patients. 
In this part we shall constantly speak of patients with intraocular tumours rather 
than of eyes. Firstly, because the objective is to examine, and to attempt to treat patients. 
Also, because it is statistically more correct to consider patients rather than isolated eyes. 
Uveal metastases frequently occur bilaterally. In patients with metastases in both 
eyes, reference will be made to the findings in the eye containing the first-detected 
metastasis. If metastases were detected in both eyes simultaneously, the reference is to be 
the right eye since habitually an ophthalmologist examines first the right and then the left 
eye. Information on the other affected eye of the same patient will be given only if this is 
essential for the discussion of the results of this retrospective study. 
The study covers a period of 20 years, from 14 November 1970 to 14 November 
1990, for which period data on 769 patients with suspicion of an intraocular malignancy 
were retrieved. Of seven patients, only ophthalmoscopical photographs were available, 
further information being lacking. Three of these patients were coded as choroidal 
melanoma three as choroidal metastasis and one as choroidal tumour. These seven patients 
were excluded from the study because of the absence of virtually all relevant data. The 
study material therefore ultimately consisted of 762 patients. Table 2.1.2.1 lists the 
percentages of the patients with suspicion of an intraocular tumour who were retrieved 
from the various archives; some overlapping is possible. 
Table 2.1.2.1 Origin of 762 patients with suspicion of an intraocular tumour 
according to the different archives * 
Archive N % 
Photography 377 49 
Fluorescein angiography 493 65 
Echography 690 91 
Electrophysiology 208 27 
Histopathology 324 43 
* total % exceeds 100 because of overlap of different archives 
On average, 38 new patients with suspicion of an intraocular tumour were examined per 
year. This number showed a substantial tendency to increase from only a few patients in 
the first few years of the study to over 70 patients per year from 1987. 
In 324 patients (43%) the diagnosis was confirmed histopathologically. On 438 
patients (57%) only clinical data were available, however. The diagnosis was then made 
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on the basis of the case history, the clinical features, the results of the various 
supplementary examinations and the course of the condition, using the entena applied in 
literature and desenbed in the first part of this dissertation. 
That the differential diagnosis of intraocular tumours may sometimes be very 
difficult appears from the fact that in the literature several patients are desenbed in whom 
an eye was enucleated under the false diagnosis of 'malignant melanoma'. At 
histopathological examination the eye proved to contain a metastasis (Ferry, 1973; Jarrett, 
1976; Ossoimg and Hame, 1983). Therefore, the clinical diagnosis unfortunately is not 
correct in all cases. This might be an important item of cnticism on this study since in a 
substantial part of our patients the affected eye was not available for histological 
examination. 
All available data on the 762 patients with suspicion of an intraocular malignancy 
were collected. When important data, such as the results of histopathological 
examinations, were lacking, an attempt was made to retneve them from the family doctor 
or refemng ophthalmologist. A maximum of information was gathered on the follow-up of 
patients with intraocular tumours in as far as these patients were not followed up in our 
own clinic. This was done in any case in all patients whose definite diagnoses were not 
known 
On the basis of these data the patients were subdivided into the following seven 
groups: uveal metastases, malignant uveal melanomas, uveal haemangiomas, uveal naevi, 
retinoblastomas, miscellaneous intraocular conditions and lesions of unknown nature 
(Table 2.1.2.2). 
Table 2.1.2.2 Diagnosis in 762 patients with suspicion of an intraocular tumour 
Diagnosis N % 
Uveal metastasis 
Malignant uveal melanoma 
Uveal haemangioma 
Uveal naevus 
Retinoblastoma 
Miscellaneous intraocular tumours * 
Lesions of unknown nature 
* see Table 2 123 
The group 'miscellaneous intraocular conditions' includes apart from a number of tumours 
and lymphoprohferative diseases also benign conditions such as subretinal neo-
vasculanzations and haemorrhages, detachments of retina, pigment epithelium and choroid 
and patients with inflammatory lesions onginally believed to be malignant intraocular 
tumours (Table 2.1.2.3). 
87 
422 
27 
60 
25 
53 
88 
11 4 
55 4 
35 
79 
33 
70 
11 5 
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Table 2.1.2.3 Diagnosis in 53 patients with 'miscellaneous intraocular disorders' 
Diagnosis 
Leukaemia 
Lymphoma 
Leiomyoma 
Adenoma of the non-pigmented ciliary epithelium 
Medulloepithelioma 
Retinal angioma 
Osteoma 
Melanocytoma 
Hamartoma 
Ins cyst 
Choroidal detachment 
Retinal detachment 
Detachment of the retinal pigment epithelium 
Subretmal haemorrhage 
Neovascularization * 
Benign reactive lymphoid hyperplasia 
Juvenile xanthogranuloma 
Posterior sclentis 
Tuberculoma 
Toxocariasis 
Cryptococcosis 
Vortex vein 
Alterations of pigment epithelium after trauma 
17 
15 
4 
4 
2 
2 
2 
2 
2 
2 
* Kuhnl Junius N= 7 
The group of 88 patients with 'lesions of unknown nature' could not be further 
differentiated for the following reasons: 
- 36 patients (41%): examined only once, no follow-up and no characteristic picture; 
- 12 patients (14%): with follow-up of 3 months or shorter, without a characteristic 
picture; 
- 8 patients (9%): followed up for 3 to 6 months without characteristic picture; 
- 14 patients (16%): flat pigmented lesion without growth which at follow-up did not 
appear suspicious for a malignancy; 
- 5 patients (6%): died before a diagnosis could be made; 
- 4 patients (5%): iris lesion without growth at observation; 
- 9 patients (10%): diagnosis unknown in spite of follow-up of longer than 6 months 
without one of the above reasons being involved. 
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The data on all 762 patients with suspicion of an intraocular tumour were subdivided and 
coded according to: 
- general data (age, sex, etc.) 
- signs and symptoms 
- ophtha!mological examination, including optometry, slit lamp examination and 
tonometry 
- ophthalmoscopy 
- echography 
- fluorescein angiography 
- other examination techniques 
- histopathological data 
- course and follow-up (including metastasization and mortality) 
- treatment. 
Using this material, patients with uveal metastases were studied and the data compared 
with those on the other patients with intraocular tumours. 
In the following chapters these data will be described in detail. With a view to the 
differential diagnostics, the other patient material will also be concisely discussed. 
With the aid of these data a survey is presented of the diagnostic and differential-
diagnostic features of uveal metastases. 
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2.2 Epidemiology 
2.2.1 Number of new patients 
In the Ophthalmological Clinic of Nijmegen University Hospital in the period from 14 
November 1970 to 14 November 1990, a total of 87 patients with uveal metastases were 
examined, an average of 4.4 patients per year. Incidence figures of uveal metastases could 
not be calculated for lack of a single distinctly defined patient population from whom the 
patients with uveal metastases examined derived. We can only refer to the frequency of 
observation of this condition in our clinic. 
Table 2.2.1.1 Number of patients with suspicion of an intraocular tumour in the 
Ophthalmological Clinic of Nijmegen University Hospital per year 
Year Uveal Uveal Total number of lesions 
metastases melanomas with suspicion of an 
intraocular tumour 
1970 * 
1970 ** 
1971 
1972 
1973 
1974 
1975 
1976 
1977 
1978 
1979 
1980 
1981 
1982 
1983 
1984 
1985 
1986 
1987 
1988 
1989 
1990 *** 
0 
0 
0 
0 
1 
2 
4 
4 
2 
4 
6 
5 
6 
7 
2 
7 
2 
6 
6 
11 
5 
7 
4 
1 
0 
2 
3 
3 
10 
16 
15 
20 
29 
36 
17 
14 
21 
20 
24 
23 
46 
53 
38 
27 
9 
1 
2 
5 
5 
10 
21 
26 
27 
31 
46 
50 
31 
31 
36 
36 
42 
38 
75 
92 
75 
73 
Total 87 422 762 
* patients with suspicion of tumour before 14 November 1970, but referral after thai date; ** from 14 
November 1970; *** until 14 November 1990 
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Uveal metastases account for 11.4% of all patients examined with suspicion of an 
intraocular tumour. Malignant melanomas of the uvea were diagnosed five times as often. 
Table 2.2.1.1 presents a survey of the number of new patients with uveal metastases in 
the past 20 years. This table also lists the number of patients with uveal melanomas and 
the total number of patients with suspicion of an intraocular tumour. The number of 
patients, although subject to fluctuations, has increased during this period (see also Figure 
2.2.2.1). It should be mentioned that in March 1989 a prospective search for uveal 
metastases in patients with breast cancer was started. Where this retrospective study is 
concerned, this fact may have exerted some negative influence on the number of patients 
with intraocular metastases examined since March 1989. An occasional patient who 
otherwise would have been referred by the department of Internal Medicine for suspicion 
of a metastasis may have been enrolled in the prospective study. 
According to the literature (see Chapter 1.3.1), uveal metastases account for 2 to 
9% of all intraocular tumours. Compared with this, the proportion of 11.4% reported in 
this study is large. It should be noted in this connection that the percentages of occurrence 
mentioned in the literature vary greatly, that the patient populations are frequently 
described incompletely and that many older publications and histopathological 
examinations are included. The number of patients with uveal metastases in our study is 
related to a patient population with suspicion of an intraocular tumour in which naevi, 
subretinal haemorrhages, neovascularizations, etcetera have also been included, as well as 
lesions of unknown nature. Had these conditions not been included, the proportion of 
metastases in relation to all intraocular tumours would have been even higher, namely 
15%. 
2.2.2 Primary tumours 
As was to be expected on the basis of the literature, most uveal metastases in our study 
originated from breast cancer, viz. in 52 of the 87 patients (60%). The second most 
frequently diagnosed primary malignancy was lung cancer (20 patients: 23%) (Table 
2.2.2.1). 
Of the lung tumours, six were defined as small cell anaplastic carcinoma, three as 
large cell anaplastic carcinoma, four as squamous cell carcinoma and three as 
adenocarcinoma (four pulmonary tumours classification unknown). 
Two patients were observed with a metastasis of a thyroid carcinoma (one 
follicular and one anaplastic), two of a pancreatic carcinoma, one of a testicular tumour 
(moderately to poorly differentiated seminoma with areas of teratoma), one of a prostatic 
carcinoma, one of a transitional cell carcinoma of the bladder, one of a clear-cell 
carcinoma of the kidney (Grawitz tumour), two of an adenocarcinoma probably originating 
from the colon and five patients in whom the primary tumour had not been determined. 
Among the last-mentioned five patients with uveal metastases there were four with an 
adenocarcinoma of unknown origin, in three of whom histological confirmation of the 
uveal metastasis was obtained. 
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Table 2.2.2.1 Localization primary tumour in 87patients with uveal metastases 
Localization 
primary tumour 
Total Females Males 
Breast 
Lung 
Pancreas 
Thyroid 
Kidney 
Bladder 
Prostate 
Testis 
Probably colon 
Unknown 
52 
20 
2 
2 
1 
1 
1 
1 
2 
5 
60 
23 
2 
2 
1 
1 
1 
1 
2 
6 
52 
6 
1 
2 
-
-
-
-
1 
3 
80 
9 
2 
3 
-
-
-
-
2 
5 
-
14 
1 
-
2 
-
64 
5 
-
5 
5 
5 
5 
5 
9 
Total 87 65 22 
number of patients 
45 
40 
35 
3(H 
25 ; 
I 
20 
15 
10 
5 
Ϋ%ΖΆ Miscellaneous 
All 
0 I У7777ШЛ 
1970-1975 * 1976-1980 1981-1985 1986-1990 ' 
Figure 2.2.2.1 Number of patients with uveal metastases according to the 
localization of the primary tumour per year; *from 14 November 1970; ** until 
14 November 1990 
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According to literature data, uveal metastases detected clinically are secondary to 
breast cancer in 72% of the cases and to lung cancer in 12% (see Table 1.3.2.4). In our 
study metastases were found to derive from breast cancer relatively less often than in the 
literature, and more frequently from lung cancer. However, the present study covers a 
more recent period than other major survey articles hitherto published. It is known that 
the incidence of lung cancer has increased markedly whereas that of breast cancer has 
remained stable (Silverberg et al., 1990). This may have affected the ratio of incidence of 
uveal metastases originated from these tumours. In our patient material, the number of 
patients with uveal metastases from lung cancer has indeed increased, as has the number 
of metastases from the miscellaneous primary tumours. With the exception of the first 
five-year period, during which only few uveal metastases were diagnosed, the number of 
metastases from breast cancer has remained at approximately the same level (Figure 
2.2.2.1). 
In our group of patients, uveal metastases were diagnosed in 66 patients (76%) at a 
time when a primary malignancy was already known. The mean interval between the 
primary tumour and the ocular metastasis was 47 months (SD 43; median 32), ranging 
from 8 days to 14 years (Tables 2.2.2.2 and 2.2.2.3). In patients with a metastasis from 
breast cancer this interval was 56 months on average (SD 43; median 46 months; range 5 
weeks to 14 years), while in patients with lung cancer it was only 14 months (SD 21; 
median 6 months; range 8 days to 5.3 years). 
Table 2.2.2.2 Relationship between time of diagnosis of primary tumour and time 
of diagnosis of uveal metastasis 
Uveal metastasis detected first 
N % Localization primary tumour 
Primary tumour detected first 
N % 
Breast 
Lung 
Other 
Thyroid 
Pancreas 
Testis 
Prostate 
Bladder 
Kidney 
Adenocarcinoma, probably colon 
Unknown 
51 
9 
6 
2 
1 
1 
98 
45 
40 
1 
* 11 
9 
-
1 
-
2 
55 
60 
Total 66 76 21 24 
* in one patient pulmonary tumour and uveal metastasis diagnosed on the same day 
The mean interval between the detection of the primary tumour and the detection of the 
uveal metastases, as established in the patients of our study, is in accordance with data in 
the literature in which a mean interval of 42 to 43 months is reported (Schiffer et al., 
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1978; Stephens and Shields, 1979). 
It was in only 14% of the patients with breast cancer that uveal metastases were 
diagnosed within one year after the detection of the primary tumour. In five patients 
(10%) this interval was longer than 10 years with a maximum of 14 years. In patients 
with lung cancer, on the other hand, the uveal metastasis was discovered within one year 
after the detection of the primary tumour in 67%. 
The mean interval between primary tumour and uveal metastasis was substantially 
longer in patients with breast cancer than in patients with metastases of lung cancer or of 
other primary tumours (Table 2.2.2.3). 
Table 
Pnmary 
Primary 
Breast 
Lung 
Other 
Total 
Primary 
Breast 
Lung 
Other 
Total 
2.2.2.3 Interval between 
tumour 
tumour 
tumour 
metastasis 
Number of 
patients 
diagnosis 
diagnosed before uveal metastasis: 
* 49 
# 9 
6 
* 64 
diagnosed after uveal metastasis: 
1 
# 10 
** 3 
** 14 
of primary 
Mean 
56 
14 
21 
47 
1 
1 
3 
2 
tumour 
Interval 
SD 
43 
21 
19 
43 
-
2 
4 
3 
and diagnosis of uveal 
(months) 
Median 
45.9 
5.8 
18.3 
32.5 
-
0.6 
1.3 
1.0 
Range 
1.2-169.5 
0.3-64.9 
1.5-55.6 
0.3-169.5 
-
0.2-8.1 
1.0-7.8 
0.2-8.1 
* ofihe 51 patients with breast cancer: two patients with unknown interval not included; ** of the nine 
patients with miscellaneous primary tumours: five patients with unknown primary tumours and one patient 
with suspicion of a colonic carcinoma after diagnosis of intraocular tumour not included; # in one patient 
pulmonary tumour and uveal metastasis diagnosed on the same day 
Not in all cases did uveal metastases follow a malignancy that was already known. In 
seven of the 87 patients (8%) the primary tumour even was not detected at all, in spite of 
extensive examinations. In two patients, the metastasis probably originated from a colonic 
carcinoma while metastases elsewhere in the body were known as well. In one of these 
two patients presence of a colonic carcinoma was already suspected before the intraocular 
tumour was discovered. In five other patients no primary malignancy could be found. In 
three of these patients, histological data of the intraocular tumour were obtained. In the 
first patient an eye was enucleated under the diagnosis of 'malignant choroidal melanoma'. 
At histopathological examination it proved to be a metastasis of a moderately 
differentiated adenocarcinoma. In a second patient, enucleation was performed because of 
total loss of the function of the eye. Histological examination revealed a metastasis of ал 
adenocarcinoma with extrascleral spread. In a third patient, enucleation was decided upon 
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because the eye was blind and painful. Histological examination revealed a metastasis of 
an adenocarcinoma. In the two other patients with metastases of unknown localization, 
metastases elsewhere in the body developed after the ophthalmological diagnosis and the 
patients' general condition deteriorated very fast. 
In 14 patients, no malignancy was known at the time of the diagnosis of the uveal 
metastasis, but a primary tumour was discovered later, after a mean interval of 8 weeks 
(median 4; range 6 days to 8 months). The primary tumours were a lung carcinoma in 10 
patients, and a breast carcinoma, a pancreatic carcinoma, a prostatic carcinoma and a 
clear-cell carcinoma of the kidney in one patient each. The length of this interval naturally 
depends greatly on how, and how quickly, diagnostic examinations for detection of a 
primary tumour are performed. In none of these cases were metastases elsewhere in the 
body known at that time. 
A uveal metastasis was discovered before a malignancy elsewhere in the body was 
known in a total of 20 patients (23%) which proportion agrees with literature data. 
In one patient, finally, the uveal metastasis was established on the same day that 
lung cancer was diagnosed. 
To be noted is the large proportion (55%) of patients with lung cancer in whom the 
tumour was diagnosed simultaneously with (one patient) or after the detection (10 patients) 
of an intraocular tumour. This is known from the literature as well (see Table 1.3.2.9). In 
the 10 patients in whom the uveal metastasis preceded the pulmonary tumour, lung cancer 
was detected 6 weeks on average after the finding of the uveal metastasis, ranging from 6 
days to 8 months. The median was only 17 days, however. In eight of the ten patients the 
pulmonary tumour was detected within one month after the uveal metastasis. Besides, in 
four of nine other patients in whom the diagnosis of the primary tumour preceded the 
diagnosis of the intraocular metastasis, the pulmonary tumour had been known for less 
than one month before the ophthalmological diagnosis. 
In only one patient with breast cancer was the uveal metastasis detected before the 
primary tumour. 
Over one-half of all patients in whom a uveal metastasis is determined before a 
primary tumour is known therefore prove to have lung cancer. The probability of breast 
cancer is very low in such cases. 
2.2.3 Connection with metastases elsewhere in the body 
If a malignancy is suspected, specific roentgenological examination of the chest is 
practically always carried out. A search for cerebral metastases, on the other hand, is 
usually performed only if there are clinical indications of cerebral dissemination. In spite 
of specific examinations, existing metastases in some cases may fail to be diagnosed, for 
instance because they are too small for the examination techniques available. The clinical 
description of metastases elsewhere in the body in patients with uveal metastases is limited 
to the known diagnosed metastases. 
In our study, in 44 patients with uveal metastases (51%) metastases elsewhere in 
the body were also known at the time of the ophthalmological diagnosis. In 36 patients 
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(41%), on the other hand, the uveal metastasis was the first sign of dissemination. Of the 
other seven patients (8%), no data concerning metastasization in the penod before the 
detection of the uveal tumour were available. 
In 20 patients with uveal metastases the pnmary tumour was detected only after the 
diagnosis of the intraocular tumour. In these patients at that moment no metastases 
elsewhere in the body were known. In 15 of the 66 patients (23%) with uveal metastases 
in whom a pnmary tumour was already known before diagnosis of the ophtha!mological 
lesion, the uveal metastasis was the first sign of dissemination, while in 45 patients (68%) 
metastases elsewhere were already known [in six patients (9%) no data on metastasization 
before the ophtha!mological diagnosis were available]. 
Uveal metastases therefore frequently were the first sign of dissemination in 
contrast to what was reported by, among others, Guthert et al. (1965), Meur et al. (1974) 
and Nelson et al. (1983). Saßmannshausen et al. (1990) observed metastases elsewhere in 
the body in 60% and Timm (1967) in 82% of the patients. In our study group, however, 
this was the case in less than 50% of all patients. 
After the detection of the uveal metastasis, metastases elsewhere in the body were 
established in 61 patients (70%). In three patients (3%) this was not the case [23 patients 
(26%) unknown]. 
Pulmonary metastases allegedly precede uveal metastases in nearly all cases, 
because tumour emboli have to pass through the lungs before they can reach the uvea 
(Ferry, 1967; Gillet, 1971; François et al., 1976). However, in our study group 
pulmonary metastases were descnbed in only 27 patients (31%). In 20 patients these were 
diagnosed before the uveal metastasis (average 9 months; median 1; range 2 days - 50 
months). In seven patients, the pulmonary metastases were searched for and detected after 
the finding of intraocular metastases (on average after 19 months; median 21, range 1-38). 
If pulmonary metastases were discovered, this occurred in 16 of the 27 patients (59%) 
within a penod of one year before or one year after the detection of the uveal metastases, 
and in 85% within a penod of two years. This means that in only 18% of all patients with 
uvea! metastases pulmonary metastases were known in a penod of one year, and in 26% 
in a penod of two years before or after the date of the ophthalmological diagnosis. It 
appears, therefore, that in the patients of our study there was no connection between 
pulmonary and uveal metastases. The finding of Mewis and Young (1982) that pulmonary 
metastases were known in 60% of patients with breast cancer therefore is not in agreement 
with the proportion of 35% in our study. 
Considering the blood supply of the eye and the brain, a relationship between uveal 
and cerebral metastases might be expected (Allen, 1968; Jensen, 1970; Abramson, 1980). 
In our study group, cerebral metastases were known in 15 of the 87 patients with 
uveal metastases (17%): 12 times before and 3 times after the ophthalmological diagnosis. 
If cerebral metastases occurred before the uveal metastases, this was on average 6 months 
earlier (median 4; range 3 days to 18 months). If cerebral metastases were detected only 
after the diagnosis of the uveal metastases, the average interval was 22 months (median 7; 
range 3 to 56). Twelve of the 15 cerebral metastases (80%) developed within one year 
before or one year after detection of the intraocular tumour and 93% within two years. 
Therefore, a cerebral metastasis was diagnosed in 14% of all patients with uveal 
metastases within a penod of one year, and in 16% within a penod of two years before or 
174 
after the diagnosis of the uveal metastasis. So, where cerebral metastases are concerned, 
no distinct relation with uveal metastases existed, either. 
Thatcher and Thomas (1975) reported cerebral metastases in 12% of the patients 
with a uveal metastasis of breast cancer. Mewis and Young (1982) on the other hand, 
encountered metastases in brain, spinal cord or meninges in 45% of the patients and 
concluded that metastases in the central nervous system appeared to manifest themselves at 
the same time as metastases in the uvea. However, cerebral metastases were known in 
only 13% of our patients with a uveal metastasis of breast cancer. 
The occurrence of pulmonary and cerebral metastases in relation to uveal 
metastases therefore has to be considered in a more general connection: development of 
uveal metastases is a sign of dissemination of the primary tumour which may give rise to 
metastases elsewhere in the body, as well, depending on the pattern of metastasization of 
the malignancy in question. In our patient material, no other clear relationship of the 
intraocular metastases with metastases in lungs or brain was demonstrable. However, 
metastatic cells have to break through the blood-brain barrier to reach the brain. For uveal 
metastases no such barrier exists. 
2.2.4 Demography 
Of the 87 patients with uveal metastases, 65 (75%) were of the female and 22 (25%) of 
the male sex (Table 2.2.4.1). The fact that breast cancer so often is the primary tumour is 
an important cause of this sex distribution, which is in accordance with the results of 
clinical studies of other authors in which 70 to 85 % of the patients with uveal metastases 
are of the female sex (see Table 1.3.3.1). 
The mean age of patients with uveal metastases was 57 years, with a median of 58 
years. The youngest patient was a male aged 27 years with a testicular carcinoma, the 
oldest a male aged 80 years with a clear-cell carcinoma of the kidney (Table 2.2.4.1). 
Literature data indicate a mean age of patients with uveal metastases between 50 
and 57 years. For patients with breast cancer this mean age is 49 to 61 years and for 
patients with lung cancer, 51 to 55 years (see Table 1.3.4.2). 
The age distribution of patients with uveal metastases in our retrospective study 
reached a peak in the 7th decade (between 60 and 69 years). Of all patients, 89% were 
between 40 and 79 years old. 
All patients in our study had Dutch nationality and were of the Caucasian race. 
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Table 2.2.4.1 
Pnmary tumour 
Age of patients with uveal metastases from different primary tumours in years 
Total Female 
N Mean SD Median Range N Mean SD Median Range N 
Male 
Mean SD Median Range 
Total 87 57 13 58 27-80 65 56 12 58 29-79 22 60 13 62 27-80 
Breast 
Lung 
Other 
Pancreas 
Thyroid 
Kidney 
Bladder 
Prostate 
Testis 
Probably colon 
Unknown 
52 
20 
15 
2 
2 
1 
1 
1 
1 
2 
5 
56 
60 
59 
55 
72 
80 
67 
46 
27 
67 
55 
11 
12 
16 
16 
56 
61 
59 
55 
35-79 
29-76 
27-80 
42-68 
70-74 
-
-
60-74 
33-77 
2 
6 
7 
1 
2 
56 
55 
61 
42 
72 
11 
16 
17 
56 
57 
64 
35-79 
29-72 
33-77 
70-74 
74 
56 
14 
8 
62 
57 
10 
16 
65 
58 
38-76 
27-80 
58 33-77 
68 
80 
67 
46 
27 
60 
54 52-55 
2.2.5 Conclusions 
In a period of 20 years, uveal metastases were diagnosed in 87 patients. The primary 
tumour was breast cancer in 60% and lung cancer in 23%. In one-quarter of the patients 
detection of the intraocular tumour preceded the diagnosis of the primary malignancy, 
which was then mostly lung cancer or a tumour of unknown nature. 
In 41% of the patients the uveal metastasis was the first sign of dissemination. This 
is in contrast to the generally held opinion that uveal metastases occur in patients with a 
widely disseminated malignancy. In our study population, no evident relationship between 
uveal metastases and metastases elsewhere in the body was found. Uveal metastases, 
therefore, do not follow lung metastases and do not occur simultaneously with cerebral 
metastases as is frequently described in literature. 
Patients with uveal metastases were three times as often of the female as of the 
male sex. The mean age at the time of diagnosis was 57 years. 
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2.3 Diagnostics and differential diagnostics 
In the diagnostics of intraocular tumours numerous examination techniques are nowadays 
available. In the majority of the patients of this retrospective study, not all those 
• examinations have been used. This on the one hand because not all intraocular lesions are 
accessible to all examination techniques, on the other because certain techniques have only 
recently been introduced into the diagnostics of ' tumours. For instance, fluorescein 
angiography of tumours restricted to the ciliary body is possible only to a limited extent 
because of the peripheral localization, echography is not carried out in all cases of 
opthalmoscopically flat lesions and electro-oculography has only recently gained a place in 
the diagnostics of intraocular tumours. Conversely, certain examinations were carried out 
several times before a treatment was instituted, for instance if the diagnosis was uncertain 
or when an expectative policy was decided upon. 
In the following chapters, the data referred to are always, unless otherwise stated, 
those obtained at the first examination at presentation of the patient. Beside the diagnosis, 
the differential diagnosis of uveal metastases will also be discussed. In this manner it is 
attempted to give as complete a picture as possible of the modes of presentation of uveal 
metastases and other intraocular tumours in our clinic. 
After a description of the signs and symptoms, we shall successively discuss the 
findings obtained with the various examination techniques. The following arrangement will 
be used every time: 
- a survey and evaluation of the results of the examination in question in uveal 
metastases and a comparison of these with the findings of other authors; 
- a summary of the findings in uveal metastasis obtained at the examination in 
question; 
- a table listing the principal findings in patients with metastases, melanomas, 
haemangiomas and naevi of the uvea; 
- a short description of the differential-diagnostic aspects; 
- conclusions in regard to the value of the technique in question for the differential 
diagnosis of uveal metastases. 
In connection with the differential diagnosis of uveal metastases from other intraocular 
disorders and phenomena, Table 2.3.1 presents a survey of a number of epidemiological 
data in patients with metastases, melanomas, haemangiomas and naevi of the uvea from 
our retrospective study. 
As mentioned before, patients with uveal metastases were predominantly of the 
female sex, which fact is to be ascribed to the frequent occurrence of breast cancer as the 
primary tumour. In uveal melanomas in our study group, females were concerned with 
equal frequency as males, whereas in haemangiomas the proportion of males was larger. 
Of patients with uveal naevi, more were of the female than of the male sex. Sixty percent 
of patients with a retinoblastoma was of the male, 40% of the female sex. 
In miscellaneous disorders, sex distribution was about even. Patients with an 
intraocular lesion of unknown nature were female in 65% of the cases. 
The mean ages of the patients with metastases, melanomas or naevi varied only 
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little (57 to 59 years). An exception were patients with haemangiomas, who were marked-
ly younger (average 44 years). These data are in accordance with those in the literature on 
melanomas (Wilder and Paul, 1951), haemangiomas (Gass, 1974) and naevi (Gass, 1977). 
Patients with a choroidal detachment and with age-related macular degeneration 
were substantially older, 72 years on average. The mean age of the nine patients with a 
subretinal haemorrhage was 65 years, that of patients with a leiomyoma, 52 years. A 
distinctly lower mean age was observed in patients with lymphoproliferative diseases, viz. 
26 years. In patients with a retinoblastoma, the mean age was 12 months. The oldest 
patient with a retinoblastoma was 10 years of age. The mean age of patients with lesions 
of unknown nature was 60 years. 
Table 2.3.1 Epidemiological data on patients with metastases, malignant melanomas, 
haemangiomas and naevi 
Intraocular tumour 
Metastasis Melanoma Haemangioma Naevus 
Number of patients 87 422 27 60 
Sex: 
Male 25% 51% 70% 42% 
Female 75 49 30 58 
Age. mean (SD): yrs 57.2(12.6) 57.9(15.1) 44.4(12.2) 58.6(16.0) 
Malignancy elsewhere m the body 76% 3% 
before diagnosis of intraocular 
tumour 
In patients with uveal metastases, as mentioned in Chapter 2.2.2, a malignancy elsewhere 
in the body was known at the time of the ophthalmological diagnosis in 76% of the cases. 
This malignancy was mostly breast cancer and less often, lung cancer. 
In 14 patients with a uveal melanoma (3.3%) a malignancy elsewhere in the body 
was known at the time of the first ophthalmological examination. The mean interval 
between the diagnosis of this malignancy and the detection of the intraocular tumour 
amounted to 7.5 years, ranging from one day to 33 years. In nine other patients, after 
diagnosis of the uveal melanoma, a second malignancy was detected (after a mean interval 
of 45 months). In four other patients a second primary malignancy was described, but the 
time at which this diagnosis was made was not known. 
In all, therefore, in 27 patients with a uveal melanoma (6.4%), a second 
malignancy elsewhere in the body was known. This is in agreement with the finding of 
other investigators (Hart, 1962; Jensen, 1963; Char, 1989). 
In four patients, the interval between the detection of the uveal melanoma and the 
finding of a second malignancy was remarkably short. In one patient, a basocellar 
carcinoma of the skin was diagnosed, after which one day later a choroidal melanoma was 
discovered. The ocular diagnosis could be confirmed histologically. In another patient four 
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days before the diagnosis of choroid melanoma, a squamous cell carcinoma of the buccal 
mucosa was detected. At histological examination of the ocular tumour the diagnosis 
proved to be correct. In a third patient, the presence of a multiple myeloma had only been 
known one week when a choroidal melanoma was established. In a last patient, a 
histologically confirmed choroidal melanoma was diagnosed while a non-Hodgkin 
lymphoma was detected 1.5 months later. In these patients it is quite well possible that a 
uveal metastasis will be considered rather than a melanoma. 
Table 2.3.2 lists the various disorders that were established as an independent 
malignancy in patients with a uveal melanoma. In our study group there was no distinct 
relationship between the occurrence of uveal melanomas and any particular malignancy. In 
one patient, a carcinoma of the bladder and a lung carcinoma were already established and 
the patient was also known with chronic lymphatic leukaemia when a choroidal melanoma 
was diagnosed. In all, therefore, four separate malignancies were involved. In the 
literature, only one single similar patient, with four malignancies including a malignant 
uveal melanoma, is described, namely by Pheasant et al. (1979). 
Table 2.3.2 Second primary malignancy in 27 patients with malignant uveal melanomas 
Second primary malignancy detected before uveal melanoma (N=14): 
Breast cancer (1); lung cancer (1); probably lung cancer (2); 'tumour' of the testis (1); prostatic cancer 
(1); basocellular carcinoma of the skin (1); squamous cell carcinoma of the skin (1); squamous cell 
carcinoma of the nipple (I); buccal squamous cell carcinoma (I); bladder cancer + lung cancer + 
chronic lymphatic leukaemia (1); non-Hodgkin lymphoma (1); histiocytic lymphoma (1); multiple 
myeloma (1) 
Second primary malignancy detected after uveal melanoma (S=9): 
Meningeoma (2); astrocytoma (1); osteosarcoma (1); carcinoma of the cervix uten (1); probably 
malignancy of the skin (2); probably malignancy of the kidney (1); non-Hodgkm lymphoma (1) 
Moment diagnosis second primary malignancy in relation to uveal melanoma unknown (N=4): 
Breast cancer (1); lung cancer (1); colonic cancer (1); malignant melanoma skin (1) 
The malignancies found in patients with a uveal melanoma in additon to the ocular 
tumour, therefore, are of an entirely different nature than the primary tumours as 
described in patients with uveal metastases. While in uveal metastases the primary tumour 
was breast cancer in 60% of the cases and lung cancer in 23%, in uveal melanomas the 
nature of the second malignancy was breast cancer in only 7% and lung cancer in 11%. In 
the other cases the malignancy was of a different nature. 
To the individual patient who is known with a malignancy and in whom an 
intraocular tumour is noticed, these findings are of only limited value, however. 
In not one of the patients of our study with a haemangioma, naevus, leukaemia or 
lymphoma or some other intraocular disorder was a malignant tumour elsewhere in the 
body known. 
In five of the 88 patients with an intraocular lesion of unknown nature (6%) at the 
time of the first ophthalmological examination, a malignancy elsewhere in the body was 
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known: once breast cancer, once a clear cell carcinoma of the kidney (Grawitz tumour), 
once a uterine carcinoma, once breast cancer coexistent with a thyroid carcinoma and 
once, a malignancy of an unknown nature. These tumours had on average been known for 
as long as 12 years (range 4 months - 31 years). In three patients, a malignancy elsewhere 
in the body was discovered after the ocular tumour: once lung cancer, once probable lung 
cancer and once, a carcinoma of the colon. The mean interval after the ocular tumour was 
19 months (range 4-42 ). In one other patient with a colonic carcinoma, the exact moment 
of diagnosing in relation to the ocular tumour was not known. In all these patients there 
were insufficient indications that an intraocular metastasis was concerned. 
2.3.1 Signs and symptoms 
As already mentioned in Chapter 2.1.2, inter alia for statistical reasons, in the description 
of data and results of examinations, one affected eye per patients is always postulated, viz. 
the tumour eye in patients with a unilateral tumour, the eye first diagnosed in patients with 
bilateral tumours which were detected at different times and the right eye in patients with 
bilateral tumours in whom tumours were observed in both eyes at the same time. In the 
description of the signs and symptoms of patients with uveal metastases, therefore, only 
one single eye is considered. 
Ophthalmological complaints were present in our study in 64 of the 87 patients 
with uveal metastases (74%). Of these 64 patients, 54 (86%) had only one complaint. 
The most frequently reported complaint was deterioration of the visual acuity, 
which was mentioned as the principal symptom by 54% of the patients. Visai field defects 
and spots before the eyes were the principal complaint in 7% of the patients and was 
mentioned as one of the symptoms by 18% of the patients. A few patients manifested 
themselves with photopsia (appearance of sparks or flashes), metamorphopsia, a painful or 
red eye or diplopia. 
Presence of more than one symptom in most cases involved, next to complaints 
about blurred vision, complaints about visual field defects (Table 2.3.1.1). 
In two of the five patients complaining about photopsia, ophthalmoscopy revealed 
no retinal detachment; in the three others such detachment was present. Complaints about 
photopsia accordingly were not clearly connected with the presence of a retinal 
detachment. 
In none of the patients complaining about metamorphopsia an Amsler test appeared 
to have been performed. This test had been executed, on the other hand, in nine patients 
without complaints about distorted vision. In three of them this test was normal, in six, 
abnormal. If the Amsler test was normal, the margin of the tumour was found to be 2.3 
disk diameters (DD) distant from the fovea. In an abnormal test, this was only 0.4 DD on 
average. However, this concerned a small number of performed tests of which the pre-test 
selection was not known. 
Uveal metastases may also be asymptomatic. This was the case in 11 patients 
(13%). In nine of these patients the shortest distance between the margin of the tumour 
and the fovea was known. It was 2.8 DD on average, ranging from a localization in the 
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fovea to a distance of 6.0 DD. In one patient, known with amblyopia of the eye in 
question, the tumour was located in the macular area without having given rise to 
symptoms. 
In five of the 11 patients in whom no symptoms were established in the tumour 
eye, metalases were present in the other eye which had caused deterioration of the visual 
acuity and had occasioned the ophtha!mological examination. In these patients, therefore, 
the eye taken into consideration was asymptomatic but there were symptoms in the 
contralateral eye. Two other patients had been referred to the ophthalmologist by a 
neurologist and one patient by a surgeon, for evaluation of the disk. One patient was being 
treated for a pterygium; at control examination two weeks later, the visual acuity had 
decreased from 5/6 to 5/20 and ophthalmoscopy revealed a uveal tumour. In another 
patient with age-related macular degeneration, control fluorescein angiography showed a 
tumour in a temporal superior localization which proved to be a metastasis. Finally, at a 
control examination of a patient with a macular scar and poor eyesight, retinal detachment 
was detected which was found to be due to a metastasis. 
Of 12 patients with uveal metastases in our study (14%) no data concerning ocular 
symptoms were known. This concerned inter alia three patients with a tumour arising 
solely from the iris or the ciliary body. 
Table 2.3.1.1 
Complaint 
Decreased visual acuity 
Visual field defect 
Metamorphopsia 
Photopsia 
Ocular pain 
Headache 
Diplopia 
Red eye 
Asymptomatic 
Unknown 
Ophthalmological 
1 blurred vision 
complaints in 87 patients 
Number of times noted 
N 
47 
16 
6 
5 
4 
3 
2 
2 
11 
12 
* % 
54 
18 
7 
6 
5 
3 
2 
2 
13 
14 
with uveal metastases 
N 
47 
6 
3 
3 
3 
-
1 
1 
11 
12 
Most important 
compi aint 
% 
54 
7 
3 
3 
3 
-
1 
1 
13 
14 
* /ο/α/ % exceeds 100 because some patients had more than one complaint 
In the 84 patients with a tumour originating from the choroid the complaint was related to 
the shortest distance between the margin of the tumour and the fovea. In 18 patients 
(21%) this distance was not known, however. 
In 21 patients (25%) the metastasis was localized in the macular region. In 67% of 
these patients this gave rise to deterioration of the visual acuity, 19% complained of visual 
field defects, 10% about metamorphopsia and 10% about a painful eye. Other symptoms 
182 
such as photopsia and diplopia were not encountered in these patients. 
In 46 patients (55%) the margin of the tumour was situated at most 1 DD from the 
fovea. In 63% of these patients this caused complaints about blurred eyesight, in 20% 
about visual field defects, in 9% metamorphopsia, in 7% ocular pain, in 4% photopsia 
and in 2%, diplopia. 
In patients complaining about loss of visual acuity, the distance to the fovea was 
1.5 DD on average while in patients without ocular complaints it was 2.9 DD. This is in 
accordance with the expectation that tumours situated entirely or partly in the macula will 
cause complaints about the eyesight more frequently than lesions at a distance from the 
macula. Standard error was large, however: 1.3 and 1.9 DD, respectively. 
However, uveal metastases do not always cause complaints about visual acuity, not 
even when they are localized in the macular area. Conversely, a metastasis at a large 
distance from the fovea may lead to complaints about the eyesight such as blurred vision 
(Table 2.3.1.2). 
Table 2.3.1.2 Primary complaint in 66 patients with choroidal metastases related 
to the shortest distance between the tumour margin and the fovea * 
Number Distance between tumour margin and fovea (DD) 
Complaint 
Decreased visual acuì 
Visual Held defect 
Metamorphopsiia 
Photopsia 
Ocular pain 
Diplopia 
A.symplomatic 
Unknown 
* in 18 patients with 
Ky 
a 
of — 
patients 
choroidal 
38 
4 
3 
3 
2 
1 
10 
5 
metastasis 
Mean 
1.0 
1.6 
1.3 
2.7 
0.5 
1.0 
2.9 
0.3 
distance to the fovea 
SD 
1.3 
2.3 
1.5 
1.5 
0.7 
-
1 9 
0.5 
unknown; DD: 
Mini imum 
0 
0 
0 
1.0 
0 
1.0 
0 
0 
disk diameters 
Maximum 
6.0 
5.0 
3.0 
4.0 
1.0 
1.0 
6.0 
1.0 
Seventeen patients at the time of the diagnosis of the uveal metastases in the affected eye 
also complained about decreased eyesight in the contralateral eye. Thirteen times at that 
moment metastases were also diagnosed in the contralateral eye. In two instances this 
diagnosis was made at a later time. One patient suffered from abducens paresis, probably 
due to a cerebral metastasis. In one patient no ophthalmological abnormalities could be 
established in the contralateral eye with impaired eyesight. 
The visual acuity with own conection (with own glasses in patients wearing 
spectacles, without correction in patients without glasses) was known of only 22 patients 
with uveal metastases and on average amounted to 0.42, ranging from 1/300 to 1.20. 
In 70 of the 87 patients the optimal visual acuity could be found out in retrospect. 
This was the best possible visual acuity that could be achieved after optimal correction of 
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any refraction abnormalities. This optimal visual acuity was 0.49 on average. 
The best visual acuity known was defined as the optimal visual acuity or, if this 
was not known, the visual acuity with own correction. This was known in 75 patients, 
amounted to 0.49 on average and ranged from Lp+ to 1.25 (Table 2.3.1.3). In this table 
the visual acuity of the non-affected eye is also given, depending on whether or not a 
metastasis was encountered in it, and the difference in visual acuity between the two eyes 
(if known). 
Table 2.3.1.3 Visual acuity in patients with uveal metastases 
Tumour eye: 
With no correction 
With own correction 
With optimal correction 
With best known correction * 
Contralateral unaffected eye: 
With no correction 
With own correction 
With optimal correction 
With best known correction * 
Contralateral affected eye: ** 
With no correction 
With own correction 
With optimal correction 
With best known correction * 
N 
20 
22 
70 
75 
10 
15 
43 
45 
8 
6 
15 
17 
Difference between unaffected contralateral 
With no correction 
With own correction 
With optimal correction 
With best known correction * 
7 
10 
43 
45 
Mean 
0.25 
0.42 
0.49 
0.49 
0.91 
0.87 
0.89 
0.89 
0.47 
0.61 
0.62 
0.56 
SD 
0.32 
0 35 
0.32 
0.32 
0.23 
0.20 
0.22 
0.22 
0.42 
0.40 
0.40 
0.41 
eye and tumour eye: 
0.68 
0.49 
0.44 
0.44 
0.41 
0.38 
0.37 
0.38 
Visual acuity 
Median 
0.12 
0.35 
0.50 
0.50 
0.90 
0.80 
1.00 
1.00 
0.65 
0.75 
0.60 
0.60 
0.60 
0.50 
0.40 
0.40 
Minimum 
lp-
1/300 
lp + 
lp + 
0.60 
0.40 
0.05 
0.05 
1/60 
1/300 
ip+ 
lp + 
0 
0 
-0.85 
-0.85 
Maximum 
1.00 
1.20 
1.25 
1.25 
1.25 
1.20 
1.25 
1.25 
1.00 
1.00 
1.00 
1.00 
1.22 
0.98 
1.13 
1.13 
* visual acuity with optimal correction or in case optimal correction is unknown, with own correction 
** if at the time of ophthalmological examination a metastasis in the contralateral eye was known 
As Table 2.3.1.3. shows, the visual acuity in the contralateral eye, if no metastasis was 
known in it, was almost twice as high as in the tumour eye. 
In eight patients in whom the distance between the margin of the tumour and the 
fovea was known, and in whom a visual acuity of less than 3/60 was observed, the 
tumour in six cases was situated at the site of the macula, once at a distance of 1 DD 
from the macula and once, at a distance of 3 DD. 
184 
In contrast, in six of the 19 patients with a tumour localized at the site of the 
fovea, a visual acuity of less than 3/60 was established while in only four it equalled or 
was larger than 0.6. 
Figure 2.3.1.1 lists the best visual acuities in the 75 patients with choroidal 
metastases and known visual acuity in a graph. 
number of 
13 -, 
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i l ­
io 
9 -
8 -
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7 1 
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5 -
4-
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2 
i-l 
0 -J ι—' 
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1 
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Figure 2.3.1.1 Best visual acuity in 75 patients with choroidal metastases and known visual acuity 
There was no distinct correlation between the best possible visual acuity of the tumour eye 
and the nature of the primary tumour. In patients with breast cancer, the mean visual 
acuity was 0.51, in lung cancer it was 0.52 and in metastases of one of the other 
malignancies, it was 0.36 on average. 
To detect the development of hypermetropia, if any, the spherical equivalent of the 
patient's own correction was compared with that of the correction that ensured the best 
possible visual acuity. 
In 27 patients the spherical equivalent of the patient's own correction of both the 
metastatic eye and the contralateral healthy eye were known. Between the two, no 
significant difference was observed (mean difference +0.08 diopter for tumour eye minus 
healthy eye; median 0; range -0.75 to +1.25). 
In 34 patients both the spherical equivalent of the patient's own correction and that 
of the correction to ensure optimal visual acuity were known. With optimal correction this 
was on average 0.83 diopter higher in the tumour eye which indicates distinct 
development of hypermetropia. Also, in three other patients, development of hyper­
metropia was noted without mentioning the patient's corrections. 
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In the ophthalmological anamnesis of patients with uveal metastases, in nine 
patients at the time of examination other ocular abnormalities than the metastases were 
already known. Three patients were already being followed up with cataract and one, with 
amblyopia. In addition, in one patient with a visual acuity of 0.80 an abducens paresis and 
complaints about blurred eyesight, probably due to cerebral metastases, were known. One 
patient had an anamnesis with a steel splinter in the eye which had caused visual acuity to 
decrease to 1/60, another patient suffered from an occlusion of the central retinal artery 
with a visual acuity of 0.40 and one patient was known with diabetic retinopathy and a 
visual acuity of 0.50. A last patient, with a ptosis and paresis of the oculomotor nerve 
complained of loss of the field of vision. This was probably brought about by a metastasis 
in the sphenoid or at the back of the orbit. The visual acuity of this patient was not 
known. 
In 63 patients at the time of examination no other ocular abnormalities were 
present (15 patients: unknown). 
The best visual acuity of the tumour eye in 59 of the 63 patients without known 
ocular abnormality amounted to 0.53 on average (four patients unknown). In eight patients 
in whom ocular abnormalities were known, the best visual acuity on average was 0.22 
(one patient unknown). 
At external examination of the tumour eye dilated episcleral vessels were observed 
in two of the 87 patients: once in a patient with a ciliary metastasis of lung cancer and 
once in a patient with a choroidal metastasis of breast cancer. In one patient with an iridai 
metastasis of lung cancer scleral hyperaemia was described. In 81 patients (93%) no 
vascular dilatation or hyperaemia of conjunctiva or sclera was reported (three patients 
unknown). 
Asymmetry of the iris was present in two patients: once in a patient with a ciliary 
metastasis and once in a patient with metastases in the choroid and iris. 
No iridai heterochromia was observed. 
Clear media are required for good assessment of the ocular fundus. However, in 
28 patients (32%) opacities of media were present which rendered good ophthalmoscopy 
difficult. In one patient with bilateral uveal metastases opaque comcas were observed in 
both eyes, with a hyposphagma in one eye. 
Lens opacifications were observed in 25 patients (29%). In 41 patients (47%) the 
lens was clear [21 patients (24%) unknown]. In 20 patients, increased opacity of the lens 
was described. A moderate dense cataract was seen three times and a dense cataract, 
twice. In the five patients with a moderate dense to dense cataract the abnormalities of the 
lens were symmetrical, as they were in 18 of the 20 patients with mild forms of lenticular 
opacities. 
In one patient the fundus could not be inspected adequately because of a dense 
vitreous haemorrhage, in two patients visualization was impaired by a slight intravitreous 
haemorrhage. 
Finally, a secondary retinal detachment or a subretinal haemorrhage may impede 
adequate description and evaluation of the underlying lesion. 
Information concerning Tyndall or cells in the anterior chamber or vitreous 
humour were lacking in most of the patients in our study (Table 2.3.1.4). In general, 
such data were recorded only if abnormal results were obtained; this also applied to 
rubeosis of the iris. 
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Table 2.3.1.4 
Tyndall anterior chamber 
Cells anterior chamber 
Tyndall vitreous 
Cells vitreous 
Occurrence of Tyndall t 
vitreous in patients with 
N 
2 
1 
0 
0 
Distinct 
% 
2 
1 
ind/or 
ι uveal 
N 
2 
3 
3 
5 
cells in the 
metastases 
Some 
2 
3 
3 
6 
anterior 
N 
34 
33 
12 
15 
chamber and/or 
Negative 
% 
39 
38 
14 
17 
Unknown 
N % 
49 56 
50 57 
73 83 
67 77 
Table 2.3.1.4 shows that Tyndall in the anterior chamber was described in 4% of the 
patients with uveal metastases and cells also in 4%. In addition, 3% had Tyndall and 6% 
cells in the vitreous humour. However, owing to the large number of patients in whom 
these data were lacking no conclusions can be drawn from these figures. 
Rubeosis of the iris was observed in two of the 87 patients: once in a patient with 
a ciliary metastasis and once in a patient with a choroidal metastasis. Rubeosis was absent 
in 58 patients (67%) [27 patients (31%) unknown]. 
In all, 12 patients (14%) showed Tyndall or cells in the anterior chamber or 
vitreous humour or showed rubeosis. The primary tumours were four times breast cancer, 
six times lung cancer, once thyroid carcinoma and once, clear cell carcinoma of the 
kidney. A noticeable aspect is the large number of patients with a pulmonary carcinoma in 
this group of patients. 
The localization of the uveal metastasis was of major importance for these 
phenomena. In the patient with the iridai metastasis the anterior chamber was initially 
filled with fibrin. This cleared up after a subconjunctival injection of corticosteroids; only 
then did the iridai tumour become visible. One of the patients with a ciliary metastasis 
presented with an iridocyclitis and redness of the eye with normal ocular pressure. There 
was a pigment coating on the lens and the tumour had broken through the iris. There was 
substantial vascular injection of the iris, ciliary body and angle of the anterior chamber, 
and corneal injection with posterior synechiae. In the anterior chamber distinct Tyndall 
and numerous cells were observed. In the second patient with a metastasis in the ciliary 
body a secondary glaucoma developed. The patient with a metastasis in the iris as well as 
in the choroid presented with a red eye and the picture of anterior uveitis with some 
Tyndall and cells in the anterior chamber. 
The occurrence of signs of irritation of the anterior segment of the eye is in 
accordance with the data of, among others, Ferry and Font (1975). In the four patients in 
our study with metastases in the anterior segment all four were metastases from lung 
cancer. Other investigators have also frequently described signs of uveitis in metastases of 
lung cancer in the iris or the ciliary body (Duke and Kennedy, 1958; Talegaonkar, 1969; 
Reese, 1976). 
Of 62 patients, the ocular pressure in the tumour eye was reported. It amounted to 
14.3 mm Hg on average (SD 3.4), ranging from 8 to 24 mm Hg with a median of 14 mm 
Hg. A pressure in excess of 20 mm Hg was found only twice, both times 24 mm Hg 
(once in a patient with a clear cell carcinoma of the kidney and once in a patient with 
breast cancer). In the contralateral healthy eye of patients with uveal metastases there 
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were no manifest abnormalities of pressure, the mean pressure being 15.2 mm Hg (SD 
3.1). 
In one patient with a ciliary metastasis of lung cancer of whom the pressure in the 
tumour eye was not known, a secondary glaucoma was mentioned. Three other patients 
developed glaucoma later on: in one patient with a ciliary metastasis of lung cancer the 
ocular pressure initially was 12 mm Hg but it rose to 36 after one month and to 45 mm 
Hg after two months; in another patient with a choroidal metastasis of lung cancer, the 
pressure increased from 16 mm to 32 mm Hg nine months later; in a third patient, with a 
metastasis of a thyroid carcinoma in whom the ocular pressure at the first examination 
was not stated, the pressure at a later date was 50 mm Hg. 
If glaucoma developed, the lesion in two of the four cases originated from the 
ciliary body and the primary tumour in three of the four patients was lung cancer. 
Summary of the signs and symptoms in patients with uveal metastasis: the most 
frequent complaint of patients with uveal metastases was decrease of the visual acuity 
followed by complaints about visual field defects. In patients without ophtha!mological 
complaints the margin of the tumour in general was situated farther from the macula than 
in patients who did have complaints. 
The mean visual acuity of the affected eye, with patient's own correction, 
amounted to 0.42 and the best possible visual acuity was 0.49 on average. Patients with 
poor eyesight in general had a macular localization of the tumour. In the tumour eye a 
distinct hypermetropization had taken place, of 0.83 diopters. 
In 32% of the cases there were opaque media, mostly caused by a mild form of a 
symmetrica] cataract. External dilated vessels or hyperaemia of the eye were observed 
only sporadically, as were signs of Tyndall and cells in the anterior chamber or the 
vitreous humour or rubeosis of the iris. If these were present, in most cases a metastasis 
in the anterior segment was concerned, originating from lung cancer. 
The mean ocular pressure in the eye with the metastasis was 14.3 mm Hg. A 
pressure above 20 mm Hg was measured only twice, both times 24 mm Hg. In three 
patients glaucoma developed later on. 
Table 2.3.1.5 presents a review of the signs and symptoms in patients with 
metastases, melanomas, haemangiomas and naevi of the uvea. 
In patients with a melanoma of the uvea, the pattern of complaints was similar to 
that of uveal metastases and there was no difference either where visual acuity was 
concerned. However, the hypermetropization was substantially, although not significantly 
(P <0.10) less in melanoma than in metastases of the uvea, viz. only 0.18 diopters (SD 
1.34) as against 0.83 (SD 1.42) diopters in metastases. 
Lens opacities were observed in similar proportions of melanoma patients and 
patients with metastases. On the other hand, melanoma patients more frequently had 
dilated vessels or hyperaemia of the eye and signs of inflammation. 
The mean intraocular pressure in melanoma amounted to 16.4 mm Hg. Pressures 
in excess of 20 mm Hg were measured in 10% of the melanoma patients as against 2% in 
metastases. 
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Table 2.3.1.5 Signs and symptoms in patients with metastases, malignant 
melanomas, haemangiomas and naevi 
Number of patients 
Complaints: * 
Decreased visual acuity 
Visual field defect 
Photopsia 
Metamorphopsia 
Miscellaneous 
Asymptomatic 
Unknown 
Visual acuity: mean (SD) 
With own correction 
Optimal visual acuity 
Opacifications of the lens: 
none 
increased 
moderately dense 
dense 
unknown 
Dilated episcleral vessels 
Scleral/conjunctival hyperaemia 
Tyndall anterior chamber 
Cells anterior chamber 
Tyndall vitreous 
Cells vitreous 
Rubeosis indis 
Intraocular pressure (mm Hg): 
Mean (SD) 
Range 
Metastasis 
87 
54% 
18 
6 
7 
13 
13 
14 
0.42 (0.35) 
0.49 (0.32) 
47% 
23 
3 
2 
24 
2% 
1 
4% 
4 
3 
6 
2 
14.3 (3.4) 
8-24 
Intraocular tumour 
Melanoma 
422 
53% 
18 
10 
4 
7 
9 
19 
0.40 (0.35) 
0.46 (0.37) 
32% 
19 
9 
1 
39 
7% 
3 
7% 
7 
3 
12 
2 
16.4(8.1) 
1-80 
Haemangioma 
27 
52% 
-
-
-
11 
4 
37 
0.29 (0 34) 
0.39 (0.32) 
56% 
7 
4 
-
33 
-% 
-
-% 
-
-
4 
-
13.9 (4.8) 
6-20 
Naevus 
60 
18% 
2 
-
-
12 
67 
5 
0.62 (0.33) 
0.69 (0.45) 
37% 
28 
18 
2 
15 
2% 
-
-% 
-
-
-
-
17.7(6.1) 
9^5 
* total % exceeds 100 because some patients had more than one complaint 
In haemangioma decrease of the visual acuity was the principal complaint of the majority 
of the patients. There were no reports of complaints about visual field defects, which 
occurred in 21% of the patients with metastases. The visual acuity in haemangioma was 
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markedly lower than in metastases and melanomas. This was due to the frequent 
localization of the lesion in the macular region (see Chapter 2.3.2). 
Lens opacities were observed relatively infrequently in haemangioma patients, due 
in part to the fact that the mean age was lower than in metastases and melanomas of the 
choroid. Signs of inflammation rarely occurred. In no case were hyperaemia of the eye or 
dilated vessels observed. 
The intraocular pressure was 13.9 mm Hg on average and never exceeded 20. 
Naevi in 67% of the cases caused no complaints. If complaints were present, these 
mostly concerned deterioration of the visual acuity. However, the patients with naevi 
examined in our study group constituted a selection of patients who had consulted the 
ophthalmologist because of signs or symptoms. 
The mean visual acuity was markedly higher as in patients with a metastasis or a 
melanoma. 
An opaque lens was encountered with a high frequency, namely in one-half of the 
patients. This also, however, probably was a consequence of the above-named patient 
selection. In only one patient were dilated vessels encountered. Signs of inflammation 
were never seen. 
The mean intraocular pressure in patients with a naevus was 17.7 mm Hg. In 15% 
a pressure in excess of 20 mm Hg was measured. 
In general, in patients with retinoblastoma the parents observe that something is 
wrong with one or both eyes of their child. In 36% a leukokoria was the reason for 
ophthalmological examination, in 28% strabismus, in 20% absence of eye-contact or 
decrease in visual acuity. 
Complaints of patients with intraocular lesions suggestive of a tumour other than 
metastases, melanomas, haemangiomas, naevi or retinoblastomas had a pattern similar to 
that in uveal metastases. However, choroidal detachments in a large proportion (60%) ran 
an asymptomatic course. Of patients with other disorders the majority had a decreased 
visual acuity. 
The mean best possible visual acuity in patients with a subretinal haemorrhage was 
low, viz. 0.19 with a median of 1/300. In patient with aged-related macular degeneration 
these values were even lower, viz. 0.01 and 1/300, respectively. This made the mean of 
the best visual acuity far lower than in metastases, melanomas, haemangiomas or naevi of 
the choroid. Patients with a choroidal detachment had a mean visual acuity of 0.35 
(median 0.32), those with a leiomyoma one of 0.50 (median 0.50) and those with a retinal 
detachment, one of 0.24 (median 1/60). Of only two of the seven patients with a 
lymphoproliferative disease the visual acuities were known; they were lp+ and and 0.45, 
respectively. 
Opacities of the lens were encountered noticeably often: 22% of the patients with a 
subretinal haemorrhage had a mild form and 67%, a moderately dense form of cataract. In 
age-related macular degeneration these proportions were 14% and 43%, respectively. In 
the other lesions the proportion ranged from 60 to 67%. This could be attributed partly to 
the more advanced age of many of these patients. 
The intraocular pressure was lower than 20 mm Hg in all patients but one. The 
exception was a patient with an osteoma in whom an intraocular pressure of 26 mm Hg 
was measured. Thickened episcleral or conjunctival vessels were observed in one patient 
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with scleritis and in one patient with benign reactive lymphoid hyperplasia. 
In one patient with a lymphoproliferative disease, TyndaJl and cells in the anterior 
chamber were seen, and in one patient, Tyndall and cells in the vitreous humour. 
Of the patients from the group with lesions of unknown origin, only 28% 
complained about decrease of the visual acuity. Consequently, the mean of the best known 
visual acuity was relatively high, viz. 0.65. Some degree of cataract, mostly moderately 
dense, was present in 40% of the patients. The mean intraocular pressure was 14.8. These 
data are insuffciently specific to allow a conclusion about the possible nature of these 
lesions. 
Conclusion: the pattern of signs and symptoms in patients with uveal metastases is 
not characteristic. The same complaints and symptoms may also occur in patients with 
other intraocular lesions. In patients with miscellaneous intraocular lesions (other than 
metastases, melanomas, haemangiomas or naevi) a variable picture was observed. It was 
only in naevi cases that complaints mentioned were clearly less frequent and the mean 
visual acuity was higher than in patients with metastases. However, where the differential 
diagnosis of uveal metastases is concerned, these differences are too little specific. 
2.3.2 Ophthalmoscopy and slit lamp examination 
Adequate evaluation of the fundus of the eye requires clear media. As mentioned before, 
this condition was not fulfilled in all patients with uveal metastases in our study. In 
Chapter 2.2.2 it was already mentioned that opacifications of the media were present in 28 
patients (32%). A secondary retinal detachment or a subretinal haemorrhage also may 
impede good observation and evaluation of the underlying lesion. 
As regards the localization of the metastases, in 83 of the 87 patients (95%) the 
tumour was situated in the choroid. In two patients the tumour was localized primarily in 
the ciliary body and in one patient, in the iris. In one patient, a metastasis was observed 
in the choroid as well as in the iris. The percentage of metastases in the anterior segment 
in our study group was 5%, substantially lower than in the literature where proportions up 
to 29% are described (Ferry and Font, 1974/1975; Stephens and Shields, 1979; Castro et 
al., 1982). 
In connection with the blood supply of the eye it is to be expected that most uveal 
metastases will be found in the posterior pole of the eye (see Chapter 1.2.1.4). For the 
description of the fundus localization of the metastasis in the choroid in the 84 patients in 
this study, we have based ourselves on the largest tumour in the eye first affected. In 60 
patients (71%) the choroidal metastasis was localized temporally of the disk and in 21 
patients, nasally (25%) [three patients (4%) unknown] (Colour plates 1-3). This is in 
accordance with the findings of other investigators (see Chapter 1.6.2). 
If the fundus is divided into an superior and an inferior part, the localization of the 
lesions was superior 44 times (52%) and inferior 37 times (44%) [three patients (4%) 
unknown]. The slightly higher percentage of metastases in the upper half of the fundus 
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can be attributed to the importance of the lower half of the visual field Abnormalities in 
the lower part of the visual field are noticed earlier by the patient than those in the upper 
part of the visual field, which corresponds with the lower half of the fundus. 
If these data are combined, and the fundus divided into eight identical wedge-
shaped areas with the optic disk as the centre, an arrangement is obtained as shown in 
Figure 2.3.2 1 a). Most lesions had a temporal (23%), a temporosupenor (21%) or a 
temporoinfenor (21%) localization 
Also, the localization of the choroidal metastasis m relation to the large retinal 
vessels was recorded For this purpose, a subdivision was made into lesions situated for 
over 75% of their size within the arcade of the large vessels, for more than 75% outside it 
and lesions predominantly localized at the site of these vessels. Then, the metastasis was 
situated within the arcade in 19 patients (23%), outside it in 15 patients (18%) and at the 
site of the vessels in 44 patients (52%) [six patients (7%) unknown] (Figure 2 3 2 1b) 
If we combine Figure 2 3 2 1a with the eight sectors of the choroid with Figure 
2 3 2 1 b in which the position of the metastases in relation to the large vessels is shown, 
Figure 2 3 2 1 с is obtained From this figure, the localization of the ocular tumour can 
be read out accurately 
The localizations of most lesions were either temporosupenor at the site of the 
vascular arcade (19%) or temporal within the arcade (roughly at the site of the macula 
17%) or temporoinfenor along the vascular arcade (14%). If in patients with choroidal 
metastases all 142 metastases in both eyes were considered, the localizations were in 20% 
temporosupenor at the site of the vascular arcade, 13% temporal within the vascular 
arcade and 13% temporoinfenor along the vascular arcade These findings are in 
agreement with the data that are obtained if only the largest lesion in one eye was 
considered 
In 21 patients with choroidal metastases (25%), the macular area was involved in 
the process. 
In 69 of the 84 choroidal metastases the shortest distance between the margin of 
the tumour and the fovea was known As mentioned before in Chapter 2 3 1, this distance 
affects the frequency of the patients' complaints This distance was 1 4 DD on average 
(SD 1.6; range 0 0-6 0) The distance from the tumour margin to the papilla was known 
in 68 patients and also amounted to an average of 1 4 DD (SD 1 3, range 0 0-4 0) 
Bilateral metastases threaten the sight in both eyes and therefore constitute an even 
worse impairment of the quality of life. Such bilateral metastases were established in 25 
patients (29%) In 18 patients, metastases were observed in both eyes even at the first 
examination of the patient In seven patients, metastases in the contralateral, initially 
unaffected eye were only detected at a later time. This occurred after a mean interval of 
12 months, with a range from 2 weeks to 4 years (median 3 months) All these metastases 
were localized in the choroid. Bilateral metastases with one of the lesions situated in the 
ins or the ciliary body were not encountered in our study group The proportion of 
bilateral metastases of 29% corresponds to data in the literature (see Table 1 6.9). 
Of the bilateral metastases in 25 patients, 21 were observed in patients with breast 
cancer, two with lung cancer, one with cancer of the pancreas and one, in a patient 
probably suffenng from cancer of the colon Accordingly, the vast majonty of the patients 
with bilateral metastatic lesions have breast cancer as the pnmary tumour. 
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A unknown : 4% 
В unknown : 7% 
С unknown 7% 
Figure 2.3.2.1 Localization choroidal metastasis in terms of percentage. 
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Correspondingly, bilateral metastases are established m 40% of the patients with breast 
cancer as against 10% of the patients with lung cancer and 13% of those with another 
malignancy. 
In the 62 patients with a unilateral metastasis, the right eye was affected 36 times 
(58%) and the left, 26 times (42%). In the whole group of patients, i.e. both those with 
unilateral and those with bilateral metastases, the right eye was affected 61 times (54%) 
and the left eye, 51 times (46%). In our study group, therefore, there was no question of 
a preference of metastases for the left eye as described in the older literature on uveal 
metastases (Lagrange, 1901; Sattler, 1926). 
Among the 87 patients with uveal metastases there were 76 (87%) in whom a 
solitary metastasis was encountered in the first-affected eye at initial ophthalmological 
examination In 10 patients (11%) multiple metastases were found (one patient unknown) 
(Colour plate 4; Figure 2.3.2.2 a) Five times, two lesions were observed in one eye, four 
times three lesions and in one patient, seven metastases in one eye. Multiple metastases 
may fuse to one large tumour through lateral growth of the lesions (Figure 2.3.2 2 b) In 
patients with multiple metastases, all tumours were localized in the choroid, apart from 
one patient with a metastasis in the choroid as well as in the ins. 
During the entire follow-up penod of the patients with uveal metastases, multiple 
metastases in one or both eyes or bilateral metastases were observed 29 times (33%) In 
all, there were 146 metastatic uveal lesions in 112 eyes in 87 patients. 
Of the bilateral and/or multiple metastases, 83% arose from breast cancer, 10% 
from lung cancer and 7%, from another malignancy. Of all patients with breast cancer 
almost half, namely 24 of the 52 patients (46%), had bilateral and/or multiple metastases 
as against three of the 20 patients with lung cancer (15%) and two of the 15 patients with 
one of the other malignancies (13%). 
Just as no explanation could be found of the fact that breast cancer accounted for 
such a large percentage of the primary tumours, it is not clear, either, why precisely 
breast cancer so frequently gives rise to multiple uveal metastases (see Chapter 1 3 2) 
In 63 patients with a choroidal localization the largest diameter of the metastasis 
was known. It vaned from 2 0 to 13 0 DD with a mean of 6 6 DD (SD 4.1) The smallest 
diameter was known in 64 patients; it amounted to 5.9 DD on average (SD 4.5; range 
0 5-13.0). One disk diameter (DD) equals 1.5 mm (Duke-Elder, 1946, Naumann et al , 
1966). Consequently, choroidal metastases have a broad base of 9 mm on average. 
The shape of the metastasis is often not mentioned in Ophthalmoscopical 
descriptions of these tumours Most frequently the shape appeared to be flat or dome-
shaped and less often lobulated or even mushroom-shaped (Figure 2.3 2 3) Since more 
data on this aspect are provided by echography, the shape of the tumour will be discussed 
in more detail under this heading (see Chapter 2.3.4). 
The colour of the metastasis was known in 60 of the 84 patients with a choroidal 
tumour; it was mostly yellowish-orange or cream and, less frequently, grey (Table 
2.3.2.1). Occasionally, a white, reddish-brown or greenish-blue tumour was described. If 
several metastases in one eye or bilateral metastases were established, these were of the 
same colour in all cases (Colour plates 4-6) 
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Figure 2.3.2.2 a. Fundus photograph of the left eye showing 
two separate choroidal metastases from breast cancer. 
b. Fundus photograph of the right eye of a different patient 
showing three choroidal metastases from breast cancer fusing. 
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Figure 2.3.2.3 a. Fundus photograph of the right eye showing 
a slightly elevated choroidal metastasis from breast cancer. 
b. Fundus photograph of the right eye showing a prominent 
lobulated choroidal metastasis from a seminoma (with elements 
of teratoma) of the testis. 
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Table 2.3.2.1 Colours of choroidal metastases according to the nature of the 
primary tumour 
Colour 
Yellowish-orange or cream 
Grey 
White 
Reddish-brown 
Greenish-blue 
Unknown 
All tumours 
N 
42 
11 
4 
2 
1 
24 
% 
50 
13 
5 
2 
1 
29 
Breast 
N 
26 
5 
2 
1 
1 
17 
cancer 
% 
50 
10 
4 
2 
2 
33 
Lung 
N 
8 
6 
1 
1 
-
4 
cancer 
% 
40 
30 
5 
5 
-
20 
Other 
N % 
8 67 
-
1 8 
-
-
3 25 
The colour of the metastasis was related to the nature of the primary tumour. A 
yellowish-orange choroidal metastasis was seen in 50% of the patients with a uveal 
metastasis of breast cancer and in 40% of patients with a metastasis of lung cancer. In 
lung cancer, grey metastases are encountered more frequently than in breast cancer, viz. 
in 30% and 10%, respectively. 
Of the 42 yellowish-orange uveal metastases 26 originated from breast cancer 
(62%) and 8 from lung cancer (19%). Five of the 12 grey lesions (42%) proved to be 
metastases of breast cancer, 6 of lung cancer (50%). In a yellowish-orange tumour, 
therefore, the probability of a metastasis of breast cancer is greatest, while a grey lesion 
may have arisen from lung cancer or from breast cancer with about equal degrees of 
probability. 
In 41 patients with a choroidal metastasis (49%), the pigment was distributed 
irregularly over the tumour surface, in 12 patients (14%) evenly [31 patients (37%) 
unknown]. The irregular distribution of the pigment causes the mottled tumour aspect so 
characteristic of metastases (Colour plate 7) (Reese, 1976; Shields, 1983). No relationship 
was found between this pigment distribution and the colour of the metastasis. 
In contrast to the findings of Shields et al. (1976), that the orange pigment on the 
tumour surface is observed in virtually all patients with choroidal metastases, such 
pigment was observed in only one patient with a grey-coloured choroidal metastasis from 
lung cancer of our study group. 
Regarding the presence of exudates on or round the tumour most of the case 
histories contained no information. These data could only be retrieved of patients of whom 
fundus photographs had been made. 
Reliable data concerning exudates on the tumour were available concerning 44 of 
the 84 patients with choroidal metastases. Such exudates were absent in 26 patients (59%) 
and present in 18 (41%), in six of whom they were described as 'numerous'. 
With regard to exudates round the tumour, data were known concerning 43 
patients: they were absent 38 (88%) times and present five times (12%), in one instance 
described as 'numerous'. 
Data on exudates were lacking regarding too many patients to allow conclusions to 
be drawn from the above data. 
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As known from the literature, a retinal detachment is a frequent complication in 
patients with a choroidal metastasis (Figure 2.3.2.4) (Ferry, 1967; Gass, 1972; Shields, 
1983). In 38 of the 84 patients with choroidal metastases in our patient group, 
ophthalmoscopical signs of a retinal detachment were present (45%): 20 times these were 
described as occupying less than one-quarter of the fundus and 18 times, as more than 
one-quarter. Total retinal detachment was never observed. No retinal detachment was 
present in 40 patients (48%) [six patients (7%) unknown]. 
The frequency of occurrence of a retinal detachment increased with increasing 
prominence of the tumour. The echographically measured prominence was known in 31 of 
the 38 patients with a retinal detachment; it amounted to 4.8 mm on average. In 32 of the 
40 patients without a retinal detachment this was 2.4 mm on average. 
Development of a retinal detachment was also related to the localization of the 
tumour: a retinal detachment was seen in only four of the 19 patients with a tumour 
localization within the arcade of the large retinal vessels (21%) as against 22 of the 44 
patients with a metastasis along the arcade (50%) and nine of the 15 patients in whom the 
tumour was situated outside the vascular arcade (60%). 
No relationship was found between occurrence of retinal detachments and the 
nature of the primary tumour. 
Figure 2.3.2.4 Fundus photograph of the left eye showing a 
nasally located choroidal metastasis with a secondary retinal 
detachment inferiorly in a patient with breast cancer. 
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In 13 patients with uveal metastases (15%) blood was observed on or round the 
tumour or in the vitreous (Figure 2.3.2.5). 
In 10 patients with a choroidal metastasis, haemorrhages were localized on the 
tumour surface (12%) while in 53 patients (63%) no such haemorrhages were observed 
[21 patients (25%) unknown]. 
Blood round the tumour was seen in only four patients (5%) while this was not the 
case in 60 other patients (71%) [20 patients (24%) unknown]. 
In the vitreous a haemorrhage was observed in three patients (4%) which was once 
very dense and twice, slight. In 68 patients the vitreous was clear of blood (81%), 13 
times this was not stated (15%). 
Freedman and Folk (1987) at initial ophthalmological examination of 58 patients 
with an intraocular metastasis, observed a retinal bleeding in one patient and a vitreous 
haemorrhage in two. In our group of patients with uveal metastases, haemorrhages were 
encountered much more frequently than is reported in the literature, while in many cases 
such data were lacking. 
Haemorrhages were observed in six of the 52 patients with breast cancer (12%) 
and in two of the 15 patients with lung cancer (15%). On the other hand, haemorrhages 
occurred in five of the 15 patients with some other malignancy (33%), namely in one 
patient with a thyroid carcinoma, one patient with a clear-cell carcinoma of the kidney 
(Grawitz tumour) and three patients with a tumour of unknown origin. 
Figure 2.3.2.5 Fundus photograph of the left eye showing a 
nasally located choroidal metastasis from a pancreatic 
carcinoma surrounding the optic disk. Haemorrhages into the 
retinal nerve fibre layer around the disk (white arrow) and in 
the periphery (black arrow). 
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A metastasis in the anterior segment was observed four times. 
In the patient with an iridai metastasis originating from lung cancer, after clearing 
of the abundant fibrin in the anterior chamber after a subconjunctival injection of 
dexamethasone, a white tumour was observed temporosuperiorly in the iris. Its appearance 
strongly suggested a metastasis. Opthalmoscopically, no abnormalities were observed. 
In one of the two patients with a ciliary metastasis, a swelling existed temporally in 
the fundus with vascular injection in the angle of the anterior chamber and the ciliary 
body. On the limbal side the tumour had broken through the iris and caused a hyaline 
white iridic mass there (Colour plate 2). On and round the tumour a few minor 
haemorrhages were observed, the vitreous was clear of blood. No retinal detachment was 
present. The preliminary diagnosis of a 'tumour' was made. Ten days later, lung cancer 
was diagnosed. 
In the other patient with a ciliary metastasis, lung cancer had been diagnosed as 
long as 1.5 years before the ophtha!mological diagnosis. Unfortunately, concerning the 
ophthalmoscopical image of this tumour, no data are known other than fast growth and 
break through the iris. 
In the last patient with a metastasis in the anterior segment, an adenocarcinoma of 
the lung had been diagnosed one month previously. Inferiorly on the pupillary margin, a 
grey iris process was visible (Colour plate 1). At ophthalmoscopy, nasally superior a 
second choroidal lesion was observed in the periphery without haemorrhages or retinal 
detachment. Both tumours were described only as 'prominences'. 
All these metastases in the anterior segment proved to have originated from lung 
cancer. Both Barbee et al. (1971) (in iris metastases) and Ferry and Font (1975) (in 
metastases in the anterior segment) described lung cancer as the primary tumour in 50% 
of the patients. Although the number of patients with a metastasis in our study group was 
only small, the fact that the primary tumour was lung cancer in all cases was noticeable. 
No explanation of this phenomenon can be given. 
After irradiation of a bilateral choroidal metastasis, in a fifth patient with breast 
cancer a metastasis in the ciliary body developed at a later date, with invasion of the angle 
of the anterior chamber and of the iris. 
In 62% of the patients with a metastasis in the uvea the correct ophthalmoscopical 
diagnosis was made after only history-taking and standard outpatient examinations such as 
optometry, tonometry, slit lamp examination and ophthalmoscopy. In 29%, no diagnosis 
was made and the lesion was described solely as 'tumour' or as 'suspicious lesion' (Table 
2.3.2.2). In addition, the diagnosis of malignant melanoma was made four times, a 
haemangioma once, a naevus once, a retinal detachment once and age-related macular 
degeneration (Kuhnt Junius), once. In this connection it should be noted that initial 
examination of a patient with an intraocular lesion suspicious of tumour, this lesion as a 
rule is not classified further before other examinations such as echography and fluorescein 
angiography have been performed. 
Metastases of breast cancer were mostly diagnosed correctly. Metastases of lung 
cancer that were regularly mistaken for melanomas, and metastases of one of the other 
malignancies were frequently not further classified. A number of causes of this fact may 
be mentioned: 
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In 98 % of the patients with a uveal metastasis of breast cancer, the primary tumour 
was already known at the time of diagnosis of the intraocular tumour, as compared 
with 45% of patients with a metastasis of lung cancer and 40% of patients with 
metastases of some other malignancy. In patients with breast cancer, therefore, the 
possibility of an intraocular metastasis will be considered sooner 
Multiple and bilateral metastases were observed most frequently in patients with 
breast cancer. For this reason, also, in breast cancer patients a metastasis will be 
considered sooner when an intraocular tumour occurs. 
Metastases of lung cancer ophthalmoscopically show similarities to melanomas 
This, combined with the fact that the primary malignancy is frequently only 
diagnosed after the intraocular tumour, and with the predominantly solitary and 
unilateral presence, explains why in patients with an intraocular metastasis of lung 
cancer this diagnosis initially will less readily be made 
Table 2 3.2.2 Diagnosis after standard outpatient examinations in 87patients with 
uveal metastases according to the nature of the primary tumour * 
Diagnosis 
Metastasis 
Melanoma 
Haemangioma 
Naevus 
Retinal detachment 
Kuhnt Junius 
'Tumour' 
All 
N 
54 
4 
1 
1 
1 
1 
25 
tumours 
% 
62 
5 
1 
1 
1 
1 
29 
Breast 
N 
44 
-
-
1 
1 
1 
5 
cancer 
% 
85 
-
-
2 
2 
2 
10 
Lung 
N 
5 
4 
-
-
-
-
11 
cancer 
% 
25 
20 
-
-
-
-
55 
Other 
N % 
5 33 
-
1 7 
-
-
-
9 60 
* After only hitiory taking a>\d uamiard outpatient examinations such as optometry, tonometry, slit lamp 
examination and ophthalmoscopy 
Summary of ophthalmoscopy in uveal metastases: nearly all uveal metastases were 
localized in the choroid. In only two of the 87 patients was the metastasis situated in the 
ciliary body, and in one patient in the ins. One patient presented with a metastasis in the 
choroid as well as one in the ins. In all these four patients with a metastasis in the 
antenor segment the pnmary tumour was lung cancer. 
Most metastases were situated in the temporal half of the fundus, especially along 
or within the vascular arcade Fifty per cent of the metastases were located 
temporosupenorly or infenorly along the vascular arcade or temporally within the arcade 
of the major vessels. Both the distance between the margin of the tumour and the fovea 
and that between the margin of the tumour and the disk on average amounted to 1.4 DD 
In 33% of the patients up to the moment of treatment, multiple (10 patients) and/or 
bilateral metastases (25 patients) were observed. 
The largest diameter of the tumour was 6.6 DD on average. The colour of the 
tumour in general was yellowish-orange. However, in metastases of lung cancer grey 
tumours were frequently observed. The tumour surface mostly showed a mottled 
appearance and the orange lipofuscin pigment occasionally descnbed in the literature was 
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observed only once. Exudates on the tumour surface were encountered regularly, round 
the tumour they were rare. 
In almost one-half of the metastases ophthalmoscopy revealed a retinal detachment, 
dependent on the localization and prominence of the tumour. In 15% of the tumours, 
blood on or round the tumour or in the vitreous humour was observed. 
In the patient with a metastasis of the iris, a white tumour was observed. The 
colour of the tumours in the patient with a metastasis in the choroid as well as in the iris 
was grey. A metastasis in the ciliary body, which had broken through the iris, caused a 
grey iridai mass with some haemorrhages on the tumour surface. 
In Table 2.3.2.3 the principal ophthalmoscopical features of patients with uveal 
metastases are summarized and compared with melanomas, haemangiomas and naevi of 
the uvea. Subsequently, a short description of these various tumours is given. 
Table 2.3.2.3 Ophthalmoscopical features in patients with metastases, malignant 
melanomas, haemangiomas and naevi 
Intraocular tumour 
Metastasis Melanoma Haemangioma Naevus 
Number of patients 87 422 27 60 
Localization: 
Choroid 
Ciliary body 
Iris 
Right eye 
l.eft eye 
Bilateral 
Multiple M 
Localization: # 
Temporal 
Nasal 
Unknown 
Localization: # 
Supenor 
Inferior 
Unknown 
97% * 
2 
2 * 
54% 
46 
29 
33 
71% 
25 
4 
52% 
44 
4 
90% 
7 
4 
50% 
50 
0 ** 
0 ** 
57% 
37 
5 
46% 
49 
5 
96% 
4 
-
30% 
70 
-
-
76% 
20 
4 
57% 
39 
4 
95% 
-
5 
60% 
40 
7 
7 
78% 
20 
2 
39% 
59 
2 
to be continued on next page 
202 
Table 2.3.2.3 (continued) 
Intraocular tumour 
Localization: # 
Inside vascular arcade 
Along vascular arcade 
Outside vascular arcade 
Unknown 
Mean tumour distance from: # 
Macula (DD) 
Optic disk (DD) 
Metastasis 
23% 
52 
18 
7 
1.4 
1.4 
Melanoma 
16% 
43 
25 
17 
1.4 
1.5 
Haemangioma 
41% 
44 
7 
7 
1.4 
1.4 
Naevus 
23% 
42 
30 
5 
2.3 
3.0 
Macular involvement 0 25 % 
Mean tumour diameter #oo (DD) 6.6 
14% 
9.5 
35% 
5.7 
5% 
2.0 
Colour: # 
Yellowish-orange/cream 
Grey 
White 
Reddish-brown 
Greenish-blue 
Black 
Salmon-pink 
Unknown 
50% 
13 
5 
2 
1 
29 
12% 
28 
7 
4 
5 
2 
42 
19% 
15 
4 
11 
26 
26 
7% 
49 
5 
2 
37 
Mottled aspect 0 49% 
Orange lipofuscin pigment on 1 
tumour surface # 
41% 
13 
50% 
8 
429 
4 
Exudates: H 
On tumour surface 
Surrounding the tumour 
21% 
6 
18% 
3 
4% 20% 
15 
Retinal detachment 45% 45% 33% 
Blood: 
On tumour surface 
Surrounding the tumour 
In vitreous 
12% 
5 
4 
13% 
6 
6 
DD: disk diameter; * one patient metastasis in the choroid as well as in the iris; ** one patient; it in 
choroidal tumours; Hit bilateral and/or multiple in one eye; oo mean of the largest diameter 
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Melanomas compared with metastases were situated more frequently in the anterior 
segment and often nasally in the fundus and outside the arcade of the major retinal 
vessels. Less frequently the melanoma was encountered at the site of the macular area. A 
bilateral melanoma was established in only one patient, and a multiple melanoma in one 
eye in one other patient. 
The maximal diameter of the lesion was significantly larger than in metastases. The 
most frequently observed colour of a melanoma was grey with, almost as often as in 
metastases, a mottled appearance of the tumour surface. The orange lipofuscin pigment 
was described in 13% of the patients with a melanoma (Colour plate 8; Figure 2.3.2.6). 
With regard to the incidence of exudates, retinal detachment and haemonhages, no 
distinct differences existed between metastases and melanomas. 
The preliminary diagnosis after history taking and standard examination was 
melanoma in 44% of the cases and 'tumour' in 47%. In five patients the melanoma was 
diagnosed as a metastasis, although no other malignancy elsewhere in the body was 
known. The ophtha!moscopical picture of a choroidal metastasis of lung cancer may show 
many points of similarity with that of a choroidal melanoma. 
Haemangiomas of the iris did not occur in our study group. Once, a haemangioma 
of the ciliary body was observed, the other haemangiomas were situated in the choroid. 
Even more frequently than metastases, haemangiomas were localized in the temporal half 
of the fundus and frequently within the arcade of the major retinal vessels. Of all 
haemangiomas, 35% were localized in the macular area (Colour plate 9). 
The colour was salmon-pink in 26% of the cases. In other tumours than 
haemangiomas this colour was never observed. In 19% of the haemangiomas the colour 
was yellowish-orange. The orange lipofuscin pigment was seen only sporadically in 
haemangiomas. In contrast to melanomas or metastases, exudates on or round the tumour 
were encountered only rarely. Retinal detachment occurred in 33%, presence of blood was 
never observed. 
The ophthalmoscopical diagnosis was haemangioma in 41%, 'tumour' in 48% of 
the cases. One single time the diagnosis was metastasis. 
Most naevi that were suspected of being tumours were localized in the choroid, an 
occasional one in the iris. Of the naevi, 78% were localized temporally. The lesions lay 
scattered over the entire ocular fundus and were not limited to the area within the vascular 
arcade. Only 5 % were localized in the macular area. Bilateral naevi were established four 
times. Naevi were substantially smaller than the other intraocular tumours, with a mean 
maximal diameter of only 2.0 DD. 
The colour was mostly grey. Naevi, also, frequently displayed a mottled tumour 
aspect, and orange pigment was described twice. In naevi, exudates on and round the 
tumour were observed regularly. Retinal detachments were never observed. Intraocular 
haemorrhages were extremely rare in naevi (Colour plate 10; Figure 2.3.2.7). 
The diagnosis after history taking and standard examination was naevus in 57% 
and 'tumour' in 40%. One time, the diagnosis of metastasis was made. 
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In 61% of the 15 patients with retinoblastomas the tumour was located in the right 
eye, in 39% in the left eye. In 32% of the patients, bilateral lesions were observed and 
multiple lesions in one eye in two patients. All retinoblastomas were white in colour and 
filled the entire ocular cavity in most cases. In 92% of the cases a diagnosis of 
retinoblastoma was made ophthalmoscopically (Figure 2.3.2.8). 
Miscellaneous intraocular lesions. In the patients with a lymphoma or leukaemia 
the choroid was involved. In four of the five patients, both eyes were affected and 
multiple lesions were established in all patients. All lesions were situated within the arcade 
of the major vessels, both temporally and nasally. The colour varied from white to 
yellowish-orange and grey. Blood on or round the tumour was observed in most cases, 
and in one patient a vitreous haemorrhage was present. In no case was a retinal 
detachment observed. In over one-half of the cases the outpatient diagnosis was consistent 
with a malignant haematological lesion. 
Subretinal haemorrhages were present bilaterally in two of the nine patients, but 
never multiple in one eye. In one patient, a macular degeneration in the contralateral eye 
was known. All lesions were localized temporally, and only rarely outside the vascular 
arcade. Three of the nine subretinal haemorrhages were situated at the site of the macular 
area. The colour was mostly grey, but one black and one white tumour were observed. 
Retinal detachment was present in two patients. In only one patient was the 
ophtha!moscopical diagnosis of haemorrhage made. In six patients the lesion was classified 
as a 'tumour'. 
Among the seven patients with age-related macular degeneration one patient with a 
distinct bilateral tumour was reported. The colour of the macular tumour varied: 
yellowish-orange, grey or reddish brown. In two patients a retinal detachment was 
observed, in six patients a vitreous haemorrhage. The diagnosis was twice Kuhnt Junius 
and four times, 'tumour' (once no diagnosis possible because of vitreal haemorrhage) 
(Figure 2.3.2.9). 
In the five patients with a choroidal detachment, the detachment was situated 
nasally slightly more frequently than temporally and never within the vascular arcade. The 
colour was yellowish-orange, grey or reddish brown. Lipofuscin pigment on the surface 
was observai in one patient. In no case were haemorrhages established. In all cases this 
diagnosis had been made ophthalmoscopically as well. 
All three leiomyomas were localized in the ciliary body. The colour of the tumour 
was grey or white. Haemorrhage or retinal detachment were never present. Once, the 
leiomyoma was mistaken for a melanoma and twice it was classified as a 'tumour'. 
In all three patients with a retinal detachment which was suspected of being a 
tumour, a vitreous haemorrhage was present, owing to which in one case the fundus could 
not be evaluated adequately. In the other two patients the initial diagnosis was melanoma. 
In two of the 88 tumours of unknown nature, the ophthalmoscopical diagnosis of 
metastasis was made without subsequent confirmation. One case concerned a patient who 
had been known for 8 years with a renal carcinoma and in whom a unilateral yellowish-
orange tumour in the choroid was observed without retinal detachment or haemorrhage. In 
the other patient, with a grey choroidal tumour, no malignancy elsewhere in the body was 
known. 
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Figure 2.3.2.6 a. Fundus photograph of the lefi eye showing a 
prominent pigmented choroidal mass: malignant melanoma of 
the choroid, b. Fundus photograph of the right eye of a 
different patient showing a mushroom-shaped amelanotic 
malignant melanoma of the choroid just inferiorly and 
obstructing the view of the optic disk. 
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Figure 2.3.2. 7 Fundus photograph of a grey-coloured slightly 
elevated choroidal lesion located temporally of the macula in 
the right eye: naevus of the choroid. 
Figure 2.3.2.8 External photograph of the right eye showing a 
retinoblastoma. 
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Figure 2.3.2.9 Fundus photograph of the right eye showing a 
prominent subretinal tumour in the macular area: age-related 
macular degeneration (Kuhnt Junius). 
Conclusion: ophthalmoscopy makes an essential contribution to the differential 
diagnostics of intraocular tumours, although no ophthalmoscopic picture pathognomonic of 
uveal metastases exists. Great importance attaches to the bilateral and/or multiple presence 
of the lesions, as frequently observed in metastases in contrast to the findings in 
melanomas and haemangiomas of the uvea. In retinoblastoma, bilateral lesions are 
observed in a high percentage, also. Multiple lesions are also encountered in naevi, 
retinoblastomas, lymphoproliferative diseases, subretinal haemorrhages and macular 
degenerations. 
Melanomas of the uvea mostly have a grey colour, unlike the yellowish-orange 
lesions in metastases. The orange lipofuscin pigment that may be present in melanomas is 
only rarely observed in metastases. 
Haemangiomas may be typically salmon-pink in colour. In many respects the 
ophthalmoscopical picture may resemble that of metastases. However, intraocular 
haemorrhages in haemangiomas were not described in our study group. 
Naevi are relatively small lesions, nearly always with a grey colour and without 
secondary retinal detachment or haemorrhages. Consequently, differentiation from 
metastases in most cases is quite well possible. 
Retinoblastomas are white, highly prominent lesions and have ophthalmoscopically 
distinct features from other intraocular tumours. 
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2.3.3 Fluorescein angiography 
In our study group, fluorescein angiographic data were available of 49 of the 84 patients 
with choroidal metastases. 
In 35 patients (71%) sufficient details could be observed for adequate evaluation of 
the fluorescein angiogram. Figure 2.3.3.1 shows an example of fluorescein angiography in 
a patient with multiple choroidal metastases from breast cancer. In 14 patients (29%), only 
poor evaluation was possible, either due to opaque media (nine patients) or in connection 
with technical problems such as a peripheral localization of the tumour (five patients). 
Thus, of many patients no or only limited fluorescein angiographic data were 
available. Partly this was due to the large number of patients who were examined in the 
outpatient department only once or were referred specifically for one particular 
examination, e.g. echography. Consequently, the data given below concern only patients 
of whom at the time of the retrospective study photographs or an extensive report of the 
fluorescein angiographic examination were available. 
Fluorescein angiography was performed in one patient with a ciliary metastasis and 
break through the iris. This patient will be described separately. 
As regards the moment of staining, in the 49 patients with choroidal metastases 
staining of the choroid occurred after an average of 13 seconds and filling of the retinal 
arteries after 12 seconds (Table 2.3.3.1). The retinal veins filled with fluorescence 15 
seconds on average after the injection of the dye, 3 seconds later than the arteries. A first 
fluorescence of the tumour was observed after 21 seconds. 
Table 2.3.3.1 Moment of staining of various intraocular structures after injection 
of fluorescein in patients with choroidal metastases 
Choroid 
Retinal artenes 
Retinal veins 
Tumour 
N 
35 
33 
35 
35 
Mean 
13 
12 
15 
21 
Moment of staining (sec) 
SD 
6 
5 
6 
29 
Range 
3-29 
3-25 
4-32 
4-142 
In the patients of whom both the moment of staining of the tumour and of the surrounding 
choroid were known, the tumour on average stained 5 seconds after the choroid. In case 
of known moment of staining of the tumour and of filling of the retinal arteries, the 
tumour stained 2 seconds after the retinal arteries and, in case of known moment of 
staining of the tumour and of filling of the veins, 3 seconds after the retinal veins. This 
interval was not connected with the colour of the metastases but clearly related to the 
nature of the primary tumour. In relation to the retinal arteries, the metastases of the 
different primary tumours stained simultaneously. However, metastases of breast cancer or 
of one of the other malignancies started to fluoresce in a period from 0 to 1 second before 
the retinal veins, while in metastases of lung cancer fluorescence on average only took 
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gure 2.3.3.1 a. Fundus photograph of three choroidal metastases from breast cancer in the . 
e (arrows) b-f. Fluorescein angiography of the same lesions: b. Arterial phase with diffi 
pofluorescence at the site of the metastatic lesions. 
Figure 2.3.3.1 (continued) с. Early venous phase: the lesions remain relatively hypofluoreso 
i. Venous phase: hypofluorescence of the lesions with grossly mottled hyperfluorescence. 
igure 2.3.3.1 (continued) e. and f. Late venous and late phases with hypeifluorescence of 
etastases showing some hyperfluorescent spots on the tumour margin (arrows). 
place 22 seconds after the veins. In relation to the surrounding choroid, metastases of 
breast cancer on average stained 2 seconds later, metastases of one of the other tumours 1 
second later and metastases of lung cancer as long as 25 seconds later. Between the 
various primary tumours there existed no distinct differences with regard to the interval of 
staining between veins and arteries on the one hand and the surrounding choroid and 
arteries on the other. 
It appears, therefore, that metastases of lung cancer at fluorescein angiography 
stain relatively late compared with metastases of other malignancies. 
Of more importance than the timing is the pattern of staining. For instance, a 
tumour may show some fluorescence even in an early phase, but subsequently lag behind 
in relation to the staining of the surrounding choroid so that the tumour is classified as 
relatively hypofluorescent. 
Staining of the tumour occurred usually simultaneously with, and less frequently 
after staining of the surrounding choroid. In relation to the retinal arteries, staining was 
observed as often simultaneously with as after these vessels, in relation to the retinal veins 
as often before as simultaneous and less often, later (Table 2.3.3.2). 
Table 2.3.3.2 Moment of staining of choroidal metastases in relation to the 
moment of staining of the surrounding choroid, the retinal arteries 
and the retinal veins 
Choroid 
Retinal artenes 
Retinal veins 
N 
1 
1 
13 
Before 
% 
2 
2 
27 
Staining choroidal 
Simultaneous 
N 
21 
16 
12 
% 
43 
33 
24 
metastasis 
N 
12 
15 
8 
After 
% 
24 
31 
16 
Unknown 
N % 
15 31 
17 35 
16 33 
In our study, the fluorescence of the tumour was classified in three categories: 
1. predominantly hypofluorescent; 
2. predominantly hyperfluorescent; 
3. fluorescence of the same intensity as that of the surrounding choroid. 
The moments at which the pattern was determined were (Table 2.3.3.3): 
a. early arterial phase: the moment of the first filling of the retinal arteries with 
fluorescein; 
b. arterial phase: the moment halfway between the staining of the arteries and that of 
the veins; 
с early venous phase: the moment of initial staining of the retinal veins; 
d. late venous phase: the late phases after the fluorescein had passed from the retinal 
veins. 
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Table 2.3.3.3 Fluorescein angiographic patterns in various phases in relation to 
the surrounding choroid in patients with choroidal metastases 
Hypofluorescence 
Iso fluorescence 
Hyperfluorescence 
Unknown 
Early arterial 
phase 
N 
31 
7 
2 
9 
% 
63 
14 
4 
18 
Artenal 
phase 
N 
25 
13 
2 
9 
% 
51 
27 
4 
18 
Venous 
phase 
N 
9 
31 
5 
4 
% 
18 
63 
10 
8 
Late venous 
phase 
N % 
1 2 
39 80 
8 16 
1 2 
In the two arterial phases, metastases were predominantly hypofluorescent. Early 
hyperfluorescence was rare. At the moment of staining of the retinal veins, however, a 
change in the staining of the choroidal metastases had occurred, from predominantly hypo-
to isofluorescent. Only 18% of the metastases still showed hypofluorescence in the early 
venous phase while 63% showed a fluorescence of the same intensity as the surrounding 
choroid. In the late venous phase, a hypofluorescent tumour was observed in only one 
patient (Figure 2.3.3.2). 
Figure 2.3.3.2 a. Fluorescein angiogram of a choroidal 
metastasis in the right eye in a patient with presumed colonic 
carcinoma. Early venous phase with hypofluorescence of the 
tumour (arrows). 
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Figure 2.3.3.2 (continued) b. Fluorescein angiogram of a 
choroidal metastasis temperoinferior in the right eye in a 
patient with breast cancer. Venous phase with a fluorescence of 
the tumour (arrows) of almost the same intensity as the 
surrounding choroid, с Fluorescein angiogram of a choroidal 
lesion in the right eye in a patient with pancreatic carcinoma 
superior to and surrounding the optic disk, compatible with 
choroidal metastasis (arrows). Late venous phase with 
hyperfluorescence of the tumour. 
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The nature of the primary tumour had no appreciable influence on this 
fluorescence. The only noticeable element was that metastases of tumours other than 
breast or lung cancer in the late venous phase were never isofluorescent but half were 
hypo- and half hyperfluorescent. However, a highly varied patient population was 
concerned here. 
The large proportion of hypofluorescent tumours in patients with uveal metastases 
is in agreement with the findings of Norton et al. (1964) and Gass (1972). In general, 
staining of the tumour started only in the venous phases, as also described by Offret and 
Haye (1971), Orsoni (1968) and Bonnin (1986). 
This division into hypo-, iso- and hyperfluorescence is fairly rough, however. 
Therefore, hypofluorescence of the metastases was specified further as a diffuse 
hypofluorescence of the tumour, without staining of clearly distinguishable fluorescent 
areas, a predominant hypofluorescence of the tumour with areas of finely mottled 
hyperfluorescence and a hypofluorescent lesion with grossly mottled hyperfluorescence. If 
the intensity of the staining of the larger part of the tumour was the same as that of the 
surrounding choroid, a subdivision was made into diffuse isofluorescent tumours and 
isofluorescence with either finely mottled or grossly mottled hypo- or hyperfluorescence. 
The hyperfluorescent metastases, finally, were subdivided into diffuse hyperfluorescent 
tumours, hyperfluorescence with finely mottled hypofluorescence and hyperfluorescence 
with grossly mottled hypofluorescence (Table 2.3.3.4). 
In the majority of the patients, the hypofluorescence of the tumour in the early 
arterial phase was diffuse without clearly staining areas (see Table 2.3.3.2). In the arterial 
phase, however, in most patients with a hypofluorescent tumour a grossly mottled 
hyperfluorescence was also observed. The fluorescence of the tumour, which in the early 
and late venous phases showed the same intensity as the surrounding choroid, in the vast 
majority of the patients was accompanied by either a finely mottled or a grossly mottled 
hyperfluorescence (Figure 2.3.3.3). 
To summarize the principal fluorescence patterns in choroidal metastases in the 
various phases, in the early arterial phase 43% of the tumours showed diffuse 
hypofluorescence, in the arterial phase 29% a hypofluorescence with grossly mottled 
hyperfluorescence. In the early venous phase, 33% of the metastases showed the same 
fluorescence as the environment with a grossly mottled hyperfluorescence and 22% with a 
finely mottled hyperfluorescence. In the late venous phase, 47% showed isofluorescence 
with grossly mottled hyperfluorescence and 33%, isofluorescence with a finely mottled 
hyperfluorescence. 
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Table 2.3.3.4 
Hypofluorescenee: 
diffuse 
+ finely mottled 
hyperfluorescence 
+ grossly mottled 
hyperfluorescence 
Isofluorescence: 
diffuse 
+ finely mottled 
hypofluorescenee 
+ grossly mottled 
hypofluorescenee 
+ finely mottled 
hyperfluorescence 
+ grossly mottled 
hyperfluorescence 
Hyperfluorescence: 
diffuse 
+ finely mottled 
hypofluorescenee 
+ grossly mottled 
hypofluorescenee 
Unknown 
Fluorescein angiographu 
the surrounding choroid 
Early arterial 
phase 
N 
21 
4 
6 
4 
-
-
2 
1 
2 
-
-
9 
% 
43 
8 
12 
8 
-
-
4 
2 
4 
-
-
18 
: patterns in various 
in patients 
Arterial 
phase 
N 
7 
4 
14 
3 
-
2 
5 
3 
-
-
2 
9 
% 
14 
8 
29 
6 
-
4 
10 
6 
-
-
4 
18 
phases in relation to 
with choroidal metastases 
Venous 
phase 
N 
-
4 
5 
3 
-
1 
11 
16 
1 
2 
2 
. . _ 
% 
-
8 
10 
6 
-
2 
22 
33 
2 
4 
4 
~8 
Late venous 
phase 
N % 
-
1 2 
. 
-
-
-
16 33 
23 47 
4 8 
2 4 
2 4 
j ¿ 
As regards the course of the fluorescein angiography, it was only in 39 of the 49 patients 
that data of all phases of the fluorescein angiography were available. The vast majority of 
these patients (67%) showed increasing fluorescence from the early arterial to the late 
venous phase (Figure 2.3.3.4). In 15% of the patients, the fluorescence of the tumour 
remained constant throughout all phases, and in 10% the staining initially increased and 
subsequently decreased again. In two patients, the fluorescence first decreased and 
subsequently increased again, and in one patient the fluorescence decreased from the first 
phase of the examination (Table 2.3.3.5). 
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Figure 2.3.3.3 a. Fundus photograph of the right eye in a 
patient with breast cancer showing three fused choroidal 
metastases with pigment clumping on the tumour surface. 
b-d. Fluorescein angiogram of the same lesions: b. Arterial 
phase with diffuse hypofluorescence of the lesions and with 
tumour vessels (arrow). 
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Figure 2.3.3.3 (continued) с. Early venous phase. 
Hypoßuorescence of the tumours with grossly mottled 
hyperfluorescence. d. Late venous phase with staining of the 
lesions and hypofluorescent spots at the site of the pigment 
clumps on the tumour surface. 
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Figure 2.3.3.4 a. Fundus photograph of the right eye with a 
yellowish-orange choroidal tumour in a presumably healthy 
patient, b-d. Fluorescein angiogram of the same lesion: 
b. Arterial phase with hypofluorescence of the lesion. 
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Figure 2.3.3.4 (continued) с. Early venous phase with 
hypofluorescence of the lesion and grossly mottled 
hyperfluorescence on the tumour surface, d. In the late venous 
phase the tumour fluoresces with almost the same intensity as 
the surrounding choroid. Note the hypofluorescent margin 
(white arrow) and some hyperfluorescent spots at the tumour 
margin (black arrow). Choroidal metastasis from lung cancer. 
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Table 2.3.3.5 Course of the fluorescein angiographic pattern in 39 patients with 
choroidal metastases 
Fluorescein angiographic pattern 
Early arterial 
phase 
hypo 
hypo 
hypo 
hypo 
hypo 
hypo 
hypo 
hypo 
hypo 
hypo 
ISO 
ISO 
hyper 
hyper 
Arterial 
phase 
hypo 
hypo 
hypo 
hypo 
hypo 
ISO 
ISO 
iso 
hyper 
hyper 
hypo 
ISO 
iso 
iso 
Venous 
phase 
hypo 
iso 
iso 
hyper 
hyper 
hypo 
iso 
hyper 
iso 
hyper 
iso 
iso 
iso 
iso 
Late venous 
phase 
iso 
iso 
hyper 
iso 
hyper 
iso 
iso 
hyper 
iso 
hyper 
iso 
iso 
iso 
hyper 
N 
6 
12 
2 
1 
2 
2 
2 
1 
1 
1 
1 
6 
1 
1 
hypo: hypofluorescence; iso: isofluorescence; hyper: hyperfluorescence 
Figure 2.3.3.5 Fluorescein angiogram showing a choroidal 
metastasis from lung cancer in the right eye with hypo- ami 
hype/fluorescent areas. 
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The most frequently observed course in fluorescein angiography of choroidal 
metastases was a pattern of hypofluorescence in the two arterial phases and a fluorescence 
similar to that of the environment in the two venous phases (31%). In 15% of the 
tumours, hypofluorescence was observed up to and including the early venous phase, with 
isofluorescence in the late venous phase. In 15% of the patients the fluorescence remained 
constant in all phases, with the same intensity as that of the surrounding choroid. Other 
patterns of fluorescence were seen only exceptionally. No different patterns for different 
primary tumours could be distinguished. Even when the course of the fluorescence was 
specified further into the patterns as listed in Table 2.3.3.4, no specific pattern for 
choroidal metastases could be discerned and many different patterns were described. There 
was no question, therefore, of a characteristic fluorescein angiographic image in choroidal 
metastases (see also literature: Chapter 1.4.3). 
In 14 patients (29%), clearly distinguishable large hypofluorescent areas in the 
metastases were described. Hyperfluorescent areas were observed in three patients (6%) 
(Figure 2.3.3.5). No relationship existed between the occurrence of these hypo- or 
hyperfluorescent areas and the nature of the primary tumour. 
In 30 patients, the pigment distribution on the tumour surface could be compared 
with the fluorescence pattern of the metastasis. Eighteen times, areas of ophtha!moscopical 
hyperpigmentation corresponded to hypofluorescence and once, in a patient with lung 
cancer, to hyperfluorcscence. In 11 patients, this pigmentation showed no clear correlation 
with hypo- or hyperfluorescent areas in the tumour. Intraocular blood stays 
hypofluorescent (Figure 2.3.3.6). 
The maxima] diameter of the tumour in the fluorescein angiogram was 8.1 disk 
diameters (DD) on average (SD 4.3; range 1.5-14.0), the minimal diameter was 7.1 DD 
(SD 5.2; range 1.0-13.0). 
Of 38 patients, both fundus photographs and fluorescein angiograms were available 
so that the tumour sizes measured could be compared. This revealed that the maximal 
diameter of the metastasis at fluorescein angiography on average was 1.4 times (SD 0.8) 
that measured at ophthalmoscopy. Five times, a smaller tumour was measured at 
fluorescein angiography, 18 times a tumour of exactly the same size and 15 times, a 
larger tumour. This indicates that at fluorescein angiography, metastases apparently in 
39% of the cases extend farther into the choroid than could be observed 
ophtha! moscopically. 
In 36 patients (73%), a hypofluorescent margin round the tumour was seen, which 
margin was absent in 10 patients (20%) [three patients (6%) unknown]. No distinct 
relationship with the nature of the primary tumour existed. 
223 
Figure 2.3.3.6 Stereo fluorescein angiogram showing 
intraretinal haemorrhages on different levels of the retina in the 
left eye of a patient with pancreatic carcinoma. (Same patient 
as in Figure 2.3.2.5). 
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In five patients (10%), fluorescein angiography revealed tumour vessels (double 
circulation): three times in a patient with breast cancer, once in a patient with lung cancer 
and once in a patient with a thyroid carcinoma (Figure 2.3.3.7 and Figure 2.3.3.8). The 
presence of such vessels was doubtful in seven other patients (14%): three patients with 
breast cancer, one patient with a testicular tumour, one with a probable carcinoma of the 
colon and two with unknown primary tumours. In 37 patients (76%), no tumour vessels 
could be demonstrated. 
Therefore, just as in the studies of Gass (1974) and Wessing (1977), in our study 
tumour vessels were observed in patients with metastases, in contrast to the findings of 
Davis and Robertson (1971), Hayreh (1974) and Danis (1979). 
Figure 2.3.3. 7 Fluorescein angiogram of a choroidal lesion in 
the lefi eye in a presumably healthy patient. Early arterial 
phase with double circulation: retinal arteries (thick white 
arrows); retinal veins (thin white arrows); tumour vessels (black 
arrow). Histopathology of the enucleated eye: metastasis of an 
adenocarcinoma of unknown localization. 
In 31 patients with choroidal metastases (63%) hype/fluorescent spots were 
distinguishable, namely 21 times at the margin of the tumour and 10 times scattered over 
the entire tumour surface (Figure 2.3.3.9). In 18 patients (37%) such spots were absent. 
The moment of staining of these spots was 61 seconds on average after the staining 
of the retinal arteries (SD 72; median 23; range 2-225). This is in accordance with the 
findings of Famarier et al., (1973) and Shields (1983). 
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Figure 2.3.3.8 Stereo fluorescein angiogram in the venous 
phase showing a prominent choroidal metastasis from lung 
cancer. Note the retinal and choroidal vesseb. These choroidal 
vessels should not be confused with tumour vessels. 
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Figure 2.3.3.9 Fluorescein angiography of the right eye 
showing a choroidal metastasis from breast cancer. Late venous 
phase with multiple hyperfluorescent spots on the tumour 
surface. 
Fluorescein angiographic signs of a retinal detachment were present in 24 patients (49%) 
and absent in 21 (43%), while in four patients (8%) this was unknown. A retinal 
detachment was observed ophthalmoscopically in 45% and echographically in 52% of the 
patients. 
The fluorescein angiographic diagnosis 31 times was metastasis (63%), 5 times 
melanoma (10%) and 13 times, 'tumour' (27%). This diagnosis was connected with the 
nature of the primary tumour. For instance, 84% of the metastases of breast cancer were 
designated at fluorescein angiography as metastasis, as against only 38% of the metastases 
of lung cancer and 20% of the metastases of one of the other malignancies. On the other 
hand, metastases of lung cancer or of another malignancy were classified as melanoma in 
25 and in 30% of the cases, respectively, as against in only one patient with a metastasis 
of breast cancer. Finally, 13% of the metastases of breast cancer were classified as 
'tumour', as were 38% of the metastases of lung cancer and 60% of the metastases of one 
of the other malignancies. 
At fluorescein angiography just as at ophthalmoscopy, metastases of breast cancer 
were classified correctly more often than metastases of lung cancer or of one of the other 
malignant tumours, while the fluorescein patterns of these tumours were not clearly 
different from one another. The examiner's awareness of the presence of a primary 
tumour and of multiple and bilateral lesions, as is often the case in patients with uveal 
metastases of breast cancer, will doubtless have played a part in this connection. 
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'igure 2.3.3.10 a. External photograph of the iridai part of a ciliary tumour in the righ 
ye which has broken through the temporal part of the iris (arrows) (see also Colou 
late 2). b-d. Fluorescein angiography of the iris: b. Tortuous iridai vessels at th 
tmour margin in the early phase. 
'igure 2.3.3.10 (continued) c-d. Relative hypofluorescence of the tumour in all phases. 
'ote pigment coating on the lens. Metastasis from lung cancer in the ciliary body with 
xtension through the iris. 
In one patient with a ciliary metastasis with break through the iris, fluorescein 
angiography was performed. Photographs were made only of the iridic portion of the 
tumour. At the margin of this lesion, from the early phase dilated tortuous iris vessels 
were visible which were connected with vessels in the superficial layers of the tumour. 
The tumour itself stained slightly, with a relative hypofluorescence in the late phases 
Figure 2.3.3.10). 
Summary of fluorescein angiography in uveal metastasis: choroidal metastases on 
average stained 21 seconds after the injection of the dye, which is 5 seconds after the 
staining of the choroid and 2 seconds after the retinal arteries. Fluorescence of the tumour 
was observed before staining of the retinal arteries in one case, at the same time in 16 and 
later, in 15 cases (17 unknown). Metastases of lung cancer showed a relatively late 
staining. 
In the arterial phase, most metastases were hypofluorescent which 
hypofluorescence in the early arterial phase was mostly uniform, but subsequently in part 
grossly mottled. Starting from the venous phases, in an increasing proportion a 
fluorescence was observed of the same intensity as the surrounding choroid, with an 
overlying finely or grossly mottled hyperfluorescence. Hyperfluorescent tumours were 
observed only rarely. The most frequent pattern was a hypofluorescent tumour in the early 
arterial phases with isofluorescence from the early venous phase, which was described in 
31% of the patients. In addition, in 15% of the patients a hypofluorescence was observed 
until in the early venous phase, following which isofluorescence developed, while 15% of 
the patients had isofluorescence in all phases. The nature of the primary tumour proved 
not to influence the fluorescein angiographic pattern in choroidal metastases. A fluorescein 
angiographic pattern clearly recognizable as a metastasis proved not to be demonstrable. 
In 29% of the patients circumscribed large hypofluorescent areas were observed. 
Hyperfluorescent areas were present in 6% of the patients. 
A hypofluorescent margin round the tumour was described in 73% of the 
metastases. In 63%, hyperfluorescent spots on the tumour surface were observed, mostly 
only at the margin of the lesion. Distinct vessels in the tumour were described in 10%, 
doubtfully present vessels in 14%. 
The ratio of the tumour bases measured at fluorescein angiography and at 
ophthalmoscopy amounted to 1.4. Metastases therefore extend farther into the choroid 
than can be observed ophthalmoscopically. 
The fluorescein angiographic diagnosis in 49 patients with choroidal metastases 
was metastasis in 63%, melanoma in 10% and 'tumour' in 27%. This was dependent on 
the nature of the primary tumour: metastases of breast cancer in general were classified 
correctly, while metastases of lung cancer and of other malignancies as a rule were 
designated as melanoma or as 'tumour'. This was not based, however, on separate 
fluorescein angiographic patterns. 
In a patient with a ciliary metastasis with break through the iris, tortuous iris 
vessels were observed at the tumour margin. The tumour itself remained relatively 
hypofluorescent. 
Table 2.3.3.6 presents a survey of the principal fluorescein angiographic features 
for the differential diagnosis of choroidal metastases. 
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Table 2.3.3.6 Fluorescein angiographic features inpatients with metastases, 
malignant melanomas, haemangiomas and naevi of the choroid 
Number of patients 
Moment of staining tumour: 
mean (SD): sec. 
Interval between staining retinal 
arteries and tumour: sec. 
Metastasis 
49 
21 (29) 
2 
Intraocular tumour 
Melanoma 
291 
17 (38) 
1 
Haemangioma 
13 
12(5) 
-1 
Naevus 
35 
16 (10) 
2 
Staining tumour: 
Before retinal arteries 2% 
At the same time as retinal arteries 33 
After retinal arteries 31 
Unknown 35 
6% 
26 
11 
57 
23% 
31 
8 
38 
-% 
57 
31 
11 
Tumour fluorescence: 
Early arterial phase: 
Hypofluorescence 
Iso fluorescence 
Hyperfluorescence 
Unknown 
Arterial phase: 
Hypofluorescence 
Isofluorescence 
Hyperfluorescence 
Unknown 
Early venous phase: 
Hypofluorescence 
Iso fluorescence 
Hyperfluorescence 
Unknown 
Late venous phase: 
Hypofluorescence 
Iso fluorescence 
Hyperfluorescence 
Unknown 
Hypofluorescent margin 
63% 
14 
4 
18 
51% 
27 
4 
18 
18% 
63 
10 
2 
2% 
80 
16 
2 
73% 
42% 
14 
1 
43 
39% 
18 
1 
42 
22% 
36 
4 
38 
11% 
45 
6 
37 
54% 
15% 
62 
-
23 
23% 
54 
-
23 
-% 
-
100 
-
-% 
-
100 
-
62% 
71% 
26 
-
3 
66% 
34 
-
-
46% 
54 
-
-
49% 
51 
-
-
40% 
to be continued on the next page 
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Table 2.3.3.6 (continued) 
Hyperfluorescent spots: 
At tumour margin 
On whole tumour surface 
None 
Unknown 
Tumour vessels: 
Positive 
Doubtful 
Negative 
Unknown 
Retinal detachment 
Ratio tumour base fluorescein 
angiography and ophthalmoscopy 
Metastasis 
43% 
20 
37 
-
10% 
14 
76 
-
49% 
1.4 
Intraocular tumour 
Melanoma 
30% 
11 
21 
38 
32% 
9 
20 
39 
33% 
0.9 
Haemangioma 
15% 
-
85 
-
15% 
15 
46 
-
15% 
1.0 
Naevus 
6% 
23 
71 
-
-% 
-
97 
-
-% 
0.9 
Of one-third of the patients with a melanoma of the choroid, no fluorescein angiograms 
were available and in the other cases their descriptions were often incomplete. Therefore, 
the fluorescein angiographic differential diagnosis of melanoma from metastases of the 
choroid can only be discussed in general terms. 
Choroidal melanomas stained somewhat earlier than metastases. It was rare for 
staining to occur only after filling of the retinal arteries. 
In melanomas, just as in metastases, in both arterial phases the fluorescence of the 
lesion mostly lagged behind that of the surrounding choroid. In the venous phases, 
hypofluorescence of the tumour was described more frequently. The fluorescein 
angiographic pattern of choroidal melanomas did not differ greatly from that of 
metastases. However, a diffuse hypofluorescence of the tumour was described in 15% of 
the melanoma cases and never in metastases. 
A hypofluorescent margin round the tumour and hyperfluorescent spots on the 
tumour surface could be observed with relatively equal frequency in melanomas and in 
metastases. Tumour vessels, however, were observed far more frequently in melanomas 
than in metastases (Figure 2.3.3.11 and Figure 2.3.3.12). 
The ratio of the tumour bases measured at fluorescein angiography and at 
ophthalmoscopy was smaller in melanomas than in metastases. Apparently, therefore, 
angiographically melanomas in general do not extend farther than can be observed 
ophthalmoscopically. This in contrast to choroidal metastases. 
No convincing fluorescein angiographic distinction between metastases and 
melanomas could be made in our study group. 
The fluorescein angiographic diagnosis in patients with a choroidal melanoma was 
in general correct: the diagnosis of melanoma was made in 82%, in 13% 'tumour'. In 
only three patients was the melanoma erroneously diagnosed as a metastasis. 
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Figure 2.3.3.11 Stereo fluorescein angiogram in the venous 
phase of a mushroom-shaped malignant melanoma of the 
choroid in the left eye with very distina tumour vessels. 
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Figure 2.3.3.12 a. Fundus photograph of a choroidal 
amelanotic malignant melanoma in the lefi eye. 
b-d. Fluorescein angiogram of the same lesion: b. Arterial 
phase showing double circulation and progressive staining of 
the tumour. 
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Figure 2.3.3.12 (continued) c-d. Early venous and venous 
phases with mottled hyperfluorescence of the tumour, areas of 
hypofluorescence and some hyperfluorescent spots at the tumour 
margin. 
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Figure 2.3.3.13 a. Fundus photograph of a choroidal 
haemangioma in the lefi eye. b-d. Fluorescein angiogram 
showing the same lesion: b. Early arterial phase with 
characteristic sponge-like configuration of tumour vessels. 
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Figure 2.3.3.13 (continued) с. Early venous phase with 
progressive staining of the lesion. d. Venous phase with 
hyperfluorescence of the tumour and a hypofluorescent margin 
surrounded by a ring of hyperfluorescence caused by secondary 
changes in the pigment epithelium. 
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Figure 2.3.3.14 a. Fundus photograph of a choroidal naevus 
in the right eye with multiple drusen on the tumour surface. 
b-d. Fluorescein angiography of the same lesion: b. Arterial 
phase with blocking of the background fluorescence. 
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Figure 2.3.3.14 (continued) c-d. Venous phases with staining 
of the drusen. The lesion itself stays hypofluorescent. 
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».. 
Figure 2.3.3.15 a. Fundus photograph of the lefi eye with 
preretinal (white arrows) and subretinal (black arrows) 
haemorrhages, b. Fluorescein angiogram of the same lesion in 
the early venous phase: complete block of the choroidal 
fluorescence by the subretinal and of the retinal vessels by the 
preretinal haemorrhage. 
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Haemangiomas of the choroid stained substantially earlier than metastases or 
melanomas, frequently even before the retinal arteries filled with fluorescein. 
Accordingly, from the early arterial phase, haemangiomas showed a fluorescence of an 
intensity comparable to that of the surrounding choroid with hyperfluorescence in late 
phases. Virtually always this staining was mottled, independently of the stage of the 
fluorescein angiography. Arterially, its pattern was grossly mottled or finely mottled with 
equal frequency. In later stages, a grossly mottled staining was observed practically 
exclusively. In nine patients (33%) a characteristic fluorescein angiographic pattern was 
observed as a sponge-like configuration (Figure 2.3.3.13). 
In 70% of the haemangiomas, the fluorescence of the tumour remained stable 
during all phases, in contrast to metastases and melanomas of the choroid. Tumours with 
a hypofluorescent rim were seen in a similar proportion of the cases. Hyperfluorescent 
spots on the tumour surface, however, occurred only sporadically in haemangiomas. Just 
as in melanomas, tumour vessels were described relatively often. 
The ratio of the tumour bases measured at fluorescein angiography and at 
ophthalmoscopy was the same as that in melanoma and therefore lower than in metastases. 
In 57% of the cases the fluorescein angiographic diagnosis was haemangioma, in 
29% it was 'tumour'. In one patient, a haemangioma was mistaken for a metastasis. 
Naevi of the choroid stained at the same moment as metastases and melanomas. In 
the arterial phases, the lesion in general was hypofluorescent compared with the 
environment. From the early venous phase, isofluorescence was also regularly observed. 
Hyperfluorescence was never described. The most frequent observation was hypo-
fluorescence of the lesion in all phases of the fluorescein angiogram (Figure 2.3.3.14). 
The pattern of fluorescence in the early arterial stage was usually diffusely hypo-
fluorescent, and subsequently hypofluorescent with finely mottled hyperfluorescence. In 
the venous phases, either hypo- or isofluorescence of the tumour was mostly seen, both 
combined with a finely mottled hyperfluorescence. 
A hypofluorescent margin and hyperfluorescent spots were described regularly, 
although less frequently than in metastases and melanomas. Hyperfluorescent spots, if 
present, were rarely limited to the margin of the lesion. 
The diagnosis at fluorescein angiography was naevus in 75% of the cases and 
'tumour' in 25%. The diagnosis metastasis was never made. 
In no patient with a retinoblastoma was fluorescein angiography performed. In 
these children ophtha!mological examination was limited as much as possible. 
Of miscellaneous lesions no or only a few fluorescein angiograms were available. 
It was only of five patients with a subretinal haemorrhage that data were present. Any 
staining of the lesion occurred an average of 3 seconds after the retinal arteries. In 
general, diffuse hypofluorescence of the lesion was observed, which in later phases might 
display some hyperfluorescent spots. One patient had an isofluorescent lesion with grossly 
mottled hyperfluorescence from the earliest phases, in another patient in later stages a 
fluorescence was observed that had the same intensity as the surrounding choroid. No 
hyperfluorescent lesions were described (Figure 2.3.3.15). 
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Three of the five haemorrhages showed a hypo fluorescent margin Hyper-
fluorescent spots or indications of vessels in the lesion were never observed In the 
fluorescein angiograms, the haemorrhages were of the same size as observed 
ophthalmoscopically 
The diagnoses were twice subretinal haemorrhage, three times 'tumour' 
Conclusion: at fluorescein angiography, no characteristic pattern of metastases is 
demonstrable nor are any other specific features visible 
The pattern of staining and the presence of a hypofluorescent margin and of 
hyperfluorescent spots in melanomas is similar to that in metastases Although tumour 
vessels are observed more frequently in melanomas than in metastases, they are not 
specific For the differentiation of metastases from melanomas, fluorescein angiography is 
of only limited value 
Haemangiomas compared with metastases show a more typical picture In general 
they cause earlier and more pronounced fluorescence with in one-third of the cases a 
typical sponge-like configuration with less frequent hyperfluorescent spots and more 
frequent tumour vessels than metastases 
Naevi and subretinal haemorrhages can be reasonably well distinguished from 
metastases by means of fluorescein angiography 
Therefore, fluorescein angiography makes a certain contribution to the differential 
diagnosis of metastases from haemangiomas, naevi and subretinal haemorrhages For the 
differentiation from melanomas, on the other hand, this technique is less suitable 
2.3.4 Echography 
For ophthalmological echography (ultrasonography, USG), use is made of the 
unidimensional A-scan and the bidimensional B-scan, the results of which have to be 
combined for adequate interpretation of the total echo image The various echographical 
entena are described in detail in Chapter 1 4 4 
During the study penod three instruments were used As Α-scan the Kretz scan 
Technik 7200 MA was used, as B-scans the Bronson Turner B-scan of Grumman Health 
Systems and the Ophthascan S of Biophysic Médical 
Figure 2 3 4 1 shows an A- and B-mode echogram of a normal eye 
Echographic examinations were earned out in 72 of the 87 patients with uveal 
metastases of this retrospective study In two patients no adequate echography proved to 
be possible because of the penpheral localization of the tumour The results mentioned 
below concern 69 patients with choroidal and ciliary metastases (further termed uveal 
metastases) and one patient with a metastasis in the ins who will be discussed separately. 
If echography had been performed several times, the reference concerns the first 
examination (Figure 2.3.4 2) 
According to Coleman (1973) and Guthoff (1988), charactenstic of the echographic 
image of uveal metastases is a flat lesion with a relatively broad base In our study, the 
mean prominence of the metastasis was 3 6 mm, ranging from a choroidal infiltration 
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(prominence 0 mm) to a pronounced prominence of 15.0 mm [in a metastasis of a clear 
cell carcinoma of the kidney (Grawitz tumour)] (Table 2.3.4.1). 
The mean tumour base was known of only 53 patients; in 14 patients the base 
could not be measured since no B-scan was available (early phase of the study), in two 
patients the infiltration of the choroid was so diffuse that the tumour base could not be 
distinguished from the surrounding choroid. In the remaining 53 patients, the mean base 
of the metastasis amounted to 11.7 mm, ranging from 5.0 to 23.0 mm. 
In patients of whom both the prominence of the lesion and the tumour base were 
known, the ratio between prominence and base was determined. In metastases this was 
0.32 on average and it ranged from 0.06 to 1.40. This ratio provides some information on 
the shape of the tumour. 
Figure 2.3.4.1 A- and B-mode contact echogram 
of a normal eye. a. A-mode: white arrows: 
anterior and posterior surface of the lens; white 
arrowhead: retina/sclera; О: orbital fat; 
V: vitreous, b. B-mode: white arrow: lens; n: optic 
nerve; o: orbital fat; v: vitreous 
In Table 2.3.4.1 the prominence, base and ratio are subdivided according to the nature of 
the primary tumour. It shows that the mean prominence and ratio of metastases of breast 
cancer were substantially smaller than those of metastases of other malignancies. The 
mean base of the lesion was similar in the different malignancies, however. 
Uveal metastases are described as having a predominantly flat shape. In addition, 
dome-shaped, lobulated and even a few mushroom-shaped tumours are described 
(Coleman et al., 1974; Shields and Tasman, 1977; Kerman and Fishman, 1987; Guthoff, 
1988). 
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Figure 2.3.4.2 Immersion B-mode echogram (with the aid of a perspex 
cylinder filled with methylcellulose 2%) of three different uveal 
metastases: a. Choroidal metastasis (white arrow: cornea; white 
arrowhead: lens; black arrows: choroidal metastasis; n: optic nerve). 
b. Ciliary metastasis which has broken through the iris (L: lens; 
T: tumour; V: vitreous), e. Iridai metastasis (L: lens; t: tumour). 
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Table 2.3.4.1 Prominence, base and prominence.-base ratio according to the 
localizaton of the primary tumour in patients with choroidal and 
ciliary metastases 
— ~ ^ ^ — • ^ ~ — —
m
 — 
N Mean SD Median Minimum Maximum 
Prominence: (mm) 
Breast 
Lung 
Other 
All 
Base: (mm) 
Breast 
Lung 
Other 
All 
Prominence:base ratio: 
Breast 
Lung 
Other 
All 
36 
18 
15 
69 
26 
15 
12 
53 
26 
15 
12 
53 
2.6 
4.7 
4.5 
3.6 
11.7 
12.1 
11.3 
11.7 
0.23 
0.39 
0.41 
0.32 
1.8 
2.9 
3.6 
2.7 
4.7 
4.9 
3.5 
5.0 
0.24 
0.31 
0.30 
0.28 
2.3 
4.0 
4.0 
3.0 
10.5 
11.0 
12.0 
11.0 
0.20 
0.31 
0.37 
0.25 
0.0 
1.0 
1.0 
0.0 
6.0 
5.0 
5.0 
5.0 
0.06 
0.13 
0.11 
0.06 
8.0 
13.0 
15.0 
15.0 
23.0 
23.0 
17.0 
23.0 
1.36 
1.40 
1.15 
1.40 
In contrast to the predominantly flat shape of uveal metastases in the literature, in our 
patient population as many flat as dome-shaped tumours were observed: 41% and 39% of 
the patients, respectively (Table 2.3.4.2). In six patients (9%), the metastasis was 
lobulated. In two patients (3%), the metastasis was mushroom-shaped: once in a choroidal 
metastasis of a clear cell carcinoma of the kidney (Grawitz tumour) and once, in a ciliary 
metastasis of lung cancer. Such a mushroom shape is brought about by the tumour 
breaking through Bruch's membrane, a part of the tumour tissue being constricted by this 
membrane. It is generally assumed that such a shape is almost exclusively restricted to a 
malignant melanoma which grows predominantly in height, unlike the lateral growth of 
metastases. The present study shows, however, that a mushroom shape may also occur in 
metastases (Figure 2.3.4.3). 
In one other patient with a metastasis of lung cancer, there were indications of a 
break through Bruch's membrane. In this patient this had led not to a mushroom-shaped 
tumour but to a lobulated shape. 
In six patients (9%), the shape of the tumour could not be determined because no 
B-scan was available. 
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re 2.3.4.3 Contact B-mode echogram of choroidal metastases showing various shapes: a. I 
stasis (black arrows) from breast cancer with limited retinal detachment (white arrow) (O: orbital _ 
itreous). b. Dome-shaped metastasis (arrows) from lung cancer (O: orbital fat; V: vitreous). 
jbulated metastasis (arrows) from breast cancer with a secondary retinal detachment (white arrows) 
orbital fat), d. Mushroom-shaped metastasis (arrows) from a clear cell carcinoma of the kid 
witz tumour) (O: orbital fat; v: vacuole in the tumour). 
le 2.3.4.2 Shape of the intraocular metastasis according to the localization oj 
the primary tumour in 69 patients with choroidal and ciliary 
metastases 
The shape of the metastases was related to the nature of the primary tumour. 
Metastases of breast cancer were predominantly flat and less often dome-shaped. 
Metastases of lung cancer, on the other hand, were mostly dome-shaped and metastases of 
the other malignancies also more frequently showed a dome shape than a flat shape. 
Flat lesions of course were hardly prominent and had a lower prominence:base 
ratio. In dome-shaped and lobulated lesions, higher prominences and ratios were obtained. 
In the two mushroom-shaped metastases, the base on average was even smaller than the 
prominence, so that the ratio was 1.15 and 1.40, respectively (Table 2.3.4.3). 
Table 2.3 4 3 Shape of the tumour in 63 patients with choroidal and ciliary 
metastases * 
Shape N Mean prominence (mm) Prominence base ratio 
Flat shape 
Dome shaped 
Lobulated shape 
Mushroom-shaped 
** 23 
** 23 
6 
2 
1 6 
4 7 
4 4 
11 0 
0 18 
0 38 
0 45 
1 28 
Unknown shape ** 6 4 3 
* shape unhww η in six of the 69 patients with choroidal and ciliary metastases, 
** base unknown in five flat, four dome-shaped and all six tumours vnth unknown shape 
Statements concerning the reflectivity of the infrastructure of the intraocular tumour can 
only be made when the prominence amounts to at least 2 0 mm (Coleman et al , 1974; 
Ossoinig and Biodi, 1974) Several investigators described a highly irregular echographic 
reflectivity in metastases (Coleman, 1973; Verbeek, 1985; Poujol and Chaintron, 1988). 
In our study, 51 of the 69 echographically examined uveal metastases had a 
prominence of at least 2.0 mm. The reflectivities of these lesions, subdivided according to 
the nature of the vanous primary tumours, are listed in Table 2.3.4.4. 
Table 2 3.4.4 Reflectivity of choroidal and ciliary metastases with a prominence of 
> 2.0 mm according to the localization of the primary tumour in 
terms of percentage 
Reflectivity 
Low 
Medium 
High 
All 
(N = 51) 
29 
53 
18 
Localization 
Breast 
(N = 21) 
19 
62 
19 
primary tumour 
Lung 
(N=17) 
47 
41 
12 
Other 
(N = 13) 
23 
54 
23 
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Figure 2.3.4.4 a. A-mode echogram afa retinal detachment (white 
arrows) (white arrowhead: sclera; O: orbital fat; V: vitreous). 
b. A-mode echogram of a 5.5 mm prominent low-reflective choroidal 
metastasis from lung cancer (white arrow: retina; white arrowhead: 
sclera; O: orbital fat; t: low reflectivity of the tumour infrastructure; 
V: vitreous), c. A-mode echogram of a 3.5 mm prominent high-
reflective choroidal metastasis from breast cancer (white arrow: 
retina; white arrowhead: sclera; O: orbital fat; t: high reflectivity of 
the tumour infrastructure; V: vitreous). 
In uveal metastases, different reflectivities can be observed. They were mostly 
mid-reflective (53%) and less frequently low- (29%) or high-reflective (18%). Metastases, 
therefore, do not have a high reflectivity in the majority of the cases, as postulated in the 
literature. The reflectivity was not correlated with the prominence (Figure 2.3.4.4). 
In a large proportion of the patients with lung cancer, namely 47%, uveal 
metastases were found to be low-reflective. This is in agreement with observations of 
other investigators (Ossoinig and Harrie, 1983; Verbeek, 1985). Metastases of breast 
cancer showed a low reflectivity in only 29% of the cases. 
While the primary tumour in uveal metastases with low reflectivity was most often 
lung cancer, mid- and high-reflective tumours predominantly originated from breast cancer 
(Table 2.3.4.5). 
Table 2.3.4.5 Nature of the primary tumour in choroidal and ciliary metastases 
according to reflectivity in terms of percentage 
Reflectivity 
Localization primary tumour 
Breast 
Lung 
Other 
Low 
27 
53 
20 
Medium 
48 
26 
26 
High 
44 
22 
33 
The tumour infrastructure may show a homogeneous echographic picture, with few 
variations in reflectivity, or cause a non-homogeneous irregular pattern. This is sometimes 
called the regularity of a tumour. Uveal metastases are described as showing an irregular 
echo pattern (Verbeek, 1985; Poujol, 1986; Bigar, 1988). 
Evaluation of the regularity of a tumour requires several echo spikes and 
consequently a longer tissue tract, of 4.0 mm minimally. This was the case in 27 of the 69 
patients examined echographically in our study group: eight patients with breast cancer, 
10 with lung cancer and nine, with other malignancies (Figure 2.3.4.5). The reflectivity of 
the tumour was homogeneous in 10 patients (37%) and irregular in 16 (59%) while this 
element was unknown in one patient (4%). These findings are in accordance with the 
literature. Metastases of breast cancer in which the echographic homogeneity of the 
tumour was known showed an irregular infrastructure in seven of the eight tumours while 
only four of the 10 metastases of lung cancer and five of the nine metastases of one of the 
other primary malignancies were found to have an irregular reflectivity. In contrast to 
breast cancer metastases, lung cancer metastases, therefore, do not show the irregular 
picture characteristic of metastases as described by various authors. The picture of a 
highly irregular reflectivity, described as characteristic of metastases by various 
investigators (Coleman, 1973; Verbeek, 1985; Poujol and Chaintron, 1988) was described 
in only one patient with a metastasis of lung cancer. 
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Figure 2.3.4.5 A- and B-mode echogram of a choroidal 
metastasis from a seminoma (with elements of teratoma) 
(white arrow: retina; white arrowhead: sclera; open white 
arrow: irregular mid-reflective tumour infrastructure; 
curved black arrows: choroidal metastasis; O: orbital fat; 
T: tumour; V: vitreous). 
Low-reflective and regular tumours, more compatible with a malignant melanoma, were 
described four times: twice in patients with lung cancer, once in breast cancer and once, 
in a patient with a metastasis probably originating from a colonic carcinoma. 
Most frequently (41%), a mid-reflective irregular tumour was observed: six times 
in patients with breast cancer, twice in lung cancer, once in a testicular carcinoma and 
twice, in patients with metastases of unknown origin. 
In the literature interruption of the echographic continuity of the choroid, a 
choroidal excavation, is rarely if ever described (Coleman et al., 1974; Gonvers et al., 
1979; Kerlen, 1980; Neetens et al., 1984). Only Poujol (1986) described such an 
excavation in 42% of the metastases. 
Distinct presence of a choroidal excavation was established in 11 of the 
echographically examined patients (16%) of our study, while in four patients (6%) this 
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presence was doubtful (Figure 2.3.4.6). In 45 patients (65%), no choroidal excavation was 
described [nine patients (13%) unknown for lack of a B-scan]. There was a distinct 
correlation with the reflectivity of the tumour: in low-reflective tumours a choroidal 
excavation was seen in 50% of the cases as against 21% of the mid-reflective and none of 
the high-reflective metastases. Therefore, it seems that for a choroidal excavation to be 
brought about, part of the choroid has to be occupied by predominantly low reflective 
tissue. 
Consequently, the presence of a choroidal excavation was also correlated with the 
nature of the primary tumour. In metastases of lung cancer, a choroidal excavation was 
observed in 22%, in patients with one of the other malignancies in 20%. In only 11% of 
the breast cancer patients was the metastasis accompanied by a choroidal excavation. 
The presence of a choroidal excavation proved also to be correlated with the 
prominence of the tumour. The mean prominence in tumours with a choroidal excavation 
was 5.5 mm (SD 3.5). If an excavation was doubtfully present, mean prominence was 3.9 
mm (SD 2.1) and in absence of an excavation, it was 2.8 mm (SD 2.0) [unknown: 4.8 
mm (SD 3.9)]. Therefore, a metastasis with a choroidal excavation had a larger mean 
prominence than tumours without an excavation. 
Figure 2.3.4.6 B-mode echogram of a 4.0 mm prominent 
dome-shaped choroidal metastasis from breast cancer with a 
choroidal excavation (curved arrow) (O: orbital fat; 
T: tumour). 
An echographic vascularity of the tumour, characterized by moving echo spikes in the 
tumour infrastructure, is described only sporadically in the literature, just as a choroidal 
excavation. Determination of the presence of vascularity requires a minimal prominence of 
4.0 mm (Ossoinig and Biodi, 1974; Neetens et al., 1984; Freedman and Folk, 1987). 
In our study group, in 5 of the 27 tumours with a minimal prominence of 4.0 mm 
(19%), a distinct vascularity was observed: three times in lung cancer patients, once in a 
patient with a bladder carcinoma and once, in a patient with a probable colonic carcinoma. 
In three patients (11%) the presence of vascularity was doubtful: once in a metastasis of 
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breast cancer, once of lung cancer and once, of a carcinoma of the prostate. Vascularity, 
therefore, was established most frequently in metastases of lung cancer. In 12 patients 
(44%), vascularity was not demonstrable echographically, in seven patients (26%) this 
element was unknown. 
In literature, an orbital shadow is described only in large metastases (Neetens et 
al., 1984; Coleman and Abramson, 1989). 
In our study group an orbital shadow was established in 12 patients (17%) while in 
one other patient its presence was doubtful. In 47 patients (68%), no orbital shadow was 
described [nine patients (13%) unknown, mostly because of absence of a B-scan]. The 
larger the lesion, the more frequently an orbital shadow was described. Thus, in the 
absence of an orbital shadow, the mean prominence was 2.8 mm (SD 1.8), if the orbital 
shadow was doubtfully present the prominence was 3.0 mm, while in a distinctly present 
orbital shadow a mean prominence of 6.6 mm (SD 3.9) was measured [orbital shadow 
unknown: mean 3.4 mm (SD 2.6)]. 
An echographically manifest extraocular extension of a uveal metastasis was never 
established with certainty. However, it was doubtfully present in two patients (3%): once 
in a patient with echographic suspicion of scleral invasion and once in a patient in whom 
such invasion was supposed. In 57 patients (83%), this phenomenon was absent [10 
patients (14%) unknown, mostly because of absence of a B-scan]. 
An acoustically silent zone in the tumour infrastructure was described in five 
patients (10%) with a prominence of the metastasis of at least 2 mm. In one other patient 
this was doubtfully present and in 31 patients (61%), it was absent [14 patients (27%) 
unknown]. 
As mentioned before in the chapter on ophthalmoscopy, a retinal detachment 
occurs frequently in patients with a uveal metastasis. A retinal detachment was observed 
echographically in 36 patients (52%), while it was absent in 30 patients (43%) [three 
patients (4%) unknown]. A correlation existed between a retinal detachment and the 
prominence of the tumour: the mean prominence of a metastasis with a retinal detachment 
was 4.1 mm (SD 2.8) as against 3.0 mm (SD 2.8) if no retinal detachment was observed 
(Figure 2.3.4.7). 
On the basis of echographic examination alone, taking into account the above-
mentioned criterias, like reflectivity, regularity, choroidal excavation, vascularity, 
etcetera, without considering other clinical data, an echographic diagnosis was made in 69 
patients with choroidal and ciliary metastases (Table 2.3.4.6). In only half the cases was 
the correct diagnosis made, even if only tumours with a prominence of at least 2 mm were 
considered. In the other cases, the echographic diagnosis of melanoma was made most 
frequently, or the intraocular lesion could not be differentiated and the lesion was just 
classified as a 'tumour'. 
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Figure 2.3.4. 7 B-mode echogram of a 4.5 mm prominent 
dome-shaped choroidal metastasis from lung cancer with a 
retinal detachment (arrow) (T: tumour). 
Table 2.3.4.6 Echographic diagnosis in choroidal and ciliary metastases 
All 
Echographic diagnosis 
Prominence 
N 
27 
13 
0 
0 
1 
0 
10 
0 
^2 .0 mm 
% 
53 
25 
-
-
2 
-
20 
. 
Metastasis 37 54 
Melanoma 13 19 
Naevus 0 
Haemangioma 0 
Choroidal detachment 1 1 
Retinal detachment 1 1 
'Tumour' 16 23 
Normal I 1 
Echographic diagnoses are subdivided according to the nature of the various primary 
tumours in Table 2.3.4.7. It shows that 67% of the metastases of breast cancer were 
diagnosed correctly, while 8% were mistaken for a melanoma. Metastases of lung cancer, 
on the other hand, were diagnosed echographically as metastases in only 22% of the 
cases; in 39% of the cases the diagnosis of uveal melanoma was made. When only 
metastases with a minimal prominence of 2.0 mm were taken into consideration, the 
differences increased further: 81% of the metastases of breast cancer and 18% of the 
metastases of lung cancer were diagnosed correctly, while 14% of the metastases of breast 
cancer and 41% of lung cancer were mistaken for a melanoma. In metastases of one of 
the other malignancies, the diagnosis of metastasis was made in 58% and that of 
melanoma in 25 % of the cases. 
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Table 2.3.4.7 Echographic diagnosis in choroidal and ciliary metastases according 
to the localization of the primary tumour 
Echographie diagnosis 
Metastasis 
Melanoma 
Naevus 
Haemangioma 
Choroidal detachment 
Retinal detachment 
'Tumour' 
Normal 
Breast 
(N = 
N 
24 
3 
0 
0 
0 
1 
7 
1 
= 36) 
% 
67 
8 
-
-
-
3 
19 
3 
Lung 
(N = 
N 
4 
7 
0 
0 
1 
0 
6 
0 
= 18) 
% 
22 
39 
-
-
6 
-
33 
-
Other 
(N=15) 
N % 
9 60 
3 20 
0 
0 
0 
0 
3 20 
0 
Of the 22 patients in whom no ophtha!moscopical diagnosis could be made but 
echographic examination was performed, 10 were diagnosed echographically as metastasis 
and three as melanoma. 
It can be concluded that the echographic image of a uveal metastasis accepted in 
the literature is observed only in metastases of breast cancer. Lung cancer metastases 
cause major problems for echographic diagnostics because they may strongly resemble 
melanomas, as previously described by Verbeek (1985). Thus, they constitute a pitfall in 
the echographic diagnostics of uveal metastases. 
At echographic examination of an ms metastasis, a small convex lesion was 
described, with mid-reflectivity, which was suspected of being a metastasis. This 
metastasis originated from lung cancer. 
Summary of echography in patients with uveal metastases: in our study group at 
echography in metastases of the choroid or the ciliary body, a frequent finding was a 
lesion with a slight prominence of 3.6 mm on average. The mean tumour base measured 
11.7 mm. The prominence was much less in metastases of breast cancer than in 
metastases of other primary tumours. The shape of the metastasis was generally flat or 
dome-shaped. A few times lobulated or even mushroom-shaped tumours were described, 
especially in metastases of lung cancer. 
The reflectivity of the lesions varied, but most were mid-reflective. This 
reflectivity proved to be correlated with the nature of the primary tumour: metastases of 
breast cancer were most often mid-reflective while metastases of lung cancer were low-
and mid-reflective with the same frequency. The infrastructure of the tumour showed a 
predominantly irregular reflectivity, especially in metastases of breast cancer. 
A choroidal excavation was present in 16% and vascularity in 19% of the patients. 
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An orbital shadow was described in 17%. Extraocular extension of the tumour was never 
definitely demonstrated echographically, but in two patients there were doubtful 
echographic indications of it. Retinal detachment was described in 52% of the patients 
with ciliary and choroidal metastases. 
A characteristic echographic image of uveal metastases did not exist. In metastases 
of lung cancer a low and regular reflectivity was observed relatively frequently, the shape 
was convex or lobulated and one of the two mushroom-shaped tumours originated from 
lung cancer. The prominence was higher than in metastases of breast cancer and 
vascularity was observed more often. On the basis of echographic features alone, 
metastases of lung cancer were diagnosed correctly in only 22% of the cases, as against 
67% of metastases of breast cancer and 60% of the metastases of one of the other 
malignancies. In most cases, a metastasis of lung cancer was mistaken for a malignant 
melanoma. 
Table 2.3.4.8 summarizes the echographic data of all patients with ciliary and 
choroidal metastases; the echographic data are compared with those of other intraocular 
tumours. 
Table 2.3.4.8 Echographic features in patients with choroidal and ciliary 
metastases, melanomas, haemangiomas and naevi 
Number of palients 
Prominence: mean (SD): mm 
Base, mean (SD): mm 
Prominence:ba.se ratio: mean (SD) 
Prominence >2.0 mm * 
Prominence ¿4 .0 mm * 
Shape: 
Flat shape 
Dome-shaped 
Lobulated shape 
Mushroom-shaped 
Unknown shape 
Reflectivity: It 
Low 
Medium 
High 
Unknown 
Metastasis 
69 
3.6 (2.7) 
11.7(5.0) 
0.32 (0.28) 
51 (74%) 
27 (39%) 
41% 
39 
9 
3 
9 
29% 
53 
18 
-
Intraocular tumour 
Melanoma 
400 
6.5 (3.8) 
11.3(5.7) 
0.61 (0.35) 
357(89%) 
277 (69%) 
6% 
47 
10 
22 
14 
74% 
24 
2 
1 
Haemangioma 
27 
3.4(1.1) 
7.7 (3.2) 
0.44 (0.11) 
24 (89%) 
7(26%) 
-% 
70 
-
-
30 
-% 
4 
83 
13 
Naevus 
39 
0.3 (0.5) 
1.7 (2.9) 
0.20 (0.09) 
0(0%) 
0(0%) 
92% 
3 
-
-
5 
** 
to be continued on next page 
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Table 2.3.4.8 (continued) 
Regularity: M 
Regular 
Irregular 
Unknown 
Choroidal excavation: 
Positive 
Doubtful 
Negative 
Unknown 
Vascularity: M 
Positive 
Doubtful 
Negative 
Unknown 
Orbital shadow: 
Positive 
Doubtful 
Negative 
Unknown 
Retinal detachment: 
Present 
Absent 
Unknown 
Metastasis 
37% 
59 
4 
16% 
6 
65 
13 
19% 
11 
44 
26 
17% 
1 
68 
13 
52% 
42 
6 
Intraocular tumour 
Melanoma 
66% 
33 
1 
65% 
1 
21 
14 
52% 
7 
29 
12 
42% 
2 
41 
16 
58% 
35 
7 
Haemangioma 
29% 
29 
43 
-% 
4 
63 
33 
14% 
-
29 
57 
4% 
-
67 
30 
33% 
41 
26 
Naevus 
** 
-% 
-
65 
35 
** 
-% 
-
100 
-
-% 
100 
-
* percentage of all tumours with known prominence; ** all tumours prominence <2.0 mm; # in tumours 
wuh a prominence ä 2 . 0 mm; M in tumours with a prominence '¿4.0 mm 
In our patient material, melanomas of the choroid and ciliary body were more prominent 
than metastases, viz. 6.5 mm on average as against 3.6 mm in metastases, while the mean 
base of the lesions was the same for both tumours. The mean prominence.base ratio in 
melanomas was 0.61, which is higher than the ratio in metastases (0.32). A dome-shaped 
tumour was described in 47% of the patients. The mushroom shape, characteristic of 
melanomas, was observed in 22% of the patients, in which respect melanomas differ from 
metastases. 
Between melanomas and metastases there was a considerable difference in 
reflectivity. Melanomas in the vast majority of the cases were low-reflective (74%) while 
in metastases mid-reflective tumours were observed in 61%. The reflectivity in melanoma 
was predominantly regular (66%) compared with the frequently irregular (59%) 
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reflectivity in metastases. Of all melanomas of which the reflectivity could be determined, 
56% were low-reflective and regular as against 15% of the metastases. 
A choroidal excavation occurred four times and vascularity three times as 
frequently in melanomas as in metastases. An orbital shadow was described three times as 
often in melanomas. In melanomas and metastases, retinal detachment was established 
with nearly equal frequency (Figure 2.3.4.8 and Figure 2.3.4.9). 
Figure 2.3.4.8 A- and B-mode echogram of a 11.0 mm 
prominent mushroom-shaped choroidal malignant melanoma 
with a low reflectivity, choroidal excavation, vascularity, and 
retinal detachment (white arrow: retina; white arrowhead: 
sclera; black arrow: choroidal excavation; O: orbital fat; 
t: low-reflective tumour infrastructure with vascularity; 
T: tumour; V: vitreous). 
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Figure 2.3.4.9 A-mode echogram of a malignant melanoma 
filling almost the entire globe with distinct vascularity 
(blurring of the echo spikes in the tumour infrastructure: open 
white arrows) (white arrowhead: sclera; O: orbital fat). 
Echographic signs of extraocular spread, just as in metastases, were uncommon in 
melanomas also, viz. in 4% of the cases (Figure 2.3.4.10). 
Noticeable features of a melanoma, therefore, are the relatively high prominence, 
the dome-shaped or mushroom-shaped tumour and the regular low reflectivity. Frequently, 
the tumour shows a choroidal excavation, an orbital shadow and vascularity. 
On the echographic image alone the diagnosis in melanomas with a minimal 
prominence of 2.0 mm was established as melanoma in 90%, metastasis in 2% and 
'tumour' in 8%. 
Figure 2.3.4.10 B-mode echogram of a 3.5 mm prominent 
dome-shaped malignant melanoma of the choroid (T) with 
extraocular extension (black arrows). 
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The following echographic criteria were selected as characteristic of melanoma: 
- prominence à 2.Omm 
- low reflectivity 
- regular infrastructure 
- choroidal excavation 
- vascularity. 
Of all the different intraocular tumours, 71 (18%) of all melanomas and one (1%) of all 
metastases met all these conditions (Table 2.3.4.9). 
Table 2.3.4.9 Echographic characteristics of melanomas in various intraocular 
tumours in terms of percentage * 
Diagnosis 
Number of echographic 
entena fulfilled * 
three 
four 
five 
Melanoma 
91 
98 
99 
Metastasis 
5 
1 
1 
Haemangioma 
0 
Miscellaneous 
tumours 
2 
0 
Tumours of 
unknown 
nature 
2 
1 
* prominence ä 2.0 mm; low reflectivity; regularity; choroidal excavation; vascularity 
If at least four of the five echographic melanoma criteria have to be fulfilled, 98% of the 
tumours are melanomas. This requirement is met by 50% of all echographically examined 
ciliary and choroidal melanomas and by 3% of the metastases: one patient with a 
metastasis probably arisen from a colonic carcinoma fulfilling all five criteria and one 
patient with an irregular metastasis of lung cancer fulfilling four criteria. At least three of 
the five criteria are met by 72% of the melanomas and 22% of the metastases. 
Haemangiomas showed a prominence comparable to that of metastases, but the 
mean base of the lesion was smaller. In all cases, the tumour was dome-shaped. Low-
reflective haemangiomas did not occur in our study group: nearly all lesions (83%) were 
high-reflective. Choroidal excavation and vascularity were present only exceptionally. A 
retinal detachment was described less frequently than in metastases or melanomas. Signs 
of extraocular extension were never present (Figure 2.3.4.11). 
In not a single case was a haemangioma echographically diagnosed as metastasis or 
melanoma. In haemangiomas with a prominence of ^2.0 mm, the echographic diagnosis 
was haemangioma in 79% and 'tumour' in 21%. 
All naevi in our study were flat lesions with a maximal prominence of 1.5 mm. 
Once, a dome-shaped lesion was described. Owing to the low prominence, naevi 
echographically could at the most be detected but not differentiated from intraocular 
tumours with adequate reliability. 
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Figure 2.3.4. Π A- and B-mode echogram of a 3.5 
mm prominent high-reflective dome-shaped choroidal 
haemangioma (black arrows: haemangioma; white 
arrow: retina; white arrowhead: sclera; N: optic 
nerve; O: orbital fat; t: high-reflective tumour infra­
structure; T: tumour). 
In 18 patients with a retinoblastoma echography was performed, showing a high 
reflectivity and shadows in the orbital fat pattern due to intratumoral calcifications in all 
cases. In only one patient was the echographic diagnosis 'tumour' instead of 
retinoblastoma (Figure 2.3.4.12). 
In patients with miscellaneous intraocular tumours echography was carried out in 
four patients with a choroidal localization of a lymphoproliferative disease. The 
prominence never exceeded 1.5 mm. The lesions were flat, so that echographically they 
could not be differentiated with adequate reliability. 
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Figure 2.3.4.12 A- and B-mode echogram 
of a retinoblastoma almost filling the entire 
globe (white arrow: retinal surface; small 
while arrows: high-reflective tumour 
infrastructure: no partition from the orbital 
fat pattern can be distinguished; t: tumour). 
In eight patients with a subretinal haemorrhage echography was performed. The mean 
prominence of the lesions was 3.3 mm, the mean base 10.7 mm and the mean 
prominence:base ratio 0.29, similar to a metastasis. The shape was flat three times, 
convex three times, lobulated once and mushroom-shaped once. Reflectivity was low, mid 
and high with equal frequency, and three times irregular and once, regular (four times: 
too small). A choroidal excavation was described in three patients. Vascularity was not 
observed. An orbital shadow occurred frequently: three times it was definitely and twice, 
possibly present. A retinal detachment was described in one patient. The echographic 
diagnosis was five times haemorrhage, once melanoma and twice, 'tumour' (Figure 
2.3.4.13 a). 
The mean prominence in seven patients with a Kuhnt Junius amounted to 3.4 mm 
with a base of 12.2 mm and a prominence:base ratio of 0.24. The lesion was 
predominantly dome-shaped with three times mid, twice low and once, high reflectivity 
(once too small). The tumour infrastructure was twice irregular and once, regular (five 
times too small). Choroidal excavation was described in two patients. Vascularity was 
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never present. Retinal detachment occurred in two patients. The diagnosis at echography 
was three times Kuhnt Junius, twice melanoma and twice, 'tumour' (Figure 2.3.4.13 b). 
Figure 2.3.4.13 a. B-mode echogram of a 2.5 mm prominent 
dome-shaped subretinal haemorrhage (black arrows) with 
intravitreous haemorrhages (white arrows). b. B-scan 
echogram of a 3.0 mm prominent dome-shaped age-related 
macular degeneration (Kuhnt Junius: black arrows) with 
intravitreal haemorrhages (white arrows) (0: orbital fat). 
In the five patients with a choroidal detachment, a dome-shaped tumour was described 
with a mean prominence of 4.8 mm, a base of 7.5 mm and a prominence:base ratio of 
0.53 with low reflectivity. A choroidal excavation was observed once, vascularity never. 
The echographic diagnosis was twice choroidal detachment, twice retinal detachment and 
once, 'tumour'. 
The prominence and base in the three patients with a leiomyoma were 8.0 mm on 
average with a ratio of 1.0. The lesion was twice dome-shaped, once mushroom-shaped. 
The tumour was low-reflective, regular, without choroidal excavation. Once a doubtful 
vascularity was present, and once, a retinal detachment. The diagnosis was once 
melanoma and twice, 'tumour'. 
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The three retinal detachments which initially were mistaken for solid intraocular 
tumours, echographically were 4.0 mm prominent on average and dome-shaped. The 
echographic diagnosis caused no problems. 
Conclusion: echography occupies an important place in the differential diagnostics 
of uveal metastases. Differentiation of the malignant melanoma of the uvea is adequately 
possible in many cases. However, metastases from lung cancer may give rise to problems, 
showing an echographic image compatible with melanoma. In many cases, metastases can 
also be differentiated from haemangiomas. In no patient with a metastasis was the 
echographic diagnosis of haemangioma made and in no patient with a haemangioma was 
the diagnosis of metastasis made. Retinoblastomas showed a characteristic image. In small 
tumours (prominence <2.0 mm) echography does not give sufficient information for 
adequate differential diagnosis. However, in these cases echography still may be important 
for detecting possible extraocular extension of the tumour. 
2.3.5 Perimetry 
Perimetry, or examination of the visual field, was not one of the ophthalmological 
examinations carried out routinely in patients with an intraocular tumour. In general, 
perimetry was performed only on indication, for instance because a patient complained 
about visual field defects or because of the insights and interests of the individual 
physician in charge. 
In our study, perimetry was carried out in 25 patients with uveal metastases, 
namely in 24 patients with a choroidal metastasis and one patient with a ciliary metastasis. 
A visual field defect was established in 22 patients: an absolute scotoma in 16 patients, a 
relative scotoma in five patients and a scotoma of unknown depth in one patient. In two 
patients a general decrease of sensitivity was observed and one patient showed no 
abnormalities (Table 2.3.5.1; Figure 2.3.5.1). 
In five patients with a scotoma, apart from the visual field defect, a general 
decrease of sensitivity was also observed and in one patient, a central decrease of 
sensitivity was established. 
The prominence of the tumour in patients with an absolute scotoma was usually 
higher (mean 4.6 mm; SD 3.3) than that in patients with a relative scotoma (mean 3.0 
mm; SD 2.0). No correlation could be observed between the depth of the scotoma and the 
nature of the primary tumour. 
If perimetry had been performed, a scotoma, mostly an absolute one, was observed 
in 88% of the cases. This percentage must not be extrapolated to our entire study group, 
because the definition of the indication for this examination may affect the results. 
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Table 2.3.5.1 Perimetry in 25 patients with choroidal and ciliary metastases 
Normal 
Scotoma: 
Absolute 
Relative 
Scotoma of unknown depth 
16 
5 
1 
64 
20 
4 
General decrease of sensitivity 
ICHTSVtLOMEflNC 
Figure 2.3.5.1 Perimetry in a patient with bilateral choroidal metastases from breast cancer. Right eye: 
infero!emparai absolute scotoma with a steep to sloping inclination (metastasis located superiorly of the optic 
disk with secondary retinal detachment extending to the macular area). Left eye: inferonasal absolute 
scotoma with sloping margins (metastasis located temperosuperiorly with secondary retinal detachment). 
If a scotoma is present its inclination can be determined. This inclination was known in 17 
of the 22 patients with a scotoma. Six times (27%) it was steep, four times (18%) sloping 
to steep and seven times (32%), sloping [five patients (23%) unknown]. No correlation 
between the depth and the inclination of the scotoma was established. 
In 21 of the 22 patients with a scotoma, the ophtha! moscopical localization of the 
uveal metastasis and the localization of the visual field defect were known. Eighteen times 
(82%) the scotoma corresponded to the ophthalmoscopical localization of the metastasis. 
Three times (14%) the scotoma was situated in a different place: once in a patient with a 
tumour localized superiorly in the fundus and a secondary retinal detachment inferiorly 
with a related visual field defect superiorly; twice in patients with a minimal visual field 
defect. The cause of this discrepancy could not be ascertained. One of these two patients 
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was the one with a ciliary metastasis in whom a relative scotoma with a general decrease 
of sensitivity was established. 
Summary of perimetry in patients with uveal metastases: when perimetry was 
carried out a scotoma, which was mostly absolute, was detected in 88% of the cases. In 
patients with an absolute scotoma a higher prominence of the tumour was measured than 
in patients with a relative scotoma. The inclination of this scotoma might be sloping or 
steep. This was not correlated with the depth of the scotoma. The localization of the 
scotoma as a rule corresponded to the ophthalmoscopical site of the metastasis (Table 
2.3.5.2). 
Table 2.3.5.2 Perimetric features in patients with choroidal and ciliary metastases, 
melanomas, haemangiomas and naevi 
Number of patients 
Visual field defect: 
None 
Scotoma: 
Absolute 
Relative 
Depth unknown 
General decrease of sensitivity 
Central decrease of 
Inclination of scotoma; 
Steep 
Sloping to steep 
Sloping 
Unknown 
sensitivity 
; * 
Metastasis 
25 
4% 
8g 
64 
20 
4 
8 
-
27* 
18 
32 
23 
Intraocular tumour 
Melanoma 
165 
6% 
91 
77 
10 
4 
2 
1 
36% 
27 
5 
33 
Haemangioma 
16 
-% 
100 
56 
38 
6 
-
-
25% 
19 
13 
44 
Naevus 
24 
50% 
29 
4 
17 
8 
10 
17 
14% 
29 
14 
43 
* in presence of a scotoma 
In melanomas a scotoma was observed as often as in metastases. Even more 
frequently than in metastases this scotoma was absolute. The inclination of the scotoma 
was only rarely sloping. 
Haemangiomas at perimetry in all cases showed an absolute or relative scotoma. 
Inclination of the scotoma could be either steep or sloping. 
In naevi a visual field defect was described in one-half of the patients. The 
scotoma was usually relative, the inclination steep or sloping. 
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In the miscellaneous tumours, perimetric examination had been performed only 
sporadically and insufficient data were available for differentiation of these lesions from 
metastases. 
Conclusion: perimetry makes no contribution to the differential diagnostics of 
uveal metastases. 
2.3.6 Electrophysiology 
2.3.6.1 Electro-oculography (EOG) 
In a retrospective study (Brink et al., 1989), an attempt was made to develop a method for 
application of EOG to the differential diagnostics of malignant melanomas, metastases and 
naevi of the choroid and ciliary body and rhegmatogenous retinal detachments. To this 
purpose a study was made of the EOG data of 64 patients with a malignant melanoma of 
the choroid or the ciliary body as well as of the data of 11 patients with choroidal 
metastases, 11 patients with choroidal naevi and 27 patients with a rhegmatogenous retinal 
detachment. By using the dark trough (Dt) and the light peak - dark trough ratio (Lp/Dt 
ratio), a diagram could be composed for the EOG classification of these lesions suspicious 
of tumour (Figure 2.3.6.1). This diagram could be applied exclusively to the 
differentiation of the above-named lesions since only for melanomas, metastases, naevi 
and retinal detachments a specific area is indicated. If further lesions are to be considered 
for the differential diagnosis, this diagram should not be used. 
The EOG classifications of patients with a choroidal metastasis proved to be 
scattered over the entire diagram without any concentration in a particular area. This may 
be a consequence of the heterogeneity that is typical of metastases. It was found that not a 
single metastasis could be classified correctly. That an area for the diagnosis of 
'metastasis' was nevertheless constructed was because the probability of one of the other 
three lesions in this area was even smaller than the probability of a metastasis. 
In a prospective study, it was found again that metastases could not be classified 
correctly by means of this EOG method. Accordingly, it was concluded that metastases 
cannot be differentiated electro-oculographically from malignant melanomas of the uvea 
(Brinketal., 1990). 
Electro-oculography was carried out in 16 of the 87 patients with uveal metastases 
in this retrospective study. In all cases the metastases were situated in the choroid. Table 
2.3.6.1.1 presents a survey of the different values of the various EOG parameters in these 
patients, of the mean values in a normal control group of 151 persons and of the lower 
limit of normal. The lower limit of these normal values is defined as the value in the 
normal patient on the lowest fifth percentile. The percentage of abnormal values in 
metastases is also given. 
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Figure 2 3.6 1 EOG probability score for various intraocular lesions. Indicated are four 
areas with the highest probabilities of a specific disease group, using Dtpa and Lp/Dtpa-ratio. 
The broken lines represent the probabilities (as indicated) of a specific disease (Dtpa: dark 
trough pathological eye, Lp/Dtpa-ratio. light peak divided by dark trough of the pathological 
eye). 
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Figure 2.3.6.2 EOG registration in a patient with a metastasis from lung cancer in the right 
eye Abnormal results ¡n the right eye, compatible with malignant melanoma; normal results 
in the left eye. 
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Table 2.3.6.1.1 Results of various EOG parameters in the affected eye of patients with choroidal metastases 
related to normals 
Iv OiV) 
Lower limit of normal: 
300 
Normal control: (N=151) 
Mean 568 
SD 198 
Choroidal metastases: (N = 
Mean 619 
SD 308 
16) 
Dt (MV) 
200 
430 
152 
534 
206 
Lp GiV) 
500 
972 
315 
783 
296 
Lp/Dt ratio 
1.78 
2.32 
0.43 
1.52 
0.49 
A-criterium 
+ 30 
+ 244 
151 
-69 
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Percentages of abnormal values in choroidal metastases: 
0% 0% П% 75% 75% 
Iv = initial value; Dt = dark trough; Lp = light peak; Lp/Dt ratio = light peak : dark trough ratio; 
A-criterium = Lp - [(0.6 χ ¡ν) + (0.9 χ Dt)/ 
In metastases a distinctly abnormal EOG was registered, without abnormalities in initial 
value and dark trough, but with abnormalities in light peak and major abnormalities in 
ratio and A value. 
This manifested itself also in the EOG classification of the choroidal metastases: in 
12 patients the EOG diagnosis was malignant uveal melanoma (75%), in two patients 
naevus and in two other patients, retinal detachment. The diagnosis of metastasis was 
never made (Figure 2.3.6.2). The EOG diagram therefore is a poor method for the 
differential diagnostics of uveal metastases. It appears, however, that it is a good method 
to trace an abnormality in the natural potential difference of the eye. The cause of the 
abnormal EOG in uveal metastases is unknown, just as in the case of melanomas. 
Table 2.3.6.1.2 presents a survey of the mean values of the various EOG 
parameters in the various tumours and the percentages of abnormal values. The EOG 
diagnoses are described in Table 2.3.6.1.3. In this connection it should be noted that EOG 
diagnostics of intraocular tumours, as applied by us, should be used only in the 
differentiation of metastases, melanomas, naevi and retinal detachments; other tumours, 
namely, have not been included in the calculations. For purposes of illustration, 
haemangiomas, miscellaneous tumours and tumours of unknown nature have nevertheless 
been included in Table 2.3.6.1.3. 
These two tables show that in melanomas abnormal values were established in a 
large proportion of the cases. In 83 % of the patients classification was correct. 
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Table 2.3.6.1.2 Values of various EOG parameters and percentages of abnormal values in the affected eye of patients with 
various intraocular lesions 
Value: 
Metastasis 
Melanoma 
Haemangioma 
Naevus 
Other 
Unknown lesion 
Percentage ofabnorn 
Metastasis 
Melanoma 
Haemangioma 
Naevus 
Other 
Unknown lesion 
N 
16 
116 
3 
36 
9 
25 
nal values: 
16 
116 
3 
36 
9 
25 
Iv ΟΛΟ 
Mean SD 
619 
578 
500 
602 
572 
512 
% 
0 
4 
0 
3 
0 
4 
308 
251 
100 
213 
505 
189 
Dt (MV) 
Mean SD 
534 
520 
346 
481 
511 
434 
0 
2 
0 
3 
0 
4 
206 
229 
64 
190 
179 
147 
Lp OiV) 
Mean SD 
783 
691 
446 
978 
822 
781 
13 
22 
33 
3 
22 
12 
296 
339 
173 
317 
443 
336 
Lp/Dt 
Mean 
1.52 
1.38 
1.25 
2.12 
1.57 
1.80 
75 
82 
100 
19 
56 
44 
ratio 
SD 
0.49 
0.47 
0.30 
0.44 
0.50 
0.51 
A-cntenum 
Mean 
-69 
- 123 
- 165 
+ 183 
+ 19 
+ 83 
75 
80 
100 
19 
56 
36 
SD 
263 
207 
64 
167 
259 
189 
to 
о 
Table 2.3.6.1.3 EOG diagnosis in patients with uveal metastases, melanomas and naevi and with retinal detachments 
EOG diagnosis 
Metastasis 
Melanoma 
Naevus 
Retmal detachment 
Total 
Metastasis 
N 
0 
12 
2 
2 
16 
% 
-
75 
13 
13 
100 
Melanoma 
N 
0 
95 
11 
9 
115 
* 
% 
-
83 
10 
8 
100 
Ultimate 
Haemaneioma 
N 
0 
2 
0 
1 
3 
** 
% 
-
67 
-
33 
100 
diagnosi IS 
N 
0 
13 
23 
0 
36 
Naevus 
% 
-
36 
64 
-
100 
N 
0 
6 
2 
1 
9 
Other 
** 
% 
-
67 
22 
11 
100 
Unknown nature 
N 
0 
16 
7 
2 
25 
#* 
% 
-
64 
28 
8 
100 
* one of 116 melanomas could not be classified due to a very high dark trough (1575 μΥ); ** when classified as metastasis, melanoma, naevus or retinal 
detachment 
In only three patients with a haemangioma was electro-oculography performed, at 
which abnormal values were found. Although Diagram 2.3.4.1.1 must not be used for the 
diagnostics of haemangiomas, Table 2.3.4.1.3 for purposes of comparison lists the EOG 
diagnoses that would have been made if the EOG criterion had been applied to 
melanomas. 
Naevi in general show a normal EOG. Nevertheless, an abnormal ratio was 
registered in as many as 19% of the cases while 36% of the naevi were incorrectly 
classified as melanomas. 
The group of miscellaneous tumours consisted of various lesions. An abnormal 
ratio was recorded in a patient with a choroidal detachment, a benign reactive lymphoid 
hyperplasia, a tuberculoma, a detachment of the retinal pigment epithelium and a Kuhnt 
Junius. A normal ratio was established in a patient with leiomyoma, a detachment of the 
retinal pigment epithelium, a vorticose vein and a subretinal haemorrhage. 
In patients with intraocular lesions of unknown nature, an abnormal ratio was 
observed in 44% of the cases. This is a significantly smaller proportion than those found 
in metastases and melanomas. 
Conclusion: electro-oculography makes no contribution to the differential 
diagnostics of uveal metastases from uveal melanomas, and only a limited contribution to 
the differentiation from choroidal naevi. 
2.3.6.2 Electroretinography (ERG) 
In six patients with uveal metastases, electroretinography was found to have been 
performed. The electroretinograms were abnormal in four patients, subnormal in one and 
normal in one patient. 
The number of patients examined electroretinographically was only small; 
therefore, no conclusions can be drawn from these figures. 
Electroretinography had been performed in 16 patients with a melanoma, with 
normal results in seven, subnormal results in four and abnormal results in five cases. 
2.3.7 Miscellaneous examination techniques 
Only sporadically were other examinations than described in the preceding chapters 
carried out in patients with uveal metastases. With the exceptions of one patient in whom 
a tumour was punctured and some patients in whom transillumination was performed, all 
these cases concerned examinations carried out outside our clinic. 
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Computed tomography (CT scan) was performed in only two patients with a 
choroidal metastasis. Both patients echographically had a choroidal metastasis with 3 mm 
prominence originating from lung cancer. The outcome of the CT scanning was scleral 
thickening in one patient, and 'tumour' in the other. 
In 17 patients with a uveal melanoma, CT scanning was performed leading to the 
diagnoses of melanoma four times, 'tumour' eight times and haemorrhage once, while no 
abnormalities could be established in four cases. 
Compared with echography, the CT scan provided no additional information. 
In three patients with a retinoblastoma an intraocular tumour with calcifications 
was observed. 
Magnetic Resonance Imaging (MRI) was not carried out in any patient with a 
uveal metastasis. 
Puncture or biopsy of the intraocular tumour was carried out in only one patient 
with a choroidal metastasis of unknown origin, but the quantity of material obtained was 
insufficient for cytological examination. 
Isotope testing, for instance with the aid of isotope 32P, was not carried out in any 
patient with a uveal metastasis in our study group. 
Transillumination of the tumour was carried out in four patients with a uveal 
metastasis: three times clinically and once, after enucleation of the eye. The results of the 
clinical examinations were as follows. In a patient with a metastasis of breast cancer, 
prominence 1.5 mm, diaphany at the tumour site was observed. A metastasis of lung 
cancer with a prominence of 13.0 mm was partially diaphanous. In a metastasis of 
unknown origin with a prominence of 4.0 mm, complete extinction was observed. In a 
fourth patient, with a metastasis of lung cancer of 8.0 mm prominence and an intractible 
secondary glaucoma, transillumination of the enucleated eye showed complete extinction at 
the tumour site. 
Transillumination had also been performed in 108 patients with a uveal melanoma: 
36 times clinically and 72 times, after enucleation of the eye. The results of the 
examination were extinction in 93 cases (86%), a partially diaphanous lesion was observed 
10 times (9%) and five times, the tumour was diaphanous (5%). In melanoma cases no 
correlation between the prominence and the diaphany of the tumour existed. 
In haemangiomas, clinical transillumination of the tumour was performed five 
times: four times the tumour was completely and once, partially diaphanous. 
Of all tumours examined by diaphanoscopy, one-half of the diaphanous lesions had 
a yellowish-orange colour. Tumours which at transillumination showed extinction were 
mostly grey. Probably, therefore, the colour of the tumour plays a more important part 
than the prominence at transillumination. 
Diaphanoscopy makes no essential contribution to the differential diagnosis of 
intraocular tumours. 
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Conclusion: penmetry, electrophysiology, CT scanning, MRI, punctures and 
biopsies, isotope tests and transillumination as far as can be ascertained make no 
contribution to the differential diagnosis of uveal metastases. 
2.3.8 Histopathological examination 
In eight patients with uveal metastases, the clinical diagnosis was confirmed 
histopathologically. Seven times, histopathological examination was earned out while the 
patients were alive, after enucleation of the affected eye. Once, histopathological 
examination was earned out at autopsy. This concerned a patient with a metastasis of 
breast cancer in whom scleral invasion by the choroidal metastasis was observed. 
The case histories of these patients will be briefly reviewed and a summary of the 
histopathological findings will be presented 
In a female aged 33 years, in 1974, a large yellowish-orange prominent mass 
situated temporosupenorly within the macular area of the left eye was observed, with 
suspicion of a melanoma, with a secondary retinal detachment. There was no history of 
malignancies or operations. At radiological examination of the thorax and skeleton no 
abnormalities were established At fluorescein angiography, the lesion was suspected of 
being a melanoma, echographically the tumour was described as a mass with 4 mm 
prominence It was decided to perform enucleation of the left eye. 
At histological examination the choroid was found to contain a tumoral 
proliferation of fairly large polygonal, partially well-delimited and partially poorly 
delimited tumour cells which formed solid trabeculae and nests with glandular tubuli. The 
cytoplasm of the cells was clearly basophilic, the nuclei dark with anisokaryosis Mitoses 
were encountered regularly In a few sites, necrosis and mononuclear infiltration into the 
tumoral stroma were observed. There was penetration of the tumour into the internal layer 
of the sclera. The optic nerve was tumour-free The conclusion was a moderately 
differentiated adenocarcinoma. Determination of the localization from the morphology was 
not possible. 
Further examination revealed pathological lymph nodes, a space-occupying process 
in the liver and cerebral metastases. No primary tumour was found. The patient died three 
months after the initial examination. 
A female aged 72 years was known for as long as 8 years with breast cancer when 
in 1982, temporosupenorly in the nght eye, a very large yellowish-orange pigmented 
tumour with a secondary retinal detachment was observed, suggestive of a metastasis. 
However, the fluorescein angiographic and echographic images were more compatible 
with a melanoma (Figure 2.3.8.1). Since no metastases elsewhere in the body were known 
and a malignant melanoma could not be excluded, enucleation was decided upon, partly 
because of possible complications. 
At histological examination, a large tumour was found in the choroid, composed 
largely of cuboid to cylmdncal cells ranged sometimes disorderly, sometimes in a mosaic 
pattern. Glandular tubuli and pseudoroseltes were also observed. The cell nuclei were 
little polymorphous and mitoses were observed regularly, with central necrosis in several 
fields In a few places, the tumour invaded the sclera without extraocular extension. Partly 
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on the basis of comparison with sections of the breast carcinoma, the diagnosis of 
choroidal metastasis was made. 
Eighteen months later, a choroidal metastasis developed in the other eye, which 
was treated with irradiation. 
Figure 2.3.8.1 A- and B-mode echogram of a 7.5 mm 
prominent mid-reflective dome-shaped choroidal tumour with 
an irregular infrastructure (t), choroidal excavation (black 
arrow), vascularity, orbital shadowing and suspicion of 
extraocular extension: compatible with malignant melanoma. 
Histopathological examination: metastasis from breast cancer 
(white arrow: retina; white arrowhead: sclera; 0: orbital fat; 
t: irregular tumour infrastructure; T: tumour). 
A male aged 46 years in 1988 was referred to our clinic for echographical examination of 
a pale choroidal tumour of unknown nature, situated temporosuperiorly in the left eye. 
There was no history of malignancy. At fluorescein angiography, the lesion was diagnosed 
as a melanoma. The echographic findings mostly matched a melanoma, but a metastasis 
could not be excluded (Figure 2.3.8.2). In view of growth of the tumour, enucleation was 
decided upon. 
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Figure 2.3.8.2 A- and B-mode echogram of a 5.0 prominent 
dome-shaped choroidal tumour with a base of 14.0 mm, a 
regular low to mid reflectivity (t), choroidal excavation 
(black arrow) and signs of vascularity: compatible with 
malignant melanoma. Histopathological examination: 
metastasis from prostatic carcinoma (white arrow: retina; 
white arrowhead: sclera; O: orbital fat; T: tumour). 
In the choroid, proliferation was observed of epithelioid cells arranged in solid fields with 
a partly lobulated appearance. The cells contained ample cytoplasm and were not 
pigmented. The septa in between, however, did contain pigmented pre-existent 
melanocytes. Mitoses were described as sporadic. Scattered small necrotic foci and several 
blood-filled cavities were observed. There was invasive growth in the retina and 
superficial erosion of the sclera without extraocular extension. The diagnosis was 
malignant melanoma of the choroid of the epithelioid cell type. 
Six months later, metastases were encountered in the skeleton, a primary or 
metastatic cerebral tumour was diagnosed and a carcinoma of the prostate was suspected. 
A revision of the histopathological examination of the ocular tumour was then performed 
with immunohistochemical processing of the preparation. The diagnosis subsequently 
made was a probable metastasis of a prostatic carcinoma. 
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After another six months the patient died and the prostatic carcinoma was 
confirmed at autopsy. 
In these three patients the suspicion of a malignant melanoma of the choroid was 
the reason for enucleation of an eye with a metastasis. In the third patient, with a 
metastasis of a prostatic carcinoma, histopathological differentiation from a melanoma also 
caused problems. Font et al. (1967) already mentioned the difficult differentiation between 
primary uveal melanomas and uveal metastases of cutaneous melanomas. Metastases of a 
bronchial carcinoid may also show many cytological similarities to an amelanotic 
melanoma (Font et al., 1966). As observed, the same may apply to a metastasis of a 
prostatic carcinoma. 
In two other patients, enucluation was decided upon because of uncertainty about 
the diagnosis: 
A male aged 67 years had been known for 2 years with a bladder carcinoma 
(transitional cell carcinoma with focally a tendency to squamous cell carcinoma) when in 
1976 superiorly in the right eye a large yellowish-orange prominence with irregular 
pigmentation was detected. No metastases elsewhere in the body were known. At 
fluorescein angiography and echography, no differentiation between a metastasis and a 
melanoma was possible. It was decided to await the effect of radiotherapy. However, in 
its course the prominence increased in height and visual acuity deteriorated further. 
Enucleation was then considered indicated. 
The histopathological diagnosis was a choroidal metastasis of a squamous cell 
carcinoma. 
A woman aged 58 years was referred in 1981 because of a yellowish-white 
prominence in the macular area of the left eye with suspicion of a metastasis (Figure 
2.3.8.3). The patient was otherwise healthy. At fluorescein angiography, melanoma was 
diagnosed, partly on the basis of a double vascularization. At echography, a 2.5 mm 
prominent lesion was observed, corresponding mostly to a Kuhnt Junius, possibly to a 
metastasis. Because of the expected complete loss of function of the eye, enucleation was 
decided upon. 
In the choroid, a tumour was observed with extrascleral extension via nerves, 
blood vessels and direct scleral perforation, and a minimal rupture through Bruch's 
membrane. The tumour showed the characteristic appearance of an adenocarcinoma with 
mucin-containing tubuli. The optic nerve was tumour-free. The extrascleral tumour tissue 
had not been removed completely. The conclusion of the histopathological examination 
was a choroidal metastasis of an adenocarcinoma, arising in all probability from a breast 
carcinoma or from a carcinoma of the gastrointestinal tract. 
Extensive examination failed to reveal a primary tumour. The patient died six 
months later of cachexia. 
It is interesting to note that in all five patients in whom the ophthalmological 
diagnosis was uncertain, the colour of the tumour was pale, which corresponds to a 
metastasis rather than to a melanoma. 
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Figure 2.3.8.3 Fundus photograph showing a prominent 
yellowish-white choroidal tumour in the left eye of a patient 
with no known malignancy. Histopathological examination: 
metastasis of adenocarcinoma of unknown localization. 
Figure 2.3.8.4 Fundus photograph showing an extensive 
choroidal tumour with mottled pigmentation in the right eye of a 
patient with no known malignancy. Histopathological 
examination: choroidal metastasis of adenocarcinoma of 
unknown localization. 
In two patients, the eye was enucleated because of ophthalmological complications 
resulting from the intraocular tumour: 
In a male aged 52 years, in 1987 a large flat tumour was observed in the postenor 
pole of the right eye, with a light colour and a mottled appearance corresponding to a 
metastasis (Figure 2 3.8.4). The echographic image also strongly suggested a metastasis. 
A thorough examination revealed no primary tumour. Since the visual acuity of the eye 
decreased from 0.4 to no light perception and the eye became painful it was enucleated six 
months later. 
The conclusion of the histopathological examination read· metastasis of a 
moderately to well-differentiated mucinous adenocarcinoma with as the most probable 
primary localization the gastrointestinal tract or the prostate. The stump of the optic nerve 
proved not to be free of tumour tissue. 
Shortly after the operation, pathological lymph nodes and skeletal metastases were 
established The patient died 17 months later of cachexia without the primary tumour 
having been determined. 
In another patient, a male aged 66 years, in 1982 in the left eye a large grey 
tumour mass with a retinal detachment was established, with strongest suspicion of a 
melanoma Fluorescein angiography also pointed in that direction At echography, the 
diagnosis of metastasis was made (Figure 2 3 8 5 a-b) The chest X-ray showed a shadow. 
At further examination by means of bronchoscopy this proved to be due to a small cell 
undifferentiated lung carcinoma Since an intractible secondary glaucoma developed, the 
eye was enucleated 
Histopathologically, on the ins a few dome-shaped implantation metastases were 
observed. There was a total serous retinal detachment and large areas of the retina showed 
necrosis In the choroid, a tumour was observed with invasion into the disk and optic 
nerve and with penetration through the sclera to epibulbar areas. Many mitoses were 
present as well as a few pre-existent melanocytes The larger part of the tumour was 
necrotic. The diagnosis was a metastasis of the pulmonary tumour (Figure 2.3 8.5 c). 
In only one patient, a female aged 39 years with bilateral choroidal metastases of 
breast cancer, were the eyes examined post mortem. This revealed extensive 
metastasization of the tumour in the uvea with invasion of the sclera. 
Thus, histopathological examination of uveal metastases was performed in five 
patients when enucleation had erroneously been considered indicated under the diagnosis 
of malignant melanoma of the uvea, or this lesion was assumed in a patient with a non-
functional eye. Furthermore, in two patients the eye was enucleated because of 
ophthalmological complications. At autopsy, even when indications of uveal metastases 
were present, histopathological examination of the eye was carried out only once. 
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Figure 2.3.8.5 α-b. Л- and B-mode echogram of a 9.0 mm 
prominent tabulated choroidal mass with an extensive base, 
an irregular low to mid reflectivity (t), vascularity, orbital 
shadowing and retinal detachment (white arrow in B-scan) 
and doubtful signs of a choroidal excavation: compatible with 
a choroidal metastasis (white arrow: retina; white arrow­
head: sclera; O: orbital fat; T: tumour), с Histopathol-
ogical examination: metastasis from lung cancer. 
2.3.9 Conclusions 
Although for the differential diagnosis of intraocular tumours a large number of 
examination techniques are available and tumour-specific patterns can be established in a 
number of cases, the diagnosis of these tumours in the individual patient remains a 
difficult task No pathognomonic picture of uveal metastases exists. The diagnosis is 
frequently made by exclusion or on the basis of presence of a malignancy elsewhere in the 
body 
The nature of the primary tumour plays an important part in the diagnostics of 
most uveal metastases Metastases from breast cancer show a different picture than 
metastases from lung cancer and can be differentiated better from other intraocular 
tumours In contrast to patients with uveal metastases from breast cancer, in patients with 
lung cancer the detection of the intraocular tumour precedes the diagnosis of the primary 
malignancy in one-half of the cases. 
Uveal metastases have to be differentiated in particular from melanomas, 
haemangiomas and naevi of the uvea They also have to be differentiated from a number 
of less frequently occurring tumours such as leiomyomas, adenomas and osteomas and 
from conditions that may simulate a malignant tumour such as subretinal haemorrhages, 
retinal degenerations and choroidal detachments. Retinoblastomas can be differentiated 
from metastases without problems, owing to the early age of the patients and the clinical 
features of these tumours 
Although there is no pathognomonic picture of uveal metastases, a number of 
features nevertheless are more or less specific An anamnesis with a known malignancy 
elsewhere in the body may call the investigator's attention to the possibility of intraocular 
metastasization In our retrospective patient group, in 76% of the patients with uveal 
metastases a primary tumour elsewhere in the body was known at the time of the 
ophtha!mological examination. In patients with a malignant melanoma of the uvea a 
second primary malignancy elsewhere in the body was known in 3% of the patients. In 
melanoma cases, therefore, simultaneous independent malignancies elsewhere in the body 
may be present, although rarely, and the presence of such a malignancy does not always 
indicate a metastasis. 
Another important finding is the presence of multiple and bilateral lesions. In 
melanomas and in other intraocular tumours or lesions suggestive of tumour other than 
metastases or retinoblastomas, this finding is rare. However, although characteristic of 
uveal metastases, multiple lesions occur in only 33% of the patients with intraocular 
metastases 
Uveal metastases are limited to the choroid in 95% of the cases. Localization of 
metastases in the ins or ciliary body is rare. 
The signs and symptoms in patients with uveal metastases are little specific and 
show many similarities to those described in other tumours Patients in general complain 
of loss of visual acuity. The median visual acuity after optimal correction is 0.5. Slight 
reaction of the antenor segment occurs sporadically and is mostly observed in patients 
with lung cancer and metastases in the ins or the ciliary body. 
The signs and symptoms in patients with a melanoma are comparable with those of 
patients with metastases. In haemangiomas, opaque media are reported less frequently and 
reaction of the antenor segment occurs only sporadically. In naevi there are in general no 
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complaints and no reaction of the anterior segement of the eye. It should be noted that the 
naevi in our study group constitute a selection of lesions in which initially presence of an 
intraocular malignancy was suspected. 
Ophthalmoscopy in metastases mostly reveals a yellowish-orange or cream-
coloured choroidal tumour with a mottled surface. Metastases from lung cancer often have 
a grey colour. As mentioned before, multiple or bilateral development of metastases is 
possible. The tumour is usually localized temporally in the fundus. The shape of the 
tumour at ophthalmoscopy is often left undescribed. In almost one-half of the cases the 
tumour is accompanied by a secondary retinal detachment. An intraocular haemorrhage is 
reported in 15% of the patients. Metastases in the anterior segment in our study group 
originated in all cases from lung cancer. 
Uveal melanomas are more often grey and less often yellowish-orange in colour 
than metastases. The orange lipofuscin pigment was described in 13% of the patients with 
a melanoma and only once in uveal metastases. Melanomas are localized in the temporal 
half of the fundus less frequently than metastases. Haemangiomas in 26% are typically 
salmon-pink in colour but they may show an ophthalmoscopical image similar to that of 
uveal metastases. More frequently than metastases and melanomas, haemangiomas are 
localized in the posterior pole. Intraocular haemorrhages are not observed in 
haemangiomas, in contrast to metastases and melanomas. Naevi are often substantially 
smaller than metastases and they are localized only rarely in the macular area. Mostly, 
naevi show a grey colour. Retinal detachment in naevi was not reported in our study 
group and intraocular haemorrhages were rare. 
No pathognomonic ophthalmoscopic image of uveal metastases exists, although 
multiple and/or bilateral presence and a mottled yellowish-orange pigmentation is 
regularly observed in metastases. 
Fluorescein angiography shows no characteristic pattern in uveal metastases. The 
technique is useful, however, to establish the extension of the lesion. In the early phases, 
hypofluorescence at the site of the metastasis is described. In the venous phase there is 
staining with a finely or grossly mottled pattern of hyperfluorescence. In most cases a 
hypofluorescent margin round the tumour is described, as well as hyperfluorescent spots 
on the tumour surface. 
The fluorescein angiographic picture in melanomas cannot be distinguished from 
that of metastases. However, in melanomas tumour vessels are observed more frequently. 
In haemangiomas early staining of the tumour is usually observed with less frequent 
hyperfluorescent spots and more frequent tumour vessels than in metastases. In one-third 
of the patients distinct fluorescein angiographic patterns are described, in the form of 
spongy configurations which are characteristic of haemangiomas. Naevi in most cases 
remain hypofluorescent in all phases of the examination. If hyperfluorescent spots are 
present, these are only rarely restricted to the margin of the lesion. 
Echography is of great importance for the diagnosis of metastases. Echo-
graphically, a metastasis as a rule is seen as a flat or dome-shaped mid-reflective tumour 
with a broad base and an inhomogeneous infrastructure. A noticeable aspect is the low and 
regular reflectivity that can be observed frequently in metastases of lung cancer and which 
corresponds more to a uveal melanoma. 
Apart from a low regular reflectivity, a choroidal excavation, vascularity and an 
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orbital shadow are observed more frequently in melanomas than in metastases, and a 
melanoma is more prominent. Another characteristic feature of melanomas is the 
mushroom shape which is observed in 22% of the tumours. However, such a shape is also 
described in two patients with a uveal metastasis in our study. In haemangiomas a high-
reflective dome-shaped tumour is observed without choroidal excavation or orbital 
shadow. Naevi in most cases are hardly or not observed echographically owing to the low 
prominence of the lesion. 
The perimetric findings in patients with metastases, melanomas and haemangiomas 
are comparable, with mostly an absolute scotoma. The inclination of this scotoma is 
sloping significantly more often in metastases than in melanomas. In naevi, visual field 
defects are observed far less often. The value of perimetry for the diagnosis of uveal 
metastases is limited. 
By means of electro-oculography an abnormality of the natural potential of the eye 
can be established in uveal metastases. This examination does not permit differentiation of 
metastases from melanomas, however. 
With respect to other examination techniques such as CT, MRI, isotopes, etcetera, 
we have too few data at our disposal to offer a view concerning the contribution they may 
make to the diagnosis and differentia] diagnosis of uveal metastases. The value of these 
techniques appears for the time being to be limited. 
It may be concluded that in a patient with an intraocular lesion with suspicion of 
tumour, in addition to a detailed opti thai mological and general anamnesis, 
ophthalmoscopy, echography and fluorescein angiography are necessary for the diagnosis. 
Although metastases do not show a pathognomonic picture, the various examinations 
supplement one another. Electro-oculography may be performed to provide an indication 
about the malignant or benign nature of the lesion. Absence of a visual field defect is an 
argument for the diagnosis of naevus. 
Apart from a general physical examination, in patients with an intraocular tumour-
like lesion roentgen examination of the thorax and biochemical testing have to be carried 
out in all cases to exclude a possible primary malignancy or metastases elsewhere in the 
body. In female patients with suspicion of intraocular metastases, mammography is also 
indicated. If the diagnosis remains uncertain, the lesions should be followed up accurately 
to detect any growth or any tumour-specific characteristics developing later. 
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2.4 Treatment and prognosis 
2.4.1 Management and treatment 
As mentioned in earlier chapters, uveal metastases in general are accompanied by serious 
complaints about the visual acuity. This causes major impairment of the quality of life, 
certainly in patients with bilateral involvement of the eyes. It is therefore of crucial 
importance to attempt to limit the loss of ocular function as much as possible, to arrest 
further deterioration and, if possible, to ensure improvement of the visual acuity. 
Furthermore, complications of uveal metastases such as secondary glaucoma have to be 
prevented. 
In patients with uveal metastases, the duration of survival after detection of 
intraocular metastases is only brief. Therefore, treatment not only should be effective, it 
should also be instituted without delay, cause few or no complications and require little 
after-treatment. 
Most patients with uveal metastases in our study group (60%) were subjected to 
radiotherapy (Table 2.4.1.1). Observation was decided on regularly, systemic therapy and 
enucleation occasionally and laser treatment once. In four patients the management after 
the detection of the intraocular lesion was not known. 
Table 2.4.1.1 Treatment in 87 patients with uveal metastases 
Patients 
Treatment N % 
Radiotherapy 52 60 
Observation 19 22 
Systemic therapy 5 6 
Enucleation 6 7 
Laser coagulation 1 1 
Unknown 4 5 
Patients with uveal metastases of breast cancer were found to have undergone radiotherapy 
more often (viz. 75%) than patients with lung cancer (50%) or patients with miscellaneous 
malignant tumours (20%). The last-mentioned two groups of patients were more 
frequently kept under observation, among other things for reasons of initial uncertainty on 
the diagnosis because at that moment no primary tumour was known. Lack of a known 
primary tumour was the case in 10 of the 19 patients kept under observation and four of 
the six patients in whom the eye was enucleated, as against only six of the 52 irradiated 
patients and none of the patients with systemic therapy. It was also found that in patients 
kept under observation and patients subjected to enucleation of an eye the prognosis quoad 
vitam was poorer, resulting in fewer possibilities of therapeutic intervention. 
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Table 2.4.1.2 Treatment in 87 patients with uveal metastases according to various parameters 
Treatment 
Radiotherapy 
Observation 
Systemic therapy 
Enucleation 
Laser coagulation 
Unknown 
Patients 
N 
52 
19 
5 
6 
I 
4 
% 
60 
22 
6 
7 
1 
5 
Age 
iyrs) 
Mean 
56 
64 
51 
55 
46 
63 
SD 
12 
12 
9 
14 
17 
Proimnenc« 
Median 
3.0 
3.0 
5.0 
4.5 
1.0 
(mm) 
Mean 
3.6 
3.9 
5.0 
4.9 
0.5 
2.2 
. 
SD 
2.3 
4.5 
2.0 
2.3 
1.5 
Median 
5.0 
4.5 
9.0 
13.0 
4.0 
Base 
(DD) 
Mean 
6.1 
5.6 
9.0 
11.3 
3.0 
4.3 
SD 
3.7 
4.4 
4.6 
3.5 
1.5 
Distance from 
(DD)* 
Median Mean 
1.0 
0.5 
0 
0 
0.5 
1.7 
1.3 
0.1 
0.3 
3.0 
3.5 
fovea Retinal 
detachment 
SD % 
2.4 
1.7 
0.3 
0.6 
6.4 
52 
58 
40 
83 
100 
80 
Best visual acuity 
before treatment 
Median Mean SD 
0.55 0.56 0.32 
0.40 0.38 0.32 
0.60 0.49 0.45 
0.23 0.28 0.31 
0.80 
0.45 0.45 0.07 
DD: disk diameter; * in choroidal metastases 
Table 2.4.1.2 presents a survey of a number of important parameters for the 
various methods of treatment. 
In patients in whom the eye was enucleated or who were treated with systemic 
therapy, the prominence measured echo-graphically and the tumour base as established at 
ophthalmoscopy were larger than in patients who were irradiated or observed while the 
tumour was also situated closer to the fovea. In patients in whom the eye was enucleated a 
retinal detachment was present more frequently. The best visual acuity prior to treatment 
was higher in irradiated patients (median 0.55) and in patients treated with systemic 
therapy (0.60) than in patients in whom the tumour was observed (0.40) or the eye was 
enucleated (0.23). 
The various forms of treatment or management will be discussed successively, with 
their effect on the tumour size and the visual acuity, as well as the side effects, if any. 
2.4.1.1 Radiotherapy 
Radiotherapy is an accepted method of treating uveal metastases (Orenstein et al., 1972; 
Röttinger et al., 1976; Stephens and Shields, 1979; Mewis and Young, 1982; 
Lommatzsch, 1989). The literature on radiotherapy of uveal metastases is discussed in 
Chapter 1.6.1.4. The present chapter reports the results of a personal retrospective study 
of the effect of irradiation on uveal metastases in our clinic. Special attention is paid to 
the influence of irradiation on the prominence of the metastases and on the visual acuity. 
Patients 
During the period from November 1970 to November 1990 uveal metastases were 
diagnosed in 87 patients. Fifty-two patients (60%) were irradiated. The other 35 patients 
were managed in different ways as described in Chapter 2.4.2. That chapter also describes 
how the indication for treatment was established. Irradiation of uveal metastases was 
carried out in 43 females and nine males, with an average age of 56 years (range 27-79 
years). All metastases were localized in the choroid. The primary tumour was usually 
breast cancer (75%), less often lung cancer (19%) (Table 2.4.1.1.1). 
Table 2.4.1.1.1 Primary tumour in 52 patients with irradiated choroidal metastases 
Patients 
Primary tumour 
Breast cancer 
Lung cancer 
Thyroid cancer 
Bladder cancer 
Seminoma 
39 
10 
1 
1 
1 
75 
19 
2 
2 
2 
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In 46 of the 52 patients the optimal visual acuity or the acuity with own correction 
was known. It was 0.56 on average with a median of 0.55 (range 1/300-1.25). 
Ten metastases were localized inside the vascular arcade, 10 outside and 28 at the 
site of the vascular arcade. In four patients the exact localization of the metastasis was not 
known. The shortest distance between the margin of the tumour and the fovea was known 
in 44 patients; its mean was 1.7 disk diameter (DD) (median 1.0; range 0-13). A retinal 
detachment was present in 27 patients (52%). 
The echographically measured prominence was known in 41 patients; its mean was 
3.2 mm with a median of 3.0 mm (range 0.5-8.0). For the method of determining the 
prominence, the reader is referred to Chapter 2.3.4. 
The follow-up after irradiation of patients with choroidal metastases was 7.1 
months on average with a median of 4.2 months (range 0-30). At conclusion of the study 
49 patients had died. The mean duration of survival was 13.1 months with a median of 
8.5 months (range 1-42). 
Irradiation equipment, dose and technique 
In patients with bilateral metastases the following irradiation data refer to the eye with the 
metastasis diagnosed first or, if metastases were detected in both eyes at the same time, to 
the right eye. 
Irradiation equipment: in most cases a linear accelerator was used. Use was also made of 
a CO-60 equipment or of a combination of linear accelerator and CO-60 (Table 
2.4.1.1.2). The photon energies applied when linear accelerators were used ranged from 4 
to 18 MV, the most frequently applied energies being 18 MV (eight patients) and 4 MV 
(seven patients). The electron energy ranged from 9 to 13 MeV (Table 2.4.1.1.2). 
Table 2.4.1.1.2 Irradiation equipment in radiotherapy of 52 patients with choroidal 
metastases 
• • — ' " ' " • • • — 
Patients 
Irradiation equipment N % 
Linear accelerator (4-18 MV and 9-13 MeV) 26 50 
Co-60(1.25MV) 19 37 
Linear accelerator + Co-60 2 4 
Unknown S 10 
Radiation dose and fractionation: the values stated correspond to the minimal dose in the 
target volume; they were determined by means of the computer planning. The dosage used 
and the number of fractions of the irradiation are listed in Table 2.4.1.1.3. 
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Table 2 4 113 Total and fraction dose in radiotherapy of 52 patients with choroidal 
metastases 
^ ^ = ^ ^ д ^ ^ ^ ^ а ^ ^ ^ д ^ д ^ ^ ^ ^ ι ι lb 
Total dose 
(Gy) 
20 0 
26 5 
30 0 
30 0 
30 0 
36 0 
36 0 
38 0 
40 0 
40 0 
45 0 
50 0 
50 0 
Fraction dose 
(Gy) 
5 0 
3 0/2 5 * 
2 0 
2 5 
3 0 
2 0 
3 0 
2 0 
2 0 
3 0/2 0/1 0 ** 
3 0 
2 5 
2 0 
Number of 
fractions 
4 
10 
15 
12 
10 
18 
12 
19 
20 
15 
15 
20 
25 
Patients 
N 
1 
1 
4 
2 
19 
1 
1 
1 
16 
1 
1 
1 
1 
% 
2 
2 
8 
4 
37 
2 
2 
2 
31 
2 
2 
2 
2 
Unknown unknown unknown 2 4 
* three limes 3 0 Gy and seven times 2 5 Gy, ** three times 2 0 Gy, 11 times 3 0 Gy and once 1 0 Gy 
Two schedules were used most frequently: a total dose of 30 Gy in 10 fractions of 3.0 Gy 
(37%) and 40 Gy in 20 fractions of 2 0 Gy (31 %). No other doses and fractionations were 
commonly used. 
Virtually always 5 fractions were administered per week so that with a 30 0 Gy 
scheme in 10 fractions this dose was administered in 2 to 2.5 weeks with 40.0 Gy in 20 
fractions in 4 to 5 weeks. In one patient, however, a total dose of 30.0 Gy was 
administered divided into 10 fractions over a period of 4 weeks. 
Irradiation technique: as a rule, a lateral beam was used, with or without shielding of the 
lens Less frequently, a ventral beam was used, or a combination of these two The field 
size was usually 4x4 to 5x5 sq cm (Table 2.4 1.1.4). 
In 10 of the 52 irradiated patients the metastasis was localized within the arcade of 
the major retinal vessels. In seven of these patients a lateral beam was used, in two a 
ventral beam and in one, a combination of the two The same distribution of beam 
positions was used in 10 patients with a metastasis situated outside the vascular arcade. In 
the 28 patients in whom the metastasis was localized at the site of the vascular arcade, a 
lateral beam was applied to 14 and a ventral beam to 12 metastases. In one patient, a 
lateral and a ventral beam were combined, in one patient the beam position was unknown. 
In four patients the exact fundus localization of the metastasis was not mentioned. 
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Table 2.4.1.1.4 Beam positions in radiotherapy of 52 patients with choroidal 
metastases 
Beam position 
Patients 
N % 
Lateral beam 
Ventral beam 
Combined lateral and ventral beam 
29 
17 
3 
56 
33 
6 
Unknown 
Results 
For the determination of the effect of irradiation four moments were selected at which the 
reaction of the prominence was determined as a measure of tumour size and the visual 
acuity as a measure of function of the eye. These moments were 1, 3, 6 and 12 months 
after the start of the radiotherapy. Not for all moments were data on all patients known. 
For statistical reasons the tables concerning the effect of radiotherapy also include 
the patients with unknown results and not just patients with a known results because this 
would constitute a patient selection. 
Effect of irradiation on prominence: Table 2.4.1.1.5 presents a review of the effects of 
irradiation on the prominence of the tumour. The data are always compared with the 
findings at the ophtha!mological check-up at the most recent preceding moment. In this 
manner, regrowth after an initial decrease of the prominence could be established. 
Table 2.4.1.1.5 Effect of irradiation on prominence in 52 patients with choroidal 
metastases 
Prominence 
Interval after 
radiotherapy 
1 month 
3 months 
6 months 
12 months 
Decrease 
N 
13 
23 
8 
6 
% 
25 
44 
15 
12 
Stabilization 
N 
13 
4 
9 
7 
% 
25 
8 
17 
13 
Increase 
N 
4 
1 
2 
0 
% 
8 
2 
4 
-
Unknown 
N % 
22 42 
24 46 
33 63 
39 75 
Of 13 patients (25%) no data on the prominence of the metastasis were known after 
radiotherapy. In 39 patients follow-up data were available concerning at least one moment 
after irradiation; data concerning all four moments were available of only eight patients. A 
table was compiled concerning the effect of the irradiation on tumour size without stating 
the time after irradiation at which these data were known. Decrease of prominence was 
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defined as decrease of tumour size at least once after irradiation without subsequent 
growth. Stabilization of the prominence was defined as a tumour of the same size after as 
before irradiation without a decrease or increase of prominence being established at any 
time Growth was involved if the tumour after irradiation was described at least once as 
having increased in size. 
Table 2.4.1.1.6 Effect of irradiation on prominence in 52 patients with choroidal 
metastases 
Patients 
Prominence N % 
Decrease 28 54 
Stabilization S 10 
Increase * 6 12 
13 25 
Unknown 
* m two patients intrease of prominence one month after start of radiotherapy with subsequent decrease of 
prominence, in two patients increase of prominence one month after start of radiotherapy, no subsequent 
data known 
Table 2.4.1.1.6 gives a survey of the effect of radiotherapy on the prominence of the 
choroidal metastases (Figure 2.4.1.1.1). In 28 patients (54%) a decrease of the 
prominence was established, while m five patients (10%) the tumour did not increase in 
size. In six patients (12%) tumour growth occurred in spite of irradiation. In two patients 
this was established one month after the start of the radiotherapy, following which, 
however, the tumour decreased in size. In two other patients, as well, growth was 
established during the first month after irradiation. No further follow-up data on these 
patients were known. In the last two patients growth of the metastasis occurred over a 
period of 8 months (Figure 2.4.1.1.2). 
Effect of irradiation on visual acuity: more important than the effect of radiotherapy on 
the prominence is the effect on the function of the eye, and more in particular on the 
visual acuity. 
In Table 2.4.1.1.7 the mean visual acuity at the various moments is compared with 
the most recently known visual acuity before irradiation. 
Compared with the most recently known visual acuity before the start of the 
irradiation, the mean visual acuity had decreased 1, 3 and 12 months after irradiation and 
had remained stable 6 months after irradiation. These differences are not significant, 
however (p>0.10). 
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./.7. i Л- аж/ B-mode echogram of the right (a) and left eye (d) with choroidal metastases (blai 
от breast cancer; prominence of the lesion in the right eye before irradiation 4.5 mm, in the It 
im (note: extensive retinal detachment: white arrows). Five weeks after start of radiotherai 
f the prominence to 4.0 mm in the right eye (b) and to 3.0 mm in the left eye (e). Fourteen weei 
of radiotherapy further decrease of the prominence to 2.0 mm in the right eye (c), no lesic 
in the lefl eye (f): only a limited retinal detachment remained (white arrow). 
Figure 2.4.1.1.2 a. Fluorescein angiogram in venous phase of 
a choroidal metastasis in the right eye in a patient with breast 
cancer before radiotherapy, b. Fluorescein angiogram of the 
same lesion nine months later: atrophy of retinal pigment 
epithelium as a result of the irradiation. 
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Table 2.4.1.1.7 Effect of irradiation on visual acuity in patients with choroidal 
metastases 
Visual acuity 
Before irradiation After irradiation 
Interval after irradiation 
1 month 
3 months 
6 months 
12 months 
* number of patients in 
* N 
27 
29 
21 
14 
whom the visual acuity 
Mean 
0.49 
0.51 
0.52 
0.45 
both before and 
SD 
0.32 
0.34 
0.34 
0.29 
after radiotherapy 
Mean 
0.39 
0.43 
0.54 
0.40 
was known 
SD 
0.34 
0.35 
0.35 
0.34 
Improvement of visual acuity may be defined as an increase of the acuity by at least two 
lines on Snellen's chart, a decrease of the visual acuity as a reduction of the acuity by 
minimally two lines, and stabilization as results in between (Table 2.4.1.1.8). 
Table 2.4.1.1.8 Effect of irradiation on visual acuity related to the visual acuity 
before radiotherapy in 52 patients with choroidal metastases 
Interval after 
radiotherapy 
1 month 
3 months 
6 months 
12 months 
N 
4 
6 
5 
1 
Increase 
% 
8 
12 
10 
2 
Visual acuity 
Stabilization 
N 
13 
13 
12 
9 
% 
25 
25 
23 
17 
N 
10 
10 
4 
4 
Decrease 
% 
19 
19 
8 
8 
Unknown 
N % 
25 48 
23 44 
31 60 
38 73 
In four patients, after irradiation the ophthalmologist in charge described an improvement 
in visual acuity, which was not further specified. In another such patient the visual acuity 
was stabilized. In a patient with deterioration of the visual acuity after one month, this 
acuity was found to have been measured at that moment in mydriasis, so that it was not 
valid. In another patient with a decrease of the visual acuity in the first month, there later 
occurred an increase of the acuity which was not further specified. When the effect of 
radiotherapy on the visual acuity in these seven patients is included in the results, and the 
acuity is evaluated independently of the time elapsed after irradiation, the following result 
is obtained (Table 2.4.1.1.9). 
Stabilization or improvement of the visual acuity in relation to the visual acuity 
before irradiation therefore was obtained in 62% of the patients treated with radiotherapy. 
In 19% the eyesight deteriorated in spite of treatment (Colour plates 11 and 12). In 
another 19% the effect of treatment was unknown. 
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Table 2.4.1.1.9 Effect of irradiation on visual acuity in 52 patients with choroidal 
metastases 
Patients 
Effect on visual acuity 
13 
19 
10 
25 
37 
19 
Increase 
Stabilization 
Decrease 
Unknown 10 19 
Overall effect of irradiation: although a decrease of the prominence without improvement 
of the visual acuity would appear not to contribute directly to an improvement of the 
quality of life, the risk of ocular complications is reduced in such cases, however. 
The overall effect of radiotherapy is composed of the effect on the prominence and 
that on the visual acuity. A favourable result was defined as an increase of visual acuity 
by at least two lines on Snellen's chart or a decrease of the prominence; a stabilization as 
a change of the visual acuity of less than two lines on Snellen's chart and a stabilization of 
the prominence (or one of the two if the other criterion was unknown); a result was 
classified as unfavourable if visual acuity decreased by at least two lines on Snellen's chart 
and the prominence was stabilized, increased or unknown or if the prominence increased 
while visual acuity was stabilized or unknown. In this manner, the following result was 
obtained (Table 2.4.1.1.10): 
Table 2.4.1.1.10 Overall effect of irradiation in 52 patients with choroidal metastases 
Patients 
Overall effect N % 
Improvement 
Stabilization 
Deterioration 
Unknown 6 12 
In 65% of the patients a positive result of radiotherapy was established with improvement 
of visual acuity or decrease of prominence, while in 12% the condition was stabilized 
(Colour plates 13 and 14; Figure 2.4.1.1.3). Twelve per cent of the patients showed no 
positive response to irradiation. In 12%, the effect was unknown. 
34 
6 
6 
65 
12 
12 
293 
Figure 2.4.1.1.3 a. Fundus photograph showing a choroidal 
metastasis from breast cancer in the left eye two weeks before 
radiotherapy, b. Fundus photograph of the same tumour at 
start of radiotherapy with evident growth of the lesion extending 
over the optic disk 
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Figure 2.4.1.1.3 (continued) с. Fundus photograph of the same 
metastasis four months after start of radiotherapy. The 
prominence of the lesion has decreased with pigment changes 
on the tumour surface and at the tumour margin, d. Eleven 
months after start of radiotherapy only a flat pigmented 
choroidal scar at the site of the lesion remains. 
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Figure 2.4.1.1.3 (continued) e. Fluorescein angiogram in the 
late venous phase showing the same lesion at the start of 
radiotherapy (same date as fundus photograph b). 
f Angiogram in the late venous phase four months after start of 
irradiation with marked reaction and atrophy of the lesion 
(same date as fundus photograph c). 
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Factors influencing the effect of irradiation: a number of factors may influence the 
radiotherapeutic effect on visual acuity. These are: 
1. the interval between the moment of diagnosis and the start of the irradiation; 
2. the visual acuity before treatment; 
3. the distance of the metastasis from the fovea; 
4. the presence of a retinal detachment; 
5. the nature of the primary tumour; 
6. the effect of the irradiation on the prominence of the metastasis; 
7. the radiation dose. 
1. Interval between the moment of diagnosis of the choroidal metastasis and start 
of the radiotherapy: in 15 patients radiotherapy was administered no longer than two 
weeks after the moment of diagnosis of the choroidal metastasis, in 19 patients between 
two weeks and one month and in 18 patients more than one month after the 
ophthalmological diagnosis. Stabilization or improvement of the visual acuity after 
irradiation, compared with the acuity at the time of diagnosis occurred in these three 
groups in 64, 69 and 60%, respectively, of the patients of whom the visual acuity both 
before and after treatment was known. This difference is not statistically significant. 
2. With regard to the most recently known visual acuity before irradiation, a 
distinction was made between a visual acuity <0.30 (social blindness), between 0.30 and 
0.80 and >0.80 (normal). Table 2.4.1.1.11 shows the effect of irradiation on the visual 
acuity subdivided according to the last known visual acuity. 
Table 2.4.1.1.11 Effect of irradiation on visual acuity according to the last known 
visual acuity before radiotherapy in 47 patients * with choroidal 
metastases in terms of percentage 
Visual acuily 
before irradiation 
50.30 
0.30-0.80 
50.80 
N 
15 
18 
14 
Increase 
47 
22 
14 
Visual 
Stabilization 
40 
39 
43 
acuity 
Decrease 
7 
28 
29 
Unknown 
7 
11 
14 
* visual acuity before radiotherapy m five of 52 irradiated patients unknown 
Of the patients with an initial visual acuily of maximally 0.30, 87% showed preservation 
or improvement of visual acuity as against 61% of patients with a visual acuity between 
0.30 and 0.80, and 57% of the patients whose visual acuity prior to treatment had been at 
least 0.80. 
3. A factor possibly influencing the effect of treatment might be the distance from 
the margin of the metastasis to the fovea. A tumour localized in the macular area may 
have caused irreversible damage to the sensory cells so that treatment has little or no 
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effect. In our study group, the average distance between tumour and fovea amounted to 
1.8 disk diameters (DD) in patients with a favourable effect of the irradiation on the visual 
acuity and to 2.0 DD in those whose eyesight deteriorated. In those with stabilized visual 
acuity the mean distance was 0.7 DD. 
4. The presence of a retinal detachment before treatment may affect the result of 
the irradiation. Table 2.4.1.1.12 presents a survey in which a limited retinal detachment is 
defined as a detachment occupying less than one-quarter of the fundus and an extensive 
detachment as a retinal detachment over more than one-quarter of the surface of the 
fundus. 
Table 2.4.1.1.12 Effect of irradiation on visual acuity in relation to the presence and 
extent of a retinal detachment in 52 patients with choroidal 
metastases 
Visual acuity 
Retinal detachment Increase Stabilization Decrease Unknown 
None 4 12 4 2 
Occupying < 25 % of the fundus 6 4 4 3 
Occupying ¿25% of the fundus 3 3 2 3 
Unknown - - - 2 
In 16 of the 20 patients with a choroidal metastasis without retinal detachment in 
whom the effect of the irradiation on the visual acuity was known, stabilization or 
improvement of the eyesight was established, just as in 10 of the 14 patients with a limited 
and in six of the eight patients with an extensive retinal detachment. These differences are 
not significant (p>0.10). 
5. The nature of the primary tumour and the effect of irradiation on the visual 
acuity are listed in Table 2.4.1.1.13. 
Table 2.4.1.1.13 Effect of irradiation on visual acuity according to the primary 
tumour in 52 patients with choroidal metastases in terms of 
percentage 
Pnmary tumour 
Breast cancer 
Lung cancer 
Miscellaneous * 
N 
39 
10 
3 
Increase 
23 
40 
-
Visual 
Stabilization 
38 
20 
67 
acuity 
Decrease 
21 
10 
33 
Unknown 
18 
30 
-
* once seminoma (with elements of teratoma); once thyroid cancer; once bladder cancer 
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Improvement or stabilization of the visual acuity was achieved in 61% of the 
patients with breast cancer, in 60% of the patients with lung cancer and in 67% of the 
patients with a different primary tumour. 
6. The effect of the irradiation on the prominence of the metastasis was compared 
with the effect on the visual acuity. In four of the six patients with an increase of the size 
of the tumour in spite of irradiation a deterioration of the visual acuity was observed, in 
one patient the visual acuity remained stable and once it improved in spite of growth of 
the metastasis. 
In seven of the 13 patients in whom the visual acuity improved by at least two 
lines on Snellen's chart, a decrease of the tumour size was established during the follow-
up period. In one patient, in whom the prominence initially decreased but then increased 
again, improvement of the visual acuity was nevertheless observed. In five patients, the 
effect of the irradiation on the prominence was not known. 
7. In this retrospective study, in 34 of the 52 patients two irradiation schedules 
were applied. These were a dose of 30.0 Gy in 10 fractions of 3.0 Gy, in 2 to 2.5 weeks 
(18 patients) and 40.0 Gy in 20 fractions of 2.0 Gy in 4 to 5 weeks (16 patients). One 
patient was given a dose of 30.0 Gy in 10 fractions in a period of four weeks. This 
patient, therefore, was not included in the '30.0 Gy group'. In Table 2.4.1.1.14 the 
patients of these two groups are compared. 
Table 2.4.1.1.14 Comparison of 30.0 Gy scheme and 40.0 Gy scheme on various 
parameters in patients with choroidal metastases 
30.0 Gy scheme 
(N=18) 
40.0 Gy scheme 
(N=16) 
Age: mean (SD): yrs 60 (11) 56 (15) 
Primary lumour: 
Breast cancer 
Lung cancer 
Other 
Prominence: mean/median (SD): mm 
Base: mean/median (SD): DD 
Distance from fovea: mean/median (SD): DD 
Retinal detachment 
Visual acuity before irradiation: mean/median (SD) 
Follow-up after irradiation: mean/median (SD): months 5.1/3.0 (5.6) 
13 (72%) 
5 (28 %) 
-
3.3/3.0 (1.7) 
6.0/4.0 (4.0) 
1.8/1.0 (1.8) 
11 (61%) 
0.65/0.60 (0.27) 
. .  .  
11 (69%) 
2 (13%) 
3 (19%) 
3.5/3.0 (2.7) 
6.8/5.8 (3.5) 
1.8/1.0 (3.4) 
10 (63%) 
0.40/0.40 (0.29) 
10.7/6.0 (11.3) 
DD: disk diameter 
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The various basic data of these two treated groups were comparable except for the 
visual acuity and the duration of the follow-up. The visual acuity in the group of patients 
irradiated with 30.0 Gy was significantly higher (p<0.02) (average 0.65; SD 0.28) than 
in the group irradiated with 40.0 Gy (average 0.40; SD 0.29). The follow-up after 
irradiation was shorter in patients of the 30.0 Gy group (mean 5.1 months) than in the 
40.0 Gy group (mean 10.7 months) (p<0.10). 
As regards the prominence, a decrease of the tumour size during the follow-up 
occurred in eight of the 18 patients irradiated with 30.0 Gy while in two patients the size 
remained stable. Of the 16 patients in the 40.0 Gy schedule, 12 showed a decrease and 
one, stabilization (Table 2.4.1.1.15). 
Table 2.4.1.1.15 Effect of irradiation on prominence in patients with choroidal 
metastases according to irradiation scheme 
Prominence 
Decrease 
Stabihzadon 
Increase 
30.0 Gy 
N 
8 
2 
2 
(N= 
• scheme 
12) * 
% 
67 
17 
17 
40.0 Gy scheme 
(N=15) ** 
N % 
12 80 
1 7 
2 13 
* in six of 18 patients irradiated with 30.0 Gy scheme effect on prominence unknown; ** in one of 16 
patients irradiated with 40.0 Gy scheme effect on prominence unknown 
Tables 2.4.1.1.16 and 2.4.1.1.17 present a review concerning the effect of these two 
irradiation schemes on the visual acuity. 
Table 2.4.1.1 
Interval after irra 
30.0 Gy scheme 
1 month 
3 months 
6 months 
12 months 
40.0 Gy scheme 
1 month 
3 months 
6 months 
12 months 
.16 Effect Of ii 
metastases 
idiation 
(N=18) 
(N=16) 
•radiation on 
according to 
* N 
7 
8 
7 
3 
14 
12 
8 
7 
visual acuity in patients with с 
irradiation scheme after differ 
Visual acuity 
before irradiation 
0.62 
0.67 
0.65 
0.47 
0.40 
0.42 
0.48 
0.39 
horoidal 
ent intervi 
Visual 
after irrai 
Jls 
acuity 
diation 
0.41 
0.43 
0.61 
0.35 
0.36 
0.44 
0.59 
0.46 
* number of patients with known visual acuity both before and after irradiation 
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Table 2.4.1.1.17 Effect of irradiation on visual acuity in patierus with choroidal 
metastases according to irradiation scheme irrespective of interval 
Visual acuity 
Increase 
Stabilization 
Decrease 
30.0 Gy 
N 
6 
3 
5 
( N -
• scheme 
14) Φ 
% 
43 
21 
36 
40.0 Gy scheme 
(N=15) ** 
N % 
3 20 
9 60 
3 20 
* in four of 18 patients irradiated with 30.0 Gy scheme effect on visual acuity unknown; ** in one of 16 
patients irradiated with 40.0 Gy scheme effect on visual acuity unknown 
Table 2.4.1.1.18 compares the overall effect of the two irradiation schemes on both visual 
acuity and prominence. 
Table 2.4.1.1.18 Overall effect of irradiation in patients with choroidal metastases 
according to irradiation scheme 
Overall effect 
Improvement 
Stabilization 
Deterioration 
30.0 Gy 
N 
11 
1 
3 
(N = 
• scheme 
15) + 
% 
73 
7 
20 
40.0 Gy scheme 
(N=16) 
N % 
13 81 
1 6 
2 13 
* in three of 18 patients irradiated with 30.0 Gy scheme overall effect unknown 
The difference in overall effect between the 30.0 Gy scheme and the 40.0 Gy scheme is 
not statistically significant (p>0.10). 
Side effects of radiotherapy 
The acute and late side effects of radiotherapy were minor. In 38 patients (73%) no side 
effects occurred. In nine patients (17%) conjunctivitis responding well to treatment was 
described. Once, an acute glaucoma developed due to massive tumour necrosis four weeks 
after the start of the radiotherapy (Figure 2.4.1.1.4). Of four patients no data on side 
effects were known. 
During the follow-up of the irradiated patients with choroidal metastases, no 
cataract was reported. 
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Figure 2.4.1.1.4 α. B-mode echogram of 9.0 mm prominent 
dome-shaped choroidal metastasis from thyroid cancer I 
week before radiotherapy, b. B-mode echogram of the same 
lesion during radiotherapy now showing a dense vitreous 
haemorrhage, с B-mode echogram 5 weeks after start of 
irradiation showing clearing of the blood in the vitreous and 
vacuoles in the tumour suggestive of necrosis. 
Discussion 
A disadvantage of retrospective studies is that at evaluation some of the data of the 
patients examined are found not to have been recorded. One can process only a part of the 
total material, which automatically implies a selection from the study group, or accept that 
a number of data are lacking. For the descriptions in this disseration the latter option was 
accepted. 
The purpose of irradiation of choroidal metastases is to preserve or improve the 
patient's eyesight and to prevent complications. In this way an important contribution may 
be made to the quality of the remaining period of life. 
In this study group, radiation was administered by means of a linear accelerator or 
Co-60 equipment. Vanous doses and fractionations were applied. The most frequently 
chosen schemes were total doses of 30.0 Gy in 10 or of 40.0 Gy in 20 fractions. Beams 
both from lateral and from ventral were used. For metastases at the site of the vascular 
arcade a lateral and a ventral beam were used with the same frequency while for 
metastases situated within or outside the arcade of the major vessels, a lateral beam was 
used more often. 
Owing to the brief follow-up and the short duration of survival of patients with 
irradiated choroidal metastases, it was not always possible to describe the long-term effect 
of irradiation. Moreover there was no fixed protocol concerning the moments of 
ophthalmological follow-up. This was also why in 44 of the 52 patients it was not possible 
to determine the effect of the irradiation on the visual acuity and prominence at all fixed 
moments, so that it was necessary to assess the effect regardless of the length of time 
elapsed after irradiation. 
Furthermore it is to be assumed that during the interval between the time of the 
diagnosis of the choroidal metastasis and the start of the irradiation some proliferation of 
the tumour will have occurred. This proliferation, or the development of a retinal 
detachment will have caused further deterioration of the eyesight that may have escaped 
notice. Consequently, the initial values at the start of the treatment of both visual acuity 
and prominence probably have been more unfavourable than indicated by the above-named 
results. 
Literature data refer to a decrease of the prominence in 57 to 80% of the patients 
in whom the effect of irradiation was known (see Table 1.6.1.4.5). The results of this 
study are similar, a decrease of the prominence was described in 54% of all patients. 
However, the effect of the irradiation on the prominence was unknown in 25%. 
Consequently, a decrease of the tumour size was established in 72% of those patients in 
whom the effect of radiotherapy was known. Further tumour growth in spite of irradiation 
was observed in 12% of the patients. 
Stabilization or improvement of the visual acuity after irradiation was desenbed in 
the literature in 52 to 100% of the patients. In our study group, such a result was 
observed in 62% of all patients and in 76% of the patients in whom the effect of 
irradiation on the eyesight was known. This, therefore, is also in agreement with the 
literature data and points to a good functional result of irradiation of choroidal metastases. 
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A number of possible influences on the effect of the irradiation with regard to the 
visual acuity were investigated in greater detail. 
The first of these was the interval between the moment of the diagnosis and the 
start of the treatment. Among intervals of two weeks at most, two weeks to one month 
and one month at least, no significant difference in effect on the visual acuity was 
observed. This interval, therefore, does not influence the effect of irradiation. 
The initial visual acuity is important because in patients with poor eyesight before 
treatment an improvement of the visual acuity was established more often than in patients 
with a high initial value. Obviously, no improvement of the eyesight is possible in patients 
who already have an optimal visual acuity before treatment. Consequently, for assessment 
of a favourable effect of radiotherapy both preservation and improvement of the visual 
acuity should be taken into account. 
Tumours situated close to the fovea may cause irreversible damage to the macula 
so that radiotherapy will not lead to improvement but at best to stabilization of the 
eyesight. No distinct correlation could be demonstrated in our study, however. 
With regard to stabilization or improvement of the eyesight no significant influence 
was observed of the presence or extension of a secondary retinal detachment (p>0.10). 
No clear relationship existed between the nature of the primary tumour and the 
effect of irradiation. 
The effect of irradiation on the visual acuity was distinctly correlated, however, 
with the effect on the prominence. During further growth of the metastasis, deterioration 
of the eyesight was observed in four of the six patients. In seven of the 13 patients with 
an improvement of the eyesight, a decrease of the prominence was observed, in one 
patient there was growth while in five patients this was unknown. 
Finally, the effect of irradiation with a 30.0 Gy scheme was compared with the 
effect of an irradiation scheme of 40.0 Gy. 
With the 30.0 Gy scheme, regarding fixed moments after irradiation, there was a 
tendency to further deterioration of the mean visual acuity in spite of radiotherapy, while 
patients irradiated with the 40.0 Gy scheme tended more to stabilization or improvement 
of the mean acuity. However, it should be noted that of a relatively large number of 
patients on the 30.0 Gy scheme the visual acuities both before and after radiotherapy were 
not known at all fixed moments. 
On the other hand, with the 30.0 Gy scheme, regarding the effect of irradiation 
irrespective of the moment of check-up, improvement of the eyesight was established in 
43% of the patients as against 20% with the 40.0 Gy scheme, while stabilization was 
observed in 21% and 60%, respectively. It appeared, therefore, that improvement of the 
eyesight occurred more often with the 30.0 Gy scheme and stabilization with the 40.0 Gy 
scheme. 
The initial visual acuity with the 40.0 Gy scheme was lower than with the 30.0 Gy 
scheme, viz. 0.40 and 0.65 on average which, as described before, has consequences for 
the effect of irradiation. Furthermore, the follow-up after irradiation in patients with a 
40.0 Gy scheme was twice as long (median 6.0 months) as in patients irradiated with 30.0 
Gy (median 3.0 months). Consequently, in patients irradiated with 40.0 Gy data could be 
collected over a longer period. 
As the overall effect shows, the difference between the 30.0 Gy and the 40.0 Gy 
schemes regarding improvement or stabilization of the condition compared with 
deterioration of the disorder was not statistically significant (p>0.10). However, the 30.0 
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Gy scheme causes less inconvenience to the patients because of the far shorter duration of 
the treatment. 
Side effects were slight in our study group. The most frequent side effect was 
conjunctivitis which could be adequately controlled. In only one case did an acute 
glaucoma develop due to massive tumour necrosis. 
Conclusions 
The objective of therapy is an improvement of the quality of life. Irradiation of choroidal 
metastases in this retrospective study led to a decrease or stabilization of the prominence 
of the metastases (64%) and/or stabilization or improvement of the visual acuity (62%). 
The effect of radiotherapy on the eyesight was related to the effect on the prominence and 
to the visual acuity prior to irradiation. No influence was established of the interval 
between the moment of diagnosis and the start of the irradiation, of the distance of the 
metastasis from the fovea, of the presence or absence of a retinal detachment, of the 
nature of the primary tumour or of the two irradiation schemes. Side effects were few. 
Consequently, radiotherapy makes an important contribution to the quality of life. 
Ophthalmological follow-up of irradiated patients with choroidal metastases, with 
adequate determination of the visual acuity at fixed moments is necessary if the effect of 
radiotherapy on the visual acuity is to be described accurately. However, the palliative 
character of the treatment should be kept in mind. Unnecessarily frequent and extensive 
control examinations should be avoided. 
It may be concluded that in the treatment of choroidal metastases an irradiation 
scheme of 30.0 Gy in 10 daily fractions gives an adequate result with few side effects. To 
protect the lens it is recommended in unilateral lesions to irradiate via a lateral beam 
directed 5° occipitally or via a half-beam technique. If metastases are present in both 
eyes, parallel opposed beams are advised. In metastases at the site of the equator, 
preference may be given to irradiation from ventral by means of photon or electron beams 
with shielding of the lens and of the lacrimal gland. 
2.4.1.2 Observation 
In the literature observation of uveal metastases in patients who are in a terminal phase of 
the malignant disease is an accepted course of action (Ferry, 1978). Also, an expectative 
attitude may be assumed in small lesions (Brady et al., 1982) and in patients in whom the 
fovea is not threatened by the tumour or a secondary retinal detachment (Stephens and 
Shields, 1979). 
In our study group an expectative policy was pursued in a total of 19 patients with 
uveal metastases (22%). Eight of these patients had a metastasis from breast cancer, four 
patients one from lung cancer and seven patients, one from another primary tumour. 
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In 12 of the 19 patients radiotherapy was advised. However, in 10 patients the 
clinical condition at referral was found to be too poor, for which reason treatment was 
refrained from. In one patient, irradiation was postponed because of iridocyclitis that 
could not be controlled. The twelfth patient refused irradiation. Follow-up of these 
patients was limited to two months at most: in two patients deterioration of the eyesight 
was established, in one the eyesight improved (after cataract extraction with implantation 
of an arti ficai lens) and in one patient the visual acuity remained stable. On the other eight 
patients no follow-up data were available. In these patients, therefore, only little was 
known about the period after the ophthalmological diagnosis. Consequently, no statement 
can be made on the basis of these patients about the natural course of an untreated uveal 
metastasis. 
In seven patients observation was decided upon for various other reasons. 
One patient had already been irradiated all over the neurocranium because of 
cerebral metastases. The irradiation field included the posterior parts of both orbits. It was 
decided to administer no local radiotherapy to the uvea. The visual acuity improved in one 
month from 0.6 to 1.25. Six months later visual acuity was still 1.0. 
Another patient, with a uveal metastasis of a squamous cell carcinoma of the lung 
was not irradiated because such a metastasis was believed to be insensitive to 
radiotherapy. Further follow-up data were lacking. 
In two patients at the first ophthalmological examination the metastasis appeared 
already to be partially in regression and an expectative policy was pursued. One of these 
two patients was followed up for 7 months longer during which the visual acuity remained 
stable at 0.8. 
In three patients the reason for observation was an initial uncertainty regarding the 
nature of the intraocular tumour. In one patient the visual acuity remained stable at 1/60 
for 7 months, in a second it decreased in 5 months from 0.25 to 2/60. In the third patient, 
only one check of the visual acuity was known at which time it was light perception only. 
2.4.1.3 Systemic therapy 
Five patients at the time of diagnosis of the intraocular tumour had not yet undergone 
systemic treatment for the primary malignancy, three times because at the time of the 
diagnosis of the uveal metastasis no primary tumour was known. It was decided to await 
the effect of this therapy before resorting to radiotherapeutic treatment, if necessary. 
The first patient was a female aged 43 years with deterioration of the visual acuity 
in the left eye to 1/60, in whom ophthalmoscopy revealed a lesion suspicious for a 
metastasis with a secondary retinal detachment. A few days later breast cancer was 
diagnosed for which she was treated by means of ovariectomy and chemotherapy in the 
form of fluorouracil. At ophthalmological check-up two weeks later, visual acuity had 
increased to 0.5, the prominence of the tumour had distinctly decreased and the retinal 
detachment had disappeared. One and a half years later, visual acuity had increased 
further to 0.8 and ophthalmoscopically, no tumour was present any longer. The patient 
died 3.5 years after the detection of the uveal metastasis. 
The second patient was a female aged 53 years with deterioration of the visual 
acuity in the right eye to 1/60 and an intraocular tumour which was suspected of being a 
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melanoma or a metastasis of lung cancer. Two months later, a pulmonary carcinoma with 
hepatic metastases was diagnosed. Chemotherapy was started with cisplatin and VM-26. 
After two months, the visual acuity in the right eye had increased to 0.5+ and 
ophthalmoscopically the metastasis had gone into regression. However, one month later, at 
the last check-up the visual acuity had decreased again to 0.25 without changes in the 
ophthalmoscopic image. The patient died 11 months after the diagnosis of the intraocular 
tumour. 
The third patient, a male aged 58 years, was referred with a rapidly growing 
tumour in the fundus and in the iris with secondary glaucoma. No data on this patient's 
visual acuity were available. The same day, lung cancer was diagnosed for which the 
patient was treated with irradiation of the primary lesion and chemotherapy. Within one 
month of this a decrease of the size of the uveal metastases was observed. At the last 
check-up, one year after the diagnosis of the intraocular tumour, some growth had 
occurred again, however. 
The fourth patient was a male aged 61 years in whom lung cancer had been 
diagnosed two months previously for which he had refused chemotherapy and had been 
treated primarily with radiotherapy of the pulmonary tumour. He complained of 
decreasing visual acuity in the left eye. Twenty-three years previously he had sustained a 
perforating injury in that eye, after which the visual acuity had always remained less than 
that in the right eye. The visual acuity in the left eye was 1/60 and temporosuperiorly in 
the fundus a choroidal metastasis was observed. The patient did accept chemotherapeutic 
treatment. This was started with a combination of cyclophosphamide, vincristine and 
procarbazine. However, the patient failed to return for ophthalmological check-up and 
died four months after the diagnosis of uveal metastasis. 
The fifth patient, finally, was a female aged 39 years, known since two years with 
breast cancer. The visual acuity in her right eye had decreased to 0.6 due to a choroidal 
metastasis. Radiotherapeutic treatment of this metastasis was recommended. An 
appointment for this was canceled because the patient had been hospitalized for an 
ovariectomy and treatment with neoblastine. Two months later, she came for 
ophthalmological check-up at which the vision in the right eye was found to be 0.7. The 
prominence had disappeared apart from some pigment clumping. 
In four of these five patients, therefore, the systemic therapy had a positive effect 
on the uveal metastases. In one patient, the effect was not known. Other investigators 
have already [minted out that systemic treatment of uveal metastases may be useful 
(Focosi and Salvi, 1961; Famarier et al., 1973; Smith, 1976; Stolzenbach and von 
Domarus, 1978; Turut et al., 1987). 
Such systemic hormonal or chemotherapy does not prevent uveal metastases, 
however: 12 of the 87 patients in our study received systemic treatment at the time of 
diagnosis of the uveal metastasis, while 51 patients received no systemic therapy and in 24 
patients, this was unknown. In 12 patients, therefore, uveal metastases developed in spite 
of the systemic treatment. 
It appears advisable only in a selected number of cases to await the effect of 
systemic therapy on the uveal metastases, viz. in patients who have not yet received 
systemic treatment for their malignancy. If the uveal metastasis seriously threatens the 
central visual acuity or has already impaired it, radiotherapeutic treatment of the eye, is 
recommended. 
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2.4.1.4 Enucleation 
Enucleation of ал eye with a uveal metastasis is indicated only in case of ophtha!mological 
complications (Stephens and Shields, 1979; Char, 1989). A number of authors state that in 
certain cases an indication for enucleation is also present in solitary uveal metastases 
without metastases elsewhere in the body being known (Font and Ferry, 1976; Schreck, 
1980). A controversial management is to resort to enucleation in case of a clinically 
distinct uveal metastasis in a patient with an unknown primary tumour, in order to attempt 
to determine the nature of the underlying malignancy by histopathological examination of 
the intraocular lesion (Hart, 1962; Daicker, 1981; Shields, 1983). However, most 
enucleations in patients with uveal metastases are carried out on the erroneous diagnosis of 
uveal melanoma (Ferry and Font, 1975; Colombo and Carnevali, 1985). 
In six patients of our study group the ophthalmological treatment consisted in 
enucleation of the affected eye. Three times this was done on the false diagnosis of uveal 
melanoma and only at histopathological examination was the lesion found to be a 
metastasis. In one patient the diagnosis was initially uncertain. Since the eye would be 
functionally destroyed it was enucleated after which the diagnosis of uveal metastasis was 
made. In two other patients, finally, enucleation had to be performed because of 
ophthalmological complications: once a painful right eye and once, a refractory secondary 
glaucoma. 
In one additional patient the eye was enucleated because the prominence of the 
intraocular tumour increased in height and the visual acuity deteriorated in spite of 
irradiation. This patient was included in the chapter on radiotherapy (Chapter 2.4.1.1). 
The other findings in these patients and a brief survey of the case histories are to 
be found in Chapter 2.3.8. 
2.4.1.5 Laser treatment 
In the literature, laser treatment of uveal metastases is described only a few times. On the 
whole such treatment is applied only exceptionally and then in small lesions (Weve, 1960; 
Daicker, 1981; Brady et al., 1982). 
In our study group one patient was treated with laser therapy. This was a female 
aged 46 years known with metastasized breast cancer when she began to complain of a 
spot in front of her right eye. Visual acuity was 0.8. Ophthalmoscopy revealed a choroidal 
metastasis with a prominence of 0.5 mm in a peripheral inferior position, with a local 
retinal detachment. The lesion was surrounded by a double row of laser coagulates and the 
tumour itself was subjected to extensive photocoagulation as well. After scar formation, 
the visual acuity improved to 1.2 at the last ophthalmological check-up two months later. 
The patient died one year after the diagnosis of the choroidal metastasis. 
In this patient laser treatment was efficacious. However, this involved only one 
case with low prominence from the early phase of the study (1973). In later periods, on 
the basis of experience gained in other institutes and reported in the literature, local 
radiotherapy was preferred for ophthalmological intervention because more frequent and 
better results might be expected of it and it could also be applied to prominent tumours. 
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2.4.1.6 Conclusions 
For the treatment of uveal metastases a number of possibilities are available. It is 
recommended to irradiate unilateral metastases according to a scheme of 30.0 Gy in 10 
daily fractions via a lateral beam directed 5° occipitally to protect the lens, or via a half-
beam technique. If bilateral metastases have been established, parallel opposed beams are 
advised. This treatment in most cases results in a decrease or stabilization of the 
prominence and/or stabilization or increase of the visual acuity. 
In patients with small uveal metastases without secondary retinal detachment in 
whom the visual acuity is not reduced or threatened and who have not yet received 
systemic therapy, the effect of hormonal or chemotherapy may be awaited. However, this 
necessitates thorough ophthalmological check-ups so that any growth of the metastasis or 
deterioration of the visual acuity will be detected immediately and radiotherapy can then 
be administered. 
Of laser treatment it is stated that it might be useful in metastases with low 
prominence. Our experience is limited, however. 
Enucleation of an eye with a metastasis is indicated only in a patient with an 
intractible painful blind eye due to local complications. 
Control examinations of patients with uveal metastases should be reduced to a 
minimum. It remains important, however, to examine the patient regularly in order that 
any complications or new metastases may be detected and treated as early as possible. To 
this purpose we recommend, if no particular events occur in the meantime, to examine 
patients with uveal metastases who will be irradiated in the week prior to the start of 
radiotherapy and 1, 2, 3, 6 and 12 months after the start of the treatment. In case of 
systemic therapy or an expectative policy, more frequent control examinations may be 
necessary. 
2.4.2 Prognosis 
How well the clinical course of uveal metastases can be described depends on the duration 
of the follow-up of these patients. Of the 87 patients with uveal metastases of our study 
group, nine patients were examined only once and no later clinical data were available. 
Seventy-eight patients had been examined ophthalmologically at least twice. 
The interval between the date of detection of the uveal metastasis and the date on 
which the patient was examined ophthalmologically for the last time was 7.6 months on 
average. The median was substantially lower, namely 4.5 months. This follow-up ranged 
from none to over four years. In patients with uveal metastases, therefore, data on the 
clinical course usually were known over only a brief period. 
Between the date of the last ophthalmological examination and the time of death in 
our patient group there was an interval with a mean of 5.7 and a median of 3.5 months. 
This amounts to almost one-half of the total duration of survival as known of patients with 
uveal metastases and described below. This is due to the fact that patients in the terminal 
phase of their disease in general were no longer examined ophthalmologically. 
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Figure 2.4.2.1 Kaplan-Meier survival curve for patients with uveal metastases 
(N=87). 
60 -
50 -
40 
30 
20 -
10 
0 
1 
12 
I • 1 
ί 
1 , 
1 
1 
1 1 1 
18 24 30 
y 
I 
36 
^ 
1 
42 
1 
48 
" I 
1 
54 
months 
Figure 2.4.2.2 Kaplan-Meier survival curve for patients with uveal metastases, 
subdivided according to the nature of the primary tumours: breast cancer 
(N=52); lung cancer (N=20); other localizations (N=15). 
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Consequently, data on the evolution of the ophthalmological picture and the effect of 
therapy, if any, are known for only a brief period after the diagnosis of the uveal 
metastasis. 
The Kaplan-Meier survival curve for patients with uveal metastases is shown in 
Figure 2.4.2.1. In Figure 2.4.2.2, the curve is subdivided according to the nature of the 
primary tumours. 
The follow-up of uveal metastases is determined for an important part by the 
mortality of the patients due to the underlying malignant disease. On the termination date 
of the study (13 November 1990), 76 patients were known to have died (87%); six other 
patients (7%) were still alive at that time while of the five remaining patients (6%) data 
concerning this were lacking. In 72 of the 76 patients who had died the date of death was 
known. Median duration of survival after the diagnosis of the uveal metastasis was 9.7 
months (mean 13.6). The shortest duration of survival was one week, in a patient with a 
metastasis of a pancreatic carcinoma, the longest 4 years and 4 months in a patient with 
breast cancer. Of these 72 patients, 58% had died within one year after the detection of 
the uveal metastases, 83% within two years and 93% within three years. 
In the six patients still alive at the termination date of the study, the median 
follow-up after the detection of the uveal metastases was 3.7 months (mean 5.6). The 
longest follow-up was 20 months. 
In the five patients of whom it was not known whether at the time of termination 
of the study they were still alive, the median follow-up was 1.6 months (mean 3.3) with a 
maximum of seven months. 
The longest known duration of survival after detection of a uveal metastasis, and 
also the longest known follow-up in our patient group was 4 years and 4 months (1567 
days). 
There was a distinct correlation between the duration of survival after the diagnosis 
of the uveal metastases and the nature of the primary malignancy. The median duration of 
survival of patients with breast cancer, namely, was 12.7 months (range 0.3-52; mean 
16.3; SD 13.2) while for patients with lung cancer it was only 6.4 months (range 2-37; 
mean 8.5; SD 13.2) and in patients with one of the miscellaneous malignancies 5.8 
months (range 0.2-30; mean 10.3; SD 10.0). This is in agreement with data in the 
literature in which for patients with uveal metastases of breast cancer a median or mean 
duration of survival is described of from 8.5 to 23 months and for patients with lung 
cancer of from 5.2 to 6 months (see Table 1.6.2.2). The patients' duration of survival was 
also correlated with the question whether the primary tumour was already known before 
the ophthalmological diagnosis. If the detection of the uveal metastasis preceded that of 
the primary tumour, the median duration of survival was 7.1 months (range 1-42; mean 
9.5; SD 10.0). If the metastasis was discovered in a patient already known to suffer from 
a malignancy, the median duration of survival was longer, viz. 11.4 months (range 0.2-
52; mean 14.9; SD 12.6). The most probable cause of this difference is the fact that in 
only one patient, in whom the uveal metastasis was diagnosed before the detection of the 
primary malignancy, did the metastasis originate from breast cancer, as against in 11 
patients from lung cancer. Patients with lung cancer, especially those with a small cell 
anaplastic bronchial carcinoma, have a markedly shorter life expectation than patients with 
breast cancer. The brief duration of survival of patients with lung cancer therefore may 
also account for the poor duration of survival in patients with initially unknown primary 
malignancies. 
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As already mentioned in Chapter 2.2.3, in 41% of the patients with uveal 
metastases no metastases elsewhere in the body were known at the moment of detection of 
the intraocular tumour. It is therefore definitely not true that metastases in the uvea only 
occur in case of extensive systemic dissemination of the malignancy. On the contrary, 
uveal metastases may constitute ал early sign of generalization. 
In contrast to the observation by Hemmes (1969) that patients with bilateral 
metastases of breast cancer had a better prognosis than patients with unilateral metastases, 
we found no difference between these groups (mean durations of survival 16 and 17 
months, respectively). 
The poor prognosis quoad vitam of patients with uveal metastases has been 
mentioned by other investigators as well (Duke-Elder and Perkins, 1966; Ferry, 1967; 
Gartner, 1985). The mean duration of survival as given by different authors varies from 3 
to 9.3 months (see Table 1.6.1.1). Both the median duration of survival, of 9.7 months, 
and the mean duration of survival, of 13.6 months, which we observed in our patient 
group, are higher. However, the data from our study refer to a patient population from a 
more recent study period than those of other investigators. 
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Part3 
Prospective study 

3.1 Aims of the study and study design 
3.1.1 Aims of the study 
As already mentioned in Chapter 1.3.1, determining the frequency of uveal metastases is 
difficult. This is due among other things to the facts that these metastases may remain 
asymptomatic, that they often occur in the terminal phase of the disease and that the 
diagnosis may be difficult. 
According to Jensen (1970) and François et al. (1976), the incidence of uveal 
metastases is approximately 2/100.000. Other authors, however, assert that considering 
the total number of patients with a malignancy the incidence figures of intraocular 
metastases have to be higher. In the United States, according to them, on the basis of 300 
million inhabitants, the incidence of uveal metastases is 5-15/100.000 (Nelson et al., 
1983; Вепсе, 1985). 
Clinically, uveal metastases are present in 0.07 to 2.3% of the patients with a 
known malignancy (see Table 1.3.1.3). 
One of the objectives of this study is to establish the prevalence or the development 
of uveal metastases in patients with a known malignancy. The development of uveal 
metastases depends greatly on the nature of the primary tumour. It was stated in Chapter 
1.3.1 that uveal metastases most frequently originate from breast cancer. For this reason it 
was decided to restrict the study to this patient population. 
Ophthalmological complaints of patients with a malignancy may be caused by 
metastases in the uvea. However, cytostatic and hormonal therapy may also impair the 
visual acuity. In the first part of this thesis, the ophthalmological side effects of such 
therapies are discussed (Chapters 1.6.1.2 and 1.6.1.3: Tables 1.6.1.2.1 and 1.6.1.2.2). In 
the present prospective study, an attempt is made to determine to what extent any visual 
disorders in patients with breast cancer are caused by uveal metastases and to what extent 
systemic treatment is involved. 
When patients with a known disseminated malignancy are examined ophthal-
mologically, uveal metastases are diagnosed in 2.3% of the cases (Albert et al., 1967). 
Mewis and Young (1982) diagnosed uveal metastases in 27% of the patients in different 
stages of breast cancer. Not all these patients actually had ophthalmological symptoms, 
however. Although uveal metastases occur frequently, they do not lead to complaints or 
symptoms in all cases. Consequently, one objective of the present prospective study is to 
determine the policy with respect to ophthalmological control examinations of patients 
with breast cancer for presence of ophthalmological symptoms and of uveal metastases. 
With early detection of ophthalmological symptoms and early diagnosis of (still) 
asymptomatic uveal metastases, it may be possible to treat metastases in an earlier phase 
and sometimes to improve the prognosis concerning the visual acuity. 
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Recapitulating, the aims of this prospective study are: 
- to establish the prevalence or the development of uveal metastases in patients with 
breast cancer; 
- to determine the relationship between any visual complaints and uveal metastases 
or systemic treatment; 
- to determine an optimal policy for ophtha!mological follow-up of patients with 
breast cancer for presence of uveal metastases; 
- to study the effect of early diagnosis of uveal metastases on the results of 
treatment. 
3.1.2 Patients 
Patients for this prospective study were referred in the period from 28 February 1989 to 2 
July 1991 to the outpatient clinic for Ophthalmology, in cooperation with the department 
of Internal Medicine (outpatient clinic Mammary Pathology, subdepartment Endocrine 
Diseases) of Nijmegen University Hospital. This concerned patients with breast cancer 
who were considered for some form of adjuvant therapy after treatment of the primary 
tumour (pTl-3 N+ M-) and patients with known metastases (M+). 
Patients were referred for one of the following three reasons: 
1. Referral for an initial ophthalmological examination of the patient. These were 
patients who were referred purely in the context of this study and who in other 
cases would not have been examined by an ophthalmologist. If no abnormalities 
were observed, they were again examined after one year, unless in the interval a 
reason for earlier examination emerged. 
2. Referral in connection with a modification of the systemic oncological treatment: 
this because such a change of treatment is decided upon in case of progression of 
the disease, which entails an increased risk of dissemination to the eye. These 
patients, also, in the normal course of events are not examined by an 
ophthalmologist. 
3. Finally, all patients with ophthalmological symptoms were examined, regardless of 
whether they had undergone ophthalmological examination earlier, in the context of 
this study. These patients might possibly have been referred to an ophthalmologist 
if this prospective study had not been organized. 
The prospective study was carried out during an uninterrupted period of 28 months. In all, 
107 female patients with breast cancer were examined ophthalmologically. Their mean age 
was 53.4 years (SD 12; median 55; range 24-84). 
In 44 of the 107 patients (41%) a curatively intended local or regional treatment of 
the breast cancer was performed and tumour-positive axillary glands were found (primary 
mammary carcinoma). In the other 63 patients (59%) distant metastases were known 
(Table 3.1.2.1). These were visceral metastases in 31 patients (49%). Cerebral metastases 
were never established; in one patient carcinomatous meningitis was diagnosed. 
Pulmonary metastases were observed in 18 of these patients. Bone metastases were known 
in 27 patients (43%) and only soft-tissue metastases in five patients (8%). 
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Table 3.1.2.1 Localization of metastases in 107 patients with breast cancer 
Localization 
Primary breast cancer (N=44) 
Advanced breast cancer (N=63) 
Visceral 
viz. Brain 
Carcinomatous meningitis 
Lung 
Bone 
Soft tissue 
31 49 
27 
5 
1 
18 
43 
8 
2 
29 
Table 3.1.2.2 Previous therapy at the time of initial ophthalmological examination 
in 63 patients with advanced breast cancer * 
Therapy N % 
None 22 35 
CMF 
Tamoxifen 
CMF, tamoxifen 
CMF, tamoxifen, aminoglutethimide 
CMF, tamoxifen, aminoglutelhimide, MPA 
CMF, tamoxifen, LH-RH analogues 
CMF, tamoxifen, ovanectomy 
CMF, ovanectomy 
CMF, AC 
Tamoxifen, ovanectomy 
Tamoxifen, aminoglutethimide 
Tamoxifen, aminoglutethimide, AC 
Tamoxifen, fluorouracil 
Tamoxifen, MPA, LH-RH analogues 
Tamoxifen, 4-epirubicin, cyclophosphamide 
9 
7 
3 
2 
1 
1 
1 
2 
1 
4 
2 
1 
1 
4 
1 
14 
11 
5 
3 
2 
2 
2 
3 
2 
6 
3 
2 
2 
6 
2 
Ovanectomy 1 
* not stated in sequence of therapy; AC: Adnamycin (doxorubicin) + cyclophosphamide; CMF: 
cyclophosphamide + methotrexate + fluorouracil; LH-RH: luteinizing hormone-releasing hormone; 
MPA. medroxyprogesteronacetate 
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The median duration of the interval between the date of diagnosis of the breast 
cancer and the ophtha!mological examination was 21 months (range 1-310; mean 42; SD 
55). 
The patients with primary breast cancer had not or only just been started on 
adjuvant therapy. The type of treatment depended on the menopausal stage and the 
hormone receptor status of the tumour. Premenopausal patients were given adjuvant 
chemotherapy with the combination of cyclophosphamide, methotrexate and fluorouracil 
(CMF). Postmenopausal patients with an oestradiol receptor (ER) and/or progesterone 
receptor (PgR) positive tumour were given adjuvant treatment consisting of fluorouracil 
and tamoxifen. 
In the patients with advanced breast cancer, an ophthalmological examination was 
made at the times of starting or altering the pharmacotherapy. Table 3.1.2.2 presents a 
survey of the preceding treatment in these patients. 
Chemotherapy, which might or might not be combined with hormone treatment, 
consisted usually of CMF, once fluorouracil and once, of Adnamycin (doxorubicin) and 
cyclophosphamide (AC). Hormonal therapy consisted mostly of tamoxifen and of ovari-
ectomy. Other hormonal therapy consisted of aminoglutethimide, medroxyprogesterone 
acetate (MPA) and ethinyloestradiol. 
Since the appointment for the first ophthalmological check-up was made at the start 
of adjuvant therapy or at the beginning of altered palliative therapy, most patients were 
only actually examined after initiation of this therapy. Table 3.1.2.3 presents a review of 
the therapies at the time of the ophthalmological examination in all 107 patients examined. 
Table 3.1.2.3 Therapy at the time of initial ophthalmological examination in 107 
patients with breast cancer 
Therapy N % 
Primary breast cancer: adjuvant therapy (N=44) 
CMF 16 36 
CMF + AC 1 2 
Fluorouracil + tamoxifen IS 34 
Tamoxifen 4 9 
None 8 18 
Advanced breast cancer: palliative therapy 
CMF 
Fluorouracil + tamoxifen 
Tamoxifen 
Tamoxifen + AC 
AC 
Ethinyloestradiol 
None 
flV= -63) 
25 
3 
20 
1 
3 
1 
10 
40 
5 
32 
2 
5 
2 
15 
AC: adriamyem (doxorubicin) + cyclophosphamide; CMF: cyclophosphamide + methotrexate + fluorouracil 
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Figure 3.1.2.1 Kaplan-Meier survival curve (after ophthalmological examination) for 
patients with breast cancer (N= 107). 
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Figure 3.1.2.2 Kaplan-Meier survival curve (after ophthalmological examination) for 
patients with breast cancer: primary breast cancer (N=44); — —advanced 
breast cancer (N=63). 
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Of all 107 patients with breast cancer at the termination date of the study, 30 
(28%) had died, 29 of them as a direct consequence of the breast cancer. One patient with 
primary breast cancer died 1.5 months after the ophthalmological examination of an acute 
myocardial infarction. The 30 patients included three of the 44 patients (7%) with initially 
primary breast cancer and 27 of the 63 patients (43%) with advanced breast cancer. The 
median duration of survival after the diagnosis of the primary tumour in this group was 
3.1 years (range 6 months to 15 years; mean 4.6 years). The median duration of survival 
after the first ophthalmological examination was 9 months (range 1-24, mean 9). 
The estimated durations of survival in terms of percentages after the 
ophthalmological examination of all 107 patients and of the patients with primary (N=44) 
or advanced (N=63) breast cancer, are presented in Figures 3.1.2.1 and 3.1.2.2 
respectively. 
3.1.3 Study design 
Ophthalmological examination of the patients was performed, as described above, on three 
occasions, namely: 
1. a first ophthalmological examination of 'new' patients with primary or advanced 
breast cancer without ophthalmological symptoms; 
2. examination at modification of (systemic) treatment; 
3. examination because of ophthalmological symptoms. 
Of the 107 patients with breast cancer, 37 (35%) were referred for the first 
ophthalmological examination as 'new' patients, 52 (49%) because of a modification of 
treatment and 18 (17%) because of ophthalmological symptoms. 
It was the intention that all patients would be re-examined one year after the first 
ophthalmological examination. Of all patients 25 (23%) were examined more than once, 
with a maximum of 7 times per patient (repeated examinations in general in connection 
with ophthalmological abnormalities or with alterations of treatment). Of the 52 patients of 
the first year of the study, only 15 were seen for re-examination in the second year. The 
other 37 patients were examined only once. Nineteen of these 37 patients had died before 
a second ophthalmological examination could be carried out. 
At referral of the patient for the ophthalmological examination a number of data 
were given. The first of these was the date of diagnosis of the primary mammary 
carcinoma and its localization. In addition, the presence of metastases elsewhere in the 
body was mentioned, especially of pulmonary and cerebral metastases, with date of 
diagnosis. Information was also presented concerning the treatment up to time of referral. 
Finally, an important factor was whether the patient at the department of Internal 
Medicine spontaneously reported visual symptoms. 
The ophthalmological examination consisted firstly of an extensive ophthal-
mological anamnesis including enquiries concerning the presence of visual symptoms in 
the form of blurred vision or decrease of the visual acuity, visual field defects or spots 
before the eyes, photopsia, metamorphopsia, diplopia and ocular pain. 
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Subsequently, in both eyes an Amsler test was carried out for detection of 
metamorphopsia, and perimetry according to Donders. In every patient determination of 
the visual acuity was performed without correction, with patient's own correction, if any, 
and after optimal refractionation. 
During slit lamp examination, the conjunctiva and sclera were inspected for the 
presence of hyperaemia and dilated vessels. Subsequently, the comea and lens were 
inspected, and attention was paid to the presence of Tyndall and cells in the anterior 
chamber and vitreous. The iris was examined meticulously for detection of metastases. 
Applanation tonometry was performed in both eyes. After mydriasis the fundus was 
inspected by indirect ophthalmoscopy and triple-mirror fundus contact lens examination. 
If this examination revealed abnormalities suggestive of metastases, the patient was 
subjected to fluorescein angiography, echography to the extent that the suspected lesion 
appeared to be sufficiently prominent for further echographic differentiation, electro-
oculography and, if indicated, perimetry. 
In case of doubt concerning the diagnosis, the patient was kept under 
ophthalmological surveillance. If lesions other than metastases were discovered, these 
were treated in as far as necessary. 
If no metastases were observed, the patient was re-examined after one year unless 
in the interval the systemic treatment was modified or ophthalmological symptoms 
developed. 
If the diagnosis of uveal metastases was made, the patient was treated according to 
the current policy in our clinic. This means that in case of a metastasis at or in the direct 
vicinity of the macular area radiotherapy was advocated, just as in small lesions in the 
periphery with secondary retinal detachment threatening the eyesight, in large peripheral 
tumours and in all patients with metastases in whom a deterioration of the visual acuity 
was observed. An expectative policy with thorough ophthalmological follow-up was 
pursued in case of small metastases not threatening to impair the eyesight. 
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3.2 Results 
3.2.1 Frequency of uveal metastases and case histories 
In the course of the prospective study, uveal metastases were diagnosed in five of the 107 
patients with breast cancer (5%) All five belonged to the 63 patients with advanced breast 
cancer (8%). Uveal metastases were never discovered in patients with primary breast 
cancer. The mean age of these five patients was 55 years (range 45 to 65 years). The case 
histories of these patients will be discussed in detail below. 
Patient 1011 
In May 1984, in a premenopausal woman aged 42 years, a carcinoma was diagnosed in 
the medial upper quadrant of the right breast A modified mastectomy according to Patey 
was earned out. In the axilla, one lymph node with massive tumour invasion and 
extranodular growth was resected. Testing for receptors in the tumour tissue gave a 
positive result for oestradiol receptors and a negative result for progesterone receptors. 
Axillary and parasternal irradiation were administered In July of the same year adjuvant 
chemotherapy was instituted in the form of CMF, six courses 
Pulmonary metastases developed in August 1987 In November of that year 
metastases were also found in the skin, lymph nodes and bone. It was decided to start 
tamoxifen treatment In spite of this therapy, progression of the condition occurred. 
Further treatment with chemotherapy and other endocrine measures also failed to suppress 
continued progression of the disease. On 3 April 1989 in connection with an alteration of 
the systemic therapy, she was referred to our ophthalmological outpatient department with 
no known ocular signs or symptoms 
At ophthalmological history-taking, the patient after all was found to have blurred 
vision in both eyes since six weeks with a sensation of oppression in the left eye since 
four months. There were no complaints about diplopia, visual field defects, ocular pain, 
photopsia or metamorphopsia. 
Penmetry according to Donders revealed no abnormalities in either eye. The 
Amsler test was normal on the right; on the left, temporosupenor metamorphopsia was 
noted. 
The visual acuity in the right eye was: 
without correction (= patient's own correction): 1.0+ 
with optimal correction (+0 25 sph): 1.25 
The visual acuity in the left eye was: 
without correction (= patient's own correction): 0 2 
with optimal correction (+0.25 sph): 0.2 
Externally, neither eye displayed abnormalities, in particular no conjunctival or 
scleral hyperaemia or dilated vessels. 
At slit lamp examination both corneas were clear, no cells or Tyndall were 
observed in the antenor chamber. The ins was normal, more especially free of 
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metastases. The lenses were clear and no cells or Tyndall were seen in the vitreous. 
Applanation tonometry showed pressures of 10 mm Hg on the right and 14 mm Hg on the 
left. 
Ophthalmoscopy revealed no abnormalities in the right eye. On the left 
temporoinferiorly there was a large yellowish-brown slightly elevated prominence with an 
offshoot into the macular area and an irregularly pigmented leopard-skinlike surface. No 
orange lipofuscin pigment was observed, nor haemorrhages on or round the tumour or in 
the vitreous. No retinal detachment was present. No disk abnormalities were observed. 
The picture was highly suspicious for a choroidal metastasis in the left eye (Figure 
3.2.1.1). 
Figure 3.2.1.1 Fundus photograph of an extensive choroidal 
metastasis (arrows) from breast cancer in the left eye (patient 
1011). 
At fluorescein angiography there were no abnormalities on the right. On the left, 
simultaneous with the staining of the choroid at the site of the lesion, a mottled 
fluorescence pattern became visible which slowly increased in intensity through the 
remaining exposures. No double vascularization or hypofluorescent rim were observed. In 
the late phases, a few hyperfluorescent spots became visible at the lower margin of the 
lesion. The image fitted a choroidal metastasis (Figure 3.2.1.2). 
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Figure 3.2.1.2 Fluorescein angiogram in the venoux phase 
showing the same metastasis (arrows) as in Figure 3.2.1.1 with 
mottled fluorescence of the tumour. 
At echographic examination no abnormalities were present on the right. On the left, a 
tumour was observed with a prominence of 1.0 mm without signs of choroidal excavation 
or extraocular extension. The reflectivity of the lesion was difficult to determine owing to 
the slight prominence. A minor serous retinal detachment was present. The diagnosis of a 
metastasis was made (Figure 3.2.1.3). 
Figure 3.2.1.3 B-mode echogram of the left eye of patient 
1011 with choroidal infiltration (black arrows) and a localized 
secondary retinal detachment (white arrow). 
326 
At electro-oculography, the following values were found for the various 
parameters: 
OD: Iv 400 μΥ; Dt 275 /xV; Lp 675 μΥ; ratio 2.45; A value +188. 
OS: Iv 300 μΥ; Dt 275 μΥ; Lp 300 μΥ; ratio 1.09; A value -128. 
Conclusion: on the left abnormal EOG, corresponding best to a retinal detachment. 
At the 100 Hue test, 98 errors were indicated on the right (within normal), 489 on 
the left (significantly abnormal), without a distinct axis. 
The diagnosis made was a choroidal metastasis in the left eye. When we saw the 
patient for the first time, the systemic treatment had just been switched to fluorouracil and 
tamixofen. Because of the patient's poor condition, it was decided first to await the effect 
of this systemic therapy. 
At ophthalmological follow-up examination one month later the visual acuity and 
the ophthalmoscopic and fluorescein angiographic images had not changed. The tumour 
did not show distinct changes at later check-ups, either. The patient was seen for the last 
time in October 1989. The visual acuity then was 0.8+ + in the right eye and 0.2 in the left 
eye without correction. The extension of the lesion appeared to have increased slightly, 
however. In view of the patient's clinical condition it was decided to perform no further 
examinations. 
In September 1989 cerebral metastases were established and further progression of 
the condition occurred. The patient died on 11 October 1989 as the consequence of sepsis 
during neutropenia. 
In this patient with a choroidal metastasis with only a small serous retinal 
detachment, visual complaints proved to be present which, however, were only mentioned 
after explicit enquiry. Because of the patient's рхюг general condition and the start of a 
different systemic treatment, no radiotherapy of the intraocular metastasis was 
recommended. At follow-up the ophthalmological image was found to remain stationary 
until just before the patient's death, at which time a slight increase of the size of the lesion 
was established which proved not to affect the visual acuity any further. 
Patient 1023 
In October 1987, in a premenopausal woman aged 44 years, a carcinomatous mastitis on 
the left was established with pathological lymph nodes in the neck and axilla. Mastectomy 
was performed. Apart from the lymph nodes, metastases were found already to be present 
in the lungs and the skeleton. The oestradiol and progesterone receptors were positive. 
Treatment with tamoxifen was instituted following which a regression of the lymph node 
metastases was observed. The treatment with tamoxifen was discontinued in October 1988 
because of progression established one month previously. Meanwhile, secondary 
amenorrhoea was found to have developed owing to metastasization in the hypophysis. 
Because of progression of the disease in March 1989 in the by then 'post-menopausal' 
patient, tamoxifen treatment was resumed in combination with fluorouracil. At that time 
there were visual complaints in both eyes in the form of blurred vision, which cleared 
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after this alteration of treatment. The treatment, accordingly, led to a partial remission. 
The patient was referred to us in June 1989, because of the change of therapy. 
Apart from watery eyes there were no visual complaints at that time. 
Perimetry according to Donders and the Amsler test revealed no abnormalities in 
either eye. 
The visual acuity in the right eye was: 
without correction (= patient's own correction): 0.8" 
with optimal correction (+0.25 sph): 0.8 
The visual acuity in the left eye was: 
without correction (= patient's own correction): 0.8+ + 
with optimal correction (-0.25 sph): 1.0" 
Externally, neither eye exhibited abnormalities, especially no conjunctival or 
scleral hyperaemia or dilated vessels. 
At slit lamp examination both corneas were clear, no cells or Tyndall in the 
anterior chamber were seen. The iris was normal, in particular no metastases were 
present. The lenses were clear and no cells or Tyndall were observed in the vitreous. 
Applanation tonometry showed pressures of 12 mm Hg in both eyes. 
At ophthalmoscopical examination of the right eye, a yellow slightly prominent 
lesion was observed situated temporally below the level of the vascular arcade. There was 
no lipofuscin pigment on the tumour surface and no retinal detachment. The lesion was 
suspicious for a choroidal metastasis (Figure 3.2.1.4). In the left eye no abnormalities 
were observed. 
At fluorescein angiography the lesion stained in the early phase of the examination; 
initially, the staining of the lesion kept pace with that of the surrounding choroid; in the 
late phases it showed a finely mottled hyperfluorescence. A vague hypofluorescent margin 
was observed; no hyperfluorescent spots were present and no tumour vessels were seen 
(Figure 3.2.1.5). On the left no abnormalities were observed. Conclusion: choroidal 
metastasis on the right. 
Echography was not performed because the lesion was too flat for further 
differentiation. 
At electro-oculography the following values were found for the different 
parameters: 
OD: Iv 900 μΥ; Dt 700 μΥ; Lp 1400 μΥ; ratio 2.00; A value +230. 
OS: Iv 900 μΥ; Dt 725 μΥ; Lp 1400 μΥ; ratio 1.93; A value +208. 
Conclusion: normal EOG on both sides, best compatible with a naevus. 
Perimetry revealed no abnormalities. 
At the 100 Hue test, 116 errors were made with the right and 104 with the left eye 
(within normal). 
The diagnosis made was a solitary choroidal metastasis in the right eye. Since there 
were no symptoms and because of the small size of the lesion, the absence of a retinal 
detachment and the recently instituted systemic therapy, an expectative policy was decided 
upon. At the outpatient and fluorescein angiographic check-ups three weeks and two 
months later, visual acuity had remained stable and the lesion had not increased in size. 
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Figure 3.2.1.4 Fundus photograph of the right eye of patient 
1023 showing a choroidal mtíastasls temperoinferior of the 
macular area, presumably in regression. 
Figure 3.2.1.5 Fluorescein angiogram in the venous phase of 
the same lesion as in Figure 3.2.1.4 showing hyperfluorescence 
of the metastasis. 
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The systemic therapy with fluorouracil was discontinued in March 1990. The 
disease at that time was still in remission. The treatment with tamoxifen was continued. 
Immediately thereafter, however, the condition again showed progression for which reason 
treatment with fluorouracil was resumed in May 1990. At ophthalmoscopical control 
examination, the choroidal metastasis had become slightly flatter and had not increased in 
size. The visual acuity was 0.8 in both eyes. Because of further progression of the 
extraocular disease, the treatment in June 1990 was switched to courses of CMF. We 
examined the patient for the last time in October 1990. The ophthalmological findings at 
that time were unchanged. 
In this patient, the choroidal metastasis was asymptomatic although shortly before 
the ophthalmological examination she had complained about blurred vision which 
disappeared post or propter treatment with fluorouracil and tamoxifen. This treatment may 
have controlled the metastasis in the eye as well, although later elsewhere in the body 
progression of the condition nevertheless occurred. Throughout the follow-up period of 16 
months no change in visual acuity occurred and the lesion had grown slightly flatter. The 
choroidal metastasis in this patient required no local treatment and at the moment of its 
detection appeared already partly to have gone into regression. 
Patient 1049 
In January 1984, in a postmenopausal woman aged 54 years, a mammary carcinoma 
situated medioinferiorly on the left was established for which mastectomy was carried out. 
Invasion into the muscular layer was found to be present and two lymph nodes were 
infiltrated by tumour tissue (mammary carcinoma stage pT4NlM0). For this reason, total 
locoregional postoperative irradiation was administered. The oestradiol receptors were 
negative, those for progesterone positive. 
Four years later, in July 1988, bone metastases were established for which local 
radiotherapy was instituted. In September 1989 progression of the disease was found to 
have occurred. Retesting for oestradiol and progesterone receptors in a cutaneous 
metastasis now gave positive results for both. Systemic therapy in the form of tamoxifen 
was instituted. In connection with this switch of treatment the patient, according to 
protocol, was referred to our outpatient department. 
We examined the patient for the first time on 23 January 1990. She complained of 
an intermittent burning and itching sensation in both eyes. There were no complaints about 
the visual acuity, especially no blurred vision, spots before the eyes, visual field defects or 
metamorphopsia. 
At perimetry according to Donders there was some decreased sensitivity nasally in 
the right eye, while no abnormalities were observed in the left eye. The Amsler test was 
normal on both sides. 
The visual acuity in the right eye was: 
without correction: 0.6" 
with patient's own correction (+1.75 sph -0.75 ex 60°): 1.25" 
(= optima] correction) 
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The visual acuity in the left eye was: 
without correction: 0.6 
with patient's own correction (+1.25 sph -0.25 ex 120°): 1.25" 
(= optimal correction) 
Externally, neither eye showed abnormalities, especially no conjunctival or scleral 
hyperaemia or dilated vessels. 
At slit lamp examination the corneas of both eyes were clear, no cells or Tyndall 
were observed in the anterior chamber. On the iris of both eyes multiple benign naevi 
were observed; no metastases were present. The lenses were clear. In the vitreous no cells 
or Tyndall were present. Applanation tonometry gave 13 mm Hg bilaterally. 
At Ophthalmoscopical examination of the right eye, in a peripheral temporosuperior 
localization in the fundus, a slightly elevated, irregularly delimited mottled yellowish-
white prominence was observed with dark pigment spots on the surface (Figure 3.2.1.6). 
No lipofuscin pigment on the tumour surface was observed, nor haemorrhages on or 
round the tumour or in the vitreous. A limited secondary retinal detachment was present. 
The left eye was ophthalmoscopically normal. These findings might fit a solitary choroidal 
metastasis in the right eye. 
Figure 3.2.1.6 Fundus photograph of a choroidal metastasis 
temperosuperior in the right eye in patient 1049. Choroidal 
metastasis from breast cancer in regression. 
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At fluorescein angiography of the right eye, 16 seconds after injection of the 
fluorescein and 2 seconds after the staining of the retinal arteries, hyperfluorescence of the 
lesion developed with an irregular grossly mottled pattern. This fluorescence increased 
gradually and in the later phases stained the lesion diffusely. The tumour was not 
surrounded by a hypofluorescent margin. There were only a few hyperfluorescent spots at 
the tumour margin and no tumour vessels were observed. The serous retinal detachment 
was also described at fluorescein angiography. On the left there were no abnormalities. 
Conclusion: probably a choroidal metastasis in the right eye. 
At echography of the right eye a flat lesion with a secondary retinal detachment 
was observed (Figure 3.2.1.7). Further differentiation of the lesion was not possible 
because of the slight prominence. On the left there were no abnormalities. 
Figure 3.2.1. 7 B-mode echogram of a flat choroidal tumour 
(black arrows) with secondary retinal detachment (white 
arrow) and without choroidal excavation. 
At electro-oculography the following values were found for the various parameters: 
OD: Iv 800 μΥ; Dt 688 μΥ; Lp 925 μΥ; ratio 1.34; A value -174. 
OS: Iv 400 μΥ; Dt 300 μΥ; Lp 875 μΥ; ratio 2.92; A value +365. 
Conclusion: abnormal EOG on the right, corresponding best to a melanoma. 
At the 100 Hue test 88 errors were indicated on the right and 92 on the left (within 
normal). 
Conclusion: solitary choroidal metastasis in the right eye with a secondary serous 
retinal detachment. 
The patient was referred to the radiotherapist for irradiation of the lesion. This was 
started on 8 March 1990 using a linear accelerator (energy: 13 MeY). A total dose of 
30.0 Gy was administered in 10 fractions of 3.0 Gy in two weeks via a ventral beam. No 
side effects were established. 
At subsequent ophthalmological control examinations, the visual acuity remained 
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stable at 1.0 to 1.25 with patient's own correction. At ophthalmoscopy and fluorescein 
angiography, scarification of the lesion was observed. Echographically, a distinct 
regression was established. The EOG still showed a pathological result in the right eye 
although a distinct shift towards naevus had occurred. 
The treatment with tamoxifen did not lead to an objective general remission but 
only to a brief stabilization of the disease. In June 1990, chemotherapy in the form of 
CMF was instituted. In view of further progression of the disease this treatment was 
discontinued in February 1991 and changed one month later to a combination of 
aminoglutethimide and MPA. This treatment did not result in tumour regression, either. 
At the time of termination of the study, the patient was still alive in a reasonable 
general condition but with progressive metastasization. 
In this patient, therefore, a choroidal metastasis was detected notwithstanding the 
fact that she had no complaints about the visual acuity and the acuity was normal. In this 
patient, also, the metastasis had partly gone into regression. Because of the associated 
retinal detachment it was decided, however, to irradiate the metastasis without awaiting 
the effect of the recently instituted systemic treatment with tamoxifen. Subsequently, the 
lesion decreased in size with scar formation. Throughout the follow-up of almost 1.5 years 
the patient remained free of ocular symptoms and the good visual acuity persisted. 
Patient 1057 
In December 1989, in a postmenopasual woman aged 65 years, a carcinoma in the right 
breast was established with carcinomatous pleurisy and bone metastases. The patient had 
been known since November 1986 with a collapse of the thoracic vertebral due to 
osteoporosis and with upper abdominal complaints due to a hiatus hemia. After excision 
biopsy of the mammary tumour the diagnosis was confirmed histologically. The oestradiol 
and progesterone receptors were positive. In January 1990 treatment with tamoxifen was 
instituted and the patient was referred to our outpatient department in connection with this 
study of uveal metastases. 
We examined the patient for the first time on 20 March 1990. From the moment of 
diagnosis of the primary tumour she had complained about blurred vision in both eyes, 
worse on the right than on the left, and also of burning eyes. There were no complaints 
about spots before the eyes or visual field defects, photopsia, ocular pain or diplopia. 
Perimetry according to Donders and the Amsler test showed no abnormalities in 
either eye. 
The visual acuity in the right eye was: 
without correction: 0.16" 
with patient's own correction (+1.5 sph): 0.8" 
(= patient's own correction) 
The visual acuity in the left eye was: 
without correction: 0.2" 
with patient's own correction (+2.0 sph -0.5 ex 180°): 0.8+ 
with optimal correction (+1.75 sph): 1.0 
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Externally, no abnormalities were observed in either eye, especially no 
conjunctival or scleral hyperaemia or dilated vessels. 
At slit lamp examination both comeas were clear and no cells or Tyndall in the 
anterior chamber were established. In the iris, no abnormalities were observed, in 
particular no metastases were present. Both lenses exhibited symmetrical increases of 
opacity. In the vitreous there were no cells or Tyndall. Applanation tonometry gave values 
of 13 mg Hg bilaterally. 
At ophthalmoscopical examination, no abnormalities were encountered in either 
eye, especially no metastases. 
At the 100 Hue test, 136 errors were indicated on the right and 144 on the left 
(within normal). 
Although visual complaints were present, the visual acuity proved to be normal; no 
ophthalmological abnormalities were observed, especially no metastases. The patient was 
reassured by these findings. An appointment was made for a check-up one year later. 
The treatment with tamoxifen in the context of a clinical comparative trial (EORTC 
trial 10863: Beex and Rose, 1987) was administered intermittently and led to a partial 
remission. From December 1990 the visual acuity became impaired in both eyes, worse 
on the left than on the right. Consequently, she was once more referred for 
ophthalmological examination in January 1991. 
We examined the patient for the second time in January 1991, 10 months after the 
initial ophthalmological examination. She stated that since December 1990 she had noticed 
a spot high in the left eye, accompanied by decrease of the visual acuity and a distorted 
image. These symptoms were progressive. She had no photopsia, ocular pain or diplopia. 
In the right eye there were no symptoms. 
At perimetry according to Donders no abnormalities were found on the right. On 
the left, superiorly and nasally, a distinct restriction of the visual field was established. 
The Amsler test was normal on the right. On the left, part of the top and the right-hand 
side of the chart was not observed. 
The visual acuity in the right eye was: 
without correction: 0.16" 
with optimal correction (+1.5 sph): 0.8" 
the visual acuity in the left eye was: 
without correction: 3/60 
with optimal correction (+3.75 sph): 0.6" 
Externally, neither eye showed abnormalities, in particular no conjunctival or 
scleral hyperaemia or dilated vessels. 
At slit lamp examination the comeas of both eyes were clear and no cells or 
Tyndall in the anterior chamber were established. The iris showed no abnormalities, in 
particular no metastases. In the ocular lenses, symmetrical increases of opacity were 
observed. In the vitreous, no cells or Tyndall were present. Applanation tonometry gave 
values of 15 mm Hg on the right and 11 mm Hg on the left. 
Ophthalmoscopical examination revealed no abnormalities on the right. In the left 
eye, temporally at the site of the vascular arcade a yellow tumour was observed, with a 
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fairly evenly pigmented surface without accompanying retinal detachment or haemorrhages 
on or round the tumour or in the vitreous. No orange lipofuscin pigment was present. The 
tumour appeared to consist of a conglomeration of three lesions which initially probably 
had been discrete. The findings corresponded completely to a choroidal metastasis in the 
left eye (Figure 3.2.1.8). 
Figure 3.2.1.8 Fundus photograph of the lefi eye in patient 
1057 showing a choroidal metastasis. The fovea is located at 
the tumour margin. 
Fluorescein angiography showed no abnormalities in the right eye. On the left, 
simultaneously with the staining of the surrounding choroid, a fluorescence of the tumour 
appeared, with a grossly mottled pattern, the intensity of which increased slowly during 
the course of the examination. There was a distinct hypofluorescent margin but there were 
no hyperfluorescent spots nor a double circulation. No indications of a retinal detachment 
were present. The fluorescein angiogram, also, was suggestive of a fusion of three lesions 
(Figure 3.2.1.9). Conclusion: choroidal metastasis on the left. 
At echography, no abnormalities were encountered on the right. Temporoinferiorly 
in the left eye a dome-shaped tumour was present, with a prominence of 4.0 mm, low-
reflective, only moderately regular without choroidal excavation or vascularity, without 
signs of scleral extension or orbital shadowing and without a retinal detachment (Figure 
3.2.1.10). These data corresponded best to the diagnosis of choroidal metastasis. 
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Figure 3.2.1.9 Fluorescein angiogram of the lefi eye of patient 
1057. a. Arterial phase with fluorescence of the tumour of 
almost the same intensity as the surrounding choroid and 
mottled hyperfluorescence. b. Venous phase with hypo-
fluorescent margin. 
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At electro-oculography, the following values were found for the various 
parameters: 
OD: Iv 700 μΥ; Dt 425 μΥ; Lp 1000 μΥ; ratio 2.35; A value +198. 
OS: Iv 500 μΥ; Dt 450 μΥ; Lp 763 μΥ; ratio 1.70; A value +58. 
Conclusion: abnormal EOG on the left, best fitting a melanoma. 
At the 100 Hue test, 176 errors were indicated on the right (within normal) and 
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Accordingly, there was a large choroidal metastasis in the left eye, 10 months after 
a thorough ophthalmological examination at which no abnormalities had been established. 
The tumour had led to a hypermetropization of 2.0 diopters. 
The patient was referred to the Department of Radiotherapy for irradiation of the 
metastasis. A CT scan of the orbit revealed a hyperdensity at the tumour site. 
Starting 25 February 1991, the patient was irradiated by means of a linear 
accelerator (6 MY) through one lateral beam with a total dose of 30.0 Gy in 10 fractions 
of 3.0 Gy in two weeks. 
On 26 February 1991 she came to our ophthalmological outpatient department for a 
check-up. On that occasion, just as four weeks previously, a visual acuity of 0.6 was 
determined. However, the hypermetropization had increased from 2.0 to 3.5 diopters. 
Echography revealed that the prominence of the tumour also had increased distinctly, from 
4.0 to 5.5 mm. This demonstrated rapid growth of the metastasis. 
Two weeks after the start of the radiotherapy the hypermetropization had stabilized 
compared with February and the prominence of the lesion had decreased by 0.5 mm. 
From that time, the positive effect of the radiotherapy became increasingly clear (Table 
3.2.1.1; Figure 3.2.1.10). 
Table 3.2.1.1 Course of optimal visual acuity, refraction and prominence in the left 
eye of patient aged 66 years with a choroidal metastasis from breast 
cancer 
20.03.90 29.01.91 28.02.91 19.03.91 09.04.91 07.05.91 04.06.91 02.07.91 
• ** *** 
Optimal visual acuity: 
0.8* 0.6" 0.6 0.6· 0.8 0.6 0.6 0.8 
Spherical equivalent optimal refraction: 
+ 1.75 +3.75 +5.25 +5.25 +4.62 +3.75 +3.25 +3.0 
Prominence: (mm) 
4.0 5.5 5.0 3.5 4.0 3.0 2.5 
* no abnormalities found; ** diagnosis of choroidal metastasis; *** one day after start of radiotherapy 
Thus, after local irradiation a distinct decrease of the prominence of the metastasis was 
observed; the optimal visual acuity was unchanged with reduction of the required 
correction. The visual acuity with patient's own correction increased in the process from 
0.125 in April 1991 to 0.16 in May, 0.25 in June and 0.4 in July. Five months after the 
start of the radiotherapy, therefore, a beneficial effect of the irradiation still persisted. 
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At repetition of the fluorescein angiography in April 1991, the image had changed 
only little from that of January. Only the fluorescence pattern had grown more grossly 
mottled and less regular. 
In the right eye, the various control examinations revealed no abnormalities and the 
optimal visual acuity remained stable at 1.0. 
Because of the detection of the choroidal metastasis, the treatment with tamoxifen 
was discontinued in February 1991. In June, cutaneous metastases were observed after 
which treatment with aminoglutethimide was instituted. 
Accordingly, a little over one year after the diagnosis of breast cancer in this 
patient, a choroidal metastasis was detected in the left eye. Shortly after the diagnosis of 
the mammary tumour, the patient had already undergone an extensive ophtha!mological 
examination in the context of this study of uveal metastases, at which examination no 
abnormalities had been observed. Ten months later, a metastasis was found to have 
developed in the left eye. The tumour showed rapid growth and responded well to 
radiotherapy. During this treatment, the prominence of the tumour decreased distinctly and 
the visual acuity with patient's own correction increased. The optimal visual acuity 
remained stable at 0.6 to 0.8 while the hypermetropization decreased. Five months after 
the start of the radiotherapy a distinct effect of the irradiation continued to be present. 
Patient 1078 
In August 1988, in a postmenopausal woman aged 53 years a carcinoma was diagnosed 
mediosuperiorly in the left breast (T2NOMO) which was treated with a modified radical 
mastectomy according to Madden. Subsequently, the patient was irradiated over the 
parasternal lymph nodes. Oestradiol receptor testing gave a positive, progesterone receptor 
testing a low positive result. 
In March 1990, hepatic metastases were established and three months later, 
pulmonary and bone metastases as well. Because of the extensive hepatic metastases, 
chemotherapy in the form of CMF was instituted. The patient spontaneously reported 
being troubled intermittently by decreased vision in the left eye, present for some time. In 
view of these symptoms and of the start of the chemotherapy, the patient according to 
protocol was referred to our ophthalmological outpatient department. 
We saw the patient for the first time on 31 July 1990. She complained about 
blurred vision in both eyes since five months, especially in the left eye. In addition, since 
the start of the chemotherapy, she had suffered from burning eyes. She did not suffer 
from spots before the eyes, visual field defect, photopsia, ocular pain or diplopia. 
At perimetry according to Donders, no abnormalities were observed in either eye. 
The Amsler test was unimpaired on the right, on the left central metamorphopsia was 
established. 
The visual acuity in the right eye was: 
without correction: 0.6 
with patient's own correction (+0.5 sph -2.0 ex 105°): 1.0" 
with optimal correction (+0.5 sph -1.0 ex 95°): 1.0 
340 
The visual acuity in the left eye was: 
without correction: 0.3" 
with patient's own correction (+0.5 sph -2.0 ex 85°): 0.16 
with optimal correction (-0.5 sph -1.5 ex 80°): 0.3 
Old records showed that previously the patient had had a visual acuity of 0.8 in 
both eyes with her own glasses. 
Externally, no abnormalities were seen in either eye, especially no conjunctival or 
scleral hyperaemia or dilated vessels. 
At slit lamp examination the corneas of both eyes were clear and no cells or 
Tyndall were observed in the anterior chamber. The iris was normal; in particular no 
metastases were present. The lenses showed symmetrical slight increases of opacity. In the 
vitreous no cells or Tyndall were established. Applanation tonometry gave 10 mm Hg on 
the right and 8 mm Hg on the left. 
At ophthalmoscopical examination there were no abnormalities on the right apart 
from a few scattered exudates. In the left eye temporally from the macula extending into 
the periphery, a large light-coloured dull yellowish-orange tumour was present with a 
mottled surface (Figure 3.2.1.11). No lipofuscin pigment on the tumour surface was 
observed, nor haemorrhages on or round the tumour or in the vitreous. Peripherally to the 
lesion there was a folded serous retinal detachment. Temporoinferiorly a small naevus was 
observed. The optic disk was not well delimitated. The findings as a whole indicated a 
solitary choroidal metastasis in the left eye. 
Figure 3.2.1.11 Fundus photograph afa choroidal metastasis 
in the left eye (patient 1078). 
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At fluorescein angiography the right eye showed no abnormalities, apart from the 
exudate already observed at ophthalmoscopy. In the left eye, 14 seconds after injection of 
the fluorescein and simultaneously with the staining of the retinal arteries, a staining 
developed in the lesion below the macula in the form of a few tumour vessels. In the 
process the other parts of the tumour initially remained dark but from the venous phases it 
locally developed an irregular hyperfluorescence in the form of a grossly mottled pattern 
which was superimposed on the hypofluorescence. The area with the tumour vessels 
immediately below the macula, on the other hand, in its entirety developed a mottled 
hyperfluorescent pattern and in the late phases showed a nearly completely diffuse 
hyperfluorescence. Nasally to the disk and temporoinferiorly, a few hypofluorescent areas 
were observed. The tumour was not surrounded by a hypofluorescent margin, nor were 
hyperfluorescent spots observed. The serous retinal detachment was described at 
fluorescein angiography as well (Figure 3.2.1.12). Conclusion: choroidal metastasis in the 
left eye. 
Figure 3.2.1.12 Fluorescein angiogram in the venous phase 
showing grossly mottled fluorescence of the choroidal metastasis 
in patient 1078. 
At echography no abnormalities were established on the right. Temporally, in the left eye 
a flat to dome-shaped irregular mid-reflective tumour was observed with a prominence of 
5.0 mm and a very large base (>20 mm) without choroidal excavation, vascularity or 
signs of scleral invasion or extraocular extension, and with a doubtful orbital shadow. The 
serous retinal detachment was confirmed echographically as well (Figure 3.2.1.13). 
Diagnosis: choroidal metastasis. 
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Figure 3.2.1.13 B-mode echogram of a 5.0 mm prominent 
choroidal metastasis (black arrows) with secondary retinal 
detachment (white arrow) without choroidal excavation. 
At electro-oculography the following values were found for the various parameters: 
OD: Iv 500 μΥ; Dt 400 μ\; Lp 813 μΥ; ratio 2.03; A value +153. 
OS: Iv 700 μΥ; Dt 613 μΥ; Lp 600 μΥ; ratio 0.98; A value -372. 
Conclusion: abnormal BOG on the left, corresponding best to a melanoma. 
Perimetry revealed a slight central decrease of the sensitivity on the right. On the 
left there was an absolute scotoma superiorly as well as an enlarged blind spot with in 
addition a decrease of the central sensitivity. The localization of the scotomas did not 
accord with the site of the tumour. 
At the 100 Hue test, 104 errors were indicated on the right (within normal) and 
524 on the left (significantly abnormal) with an axis between deutan and tritan. 
The diagnosis made was a solitary choroidal metastasis of breast cancer in the left 
eye; the patient was referred to the radiotherapist for irradiation of the intraocular tumour. 
This was started on 13 August 1990, two weeks after the detection of the choroidal 
metastasis, using a linear accelerator (energy 13 MeY). A total dose of 30.0 Gy was 
administered in 10 fractions of 3.0 Gy in two weeks, via a lateral beam. No side effects 
were noted. 
At control examination one week later, visual acuity in the right eye proved to 
have remained stable at 1.0 with patient's own correction. On the left, the optimal visual 
acuity was 0.4+ + with a correction of +1.25 sph -1.0 ex 65°. At ophthalmoscopy, there 
were no abnormalities in the right eye, in the left no changes had occurred apart from an 
increase of the serous retinal detachment. The echographic image was stable. 
Two months after the start of the radiotherapy, a subjective improvement of the 
visual acuity was present. Objectively, the visual acuity in the right eye was 0.8 with 
patient's own correction (no further correction possible) and 0.3 in the left eye with 
patient's own correction (no further correction possible). The anterior segment showed no 
abnormalities in either eye. Ophthalmoscopically, bilateral papilloedema was observed. On 
the right, apart from the exudates, no further abnormalities. On the left, the tumour had 
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decreased in prominence but the retinal detachment had become more extensive. 
Echography, also, revealed bilateral papilloedema. The prominence of the choroidal 
metastasis in the left eye had decreased from 5.0 mm to 3.0 mm, the retinal detachment 
had increased. Accordingly, after radiotherapy subjectively there was some improvement 
of the visual acuity, objectively stabilization of the visual acuity and a decrease of the 
prominence. Because of deterioration of her general condition, the patient did not return to 
our ophthalmological outpatient department after October 1990. 
In spite of the chemotherapy, ascites developed and further progression of the bone 
metastases. Therefore the chemotherapy was switched to courses of Adriamycin 
(doxorubicin) and cyclophosphamide. This failed to influence the progression of the 
condition. From January 1991, the patient's clinical condition quickly grew worse and she 
died on 17 February 1991. No autopsy was performed. In the course of the disease, no 
clinical indications of the presence of cerebral metastases had been observed. 
In this patient with breast cancer, therefore, a solitary choroidal metastasis situated 
temporally in the left eye was diagnosed. Ophthalmological examination was only carried 
out after the patient complained spontaneously of reduced eyesight, which symptom had 
been present long before known metastasization of the disease elsewhere in the body had 
developed. This emphasizes the importance of a concise ophthalmological anamnesis in 
patients with a malignancy. 
The intraocular metastasis responded well to local radiotherapy with preservation 
of the eyesight and decrease of the prominence. However, in spite of the chemotherapy, 
distinct progression of the malignancy elsewhere in the body occurred and the patient died 
seven months after the detection of the intraocular metastasis. 
3.2.2 Discussion concerning uveal metastases 
In all five patients with uveal metastases the tumours were localized in the choroid. In 
four patients the metastasis was detected at the first ophthalmological examination. In one 
patient, the first examination revealed no abnormalities and the choroidal metastasis was 
only observed at a control examination one year later. During that year the patient had 
been treated with tamoxifen almost continuously. This apparently had failed to prevent the 
development of a uveal metastasis. In one other patient, also, a metastasis had developed 
in spite of systemic treatment. 
In two of the five patients with uveal metastases the intraocular lesion at the 
moment of detection was found already to have gone into partial regression. 
In one patient cutaneous and hepatic metastases developed in spite of treatment 
with tamoxifen. At that time there also were complaints about the eyesight which, 
however, subsided after resumption of tamoxifen in combination with fluorouracil. When 
we examined the patient three months later we diagnosed a choroidal metastasis. This 
abnormality had probably been the cause of the earlier complaints. The combination of 
tamoxifen and fluorouracil had already caused the lesion to go into partial regression. 
Ophthalmologically, therefore, an expectative policy was pursued. 
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In a second patient a treatment with tamoxifen had been instituted only two weeks 
before the ophthalmological examination, in connection with progression of the disease. 
The uveal metastases discovered at that moment appeared already to have gone into partial 
regression. Since it would appear that the duration of the systemic treatment at the time 
had been too short for such an effect it may be speculated that a 'spontaneous regression' 
had been involved here. Since the lesion was still partially active, radiotherapeutic 
treatment of the choroidal metastasis was started. 
It is interesting to note that in three of the five patients with metastases the reason 
for referral was a change of treatment. One patient (with a metastasis in regression) had 
no complaints about visual acuity even at the ophthalmological examination. The other 
patient with a metastasis in regression complained of itching eyes. In a third patient, 
finally, no complaints were known at the time of referral but on specific history-taking 
complaints were nevertheless found to be present. 
Of the two patients with known ophthalmological complaints, one was referred for 
that reason alone and the other also in connection with a change of treatment. 
The mean visual acuity at the time of detection of the choroidal metastases in these 
five patients was 0.63 (range 0.20-1.25). 
All five patients were suffering from already extensively disseminated breast cancer 
which at the time of the ophthalmological examination showed progression. Two of the 
five patients died within the period with which the prospective study was concerned. 
3.2.3 Further ophthalmological description of the study group 
Of the 102 patients with breast cancer without uveal metastases, 16 (16%) were referred 
to our outpatient clinic in connection with ophthalmological complaints. The most 
frequently mentioned complaint was decrease of the visual acuity (Table 3.2.3.1). 
Table 3.2.3.1 Signs and symptoms in 16 patients with breast cancer without uveal 
metastases referred because of ophthalmological complaints 
Sign or symptom * N 
Decrease of visual acuity 13 
Burning eyes 2 
Epiphora 2 
Diplopia 2 
* total number exceeds 16 because of patients with multiple signs or symptoms 
Accordingly, 86 patients were referred for some other reason than ophthalmological 
complaints, namely in connection with ал initial ophthalmological examination or because 
of a change of the systemic treatment. However, 21 of these 86 patients when asked 
specifically in the ophthalmological outpatient department proved to have complaints after 
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all. Of these complaints, the main ones were decrease of the visual acuity and a burning 
sensation in the eyes (Table 3.2.3.2). 
Of these 21 patients, eight had primary and 13 advanced breast cancer. 
Table 3.2.3.2 Signs and symptoms in 21 patients with breast cancer without uveal 
metastases referred because of reasons other than ophthalmological 
complaints 
Sign or symptom * N 
Decrease of visual acuity 11 
Burning eyes 9 
Visual field defect 3 
Photopsia 3 
Diplopia 1 
Muscae volitantes 1 
Ocular strain I 
+ total number exceeds 21 because of patients with multiple signs or symptoms 
In all, therefore, ophthalmological complaints existed not only in four of the five patients 
with choroidal metastases but also in 37 of the 102 patients without metastases in the 
uvea. The causes of the complaints in these 41 patients are listed in Table 3.2.3.3. 
Complaints were present in 15 of the 44 patients (34%) with primary breast cancer and in 
26 of the 63 patients (41 %) with advanced breast cancer. 
Table 3.2.3.3 Cause of ophthalmological complaints in 41 patients with breast 
cancer 
Patients 
Cause of complaints N % 
Choroidal metastasis 4 * 10 
Cataract 
Membrane 
Abnormalities in refraction 
Stenosis lacrimal ducts 
Retinal degeneration 
Carcinomatous meningitis 
No ophthalmological cause known 22 ** 54 
* in afiflh patient with a choroidal metastasis no signs or symptoms were present, ** because of poor 
general condition in one patient only limited ophthalmological examination possible 
8 
1 
3 
1 
1 
1 
20 
2 
7 
2 
2 
2 
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In eight patients a sight-impairing cataract was the cause of the complaints. Within 
the study period one patient was operated for this reason. In one patient, after-cataract 
caused impairment of the vision for which she was subjected to YAG laser treatment. The 
mean visual acuity in these nine patients was 0.51 (0.30-0.80). Slight increases of the 
opacity of the lens were also present in 29 other patients. 
Abnormalities of refraction were diagnosed in three patients. In two patients these 
could be corrected adequately and a prescription for glasses was given. One patient had 
variable refraction without clear cause for which she is being followed up. 
One patient since the start of a treatment with fluorouracil and tamoxifen suffered 
from epiphora which proved to be due to occlusion of both lacrimal points. Although the 
lacrimal points could be opened surgically, the lacrimal ducts were also occluded and the 
symptoms persisted. 
In one patient thin atrophic retinal areas were observed in both eyes, with in the 
left eye a small defect. These retinal degenerations were surrounded by laser coagulates 
following which the visual acuity in both eyes remained stable at 1.0. 
In the last patient, extensive ophthalmological abnormalities were present. She was 
referred because of decrease of the visual acuity and a pupil not reacting to light on the 
left. She also complained of spots before the eyes and ocular pain on the left. Vision in 
the right eye reportedly was also reduced. Visual acuity was 0.4 in the right and 1/300 in 
the left eye, both without correction and in both with no further correction possible. On 
the left, the pupil was partly dilated and reacted to light directly but not consensually. On 
the left there was a ptosis to halfway the pupillary aperture. On the right, the ocular 
movements were slightly restricted in all directions. On the left, abduction was almost 
completely abolished, elevation and downward gaze greatly limited and adduction virtually 
normal. 
Ophthalmoscopy revealed papilloedema in the right eye without further 
abnormalities of the fundus. On the left there were no abnormalities. 
At echography a diffuse thickening round the optic nerve was seen in both eyes but 
more pronounced in the left than in the right eye, possibly due to metastastic infiltration of 
the sclera or the orbit directly behind the globe. 
In view of this involvement of several cranial nerves and indications of pressure on 
the optic nerve, the probability diagnosis of carcinomatous meningitis was made. At CT 
scanning no abnormalities of the cerebrum and orbits were observed apart from a central 
cortical atrophy. The lumbar puncture was traumatic. No malignant cells were observed in 
the cerebrospinal fluid. 
In one week the ptosis increased further and marked Chemosis of the conjunctiva 
on the left developed. In spite of the fact that no distinct metastases were found, 
radiotherapeutic treatment of the base of the skull was decided upon for neurological 
reasons. The orbits were included in the radiation field, in connection with the orbital 
abnormalities and the progression of the clinical picture. In spite of the irradiation, the 
ptosis increased further an a distinct proptosis developed as well. Echographically no 
changes were established. On local antibiotic treatment the Chemosis initially increased 
further but subsequently abated. The patient died one month after the initial 
ophthalmological examination. No autopsy was performed. 
In this patient orbital metastases may have been present. 
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Apart from five choroidal metastases, 15 other patients with breast cancer showed 
pronounced ophthalmological abnormalities. In all, therefore, ophthalmological abnor-
malities were present in 20 of the 107 patients examined (19%). In all cases these lesions 
had not been known previously. The mean visual acuity in these patients was 0.67 (0.20-
1.25). 
In 22 patients with breast cancer who had ophthalmological complaints no distinct 
abnormalities could be found. The clinical condition of one woman was too poor for an 
adequate ophthalmological examination. 
Of the other 21 patients, 13 complained among other things about reduced visual 
acuity and eight of burning eyes. All but three of these patients were being treated 
systemically at the time of the examination. Eleven were being treated with CMF, four 
with tamoxifen combined with fluorouracil, two with tamoxifen alone and one, with CMF 
and aminoglutethimide. Of tamoxifen and fluorouracil, in particular, ophthalmological side 
effects are known to occur (Griffin and Gamick, 1981; Vizel and Oster, 1982; 
Fraunfelder and Meyer, 1983; Imperia et al., 1989). This systemic therapy may have been 
the cause of the ophthalmological complaints. The mean visual acuity in these patients was 
1.11, ranging from 0.80 to 1.25. However, no distinct relationship existed between the 
complaint and the nature of the systemic therapy. 
Of the 26 patients with advanced breast cancer and ophthalmological complaints, 
four (15%) were found to have choroidal metastases. 
In the entire group of 107 patients with breast cancer the mean visual acuity was 
0.95 (SD 0.30; median 1.00; range 0.12-1.60). 
The mean intraocular pressure in the 107 patients was 13.4 mm Hg, ranging from 
6.0 to 21.0 mm Hg (median 14.0; SD 3.4). In other words, raised intraocular pressure 
was never encountered. 
In three patients, abnormalities were observed during perimetry according to 
Donders. These were one patient with a choroidal metastasis, one with cataract and one, 
with after-cataract. 
Abnormalities at Amsler testing were established in eight patients, two of them 
with metastases. Two other patients had cataracts and in four patients, no underlying 
ophthalmological abnormalities could be found. 
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3.3 Discussion and conclusions 
During a period of 28 months we examined 107 successive patients who came for control 
examination in the outpatient clinic for Internal Medicine because of breast cancer which 
had been given primary surgical treatment. These included 44 patients with primary breast 
cancer (41%) and 63 patients with advanced breast cancer (59%). In all, uveal metastases 
were diagnosed in five of the 107 patients (5%); they were localized in the choroid in all 
cases. These five patients at that time were in a progressive phase of the disease with 
extensive dissemination already present. Uveal metastases therefore were diagnosed in 8% 
of the patients with advanced breast cancer and never in patients with primary breast 
cancer. Four of the five patients had ophtha!mological complaints. In two patients, the 
uveal metastasis at the time of the examination appeared already to have gone into partial 
regression. 
Albert et al. (1967) over a period of 24 months examined 213 patients with various 
disseminated malignancies. They observed choroidal metastases in five patients (2.3%). In 
four of these patients the metastasis originated from breast cancer (n=52), in one from 
lung cancer (n=50). Choroidal metastases therefore were present in 8% of the examined 
patients with breast cancer. 
Mewis and Young (1982) examined 250 patients with breast cancer. The length of 
time during which the study was carried out was 7.5 years. Patients with known 
dissemination as well as patients without metastases were examined. Choroidal metastases 
were encountered in 67 patients (27%): 58 of the 152 patients with ophthalmological 
symptoms (38%) and nine of the 98 asymptomatic patients (9%). 
The percentages found by us, 5% of all patients with breast cancer and 8% of 
patients with advanced breast cancer, in which uveal metastases were diagnosed, are in 
agreement with the findings of Albert et al. (1967). Mewis and Young (1982), however, 
observed metastases far more frequently. We are unable to explain this discrepancy 
adequately. Admittedly, the proportion of patients with ophthalmological symptoms in the 
population of Mewis and Young was higher, namely 61%. In our study group, this 
category accounted for only 39%. Also, the duration of our study was substantially 
shorter. Of the 67 patients with choroidal metastases of Mewis and Young, 22 were 
examined only once; in one-half of the cases because of the short duration of observation 
before death. The investigators do not state what proportion of the total study population 
with breast cancer was examined more than once or whether perhaps a large proportion of 
these patients were followed up over a long period of time which might explain the more 
frequent occurrence of uveal metastases. In this connection it should also be noted that 
these authors give only a very limited description of the composition of the patient 
population. 
In our prospective study, ophthalmological complaints were established in a large 
number of the patients with breast cancer examined, viz. in 41 of the 107 patients (38%). 
The complaints most frequently mentioned concerned deterioration of the visual acuity or 
burning eyes. In 20 of these patients (19% of the total study population), distinct 
ophthalmological abnormalities were established. Apart from choroidal metastases, these 
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were sight-impairing cataracts in most cases. In a few patients the symptoms were brought 
about by abnormalities of refraction. In the remaining patients major abnormalities were 
present in the form of complete occlusion of the lacrimal ducts, retinal degeneration and 
carcinomatous meningitis possibly with orbital metastases. In one patient, the clinical 
condition was too poor for adequate investigation of the complaints. 
In the 21 patients without a clear ophthalmological cause of the complaints, 
systemic treatment (in 18 patients) may have been responsible. However, no distinct 
correlation was found between any particular therapy and the ophthalmological symptoms. 
Mewis and Young (1982) encountered ophthalmological complaints in a larger 
proportion of the patients with breast cancer (61%). Choroidal metastases were established 
in one-third of these patients. The authors omit to mention the causes of the complaints in 
the remaining patients. 
In a large proportion of the patients with advanced breast cancer in our study 
group, therefore, there were ophthalmological complaints which in one-half of the cases 
were due to a distinct ophthalmological abnormality. It is therefore of crucial importance 
that such complaints should be taken seriously and the patients be referred to an 
ophthalmologist for examination. In over one-half of these cases no ophthalmological 
complaints were known to the referring internist at the time of the referral for this 
prospective study. It was only during the visit to the ophthalmological outpatient 
department that these complaints were made clear. It is therefore advisable in patients with 
a malignancy to enquire specifically after ophthalmological symptoms and, if these are 
present, to refer the patient to an ophthalmologist. This is especially important in patients 
with progression of the malignancy because in them the probability of presence of a uveal 
metastasis is highest. However, specifically ophthalmological abnormalities may also 
occur in other patients with a malignancy. 
If only patients with ophthalmological symptoms are referred, a small proportion of 
existent uveal metastases may escape notice. Since these lesions are asymptomatic and 
during systemic therapy already instituted will not necessarily cause complaints in the 
future, either, they are clinically of limited importance and do not justify the screening for 
uveal metastases of all truly asymptomatic patients. 
The above data concern patients with breast cancer. This is the malignancy in 
which uveal metastases are diagnosed most frequently. In patients with other 
malignancies, however, intraocular metastases may also develop, although in smaller 
proportions. Whether ophthalmological abnormalities occur as frequently in these patients 
as in patients with breast cancer is not known. If, however, visual symptoms occur in 
such patients, the possibility of presence of uveal metastases or of other ophthalmological 
abnormalities should always be taken into account. 
Good visual acuity is important for everyone. This applies more in particular to 
patients who, because of their disease, have a reduced quality of life in any case. This 
study has proved that in many of these patients visual symptoms may occur which are 
often due to distinct ophthalmological abnormalities, including metastases in the uvea. In 
the majority of the cases these abnormalities can be treated with good functional results, 
thereby contributing to improvement of these patients' quality of life. 
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Summary 
In this thesis an attempt is made to present as complete a description as possible of the 
ophthalmological aspects of uveal metastases in order, where possible, to improve the 
diagnostics and treatment and thus to contribute to these patients' quality of life. 
The study consists of three parts. In the first part, an extensive review is presented 
of the literature on uveal metastases. The second part deals with the results of a 
retrospective study of intraocular tumours and lesions suspicious for tumours, with 
emphasis on uveal metastases. The third part concerns a prospective study in patients with 
breast cancer, with the objective to determine the frequency of ophthalmological 
symptoms and of uveal metastases in these patients and to consider to what extent 
screening for ophthalmological abnormalities is advisable. 
Part 1: Review of the literature 
The earliest publication on uveal metastases is a treatise by Perls from 1872 concerning 
the histological findings in a patient with lung cancer. Hirschberg in 1882 published the 
first clinical description of a choroidal metastasis. 
Regarding the pathogenesis of uveal metastases much remains uncertain. 
Metastases can only reach the uvea via a haematogenous route. The uvea receives its 
blood supply from the short and long posterior and from the anterior ciliary arteries, 
which are branches of the ophthalmic artery. The choroid receives most of its blood 
through the 20 short and in part through the two long posterior ciliary arteries. The four 
anterior ciliary arteries together with the two long posterior ciliary arteries supply the 
anterior uvea (ciliary body and iris) with blood. Owing to this vascularization, 
ophthalmological metastases are localized most frequently in the choroid. Apart from 
circulatory factors, however, local environmental factors also play a part in the 
development of uveal metastases. Uveal metastases concern extracerebral localizations. 
Uveal metastases are the most frequently occurring, although not the most 
frequently diagnosed intraocular tumours. The primary tumour is usually breast cancer. 
Metastases of lung cancer are observed much less frequently, and those of other 
malignancies only rarely. The question why the primary tumour is so often breast cancer 
cannot be answered unequivocally. Uveal metastases according to several authors only 
occur after the development of pulmonary metastases and simultaneously with cerebral 
metastases. 
The interval between the diagnosis of the primary tumour and that of the uveal 
metastasis is approximately three to four years, depending on the nature of the primary 
tumour. In 10 to 46% of the patients the detection of the uveal metastasis precedes that of 
the primary tumour. This happens only rarely in patients with breast cancer and frequently 
in patients with lung cancer. 
In connection with the frequent occurrence of breast cancer as the primary tumour 
most patients with uveal metastases are of the female sex. The mean age is between 50 
and 60 years. Uveal metastases are rarely described in children. 
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The most frequent complaint of patients with uveal metastases is decrease of the 
visual acuity. Defects of the visual field are also established regularly. Inflammatory 
reactions and raised intraocular pressure are described in patients with metastases in the 
anterior segment. A small proportion of the patients has no complaints. 
Ophthalmoscopically, a metastasis is described in general as a flat, round to oval, 
light-coloured lesion with a mottled surface situated temporally in the posterior pole of the 
eye. In the literature bilateral and multiple lesions are described with various percentages. 
The tumour is frequently accompanied by a secondary retinal detachment and sometimes 
by intraocular haemorrhages. Dark-coloured metastases are also described, especially in 
patients with lung cancer. Metastases in the iris are predominantly small diffuse lesions, 
light in colour, and with vessels on the tumour surface. Ciliary metastases are described 
only sporadically. 
At fluorescein angiography, no pathognomonic pattern is observed. In early phases 
of the examination, the tumour as a rule remains hypofluorescent, with spotty staining in 
the arteriovenous phase and a diffuse late fluorescence. Hyperfluorescent spots are 
described regularly. 
Echographically, a metastasis characteristically is a flat tumour with a relatively 
large base, a high irregular infrastructure and often without choroidal excavation or 
vascularity. Metastases of lung cancer are frequently low-reflective. 
Other examination techniques are applied only infrequently. At CT scanning and 
MRI variable images are observed. Perimetry may reveal a relative or absolute scotoma. 
Electro-oculographically an abnormal ratio is described. Puncture or biopsy might be 
useful in case of diagnostic doubt. 
Differential-diagnostically, a choroidal metastasis has to be distinguished 
particularly from (amelanotic) malignant melanoma, naevus and haemangioma. 
The choroidal melanoma in a number of cases can be distinguished adequately 
from metastases. This is the case in unilateral and solitary melanomas with frequently 
pronounced pigmentation, possibly a mushroom shape and the echographic characteristics 
of low regular reflectivity, choroidal excavation and vascularity. At fluorescein 
angiography differentiation is difficult and the picture shows many similarities to that of 
uveal metastases. Other methods of examination make no essential contributions. 
Naevi of the choroid are flat and predominantly darkly pigmented and in general 
show no growth. At fluorescein angiography, no staining of the tumour is observed in 
most cases. If a scotoma is present it is nearly always relative. Electro-oculographically, 
naevi can be distinguished adequately from metastases in the choroid. 
Choroidal haemangiomas are unilateral and solitary, and have an orange-red 
salmon colour with frequently a typical thickened and cystoid retina and a characteristic 
fluorescein-angiographic pattern. At echography they show high reflectivity and, just as in 
CT scanning, sometimes calcium deposits. 
Choroidal metastases have also to be differentiated from lymphoproliferative and 
inflammatory conditions, from serous and haemorrhagic detachments of the retina, the 
retinal pigment epithelium or the choroid, from subretinal haemorrhages and from other 
uncommon intraocular tumours. 
Metastases in the ciliary body are extremely rare. The principal differential 
diagnosis is from malignant melanoma. In addition it has to be distinguished from 
leiomyoma and from medulloepithelioma. 
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A metastasis in the iris has to be differentiated from amelanotic melanoma, from 
leiomyoma and from various inflammatory conditions. 
The natural course of uveal metastases according to the literature is characterized 
by rapid growth of the lesions with further deterioration of the visual acuity. 
Radiotherapy is the most widely used treatment of uveal metastases. Radiation in 
general is administered using a lateral or ventral beam with a total dose of 30 to 40 Gy. A 
favourable effect in the form of decrease of the tumour size and preservation or even 
improvement of the visual acuity is described in highly varying percentages. External 
irradiation of uveal metastases has only few side effects, apart from conjunctivitis which 
responds well to treatment. 
Observation is justified only in patients who are in a terminal phase of their disease 
and in patients with a peripherally localized metastasis that does not directly threaten the 
eyesight, and which patients are being treated systemically with hormonal or chemo-
therapy. However, many uveal metastases have developed in spite of such systemic treat-
ment. 
Enucleation may be necessary in a patient with a painful blind eye. Mostly, 
however, enucleation is carried out under the erroneous diagnosis of malignant melanoma. 
Treatment in the form of laser or cryocoagulation has been applied only 
incidentally. 
The development of uveal metastases allegedly means a poor prognosis quoad 
vitam. 
Part 2: Retrospective study 
During a period of 20 years (November 1970 - November 1990) data were collected on 
762 patients with intraocular tumours or lesions suspicious for tumour. These included 87 
patients with a metastasis, 422 with a malignant melanoma, 27 with a haemangioma, 60 
with a naevus, 25 with a retinoblastoma and 53 with miscellaneous intraocular lesions. In 
88 patients the ultimate diagnosis remained unknown. The frequency of diagnosis of uveal 
metastases proved to have increased during the study period. 
The uveal metastases originated from breast cancer in 60% of the patients, from 
lung cancer in 23% and from some other malignancy in 9%. In 8% of the patients the 
primary tumour was not known. In nearly one-quarter of the cases the uveal metastasis 
preceded the detection of the primary tumour. In most of these cases a metastasis from 
lung cancer was involved. In patients in whom the primary tumour was already known, 
the uveal metastasis proved to be the first sign of dissemination in 23% of the cases. No 
relationship with pulmonary or cerebral metastases could be demonstrated. 
Of the patients with uveal metastases 75 % were of the female and 25 % of the male 
sex. The mean age was 57 years. 
The metastasis was localized in the choroid in 83 patients, in the ciliary body in 
two and in the iris in one. In one patient, metastases were observed in the choroid as well 
as in the iris. 
The signs and symptoms in patients with uveal metastases were of low specificity. 
Most concerned deterioration of the visual acuity. Slight reaction of the anterior chamber 
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occurred sporadically, mostly in patients with lung cancer and metastases in the anterior 
segment. A similar pattern of signs and symptoms was observed in our study group in 
other intraocular tumours. Naevi as a rule caused no symptoms. 
Ophthalmoscopy in uveal metastases as a rule showed a yellowish-orange or 
cream-coloured choroidal tumour with a mottled surface. Multiple lesions were present in 
33% of the patients, bilateral metastases were diagnosed in 29%. The tumour as a rule 
was localized temporally in the fundus. In nearly one-half of the cases the tumour was 
accompanied by a secondary retinal detachment. An intraocular haemorrhage was 
established in 15% of the patients. Metastases of lung cancer were often solitary, grey-
coloured and consequently difficult to differentiate from malignant uveal melanomas. 
Metastases in the anterior segment in our study group originated from lung cancer in all 
cases. Malignant melanomas of the uvea were predominantly grey in colour and more 
prominent than metastases. Amelanotic tumours were also observed in our study group. 
Haemangiomas showed a characteristic salmon colour or a picture similar to that of uveal 
metastases. Naevi in the majority of the cases had a grey colour and were not 
accompanied by a retinal detachment. Ophthalmoscopically, uveal metastases appeared not 
to have clear pathognomonic features for the differential diagnosis from other tumours or 
lesions suspicious for tumour. Multiple and/or bilateral lesions were observed not only in 
metastases but also in retinoblastomas. Retinoblastomas, however, show a characteristic 
ophthalmoscopical image. 
At fluorescein angiography, uveal metastases exhibited no specific pattern. In the 
early phases hypofluorescence was observed at the site of the lesion; in the venous phase 
the lesion stained with a finely or grossly mottled pattern of hyperfluorescence. In most 
cases a hypofluorescent margin round the tumour was observed, as well as hyper-
fluorescent spots on the tumour surface. The findings in melanomas were highly similar. 
However, in melanomas tumour vessels were observed more frequently. In 
haemangiomas, early staining of the tumour was observed as a rule with hyperfluorescent 
spots observed less frequently and tumour vessels more frequently than in metastases. In 
one-third of the patients characteristic sponge-like configurations were observed. Naevi in 
most cases were hypofluorescent in all phases of the fluorescein angiography. 
Echographically, a metastasis in general was depicted as a flat or dome-shaped 
predominantly mid-reflective tumour mass with a large base and often, an irregular 
infrastructure. A noticeable aspect in metastases of lung cancer was the frequently low and 
regular reflectivity which is more typical of a uveal melanoma. In melanomas a choroidal 
excavation, vascularity and orbital shadow were described more frequently than in 
metastases, and in 23% of these patients the mushroom-shape characteristic of melanomas 
was observed. Haemangiomas showed a high-reflective dome-shaped tumour without 
choroidal excavation or vascularity. Naevi as a rule were hardly or not visible owing to 
the low prominence. Retinoblastomas showed a characteristic picture with high reflectivity 
and calcifications. 
At perimetry metastases, melanomas and haemangiomas gave similar pictures, of a 
scotoma which as a rule was absolute. The inclination of this scotoma was significantly 
more frequently sloping in metastases than in melanomas. In naevi, visual field defects 
were encountered less frequently. 
At electro-oculography, in uveal metastases an abnormal light peak, ratio and A 
value were registered. Metastases could be differentiated from naevi but not from 
melanomas. 
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With regard to other examination techniques, only few data were available in our 
study group. They appeared to make no essential contribution to the diagnostics of uveal 
tumours. 
The diagnosis of uveal metastases was often difficult, especially in the case of 
metastases of lung cancer. In patients with lung cancer the uveal metastasis in one-half of 
the cases preceded the detection of the primary tumour. In patients with suspicion for an 
intraocular tumour it is necessary in all cases apart from the anamnesis to perform 
ophthalmoscopy, echography and fluorescein angiography and sometimes, electro-
oculography as well. If the diagnosis cannot be made with certainty, the course of the 
condition should be followed up accurately. In addition, a general physical examination 
and chest X-ray have to be carried out to detect any primary tumours or metastases 
elsewhere in the body. When a uveal metastasis is suspected, mammography has to be 
carried out as well. 
In most patients with uveal metastases (60%), radiotherapy was applied; in 22% 
the tumour was kept under observation, in 6% systemic therapy was administered, in 7% 
the eye was enucleated and in one patient the tumour was subjected to laser coagulation. 
Radiotherapy in general consisted of a total dose of 30.0 Gy in 10 or of 40.0 Gy in 
20 daily fractions via a lateral or, less frequently, a ventral beam and use was made of a 
linear accelerator or Co-60 equipment. Unfortunately, in many patients data on the 
evolution after irradiation were not available. After radiotherapy a decrease of the 
prominence was observed in 54% of the patients, stabilization in 10% and further growth 
in 12% (25% unknown). The visual acuity improved in 25% of the patients, remained 
stable in 37% and deteriorated further in 19% (19% unknown). The overall effect (on 
prominence as well as visual acuity) amounted to improvement in 65% of the patients, to 
stabilization in 12% and to deterioration in 12% (12% unknown). The effect of the 
irradiation on the visual acuity was correlated with the effect on the prominence and visual 
acuity prior to treatment. There was no correlation with the duration of the interval 
between time of diagnosis and start of irradiation, with the distance of the metastasis from 
the fovea, with presence or absence of a secondary retinal detachment or with the nature 
of the primary tumour. No statistically significant difference was established between the 
results of the 30.0 Gy and 40.0 Gy schemes. Side effects of radiotherapy were slight and 
mostly consisted of well-manageable conjunctivitis. Only once did a major side effect 
develop, in the form of acute glaucoma. 
In 22% of the patients with uveal metastases an expectative policy was pursued, 
although radiotherapy had been advised in two thirds of the cases. The principal reason 
not to apply irradiation was a poor general condition of the patient. 
In five patients, the effect of not previously instituted systemic therapy was 
awaited, with a positive result in four patients. 
Enucleation as first therapy was performed six times: three times under the 
erroneous diagnosis of melanoma, twice because of uncertainty of the diagnosis and once 
because of intractible complications. 
In one case, a choroidal metastasis was treated with laser coagulation, with a good 
result. 
It is recommended to irradiate uveal metastases with a total dose of 30.0 Gy in 10 
daily fractions via a lateral beam directed 5° occipitally or with use of a half-beam 
technique. If metastases are present in both eyes, parallel opposed beams are advised. In 
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metastases at the level of the equator, preference may be given to irradiation from ventral 
with protection of the lens and of the lacrimal gland. In patients who have small uveal 
metastases without retinal detachment, not impairing or directly threatening the visual 
acuity, and who have not yet been given systemic treatment, the effect of hormonal or 
chemotherapy may be awaited. 
The median duration of survival of patients with a uveal metastasis was 9.7 months 
and was related to the nature of the primary tumour: 12.7 months in patients with breast 
cancer, 6.4 months in patients with lung cancer and 5.8 months in patients with one of the 
remaining primary tumours. 
Part 3: Prospective study 
In a period of 28 months (February 1989 - July 1991) repeated ophthalmological 
examinations were carried out in 107 female patients with breast cancer with metastases 
only in locoregional lymph nodes (N=44: primary breast cancer) or with distant 
metastases (N=63: advanced breast cancer). 
At the time of the ophthalmological examination, 83% of these patients were being 
treated systemically with adjuvant or palliative hormonal and/or chemotherapy. 
In five of the 63 patients with advanced breast cancer (8%), uveal metastases were 
observed, which in all cases were localized in the choroid. Metastases in the uvea were 
seen in not a single patient with primary breast cancer. In two of the five patients with 
uveal metastases, the lesions at the time of detection were found already to have gone into 
partial regression. Ophthalmological symptoms were present in four of the five patients. 
In all these cases the malignancy was already extensively disseminated. Of these patients, 
the case histories are described. 
Eighteen of the 107 patients with breast cancer were referred in connection with 
ophthalmological symptoms. At examination at the ophthalmological outpatient clinic, 
however, ophthalmological complaints were found to be present in a total of 41 patients. 
These complaints consisted mainly of decrease of the visual acuity and burning eyes. They 
were found to be due to uveal metastases in four patients, to cataract in eight patients and 
to stenosis of the lacrimal ducts, to retinal degenerations and to carcinomatous meningitis 
in one patient each. In one-half of the patients with ocular complaints, however, no 
ophthalmological abnormalities could be demonstrated; in these patients, the systemic 
therapy may have been responsible for the symptoms. 
From these data it can be concluded that complaints about the eyesight are present 
in a large proportion of the patients with breast cancer. The probability that these 
complaints are due to uveal metastases in patients with known distant metastases amounts 
to 15%. 
Since ocular abnormalities are observed in such a large proportion of the patients 
with breast cancer, it is recommended in patients with a malignancy to enquire specifically 
about ocular complaints and, if these are present, to refer them to an ophthalmologist for 
further examination. Screening for uveal metastases in patients with primary breast cancer 
appears not to be justified. In patients with advanced breast cancer, and in patients with 
other disseminated malignancies, on the other hand, the possibility of development of 
uveal metastases should be constantly kept in mind. 
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Samenvatting 
In dit proefschrift wordt getracht een zo compleet mogelijke beschrijving te geven van het 
oogheelkundig beeld van uveametastasen om daarmee de diagnostiek en behandeling zo 
mogelijk te verbeteren en zo een bijdrage te leveren aan de kwaliteit van leven van deze 
patiënten. 
Het onderzoek bestaat uit drie delen. In het eerste deel wordt een uitgebreid 
overzicht gegeven van de literatuur over uveametastasen. Het tweede deel behandelt de 
resultaten van een retrospectief onderzoek naar intraoculaire tumoren en voor tumor 
verdachte aandoeningen, waarbij de nadruk ligt op uveametastasen. Het derde deel betreft 
een prospectief onderzoek bij patiënten met een mammacarcinoom met het doel de 
frequentie van voorkomen van oogheelkundige klachten en van uveametastasen bij deze 
patiënten vast te stellen en te bezien in hoeverre screening op oogheelkundige afwijkingen 
bij hen zinvol is. 
Deel 1: Literatuuroverzicht 
De eerste publicatie over uveametastasen betreft een verhandeling van Perls uit 1872 
omtrent de histologische bevindingen bij een patient met een longcarcinoom. Hirschberg 
publiceerde in 1882 de eerste klinische beschrijving van een chorioideametastase. 
Over de ontstaanswijze van uveametastasen bestaat nog veel onzekerheid. 
Metastasen kunnen de uvea alleen via haematogene weg bereiken. De bloedvoorziening 
van de uvea geschiedt vanuit de korte en lange achterste en vanuit de voorste ciliair 
arteriën, welke zijtakken van de arteria ophthalmica vormen. De chorioidea ontvangt 
daarbij voornamelijk bloed via de 20 korte en voor een deel via de twee lange achterste 
ciliair arteriën. De vier voorste ciliair arteriën voorzien samen met de twee lange achterste 
ciliair arteriën de uvea anterior (corpus ciliare en iris) van bloed. Oogheelkundige 
metastasen zijn, als gevolg van de vaatvoorziening, het meest frequent in de chorioidea 
gelokaliseerd. Bij het optreden van uveametastasen spelen naast circulatoire factoren 
echter ook lokale omgevingsfactoren een rol. Uveametastasen betreffen extracerebrale 
lokalisaties. 
Uveametastasen zijn de meest frequent voorkomende, hoewel niet de meest 
frequent gediagnostiseerde, intraoculaire tumoren. De primaire tumor is meestal een 
mammacarcinoom. Veel minder frequent worden metastasen van een longcarcinoom 
gezien en zelden van andere maligniteiten. Er bestaat geen eenduidige verklaring voor het 
zo frequent optreden van het mammacarcinoom als primaire tumor. Uveametastasen 
zouden volgens verschillende auteurs pas optreden ná het ontstaan van long metastasen en 
tegelijk met hersenmetastasen. 
Het interval tussen het ontdekken van de primaire tumor en van de uveametastase 
is ongeveer drie tot vier jaar, afhankelijk van de aard van de primaire tumor. In 10 tot 
46% van de patiënten gaat de uveametastase aan het ontdekken van de primaire tumor 
vooraf. Dit gebeurt slechts zelden bij patiënten met een mammacarcinoom en frequent bij 
patiënten met een longcarcinoom. 
Samenhangend met het zo frequent optreden van het mammacarcinoom als primaire 
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tumor zijn de meeste patiënten met uveametastasen van het vrouwelijk geslacht. De 
gemiddelde leeftijd ligt tussen de 50 en 60 jaar. Bij kinderen worden uveametastasen 
zelden beschreven. 
De meest gehoorde klacht bij patiënten met uveametastasen is een visusdaling. 
Daarnaast worden regelmatig gezichtsvelddefecten vastgesteld. Inflammatoire reacties en 
verhoogde oogdruk worden beschreven bij patiënten met metastasen in het voorsegment. 
Een klein deel van de patiënten heeft geen klachten. 
Fundusscopisch kenmerkt een métastase zich over het algemeen als een vlakke, 
ronde tot ovale, licht gekleurde laesie met een mottig oppervlak welke temporaal in de 
achterpool van het oog is gelegen. In de literatuur worden bilaterale en multipele laesies in 
wisselende percentages beschreven. De tumor gaat frequent gepaard met een secundaire 
netvliesloslating en soms met intraoculaire bloedingen. Ook donker gekleurde metastasen 
worden beschreven, met name bij patiënten met een longcarcinoom. Metastasen in de iris 
zijn overwegend kleine diffuse laesies, licht van kleur, en met vaten op het 
tumoroppervlak. Ciliaire metastasen zijn alleen als casuïstiek beschreven. 
Fluorescentie angiografisch wordt geen pathognomonisch beeld gezien. In vroege 
fasen van het onderzoek blijft de tumor meestal hypofluorescent om in de arterioveneuze 
fase vlekkig aan te kleuren met een diffuse late fluorescentie. Regelmatig worden 
hyperfluorescente spots beschreven. 
Echografisch kenmerkt een métastase zich als een vlakke tumor met relatief brede 
basis, een hoge irregulaire infrastructuur, veelal zonder chorioidale excavatie of 
vasculariteit. Metastasen van een longcarcinoom zijn vaak laag reflectief. 
Andere onderzoekstechnieken worden slechts weinig toegepast. Bij CT-scan en 
MRI wordt een variabel beeld gezien. Bij perimetric kan een relatief of absoluut scotoom 
worden vastgesteld. Electro-oculografisch wordt een abnormale ratio beschreven. Punctie 
of bioptering zou zinvol kunnen zijn bij twijfel over de diagnose. 
Differentiaal diagnostisch moet een chorioideametastase met name worden 
gedifferentieerd van het (amelanotische) maligne melanoom, de naevus en het 
haemangioom. 
Het chorioideamelanoom kan in een aantal gevallen goed van metastasen worden 
onderscheiden. Het betreft dan unilateraal en solitair voorkomende melanomen met een 
veelal sterke pigmentatie, mogelijk een paddestoelvorm en echografische karakteristieken 
met een lage regulaire reflectiviteit, chorioidale excavatie en vasculariteit. Fluorescentie 
angiografisch is differentiatie moeilijk en vertoont het beeld vele overeenkomsten met dat 
van uveametastasen. Andere onderzoeksmethoden leveren geen essentiële bijdrage. 
Naevi van de chorioidea zijn vlak, overwegend donker gepigmenteerd en vertonen 
over het algemeen geen groei. Bij fluorescentie angiografie wordt meestal geen 
aankleuring van de tumor gezien. Indien een scotoom optreedt is dit vrijwel altijd relatief. 
Electro-oculografisch zijn naevi goed te onderscheiden van metastasen in de chorioidea. 
Chorioideahaemangiomen treden unilateraal en solitair op, hebben een oranje-rode 
zalmkleur met veelal een typische verdikte en cystoiede retina en een karakteristiek 
fluorescentie angiografisch patroon. Echografisch vertonen zij een hoge reflectiviteit en 
kunnen er, evenals bij CT-scan onderzoek, kalkafzettingen worden waargenomen. 
Chorioideametastasen moeten tevens worden gedifferentieerd van lymfo-
proliferatieve en inflammatoire aandoeningen, van sereuze en haemorrhagische loslatingen 
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van het netvlies, het retínale pigment epitheel of de chorioidea, van subretinale bloedingen 
en van andere weinig voorkomende intraoculaire tumoren. 
Metastasen in het corpus ciliare zijn uiterst zeldzaam. De voornaamste differentiaal 
diagnose wordt gevormd door het maligne melanoom. Daarnaast moet worden 
gedifferentieerd van het leiomyoom en het medulloepithelioom. 
Een irismetastase moet worden gedifferentieerd van het amelanotische melanoom, 
het leiomyoom en van verschillende inflammatoire aandoeningen. 
Het natuurlijk beloop van uveametastasen wordt volgens de literatuur gekenmerkt 
door snelle groei van de laesies met verdere achteruitgang van de visus. 
Radiotherapie is de meest geaccepteerde behandeling van uveametastasen. Over het 
algemeen wordt bestraald met een laterale of ventrale bundel met een totaal dosis van 30 
tot 40 Gy. Een positief effect in de vorm van afname van de tumorgrootte en behoud of 
zelfs verbetering van de visus wordt in zeer wisselende percentages beschreven. Behalve 
een goed behandelbare conjunctivitis treden bij uitwendige bestraling van uveametastasen 
slechts weinig bijwerkingen op. 
Observatie is alleen verantwoord bij patiënten die in een terminale fase van hun 
aandoening verkeren en bij patiënten met een perifeer gelegen métastase welke de visus 
niet direct bedreigt en waarbij de patient systemisch wordt behandeld door middel van 
hormonale of chemotherapie. Veel uveametastasen zijn echter ontstaan ondanks een 
dergelijke systemische behandeling. 
Enucleatie kan noodzakelijk zijn bij een patient met een pijnlijk blind oog. Meestal 
wordt enucleatie echter verricht onder de foutieve diagnose maligne melanoom. 
Therapie in de vorm van laser- of cryocoagulatie is slechts incidenteel toegepast. 
Het optreden van uveametastasen zou op een slechte levensprognose wijzen. 
Deel 2: Retrospectief onderzoek 
Over een periode van 20 jaar (november 1970 - november 1990) werden de gegevens van 
762 patiënten met intraoculaire tumoren of voor tumor verdachte laesies verzameld. Het 
betrof 87 patiënten met een métastase, 422 met een maligne melanoom, 27 met een 
haemangioom, 60 met een naevus, 25 met een retinoblastoom en 53 met overige 
intraoculaire aandoeningen. Bij 88 patiënten is de uiteindelijke diagnose onbekend 
gebleven. De frequentie van diagnose van uveametastasen bleek in de onderzoeksperiode 
te zijn toegenomen. 
Bij 60% van de patiënten was de uveametastase afkomstig van een mamma-
carcinoom, bij 23% van een longcarcinoom en bij 9% van een andere maligniteit. Bij 8% 
van de patiënten was de primaire tumor niet bekend. In bijna een kwart van de gevallen 
ging de uveametastase aan het ontdekken van de primaire tumor vooraf. Het betrof dan in 
de meeste gevallen een métastase van een longcarcinoom. Bij patiënten bij wie de primaire 
tumor reeds bekend was, bleek de uveametastase in 23% van de gevallen het eerste teken 
van disseminatie te zijn. Er kon geen relatie met long- of hersenmetastasen worden 
aangetoond. 
Van de patiënten met uveametastasen was 75% van het vrouwelijk geslacht en 25% 
mannelijk. De gemiddelde leeftijd was 57 jaar. 
361 
Bij 83 patiënten was de métastase in de chorioidea gelegen, bij twee in het corpus 
ciliare en bij één in de iris. Bij één patient werden zowel metastasen in de chorioidea als 
in de iris vastgesteld. 
De klachten en verschijnselen bij patiënten met uveametastasen waren weinig 
specifiek. Over het algemeen betroffen het klachten in de vorm van een visusdaling. 
Prikkelingsverschijnselen van het oog traden sporadisch op en werden meestal gezien bij 
patiënten met een longcarcinoom en metastasen in het voorsegment. Een zelfde beeld van 
klachten en verschijnselen werd in onze onderzoeksgroep bij andere intraoculaire tumoren 
vastgesteld. Naevi veroorzaakten over het algemeen geen klachten. 
Fundusscopisch werd bij uveametastasen meestal een geel-oranje of crème-kleurige 
chorioidale tumor vastgesteld met een mottig oppervlak. Bij 33% van de patiënten waren 
multipele laesies aanwezig, bij 29% werden bilaterale metastasen vastgesteld. De tumor 
was over het algemeen temporaal in de fundus gelokaliseerd. In bijna de helft van de 
gevallen werd de tumor begeleid door een secundaire netvliesloslating. Bij 15% van de 
patiënten werd een intraoculaire bloeding geconstateerd. Metastasen van een 
longcarcinoom waren vaak solitair, grijs van kleur en daardoor moeilijk te differentieren 
van maligne uveamelanomen. Metastasen in het voorsegment waren in onze 
onderzoeksgroep in alle gevallen afkomstig van een longcarcinoom. Maligne melanomen 
van de uvea waren overwegend grijs van kleur en meer prominent dan metastasen. 
Amelanotische tumoren kwamen in ons onderzoek eveneens voor. Haemangiomen toonden 
een karakteristieke zalmkleur of een met uveametastasen vergelijkbaar beeld. Naevi 
hadden in de meerderheid van de gevallen een grijze kleur zonder dat een netvliesloslating 
aanwezig was. Fundusscopisch leken geen pathognomonische differentiaal diagnostische 
kenmerken voor uveametastasen aanwezig te zijn ten opzichte van andere tumoren en voor 
tumor verdachte laesies. Multipele en/of bilaterale laesies traden behalve bij metastasen 
eveneens bij retinoblastomen op. Retinoblastomen vertonen echter een kenmerkend 
fundusscopisch beeld. 
Bij fluorescentie angiografie was bij uveametastasen geen specifiek patroon 
aantoonbaar. In de vroege fasen werd een hypofluorescentie ter plaatse van de aandoening 
geconstateerd welke laesie in de veneuze fase aankleurde met een fijn- of grofvlekkig 
patroon van hyperfluorescentie. In de meeste gevallen werd een hypofluorescente rand om 
de tumor vastgesteld evenals hyperfluorescente spots op het tumoroppervlak. Het beeld bij 
melanomen vertoonde hiermee veel overeenkomsten. Wel werden bij melanomen vaker 
tumorvaten waargenomen. Bij haemangiomen werd meestal een vroege aankleuring van de 
tumor vastgesteld met minder vaak hyperfluorescente spots en vaker tumorvaten dan bij 
metastasen het geval was. Bij één derde van de patiënten werden kenmerkende 
sponsachtige configuraties waargenomen. Naevi waren in de meeste gevallen 
hypofluorescent in alle fasen van de fluorescentie angiografie. 
Echografisch beeldde een métastase zich over het algemeen af als een vlakke of 
bolvormige overwegend midreflectieve tumormassa met een brede basis en vaak een 
irregulaire infrastructuur. Opvallend bij metastasen van het longcarcinoom was de veelal 
lage en regulaire reflectiviteit die meer kenmerkend is voor een uveamelanoom. Bij het 
melanoom werd daarnaast frequenter een chorioidale excavatie, vasculariteit en 
orbitaschaduw beschreven dan bij metastasen en werd bij 23% van de patiënten de voor 
melanomen kenmerkende paddestoelvorm vastgesteld. Haemangiomen lieten een hoog 
reñectieve bolvormige tumor zien zonder chorioidale excavatie of vasculariteit. Naevi 
beeldden zich door de geringe prominentie meestal niet of nauwelijks af. Retinoblastomen 
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vertoonden een karakteristiek beeld met een hoge reflectiviteit en kalkspatten. 
Bij perimetrie werd bij metastasen, melanomen en haemangiomen een vergelijkbaar 
beeld vastgesteld van een scotoom dat meestal absoluut was. De helling van dit scotoom 
was bij metastasen beduidend vaker glooiend dan bij melanomen. Bij naevi werden minder 
vaak gezichtsveldafwijkingen vastgesteld. 
Bij electro-oculografie werd bij uveametastasen een abnormale light peak, ratio en 
A-waarde geregistreerd. Metastasen konden wel van naevi, maar niet van melanomen 
worden gedifferentieerd. 
Over andere onderzoekstechnieken waren in onze onderzoeksgroep slechts weinig 
gegevens beschikbaar. Zij leken geen essentiële bijdrage te leveren aan de diagnostiek van 
uveatumoren. 
De diagnostiek van uveametastasen was vaak moeilijk, met name in het geval van 
metastasen van een longcarcinoom. Bij deze patiënten met een longcarcinoom ging de 
uveametastase in de helft van de gevallen aan het ontdekken van de primaire tumor 
vooraf. Bij patiënten met verdenking op een intraoculaire tumor moet, naast anamnese, in 
alle gevallen fundusscopie, echografie en fluorescentie angiografie worden verricht en 
eventueel electro-oculografie. Indien de diagnose niet met zekerheid kan worden gesteld 
dan moet het beloop van de aandoening nauwkeurig worden vervolgd. Daarnaast moeten 
een algeheel lichamelijk onderzoek en röntgenonderzoek van de thorax worden verricht 
om eventuele primaire tumoren of metastasen elders in het lichaam op te sporen. Bij 
verdenking op een uveametastase moet tevens mammografie worden verricht. 
Bij de meeste patiënten met uveametastasen (60%) werd radiotherapie toegepast; 
bij 22% werd de tumor geobserveerd, 6% werd met systemische therapie behandeld, bij 
7% werd het oog geënucleëerd en bij één patient werd de tumor met lasercoagulatie 
behandeld. 
Bij radiotherapie werd over het algemeen een totaaldosis van 30,0 Gy in 10 of 40,0 
Gy in 20 dagelijkse fracties toegepast via een laterale of, minder vaak, ventrale bundel en 
werd gebruik gemaakt van een lineaire versneller of Co-60 apparatuur. Bij veel patiënten 
ontbraken helaas gegevens over het beloop na bestraling. Na radiotherapie werd bij 54% 
van de patiënten een afname van de prominentie vastgesteld, bij 10% een stabilisatie en bij 
12% verdere groei (25% onbekend). De visus verbeterde bij 25% van de patiënten, 
stabiliseerde bij 37% en verslechterde verder bij 19% (19% onbekend). Het overall effect 
(op zowel prominentie als visus) hield bij 65% van de patiënten een verbetering in, bij 
12% een stabilisatie en bij 12% een verslechtering (12% onbekend). Het effect van de 
bestraling op de visus was gerelateerd aan het effect op de prominentie en aan de visus 
vóór behandeling. Er bestond geen relatie met het interval tussen het tijdstip van diagnose 
en de aanvang van bestraling, met de afstand van de métastase ten opzichte van de fovea, 
met de eventuele aanwezigheid van een secundaire netvliesloslating en met de aard van de 
primaire tumor. Er werd geen statistisch significant verschil gevonden tussen de resultaten 
van het 30,0 Gy en het 40,0 Gy schema. Bijwerkingen van radiotherapie waren gering en 
betroffen meestal goed behandelbare conjunctivitiden. Slechts één maal trad een ernstige 
bijwerking op in de vorm van acuut glaucoom. 
Bij 22% van de patiënten met uveametastasen werd een expectatief beleid gevoerd, 
hoewel in twee derde van de gevallen radiotherapie was geadviseerd. Voornamelijk kon 
bestraling niet worden toegepast in verband met de slechte algehele conditie van de 
patient. 
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Bij vijf patiënten werd het effect van niet eerder ingestelde systemische therapie 
afgewacht met een positief resultaat bij vier patiënten. 
Enucleatie als eerst ingestelde therapie werd zes maal verricht: drie maal onder de 
foutieve diagnose 'melanoom', twee maal wegens onbehandelbare complicaties en één 
maal in verband met onzekerheid over de diagnose. 
Eén maal werd een chorioideametastase met goed resultaat behandeld met 
lasercoagulatie. 
Geadviseerd wordt uveametastasen te bestralen met een totale dosis van 30,0 Gy in 
10 dagelijkse fracties via een laterale bundel die 5° occipitaal wordt ingeschoten of via 
een halve bundel techniek. Indien metastasen in beide ogen zijn gelokaliseerd worden 
parallelle opponerende bundels geadviseerd. Bij metastasen ter plaatse van de equator kan 
de voorkeur worden gegeven aan bestraling van ventraal met bescherming van de lens en 
de traanklier. Bij patiënten met kleine uveametastasen zonder netvliesloslating welke de 
visus niet hebben aangetast of direct bedreigen en die nog niet systemisch zijn behandeld 
kan het effect van hormonale of chemotherapie worden afgewacht. 
De mediane overlevingsduur bij patiënten met een uveametastase was 9,7 maanden 
en was gerelateerd aan de aard van de primaire tumor: 12,7 maanden bij patiënten met 
een mammacarcinoom, 6,4 maanden bij patiënten met een longcarcinoom en 5,8 maanden 
bij patiënten met één van de overige primaire tumoren. 
Deel 3: Prospectief onderzoek 
In een periode van 28 maanden (februari 1989 - juli 1991) werden 107 vrouwelijke 
patiënten met een mammacarcinoom met metastasen alléén in locoregionale lymfeklieren 
(N=44: primair mammacarcinoom) of metastasen op afstand (N=63: gemetastaseerd 
mammacarcinoom) herhaaldelijk oogheelkundig onderzocht. 
Ten tijde van het oogheelkundig onderzoek werd 83% van deze patiënten 
systemisch behandeld met adjuvante of palliatieve hormonale en/of chemotherapie. 
Bij vijf van de 63 patiënten met een gemetastaseerd mammacarcinoom (8%) 
werden uveametastasen vastgesteld die in alle gevallen in de chorioidea waren gelegen. Bij 
geen enkele patient met een primair mammacarcinoom werden metastasen in de uvea 
aangetroffen. Bij twee van de vijf patiënten met uveametastasen bleken de laesies op het 
moment van ontdekken reeds voor een deel in regressie te zijn gegaan. Bij vier van de vijf 
patiënten bestonden oogheelkundige klachten. In alle gevallen betrof het reeds uitgebreid 
gemetastaseerde aandoeningen. Van deze patiënten wordt de ziektegeschiedenis 
beschreven. 
Achttien van de 107 patiënten met een mammacarcinoom werden verwezen in 
verband met oogheelkundige klachten. Bij onderzoek op de polikliniek oogheelkunde bleek 
echter bij in totaal 41 patiënten sprake te zijn van oogklachten. Deze klachten bestonden 
met name uit visusdaling en branderige ogen. Zij bleken bij vier patiënten te berusten op 
uveametastasen, bij acht patiënten op cataract en bij respectievelijk één patient op een 
sténose van de traanwegen, op retinale degeneraties en op een meningitis carcinomatosa. 
Bij de helft van de patiënten met oogklachten konden echter geen oogheelkundige 
afwijkingen worden vastgesteld en was mogelijk de systemische therapie voor de klachten 
veran t woordel ij к. 
Op grond van deze gegevens kan worden geconcludeerd dat klachten van de ogen 
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in een hoog percentage van de patiënten met een mammacarcinoom voorkomen. De kans 
dat deze klachten berusten op uveametastasen is bij patiënten met reeds bekende 
metastasering op afstand 15 %. 
Aangezien oogafwijkingen in een zo hoog percentage van de patiënten met een 
mammacarcinoom werden vastgesteld, wordt geadviseerd bij patiënten met een maligniteit 
gericht te vragen naar oogklachten en indien deze aanwezig zijn hen voor nader onderzoek 
naar een oogarts te verwijzen. Screening op uveametastasen bij patiënten met een primair 
mammacarcinoom lijkt niet gerechtvaardigd. Bij patiënten met een gemetastaseerd 
mammacarcinoom, evenals bij patiënten met andere gemetastaseerde maligniteiten, moet 
men daarentegen voortdurend bedacht zijn op de ontwikkeling van uveametastasen. 
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Stellingen 
behorende bij het proefschrift 
Uveal metastases 
A clinical survey 
door 
Hendrik Μ.Λ. Brink 
Nijmegen, 24 januari 1992 
1. Uveametastasen zijn de meest frequent voorkomende maligne intraoculaire tumoren 
2. Uveametastasen dienen beschouwd te worden als extracerebrale gelokaliseerde 
uitzaaiingen 
3. Van de beschikbare oogheelkundige onderzoekstechnieken dragen fundusscopie en 
echografie het meest bij aan de diagnostiek betreffende de aard van chonoidea-
tumoren 
Dit proefschrift 
4. Electro-oculografie kan een bijdrage leveren aan de differentiaal diagnostiek van 
intraoculaire tumoren. 
Brink et al.: Doc Ophthalmol 1990, 75: 329-334 
5. De eerste keuze voor behandeling van symptomatische uveametastasen is bestraling 
met een totaal dosis van 30 Gy te geven in 10 dagelijkse fracties van 3 Gy 
Hoogenhout et al.: Strahlenther Onkol 1989; 165: 375-379 / Dit proefschrift 
6. Een afwachtend oogheelkundig beleid bij patiënten met uveametastasen is alleen 
verantwoord bij kleine asymptomatische perifeer gelegen laesies welke met gepaard 
gaan met een secundaire netvhesloslating 
7. Screenend onderzoek naar de aanwezigheid van uveametastasen bij patiënten met een 
mammacarcinoom die geen oogheelkundige klachten hebben, levert geen wezenlijke 
bijdrage aan de vroegdiagnostiek van deze afwijking Daarentegen is bij klachten 
oogheelkundig onderzoek in alle gevallen aangewezen 
Ditproefschnft 
8. Bij patiënten met een gemetastaseerd mammacarcinoom die gunstig reageren op 
chemotherapie levert vroegtijdige beëindiging van deze behandeling geen bijdrage 
aan de verbetering van kwaliteit van leven. 
Coates et al.: N Eng J Med 1987; 317: 1490-1495 
Muss et al.: N Eng J Med 1991; 325: 1342-1348 
9. Reductie van de ten aanzien van operatieve oogheelkundige ingrepen ter beschikking 
staande anaesthesietijd leidt niet tot een afname van het aantal oogoperaties, maar 
wel tot onaanvaardbaar lange wachttijden voor operaties waarvoor anaesthesie 
noodzakelijk is. 
10. Het onderscheid tussen kijken en zien is nog te weinig bekend. Binnen de oogheel-
kundige oncologie kan dit leiden tot verwarring van bol met hol. 
11. Conclusies welke alléén gebaseerd zijn op statistische bewerking van patiënten-
gegevens zeggen weinig over de onderzochte populatie maar des te meer over de 
onderzoeker. 
12. De citatie-index voor medische literatuur nodigt uit tot manipulatie. 
13. Geneeskunde laat zich niet tot kantooruren beperken. Promotie onderzoek evenmin. 
14. Men hoeft een boek niet gelezen te hebben om ervan te houden. 



